---
author-meta:
- Halie M. Rando
- Casey S. Greene
- Michael P. Robson
- Simina M. Boca
- Nils Wellhausen
- Ronan Lordan
- Christian Brueffer
- Sandipan Ray
- Lucy D\'Agostino McGowan
- Anthony Gitter
- Anna Ada Dattoli
- Ryan Velazquez
- John P. Barton
- Jeffrey M. Field
- Bharath Ramsundar
- Adam L. MacLean
- Alexandra J. Lee
- Immunology Institute of the Icahn School of Medicine
- Fengling Hu
- Nafisa M. Jadavji
- Elizabeth Sell
- Jinhui Wang
- Diane N. Rafizadeh
- Ashwin N. Skelly
- Marouen Ben Guebila
- Likhitha Kolla
- David Manheim
- Soumita Ghosh
- James Brian Byrd
- YoSon Park
- Vikas Bansal
- Stephen Capone
- John J. Dziak
- Yuchen Sun
- Yanjun Qi
- Lamonica Shinholster
- Temitayo Lukan
- Sergey Knyazev
- Dimitri Perrin
- Serghei Mangul
- Shikta Das
- Gregory L Szeto
- Tiago Lubiana
- David Mai
- COVID-19 Review Consortium
- Rishi Raj Goel
bibliography:
- content/manual-references.bib
- content/manual-references.json
date-meta: '2021-02-05'
header-includes: "<!--\nManubot generated metadata rendered from header-includes-template.html.\nSuggest improvements at https://github.com/manubot/manubot/blob/master/manubot/process/header-includes-template.html\n-->\n<meta name=\"dc.format\" content=\"text/html\" />\n<meta name=\"dc.title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta name=\"citation_title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta property=\"og:title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta property=\"twitter:title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta name=\"dc.date\" content=\"2021-02-05\" />\n<meta name=\"citation_publication_date\" content=\"2021-02-05\" />\n<meta name=\"dc.language\" content=\"en-US\" />\n<meta name=\"citation_language\" content=\"en-US\" />\n<meta name=\"dc.relation.ispartof\" content=\"Manubot\" />\n<meta name=\"dc.publisher\" content=\"Manubot\" />\n<meta name=\"citation_journal_title\" content=\"Manubot\" />\n<meta name=\"citation_technical_report_institution\" content=\"Manubot\" />\n<meta name=\"citation_author\" content=\"Halie M. Rando\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7688-1770\" />\n<meta name=\"twitter:creator\" content=\"@tamefoxtime\" />\n<meta name=\"citation_author\" content=\"Casey S. Greene\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Childhood Cancer Data Lab, Alex&#39;s Lemonade Stand Foundation, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8713-9213\" />\n<meta name=\"twitter:creator\" content=\"@GreeneScientist\" />\n<meta name=\"citation_author\" content=\"Michael P. Robson\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computing Sciences, Villanova University, Villanova, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-4859-0033\" />\n<meta name=\"citation_author\" content=\"Simina M. Boca\" />\n<meta name=\"citation_author_institution\" content=\"Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, District of Columbia, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1400-3398\" />\n<meta name=\"citation_author\" content=\"Nils Wellhausen\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8955-7582\" />\n<meta name=\"citation_author\" content=\"Ronan Lordan\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5158, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-9668-3368\" />\n<meta name=\"twitter:creator\" content=\"@el_ronan\" />\n<meta name=\"citation_author\" content=\"Christian Brueffer\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical Sciences, Lund University, Lund, Sweden\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3826-0989\" />\n<meta name=\"twitter:creator\" content=\"@cbrueffer\" />\n<meta name=\"citation_author\" content=\"Sandipan Ray\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy 502285, Telangana, India\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9960-5768\" />\n<meta name=\"citation_author\" content=\"Lucy D\\&#39;Agostino McGowan\" />\n<meta name=\"citation_author_institution\" content=\"Department of Mathematics and Statistics, Wake Forest University, Winston-Salem, North Carolina, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7297-9359\" />\n<meta name=\"twitter:creator\" content=\"@LucyStats\" />\n<meta name=\"citation_author\" content=\"Anthony Gitter\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Morgridge Institute for Research, Madison, Wisconsin, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5324-9833\" />\n<meta name=\"twitter:creator\" content=\"@anthonygitter\" />\n<meta name=\"citation_author\" content=\"Anna Ada Dattoli\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology &amp; Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1462-831X\" />\n<meta name=\"twitter:creator\" content=\"@aadattoli\" />\n<meta name=\"citation_author\" content=\"Ryan Velazquez\" />\n<meta name=\"citation_author_institution\" content=\"Azimuth1, McLean, VA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3655-3403\" />\n<meta name=\"citation_author\" content=\"John P. Barton\" />\n<meta name=\"citation_author_institution\" content=\"Department of Physics and Astronomy, University of California-Riverside, Riverside, California, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1467-421X\" />\n<meta name=\"twitter:creator\" content=\"@_jpbarton\" />\n<meta name=\"citation_author\" content=\"Jeffrey M. Field\" />\n<meta name=\"citation_author_institution\" content=\"Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7161-7284\" />\n<meta name=\"citation_author\" content=\"Bharath Ramsundar\" />\n<meta name=\"citation_author_institution\" content=\"The DeepChem Project, https://deepchem.io/\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8450-4262\" />\n<meta name=\"twitter:creator\" content=\"@rbhar90\" />\n<meta name=\"citation_author\" content=\"Adam L. MacLean\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biological Sciences, University of Southern California, Los Angeles, California, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0689-7907\" />\n<meta name=\"twitter:creator\" content=\"@adamlmaclean\" />\n<meta name=\"citation_author\" content=\"Alexandra J. Lee\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0208-3730\" />\n<meta name=\"citation_author\" content=\"Immunology Institute of the Icahn School of Medicine\" />\n<meta name=\"citation_author_institution\" content=\"Immunology Institute of the Icahn School of Medicine\" />\n<meta name=\"citation_author\" content=\"Fengling Hu\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1081-5038\" />\n<meta name=\"twitter:creator\" content=\"@hufengling\" />\n<meta name=\"citation_author\" content=\"Nafisa M. Jadavji\" />\n<meta name=\"citation_author_institution\" content=\"Biomedical Science, Midwestern University, Glendale, AZ, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3557-7307\" />\n<meta name=\"twitter:creator\" content=\"@nafisajadavji\" />\n<meta name=\"citation_author\" content=\"Elizabeth Sell\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9658-1107\" />\n<meta name=\"citation_author\" content=\"Jinhui Wang\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5796-8130\" />\n<meta name=\"citation_author\" content=\"Diane N. Rafizadeh\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-2838-067X\" />\n<meta name=\"citation_author\" content=\"Ashwin N. Skelly\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1565-3376\" />\n<meta name=\"citation_author\" content=\"Marouen Ben Guebila\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-5934-966X\" />\n<meta name=\"twitter:creator\" content=\"@marouenbg\" />\n<meta name=\"citation_author\" content=\"Likhitha Kolla\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1169-906X\" />\n<meta name=\"twitter:creator\" content=\"@lkolla2018\" />\n<meta name=\"citation_author\" content=\"David Manheim\" />\n<meta name=\"citation_author_institution\" content=\"1DaySooner, Delaware, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Risk and Health Communication Research Center, School of Public Health, University of Haifa, Haifa, Israel\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8599-8380\" />\n<meta name=\"twitter:creator\" content=\"@davidmanheim\" />\n<meta name=\"citation_author\" content=\"Soumita Ghosh\" />\n<meta name=\"citation_author_institution\" content=\"Institute of Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-2783-2750\" />\n<meta name=\"citation_author\" content=\"James Brian Byrd\" />\n<meta name=\"citation_author_institution\" content=\"University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0509-3520\" />\n<meta name=\"twitter:creator\" content=\"@thebyrdlab\" />\n<meta name=\"citation_author\" content=\"YoSon Park\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0465-4744\" />\n<meta name=\"twitter:creator\" content=\"@__yoson__\" />\n<meta name=\"citation_author\" content=\"Vikas Bansal\" />\n<meta name=\"citation_author_institution\" content=\"Biomedical Data Science and Machine Learning Group, German Center for Neurodegenerative Diseases, T\xFCbingen 72076, Germany\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0944-7226\" />\n<meta name=\"twitter:creator\" content=\"@VikasBansal1989\" />\n<meta name=\"citation_author\" content=\"Stephen Capone\" />\n<meta name=\"citation_author_institution\" content=\"St. George&#39;s University School of Medicine, St. George&#39;s, Grenada\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7231-1535\" />\n<meta name=\"citation_author\" content=\"John J. Dziak\" />\n<meta name=\"citation_author_institution\" content=\"Edna Bennett Pierce Prevention Research Center, The Pennsylvania State University, University Park, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0762-5495\" />\n<meta name=\"citation_author\" content=\"Yuchen Sun\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America\" />\n<meta name=\"citation_author\" content=\"Yanjun Qi\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5796-7453\" />\n<meta name=\"citation_author\" content=\"Lamonica Shinholster\" />\n<meta name=\"citation_author_institution\" content=\"Mercer University, Macon, GA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-6285-005X\" />\n<meta name=\"citation_author\" content=\"Temitayo Lukan\" />\n<meta name=\"citation_author_institution\" content=\"University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author\" content=\"Sergey Knyazev\" />\n<meta name=\"citation_author_institution\" content=\"Georgia State University, Atlanta, GA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0385-1831\" />\n<meta name=\"twitter:creator\" content=\"@SeKnyaz\" />\n<meta name=\"citation_author\" content=\"Dimitri Perrin\" />\n<meta name=\"citation_author_institution\" content=\"School of Computer Science, Queensland University of Technology, Brisbane, Australia\" />\n<meta name=\"citation_author_institution\" content=\"Centre for Data Science, Queensland University of Technology, Brisbane, Australia\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-4007-5256\" />\n<meta name=\"twitter:creator\" content=\"@dperrin\" />\n<meta name=\"citation_author\" content=\"Serghei Mangul\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-4770-3443\" />\n<meta name=\"twitter:creator\" content=\"@serghei_mangul\" />\n<meta name=\"citation_author\" content=\"Shikta Das\" />\n<meta name=\"citation_author_institution\" content=\"C4X Discovery, London, United Kingdom\" />\n<meta name=\"citation_author_institution\" content=\"Medical Research Council LHA, Institute of Cardiovascular Studies, University College London, London, United Kingdom\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-8291-2788\" />\n<meta name=\"twitter:creator\" content=\"@shikta_das\" />\n<meta name=\"citation_author\" content=\"Gregory L Szeto\" />\n<meta name=\"citation_author_institution\" content=\"Allen Institute for Immunology, Seattle, WA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7604-1333\" />\n<meta name=\"twitter:creator\" content=\"@greg_szeto\" />\n<meta name=\"citation_author\" content=\"Tiago Lubiana\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of S\xE3o Paulo, S\xE3o Paulo, Brazil\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-2473-2313\" />\n<meta name=\"twitter:creator\" content=\"@lubianat\" />\n<meta name=\"citation_author\" content=\"David Mai\" />\n<meta name=\"citation_author_institution\" content=\"Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9238-0164\" />\n<meta name=\"twitter:creator\" content=\"@daveomai\" />\n<meta name=\"citation_author\" content=\"COVID-19 Review Consortium\" />\n<meta name=\"citation_author\" content=\"Rishi Raj Goel\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Immunology, University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"https://orcid.org/0000-0003-1715-5191\" />\n<meta name=\"twitter:creator\" content=\"@rishirajgoel\" />\n<link rel=\"canonical\" href=\"https://greenelab.github.io/covid19-review/\" />\n<meta property=\"og:url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta property=\"twitter:url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta name=\"citation_fulltext_html_url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta name=\"citation_pdf_url\" content=\"https://greenelab.github.io/covid19-review/manuscript.pdf\" />\n<link rel=\"alternate\" type=\"application/pdf\" href=\"https://greenelab.github.io/covid19-review/manuscript.pdf\" />\n<link rel=\"alternate\" type=\"text/html\" href=\"https://greenelab.github.io/covid19-review/v/3564964529462913b8e9eb1a153f2e830073267f/\" />\n<meta name=\"manubot_html_url_versioned\" content=\"https://greenelab.github.io/covid19-review/v/3564964529462913b8e9eb1a153f2e830073267f/\" />\n<meta name=\"manubot_pdf_url_versioned\" content=\"https://greenelab.github.io/covid19-review/v/3564964529462913b8e9eb1a153f2e830073267f/manuscript.pdf\" />\n<meta property=\"og:type\" content=\"article\" />\n<meta property=\"twitter:card\" content=\"summary_large_image\" />\n<meta property=\"og:image\" content=\"https://github.com/greenelab/covid19-review/raw/3564964529462913b8e9eb1a153f2e830073267f/content/images/thumbnail.png\" />\n<meta property=\"twitter:image\" content=\"https://github.com/greenelab/covid19-review/raw/3564964529462913b8e9eb1a153f2e830073267f/content/images/thumbnail.png\" />\n<link rel=\"icon\" type=\"image/png\" sizes=\"192x192\" href=\"https://manubot.org/favicon-192x192.png\" />\n<link rel=\"mask-icon\" href=\"https://manubot.org/safari-pinned-tab.svg\" color=\"#ad1457\" />\n<meta name=\"theme-color\" content=\"#ad1457\" />\n<!-- end Manubot generated metadata -->"
keywords:
- covid-19
- coronavirus
- pandemic
- viral infection
lang: en-US
manubot-clear-requests-cache: false
manubot-output-bibliography: output/references.json
manubot-output-citekeys: output/citations.tsv
manubot-requests-cache-path: ci/cache/requests-cache
title: 'SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics'
...






<small><em>
This manuscript
([permalink](https://greenelab.github.io/covid19-review/v/3564964529462913b8e9eb1a153f2e830073267f/))
was automatically generated
from [greenelab/covid19-review@3564964](https://github.com/greenelab/covid19-review/tree/3564964529462913b8e9eb1a153f2e830073267f)
on February 5, 2021.
</em></small>

<!-- include the Font Awesome library, per: https://fontawesome.com/start -->
<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.13.0/css/all.css">
[
[]{.fas .fa-info-circle .fa-lg} **This in progress manuscript is not intended for the general public.**<br>
This is a review paper that is authored by scientists for an audience of scientists to discuss research that is in progress.
If you are interested in guidelines on testing, therapies, or other issues related to your health, you should not use this document.
Instead, you should collect information from your local health department, the [CDC's guidance](https://www.cdc.gov/coronavirus/2019-ncov/index.html), or your own government.
]{.banner .lightred}

## Authors {.unnumbered}



+ **Halie M. Rando**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-7688-1770](https://orcid.org/0000-0001-7688-1770) · ![GitHub icon](images/github.svg){.inline_icon}
    [rando2](https://github.com/rando2) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [tamefoxtime](https://twitter.com/tamefoxtime)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, United States of America
     · Funded by the Gordon and Betty Moore Foundation (GBMF 4552)
  </small>

+ **Casey S. Greene**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-8713-9213](https://orcid.org/0000-0001-8713-9213) · ![GitHub icon](images/github.svg){.inline_icon}
    [cgreene](https://github.com/cgreene) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [GreeneScientist](https://twitter.com/GreeneScientist)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Childhood Cancer Data Lab, Alex's Lemonade Stand Foundation, Philadelphia, Pennsylvania, United States of America; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, United States of America; Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, United States of America
     · Funded by the Gordon and Betty Moore Foundation (GBMF 4552); the National Human Genome Research Institute (R01 HG010067)
  </small>

+ **Michael P. Robson**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-4859-0033](https://orcid.org/0000-0002-4859-0033) · ![GitHub icon](images/github.svg){.inline_icon}
    [mprobson](https://github.com/mprobson)<br>
  <small>
     Department of Computing Sciences, Villanova University, Villanova, Pennsylvania, United States of America
  </small>

+ **Simina M. Boca**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-1400-3398](https://orcid.org/0000-0002-1400-3398) · ![GitHub icon](images/github.svg){.inline_icon}
    [SiminaB](https://github.com/SiminaB)<br>
  <small>
     Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, District of Columbia, United States of America
  </small>

+ **Nils Wellhausen**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-8955-7582](https://orcid.org/0000-0001-8955-7582) · ![GitHub icon](images/github.svg){.inline_icon}
    [nilswellhausen](https://github.com/nilswellhausen)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
  </small>

+ **Ronan Lordan**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-9668-3368](https://orcid.org/0000-0001-9668-3368) · ![GitHub icon](images/github.svg){.inline_icon}
    [RLordan](https://github.com/RLordan) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [el_ronan](https://twitter.com/el_ronan)<br>
  <small>
     Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5158, USA
  </small>

+ **Christian Brueffer**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-3826-0989](https://orcid.org/0000-0002-3826-0989) · ![GitHub icon](images/github.svg){.inline_icon}
    [cbrueffer](https://github.com/cbrueffer) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [cbrueffer](https://twitter.com/cbrueffer)<br>
  <small>
     Department of Clinical Sciences, Lund University, Lund, Sweden
  </small>

+ **Sandipan Ray**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-9960-5768](https://orcid.org/0000-0002-9960-5768) · ![GitHub icon](images/github.svg){.inline_icon}
    [rays1987](https://github.com/rays1987)<br>
  <small>
     Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy 502285, Telangana, India
  </small>

+ **Lucy D\'Agostino McGowan**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-7297-9359](https://orcid.org/0000-0001-7297-9359) · ![GitHub icon](images/github.svg){.inline_icon}
    [LucyMcGowan](https://github.com/LucyMcGowan) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [LucyStats](https://twitter.com/LucyStats)<br>
  <small>
     Department of Mathematics and Statistics, Wake Forest University, Winston-Salem, North Carolina, United States of America
  </small>

+ **Anthony Gitter**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-5324-9833](https://orcid.org/0000-0002-5324-9833) · ![GitHub icon](images/github.svg){.inline_icon}
    [agitter](https://github.com/agitter) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [anthonygitter](https://twitter.com/anthonygitter)<br>
  <small>
     Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Morgridge Institute for Research, Madison, Wisconsin, United States of America
     · Funded by John W. and Jeanne M. Rowe Center for Research in Virology
  </small>

+ **Anna Ada Dattoli**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-1462-831X](https://orcid.org/0000-0003-1462-831X) · ![GitHub icon](images/github.svg){.inline_icon}
    [aadattoli](https://github.com/aadattoli) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [aadattoli](https://twitter.com/aadattoli)<br>
  <small>
     Department of Systems Pharmacology & Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  </small>

+ **Ryan Velazquez**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-3655-3403](https://orcid.org/0000-0002-3655-3403) · ![GitHub icon](images/github.svg){.inline_icon}
    [rdvelazquez](https://github.com/rdvelazquez)<br>
  <small>
     Azimuth1, McLean, VA
  </small>

+ **John P. Barton**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-1467-421X](https://orcid.org/0000-0003-1467-421X) · ![GitHub icon](images/github.svg){.inline_icon}
    [johnbarton](https://github.com/johnbarton) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [_jpbarton](https://twitter.com/_jpbarton)<br>
  <small>
     Department of Physics and Astronomy, University of California-Riverside, Riverside, California, United States of America
  </small>

+ **Jeffrey M. Field**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-7161-7284](https://orcid.org/0000-0001-7161-7284) · ![GitHub icon](images/github.svg){.inline_icon}
    [Jeff-Field](https://github.com/Jeff-Field)<br>
  <small>
     Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  </small>

+ **Bharath Ramsundar**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-8450-4262](https://orcid.org/0000-0001-8450-4262) · ![GitHub icon](images/github.svg){.inline_icon}
    [rbharath](https://github.com/rbharath) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [rbhar90](https://twitter.com/rbhar90)<br>
  <small>
     The DeepChem Project, https://deepchem.io/
  </small>

+ **Adam L. MacLean**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-0689-7907](https://orcid.org/0000-0003-0689-7907) · ![GitHub icon](images/github.svg){.inline_icon}
    [alavendelm](https://github.com/alavendelm) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [adamlmaclean](https://twitter.com/adamlmaclean)<br>
  <small>
     Department of Biological Sciences, University of Southern California, Los Angeles, California, United States of America
  </small>

+ **Alexandra J. Lee**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-0208-3730](https://orcid.org/0000-0002-0208-3730) · ![GitHub icon](images/github.svg){.inline_icon}
    [ajlee21](https://github.com/ajlee21)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
     · Funded by the Gordon and Betty Moore Foundation (GBMF 4552)
  </small>

+ **Immunology Institute of the Icahn School of Medicine**<br> · ![GitHub icon](images/github.svg){.inline_icon}
    [ismms-himc](https://github.com/ismms-himc)<br>
  <small>
     Immunology Institute of the Icahn School of Medicine
  </small>

+ **Fengling Hu**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-1081-5038](https://orcid.org/0000-0003-1081-5038) · ![GitHub icon](images/github.svg){.inline_icon}
    [hufengling](https://github.com/hufengling) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [hufengling](https://twitter.com/hufengling)<br>
  <small>
     Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
  </small>

+ **Nafisa M. Jadavji**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-3557-7307](https://orcid.org/0000-0002-3557-7307) · ![GitHub icon](images/github.svg){.inline_icon}
    [nafisajadavji](https://github.com/nafisajadavji) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [nafisajadavji](https://twitter.com/nafisajadavji)<br>
  <small>
     Biomedical Science, Midwestern University, Glendale, AZ, United States of America; Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada
     · Funded by the American Heart Association (20AIREA35050015)
  </small>

+ **Elizabeth Sell**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-9658-1107](https://orcid.org/0000-0002-9658-1107) · ![GitHub icon](images/github.svg){.inline_icon}
    [esell17](https://github.com/esell17)<br>
  <small>
     Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
  </small>

+ **Jinhui Wang**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-5796-8130](https://orcid.org/0000-0002-5796-8130) · ![GitHub icon](images/github.svg){.inline_icon}
    [jinhui2](https://github.com/jinhui2)<br>
  <small>
     Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
  </small>

+ **Diane N. Rafizadeh**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-2838-067X](https://orcid.org/0000-0002-2838-067X) · ![GitHub icon](images/github.svg){.inline_icon}
    [dianerafi](https://github.com/dianerafi)<br>
  <small>
     Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
     · Funded by NIH Medical Scientist Training Program T32 GM07170
  </small>

+ **Ashwin N. Skelly**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-1565-3376](https://orcid.org/0000-0002-1565-3376) · ![GitHub icon](images/github.svg){.inline_icon}
    [anskelly](https://github.com/anskelly)<br>
  <small>
     Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America
     · Funded by NIH Medical Scientist Training Program T32 GM07170
  </small>

+ **Marouen Ben Guebila**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-5934-966X](https://orcid.org/0000-0001-5934-966X) · ![GitHub icon](images/github.svg){.inline_icon}
    [marouenbg](https://github.com/marouenbg) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [marouenbg](https://twitter.com/marouenbg)<br>
  <small>
     Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America
  </small>

+ **Likhitha Kolla**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-1169-906X](https://orcid.org/0000-0002-1169-906X) · ![GitHub icon](images/github.svg){.inline_icon}
    [likhithakolla](https://github.com/likhithakolla) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [lkolla2018](https://twitter.com/lkolla2018)<br>
  <small>
     Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
     · Funded by NIH Medical Scientist Training Program T32 GM07170
  </small>

+ **David Manheim**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-8599-8380](https://orcid.org/0000-0001-8599-8380) · ![GitHub icon](images/github.svg){.inline_icon}
    [davidmanheim](https://github.com/davidmanheim) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [davidmanheim](https://twitter.com/davidmanheim)<br>
  <small>
     1DaySooner, Delaware, United States of America; Risk and Health Communication Research Center, School of Public Health, University of Haifa, Haifa, Israel
  </small>

+ **Soumita Ghosh**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-2783-2750](https://orcid.org/0000-0002-2783-2750) · ![GitHub icon](images/github.svg){.inline_icon}
    [soumitagh](https://github.com/soumitagh)<br>
  <small>
     Institute of Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
  </small>

+ **James Brian Byrd**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-0509-3520](https://orcid.org/0000-0002-0509-3520) · ![GitHub icon](images/github.svg){.inline_icon}
    [byrdjb](https://github.com/byrdjb) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [thebyrdlab](https://twitter.com/thebyrdlab)<br>
  <small>
     University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America
     · Funded by NIH K23HL128909; FastGrants
  </small>

+ **YoSon Park**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-0465-4744](https://orcid.org/0000-0002-0465-4744) · ![GitHub icon](images/github.svg){.inline_icon}
    [ypar](https://github.com/ypar) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [__yoson__](https://twitter.com/__yoson__)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
     · Funded by NHGRI R01 HG10067
  </small>

+ **Vikas Bansal**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-0944-7226](https://orcid.org/0000-0002-0944-7226) · ![GitHub icon](images/github.svg){.inline_icon}
    [bansalvi](https://github.com/bansalvi) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [VikasBansal1989](https://twitter.com/VikasBansal1989)<br>
  <small>
     Biomedical Data Science and Machine Learning Group, German Center for Neurodegenerative Diseases, Tübingen 72076, Germany
  </small>

+ **Stephen Capone**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-7231-1535](https://orcid.org/0000-0001-7231-1535) · ![GitHub icon](images/github.svg){.inline_icon}
    [scapone01](https://github.com/scapone01)<br>
  <small>
     St. George's University School of Medicine, St. George's, Grenada
  </small>

+ **John J. Dziak**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-0762-5495](https://orcid.org/0000-0003-0762-5495) · ![GitHub icon](images/github.svg){.inline_icon}
    [dziakj1](https://github.com/dziakj1)<br>
  <small>
     Edna Bennett Pierce Prevention Research Center, The Pennsylvania State University, University Park, PA, United States of America
  </small>

+ **Yuchen Sun**<br> · ![GitHub icon](images/github.svg){.inline_icon}
    [kevinsunofficial](https://github.com/kevinsunofficial)<br>
  <small>
     Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America
  </small>

+ **Yanjun Qi**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-5796-7453](https://orcid.org/0000-0002-5796-7453) · ![GitHub icon](images/github.svg){.inline_icon}
    [qiyanjun](https://github.com/qiyanjun)<br>
  <small>
     Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America
  </small>

+ **Lamonica Shinholster**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-6285-005X](https://orcid.org/0000-0001-6285-005X) · ![GitHub icon](images/github.svg){.inline_icon}
    [LSH2126](https://github.com/LSH2126)<br>
  <small>
     Mercer University, Macon, GA, United States of America
     · Funded by the Center for Global Genomics and Health Equity at the University of Pennsylvania
  </small>

+ **Temitayo Lukan**<br> · ![GitHub icon](images/github.svg){.inline_icon}
    [tlukan](https://github.com/tlukan)<br>
  <small>
     University of Pennsylvania, Philadelphia, PA, United States of America
  </small>

+ **Sergey Knyazev**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-0385-1831](https://orcid.org/0000-0003-0385-1831) · ![GitHub icon](images/github.svg){.inline_icon}
    [Sergey-Knyazev](https://github.com/Sergey-Knyazev) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [SeKnyaz](https://twitter.com/SeKnyaz)<br>
  <small>
     Georgia State University, Atlanta, GA, United States of America
  </small>

+ **Dimitri Perrin**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-4007-5256](https://orcid.org/0000-0002-4007-5256) · ![GitHub icon](images/github.svg){.inline_icon}
    [SystemsResearch](https://github.com/SystemsResearch) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [dperrin](https://twitter.com/dperrin)<br>
  <small>
     School of Computer Science, Queensland University of Technology, Brisbane, Australia; Centre for Data Science, Queensland University of Technology, Brisbane, Australia
  </small>

+ **Serghei Mangul**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-4770-3443](https://orcid.org/0000-0003-4770-3443) · ![GitHub icon](images/github.svg){.inline_icon}
    [smangul1](https://github.com/smangul1) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [serghei_mangul](https://twitter.com/serghei_mangul)<br>
  <small>
     Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA, United States of America
  </small>

+ **Shikta Das**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-8291-2788](https://orcid.org/0000-0002-8291-2788) · ![GitHub icon](images/github.svg){.inline_icon}
    [shiktadas](https://github.com/shiktadas) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [shikta_das](https://twitter.com/shikta_das)<br>
  <small>
     C4X Discovery, London, United Kingdom; Medical Research Council LHA, Institute of Cardiovascular Studies, University College London, London, United Kingdom
  </small>

+ **Gregory L Szeto**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-7604-1333](https://orcid.org/0000-0001-7604-1333) · ![GitHub icon](images/github.svg){.inline_icon}
    [gregszetoAI](https://github.com/gregszetoAI) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [greg_szeto](https://twitter.com/greg_szeto)<br>
  <small>
     Allen Institute for Immunology, Seattle, WA, United States of America
  </small>

+ **Tiago Lubiana**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-2473-2313](https://orcid.org/0000-0003-2473-2313) · ![GitHub icon](images/github.svg){.inline_icon}
    [lubianat](https://github.com/lubianat) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [lubianat](https://twitter.com/lubianat)<br>
  <small>
     Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
  </small>

+ **David Mai**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-9238-0164](https://orcid.org/0000-0002-9238-0164) · ![GitHub icon](images/github.svg){.inline_icon}
    [davemai](https://github.com/davemai) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [daveomai](https://twitter.com/daveomai)<br>
  <small>
     Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA
  </small>

+ **COVID-19 Review Consortium**<br><br>
  <small>
  </small>

+ **Rishi Raj Goel**<br> ![ORCID icon](images/orcid.svg){.inline_icon}
    [https://orcid.org/0000-0003-1715-5191](https://orcid.org/https://orcid.org/0000-0003-1715-5191) · ![GitHub icon](images/github.svg){.inline_icon}
    [rishirajgoel](https://github.com/rishirajgoel) · ![Twitter icon](images/twitter.svg){.inline_icon}
    [rishirajgoel](https://twitter.com/rishirajgoel)<br>
  <small>
     Institute for Immunology, University of Pennsylvania, Philadelphia, PA, United States of America
  </small>



**COVID-19 Review Consortium:**
Vikas Bansal, John P. Barton, Simina M. Boca, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Fengling Hu, Nafisa M. Jadavji, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D\'Agostino McGowan, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Gregory L Szeto, Ryan Velazquez, Jinhui Wang, Nils Wellhausen


Authors are ordered arbitrarily.


## Abstract {.page_break_before .unnumbered}
Since late 2019, Coronavirus disease 2019 (COVID-19) has spread around the world, resulting in the declaration of a pandemic by the World Health Organization (WHO).
This infectious disease is caused by the newly identified _Severe acute respiratory syndrome-related coronavirus 2_ (SARS-CoV-2).
Research on the SARS-CoV-2 virus and the disease it causes is emerging rapidly through global scientific efforts.
Short-term mitigation of viral impacts will require public health interventions, and long-term mitigation will require new diagnostic and therapeutic technologies.
The urgency of the pandemic has led to a rapidly emerging scientific literature on SARS-CoV-2 and COVID-19.
This manuscript represents a collaborative effort to organize and consolidate this body of literature.
We present information about the virus in the context of what is known about related viruses, describe the pathogenesis of COVID-19, and synthesize studies emerging about the diagnosis and treatment of COVID-19 alongside literature about related illnesses.
We summarize this emerging literature with an eye towards discussing elements of the disease that will be fundamental to efforts to develop interventions.
Our review is a collaboratively-authored, evolving document into which we seek to incorporate the ever-expanding body of information on the topic.
This document provides a snapshot as of October, 2020.
We continue to accept new contributions and anticipate future snapshots until technologies to mitigate the pandemic are widely deployed.

## How to Contribute {.unnumbered}

We invite potential contributors to introduce themselves through GitHub: [https://github.com/greenelab/covid19-review/issues/17](https://github.com/greenelab/covid19-review/issues/17)

We have established a community chat room on a service called Gitter: [https://gitter.im/covid19-review/community](https://gitter.im/covid19-review/community)

More information about how to contribute is available in a README document on GitHub: [https://github.com/greenelab/covid19-review#sars-cov-2-and-covid-19-an-evolving-review-of-diagnostics-and-therapeutics](https://github.com/greenelab/covid19-review#sars-cov-2-and-covid-19-an-evolving-review-of-diagnostics-and-therapeutics)


## Introduction {.page_break_before}

On January 21, 2020, the World Health Organization (WHO) released its first report concerning what is now known as the Coronavirus Disease 2019 (COVID-19) [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf].
This infectious disease came to international attention on December 31, 2019 following an announcement by national officials in China describing 44 cases of a respiratory infection of unknown cause.
The first known cases were located in Wuhan City within the Hubei province of China, but the disease spread rapidly throughout China and subsequently around the world.
At the time of the WHO's first situation report [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf], 282 confirmed cases had been identified.
Most of these cases were in China, but one to two exported cases had also been identified in each of several neighboring countries (Thailand, Japan, and the Republic of Korea).
One week later, 4,593 confirmed cases had been identified, spanning not only Asia, but also Australia, North America, and Europe [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200128-sitrep-8-ncov-cleared.pdf].
On March 11, 2020, the WHO formally classified the situation as a pandemic [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf].
On April 4, 2020, the WHO reported that the global number of confirmed cases had surpassed one million [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200404-sitrep-75-covid-19.pdf].
<!--2,268,797 COVID-19 deaths had been reported worldwide as of February 3, 2021 (Figure @fig:csse-deaths).

![
**Cumulative global COVID-19 deaths since January 22, 2020.**
Data are from the COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University [@https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series].
](https://github.com/greenelab/covid19-review/raw/f91dbd581fcd3ac53f8247db97e52c9c10bcebec/csse/csse-deaths.svg "Global COVID-19 deaths"){#fig:csse-deaths secno=1} -->

As international attention remains focused on the ongoing public health crisis, the scientific community has responded by mobilizing resources and turning much of its attention to the virus and disease.
This rapid influx of information is disseminated by traditional publishing mechanisms, preprint servers, and press releases, which provide a venue for scientists to release findings without undergoing the formal publication process.
While having information available is valuable to efforts to understand and combat COVID-19, many contributions come from researchers across a wide range of fields who have varying degrees of experience working on coronaviruses and related topics.
The volume of information available, much of which has not gone through rigorous peer review, presents a significant challenge to individual efforts to keep abreast of the state of COVID-19 research [@doi:10.1038/s42254-020-0175-7].
However, research on these topics is proceeding so rapidly that any static review is likely to quickly become dated.
Our goal as a community is to consolidate information about the virus in the context of related viruses and to synthesize rapidly emerging literature centered on the diagnosis and treatment of COVID-19.
We used an open publishing framework, Manubot [@doi:10.1371/journal.pcbi.1007128], to manage hundreds of contributions from the community to create a living, scholarly document.
We designed software to generate figures, such as <!--Figure @fig:csse-deaths-->, that automatically update using external data sources.
Our primary goal is to sort and distill informative content out of the overwhelming flood of information [@doi:10.1038/s42254-020-0175-7] and help the broader scientific community become more conversant on this critical subject.
Thus, our approach has been to develop a real-time, collaborative effort that welcomes submissions from scientists worldwide into this ongoing effort.
This document represents the first snapshot, which aims to reflect the state of the field as of October, 2020.
We plan to refine and expand this document until technologies to mitigate the pandemic are widely available.

### Interdisciplinary Context

Collaboration across several broad areas of research is critical, as different areas provide different information and context necessary to understanding the virus and disease.
This review provides a biological perspective on the virus _Severe acute respiratory syndrome-related coronavirus 2_ (SARS-CoV-2) and efforts to develop diagnostic, prophylactic, and therapeutic responses to COVID-19.
We provide only brief summaries of two other important perspectives on this pandemic: epidemiology and public health.
Research in these areas often seeks to anticipate, model, and prevent outbreaks of infectious disease or to understand and manage human behavior relevant to health and disease.
Their insights are critical to mounting a global response to the pandemic.
Epidemiological analyses have investigated patterns of transmission within and between communities, the symptoms associated with and the duration of infection and/or contagiousness, and how the virus propagates, among other characteristics [@url:https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/about-epidemiology/index.html].
Epidemiology also has a close relationship to public policy because it provides model-based insights into how preventative measures and public response can shift outcomes [@url:https://covid19.healthdata.org/united-states-of-america].
Public health addresses social and human factors influencing individuals' exposure and susceptibility to pathogens, such as resource availability, inequality, human behavior, and access to accurate information.
Strategies from public health and epidemiology for managing the current epidemic have included the promotion of hand hygiene, social distancing, and personal protective equipment such as masks to mitigate spread, as well as containment approaches such as test, trace, and isolate, which depends on widespread testing, contact tracing, and quarantining.
An effective public health management strategy involves response coordination, disease surveillance, intervention monitoring, risk communication, and health education (including the containment of “infodemics” of false information) [@isbn:978-92-4-156553-0].
Epidemiology and public health intersect with the topics addressed in this manuscript because they both inform and benefit from relevant biotechnological developments.
For example, the development of accurate and fast diagnostic testing is relevant to test, trace, and isolate strategies for containment, and public education will be critical to deploying vaccines once they become available.
The present analysis focuses less on human and social factors and more on the basic biology of infection, diagnosis, and recovery, but these areas are inextricable in understanding and responding to the COVID-19 pandemic.

### Initial Characterization of SARS-CoV-2

The first genome sequence of the virus was released on January 3, 2020 and revealed that the cluster of pneumonia cases seen in Wuhan were caused by a novel coronavirus [@doi:10.46234/ccdcw2020.017].
Multiple research groups have drafted the genome sequence of SARS-CoV-2 based on sequences developed from clinical samples collected from the lower respiratory tract, namely bronchoalveolar lavage fluid (BALF), and the upper respiratory tract, in the form of throat swabs [@doi:10.1038/s41586-020-2008-3; @doi:10.1038/s41586-020-2012-7; @doi:10/ggjr43].
Analysis of the SARS-CoV-2 genome revealed significant sequence homology with two coronaviruses known to infect humans, with about 79% identity to SARS-CoV-1 and 50% to MERS-CoV [@doi:10/ggjr43].
However, the highest degree of similarity was observed between SARS-CoV-2 and bat-derived SARS-like coronaviruses (bat-SL-CoVZC45 and bat-SL-CoVZXC21) [@doi:10/ggjr43; @doi:10.1038/s41586-020-2012-7], with identity between SARS-CoV-2 and RATG13 as high as 96.2% [@doi:10.1038/s41586-020-2012-7; @doi:10.1093/nsr/nwaa036].
This evidence therefore suggests the SARS-CoV-2 virus is the result of zoonotic transfer of a virus from bats to humans.
Nevertheless, some fragments between SARS-CoV-2 and RATG13 differ by up to 17%, suggesting a complex natural selection process during zoonotic transfer.
While the _S_ region is highly similar to that of viruses found in pangolins [@doi:10.1101/2020.02.19.950253], there is no consensus about the origin of _S_ in SARS-CoV-2, as it could potentially be the result either of recombination or coevolution [@doi:10.1093/nsr/nwaa036; @doi:10.1126/sciadv.abb9153].
Though the intermediate host serving as the source for the zoonotic introduction of SARS-CoV-2 to human populations has not yet been identified, the SARS-CoV-2 virus has been placed within the coronavirus phylogeny through comparative genomic analyses.
Genomic analyses and comparisons to other known coronaviruses suggest that SARS-CoV-2 is unlikely to have originated in a laboratory -- either purposely engineered and released, or escaped -- and instead evolved naturally in an animal host [@doi:10.1038/s41591-020-0820-9].
While the position of the SARS-CoV-2 virus within the coronavirus phylogeny has been largely resolved, the functional consequences of molecular variation between this virus and other viruses, such as its bat and pangolin sister taxa or SARS-CoV-1, remain unknown [@doi:10.1038/s41591-020-0820-9, @doi:10.1038/s41586-020-2012-7].
Fortunately, the basic genome structure of coronaviruses is highly conserved, and insight into the mechanisms the virus uses to enter cells, replicate, and spread is likely to be available from prior research in coronaviruses.

### Coronaviruses and Humans Hosts

Coronaviruses have long been known to infect animals and have been the subject of veterinary medical investigations and vaccine development efforts due to their effect on the health of companion and agricultural animals [@doi:10/ckfn8b].
Most coronaviruses show little to no transmission in humans.
However, today it is thought that approximately one-third of common cold infections are caused by four human coronaviruses (HCoV): _Human coronavirus 229E_ (HCoV-229E), _Human coronavirus NL63_ (HCoV-NL63), _Human coronavirus OC43_ (HCoV-OC43), and _Human coronavirus HKU1_ (HCoV-HKU1) [@doi:10.1038/s41579-018-0118-9; @doi:10.3390/diseases4030026].
The first HCoV were identified in the 1960s: HCoV-229E in 1965 [@doi:10.3181/00379727-121-30734] and HCoV-OC43 in 1967 [@doi:10.1073/pnas.57.4.933].
Both of these viruses cause cold-like symptoms [@doi:10.1186/1743-422X-1-7; @pmid:20700397].
Two additional HCoV were subsequently identified [@doi:10.1038/nm1024; @doi:10.1128/JVI.79.2.884-895.2005].
In 2003, HCoV-NL63 [@doi:10.1038/nm1024] was first identified in a 7-month-old infant and then in clinical specimens collected from seven additional patients, five of whom were infants younger than 1 year old and the remainder of whom were adults.
CoV-HKU1 was identified in samples collected from a 71-year-old pneumonia patient in 2004 and then found in samples collected from a second adult patient [@doi:10.1128/JVI.79.2.884-895.2005].
These viruses are associated with respiratory diseases of varying severity, ranging from common cold to severe pneumonia, with severe symptoms mostly observed in immunocompromised individuals [@doi:10.1086/377612].
In addition to these relatively mild HCoV, however, highly pathogenic human coronaviruses have been identified, including _Severe acute respiratory syndrome-related coronavirus_ (SARS-CoV or SARS-CoV-1) and _Middle East respiratory syndrome-related coronavirus_ (MERS-CoV) [@doi:10.1038/nrmicro.2016.81; @doi:10.1038/s41579-018-0118-9; @doi:10.1016/bs.aivir.2018.01.001].

At the time that SARS-CoV-1 emerged in the early 2000s, no HCoV had been identified in almost 40 years [@doi:10.1038/nrmicro.2016.81].
The first case of SARS was reported in November 2002 in the Guangdong Province of China, and over the following month, the disease spread more widely within China and then into several countries across multiple continents [@doi:10.1093/ajcp/aqaa029; @doi:10.1038/nrmicro.2016.81].
Unlike previously identified HCoV, SARS was much more severe, with an estimated death rate of 9.5% [@doi:10.1093/ajcp/aqaa029].
It was also highly contagious via droplet transmission, with a basic reproduction number (R~0~) of 4 (i.e., each person infected was estimated to infect four other people) [@doi:10.1093/ajcp/aqaa029].
However, the identity of the virus behind the infection remained unknown until April of 2003, when the SARS-CoV-1 virus was identified through a worldwide scientific effort spearheaded by the WHO [@doi:10.1038/nrmicro.2016.81].
SARS-CoV-1 belonged to a distinct lineage from the two other HCoV known at the time [@doi:10.1093/ajcp/aqaa029].
By July 2003, the SARS outbreak was officially determined to be under control, with the success credited to infection management practices [@doi:10.1038/nrmicro.2016.81].
A decade later, a second outbreak of severe respiratory illness associated with a coronavirus emerged, this time in the Arabian Peninsula.
This disease, known as Middle East respiratory syndrome (MERS), was linked to another novel coronavirus, MERS-CoV.
The fatality rate associated with MERS is much higher than that of SARS, at almost 35%, but the disease is much less easily transmitted, with an R~0~ of 1 [@doi:10.1093/ajcp/aqaa029].
Although MERS is still circulating, its low reproduction number has allowed for its spread to be contained [@doi:10.1093/ajcp/aqaa029].
The COVID-19 pandemic is thus associated with the seventh HCoV to be identified and the fifth since the turn of the millennium, though additional HCoVs may be in circulation but remain undetected.

SARS-CoV-1 and MERS-CoV were ultimately managed largely through infection management practices (e.g., mask wearing) and properties of the virus itself (i.e., low rate of transmission), respectively [@doi:10.1038/nrmicro.2016.81; @doi:10.1093/ajcp/aqaa029].
Vaccines were not used to control either virus, although vaccine development programs were established for SARS-CoV-1 [@doi:10.3390/v11010059].
In general, care for SARS and MERS patients focuses on supportive care and symptom management [@doi:10.1093/ajcp/aqaa029].
Clinical treatments for SARS and MERS developed during the outbreaks generally do not have strong evidence supporting their use.
Common treatments included Ribavirin, an antiviral, often in combination with corticosteroids or sometimes interferon (IFN) medications, which would both be expected to have immunomodulatory effects [@doi:10.1038/nrmicro.2016.81].
However, retrospective and _in vitro_ analyses have reported inconclusive results of these treatments on SARS and the SARS-CoV-1 virus, respectively [@doi:10.1038/nrmicro.2016.81].
IFNs and Ribavirin have shown promise in _in vitro_ analyses of MERS, but their clinical effectiveness remains unknown [@doi:10.1038/nrmicro.2016.81].
Therefore, only limited strategy for the pharmaceutical management of COVID-19 can be adopted from previous severe HCoV infections.
Research in response to prior outbreaks of HCoV-borne infections, such as SARS and MERS, have, however, provided a strong foundation for hypotheses about the pathogenesis of SARS-CoV-2 as well as potential diagnostic and therapeutic approaches.

#### Human Immune Response to Viral Threats

Understanding the fundamental organization of the human immune response to viral threats is critical to understanding the varied response to SARS-CoV-2.
The human immune system utilizes a variety of innate and adaptive responses to protect against the pathogens it encounters.
The innate immune system consists of barriers, such as the skin, mucous secretions, neutrophils, macrophages, and dendritic cells.
It also includes cell-surface receptors that can recognize the molecular patterns of pathogens.
The adaptive immune system utilizes antigen-specific receptors that are expressed on B and T lymphocytes.
These components of the immune system typically act together; the innate response acts first, and the adaptive response begins to act several days after initial infection following the clonal expansion of T and B cells [@doi:10.1016/j.jaci.2005.09.034].
After a virus enters into a host cell, its antigen is presented by major histocompatibility complex 1 (MHC 1) molecules and is then recognized by cytotoxic T lymphocytes.

In the case of COVID-19, there is also concern about the immune system becoming over-active.
One of the main immune responses contributing to the onset of acute respiratory distress syndrome (ARDS) in COVID-19 patients is cytokine storm syndrome (CSS), which causes an extreme inflammatory response due to a release of pro-inflammatory cytokines and chemokines by immune effector cells.
In addition to respiratory distress, this mechanism can lead to organ failure and death in severe COVID-19 cases [@doi:10.1016/j.jpha.2020.03.001].
Details of how the human body responds to SARS-CoV-2, both in healthy and pathological ways, and how these mechanisms can inform the identification of diagnostic, prophylactic, and therapeutic responses are explored in detail throughout this manuscript.

#### Clinical Presentation of COVID-19

A great diversity of symptom profiles has been observed for COVID-19, although a large study from Wuhan, China suggests fever and cough as the two most common symptoms on admission [@doi:10.1056/NEJMoa2002032].
One early retrospective study in China described the clinical presentations of patients infected with SARS-CoV-2 as including lower respiratory tract infection with fever, dry cough, and dyspnea [@doi:10/ggnxb3].
This study [@doi:10/ggnxb3] noted that upper respiratory tract symptoms were less common, which suggests that the virus targets cells located in the lower respiratory tract.
However, data from the New York City region [@doi:10.1001/jama.2020.6775; @doi:10.1056/NEJMc2010419] showed variable rates of fever as a presenting symptom, suggesting that symptoms may not be consistent across samples.
These differences are present when comparing both between institutions in similar locations and between different regions experiencing COVID-19 outbreaks, leading to conflicting reports of the frequency of fever as a presenting symptom for patients upon hospital admission.
For example, even within New York City, one study [@doi:10.1001/jama.2020.6775] identified low oxygen saturation (<90% without the use of supplemental oxygen or ventilation support) in a significant percentage of patients upon presentation, while another study [@doi:10.1056/NEJMc2010419] reported cough, fever, and dyspnea as the most common presenting symptoms.
The variability of both which symptoms present and their severity makes it difficult for public health agencies to provide clear recommendations for citizens regarding what symptoms indicate SARS-CoV-2 infection and should prompt isolation.

### Role of the COVID-19 Review

<!--![**Summary of the relationships among topics covered in this review.**](images/N000-overview.png){#fig:overview secno=1}-->

Several review articles on aspects of COVID-19 have already been published.
These have included reviews on the disease epidemiology [@doi:10.1016/j.molmed.2020.02.008], immunological response [@doi:10.1016/j.immuni.2020.05.002], diagnostics [@doi:10.1126/scitranslmed.abc1931], and pharmacological treatments [@doi:10.1016/j.immuni.2020.05.002; @doi:10.1001/jama.2020.6019].
Others [@doi:10.1038/d41591-020-00026-w; @doi:10.1001/jama.2020.12839] provide narrative reviews of progress on some important ongoing COVID-19 research questions.
With the worldwide scientific community uniting during 2020 to investigate SARS-CoV-2 and COVID-19 from a wide range of perspectives, findings from many disciplines are relevant on a rapid timescale to a broad scientific audience.
Additionally, many findings are published as preprints, which are available prior to going through the peer review process.
As a result, centralizing, summarizing, and critiquing new literature broadly relevant to COVID-19 can help to expedite the interdisciplinary scientific process that is currently happening at an advanced pace.
We are particularly interested in providing background to the development of diagnostic, prophylactic, and therapeutic approaches to COVID-19.
Two major concerns within diagnosis include the detection of current infections in individuals with and without symptoms, and the detection of past exposure without an active infection.
In the latter category, identifying whether individuals can develop or have developed sustained immunity is also a major consideration.
The development of high-throughput, affordable methods for detecting active infections and sustained immunity will be critical to understanding and controlling the disease.
The identification of interventions that can mitigate the effect of the virus on exposed and infected individuals is a significant research priority.
Some possible approaches include the identification of existing pharmaceuticals that reduce the severity of infection, either by reducing the virus' virulence (e.g., antivirals) or managing the most severe symptoms of infection.
Due to the long timeline for the development of novel pharmaceuticals, in most cases, research surrounding possible pharmaceutical interventions focuses on the identification and investigation of existing compounds whose mechanisms may be relevant to COVID-19.
Other foci of current research include the identification of antibodies produced by survivors of COVID-19 and the development of vaccines.
Understanding the mechanisms describing host-virus interactions between humans and SARS-CoV-2 is thus critical to identifying candidate therapeutics.
An overview of the topics covered is visualized in <!--Figure @fig:overview.-->
Thus, in this review, we seek to consolidate information about efforts to develop strategies for diagnosis and therapeutics as new information is released by the scientific community.
We include information from both traditional peer-reviewed scientific literature and from preprints, which typically have not undergone peer review but have been critically evaluated by the scientists involved in this effort.
The goal of this manuscript is to present preliminary findings within the broader context of COVID-19 research and to identify the broad interpretations of new research, as well as limitations to interpretability.


## Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through analysis of Viral Genomics and Structure

### Abstract

The novel coronavirus SARS-CoV-2, which emerged in late 2019, has since spread around the world infecting tens of millions of people with coronavirus disease 2019 (COVID-19).
While this viral species was unknown prior to January 2020, its similarity to other coronaviruses that infect humans has allowed for rapid insight into the mechanisms that it uses to infect human hosts, as well as the ways in which the human immune system can respond.
Here, we contextualize SARS-CoV-2 among other coronaviruses and identify what is known and what can be inferred about its behavior once inside a human host.
Because the genomic content of coronaviruses, which specifies the virus's structure, is highly conserved, early genomic analysis provided a significant head start in predicting viral pathogenesis.
The pathogenesis of the virus offers insights into symptomatology, transmission, and individual susceptibility.
Additionally, prior research into interactions between the human immune system and coronaviruses has identified how these viruses can evade the immune system's protective mechanisms.
We also explore systems-level research into the regulatory and proteomic effects of SARS-CoV-2 infection and the immune response.
Understanding the structure and behavior of the virus serves to contextualize the many facets of the COVID-19 pandemic and can influence efforts to control the virus and treat the disease.

### Importance

COVID-19 involves a number of organ systems and can present with a wide range of symptoms.
Understanding how the virus infects epithelial cells, however, serves to contextualize how these systems connect.
Similarly, while the modes of viral transmission have been under debate throughout much of 2020 and the beginning of 2021, the available research suggests that these patterns are very similar to those seen in the closely related viruses SARS-CoV-1 and possibly MERS-CoV.
Exploring the structure, phylogeny, and pathogenesis of the virus therefore helps to guide interpretation of the broader impacts of the virus on the human body and on human populations.
For this reason, an in-depth exploration of viral mechanisms is critical to a robust understanding of the COVID-19 pandemic.

### Introduction

The current coronavirus disease 2019 (COVID-19) pandemic, caused by the _Severe acute respiratory syndrome-related coronavirus 2_ (SARS-CoV-2) virus, represents an acute global health crisis.
Symptoms of the disease can range from mild to severe or fatal [@url:https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html] and can affect a variety of organs and systems [@doi:10.23750/abm.v91i1.9397].
Outcomes of infection can include acute respiratory distress (ARDS) and acute lung injury, as well as damage to other organ systems [@doi:10.23750/abm.v91i1.9397; @doi:10.1002/ctm2.16].
Understanding the progression of the disease, including these diverse symptoms, depends on understanding how the virus interacts with the host.
Additionally, the fundamental biology of the virus can provide insights into how it is transmitted among people, which can, in turn, inform efforts to control its spread.
As a result, a thorough understanding of the pathogenesis of SARS-CoV-2 is a critical foundation on which to build an understanding of COVID-19 and the pandemic as a whole.

The rapid identification and release of the genomic sequence of the virus in January 2020 [@doi:10.46234/ccdcw2020.017] provided early insight into the virus in a comparative genomic context.
The viral genomic sequence clusters with known coronaviruses (order *Nidovirales*, family *Coronaviridae*, subfamily *Orthocoronavirinae*).
Phylogenetic analysis of the coronaviruses reveals four major subclades, each corresponding to a genus: the alpha, beta, gamma, and delta coronaviruses.
Among them, alpha- and betacoronaviruses infect mammalian species, gammacoronaviruses infect avian species, and deltacoronaviruses infect both mammalian and avian species [@doi:10.1146/annurev-virology-110615-042301].
The novel virus now known as SARS-CoV-2 was identified as a betacoronavirus belonging to the B lineage based on phylogenetic analysis of a polymerase chain reaction (PCR) amplicon fragment from five patients along with the full genomic sequence [@doi:10/ggjs7j].
This lineage also includes the _Severe acute respiratory syndrome-related coronavirus_ (SARS-CoV-1) that caused the 2002-2003 outbreak of Severe Acute Respiratory Syndrome (SARS) in humans [@doi:10/ggjs7j].
Because viral structure and mechanisms of pathogenicity are highly conserved within the order, this phylogenetic analysis provided a basis for forming hypotheses about how the virus interacts with hosts, including which tissues, organs, and systems would be most susceptible to SARS-CoV-2 infection.
Coronaviruses that infect humans (HCoV) are not common, but prior research into other HCoV such as SARS-CoV-1 and _Middle East respiratory syndrome-related coronavirus_ (MERS-CoV), as well as other viruses infecting humans such as a variety of influenza species, established a strong foundation that accelerated the pace of SARS-CoV-2 research.

Coronaviruses are large viruses that can be identified by their distinctive "crown-like" shape (Figure @fig:genome-structure).
Their spherical virions are made from lipid envelopes ranging from 100 to 160 nanometers in which peplomers (protruding structures) of two to three spike (S) glycoproteins are anchored, creating the crown [@isbn:978-0781760607; @doi:10/dvvg2h].
These spikes, which are critical to both viral pathogenesis and to the response by the host immune response, have been visualized using cryo-electron microscopy [@doi:10.1126/science.abb2507].
Because they induce the human immune response, they are also the target of many proposed therapeutic agents.<!-- TODO: [cite therapeutics] -->
Viral pathogenesis is typically broken down into three major components: entry, replication, and spread [@isbn:0-9631172-1-1 {chap. 45}].
However, in order to draw a more complete picture of pathogenesis, it is also necessary to examine how infection manifests clinically, identify systems-level interactions between the virus and the human body, and consider the possible effects of variation or evolutionary change on pathogenesis and virulence.
Thus, clinical medicine and traditional biology are both important pieces of the puzzle of SARS-CoV-2 presentation and pathogenesis.

### Coronavirus Structure and Pathogenesis

#### Structure of Coronaviruses

Genome structure is highly conserved among coronaviruses, meaning that the relationship between the SARS-CoV-2 genome and its pathogenesis can be inferred from prior research in related viral species.
The genomes of viruses in the *Nidovirales* order share several fundamental characteristics.
They are non-segmented, which means the viral genome is contained in a single capsid, and are enveloped, which means that the genome and capsid are encased by a lipid bilayer.
Coronaviruses have large positive-sense RNA (ssRNA+) genomes ranging from 27 to 32 kilobases in length [@doi:10.1007/978-1-4939-2438-7_1; @doi:10/ggjr43].
The SARS-CoV-2 genome lies in the middle of this range at 29,903 bp [@doi:10/ggjr43].
Genome organization is highly conserved within the order [@doi:10.1007/978-1-4939-2438-7_1].
There are three major genomic regions: one containing the replicase gene, one containing the genes encoding structural proteins, and interspersed accessory genes [@doi:10.1007/978-1-4939-2438-7_1] (Figure @fig:genome-structure).
The replicase gene comprises about two-thirds of the genome and consists of two open reading frames that are translated with ribosomal frameshifting [@doi:10.1007/978-1-4939-2438-7_1].
This polypeptide is then translated into 16 non-structural proteins (nsp), except in gammacoronaviruses where nsp1 is absent, that form replication machinery used to synthesize viral RNA [@doi:10.1002/jmv.25681].
The remaining third of the genome encodes structural proteins, including the spike, membrane, envelope, and nucleocapsid proteins.
Additional accessory genes are sometimes present between these two regions, depending on the species or strain.
Much attention has been focused on the S protein, which is a critical structure involved in cell entry.

![**Structure of SARS-CoV-2 capsid and genome.**
A) The genomic structure of coronaviruses is highly conserved and includes three main regions.
Open reading frames (ORF) 1a and 1b contain two polyproteins that encode the non-structural proteins (nsp).
The nsp include proteases such as RNA-dependent RNA Polymerase (RdRp).
The last third of the genome encodes structural proteins, including the spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins.
Accessory genes can also be interspersed throughout the genome [@doi:10.1007/978-1-4939-2438-7_1].
B) The physical structure of the coronavirus virion, including the components determined by the conserved structural proteins S, E, M and N.
](images/genome-structure.png){#fig:genome-structure secno=1}

#### Pathogenic Mechanisms of Coronaviruses

While, like most viruses, it is possible that SARS-CoV-1 and SARS-CoV-2 can enter cells through endocytosis, coronaviruses are also able to target cells for entry through fusion with the plasma membrane [@doi:10.1038/cr.2008.15; @doi:10.1146/annurev-biochem-060208-104626].
This process is conserved among coronaviruses and is closely associated with the content of their genomes.
Cell entry proceeds in three steps: binding, cleavage, and fusion.
First, the viral spike protein binds to a host cell via a recognized receptor or entry point.
Coronaviruses can bind to a range of host receptors [@doi:10.3390/v4061011; @doi:10.1016/j.jmb.2020.04.009], with binding conserved only at the genus level [@doi:10.1146/annurev-virology-110615-042301].
Viruses in the betacoronavirus genus, to which SARS-CoV-2 belongs, are known to bind to the CEACAM1 protein, 5-N-acetyl-9-O-acetyl neuraminic acid, and to the angiotensin-converting enzyme 2 (ACE2) [@doi:10.3390/v4061011].
SARS-CoV-2 has a high affinity for human ACE2, which is expressed in the vascular epithelium, other epithelial cells, and cardiovascular and renal tissues [@doi:10.1007/s00134-020-05985-9; @doi:10.1007/978-0-387-33012-9_85], as well as many others [@doi:10.15252/msb.20209610].
The binding process is guided by the molecular structure of the spike protein, which is structured in three segments: an ectodomain, a transmembrane anchor, and an intracellular tail [@doi:10.1128/JVI.02615-14].
The ectodomain forms the crown-like structures on the viral membrane and contains two subdomains known as the S1 and S2 subunits [@doi:10.1038/nrmicro2090].
The S1 (N-terminal) domain forms the head of the crown and contains the receptor binding motif, and the S2 (C-terminal) domain forms the stalk that supports the head [@doi:10.1038/nrmicro2090].
The S1 subunit guides the binding of the virus to the host cell, and the S2 subunit guides the fusion process [@doi:10.1128/JVI.02615-14].

After the binding of the S1 subunit to an entry point, the spike protein is often cleaved at the S1-S2 boundary by a host protease [@doi:10.1016/j.cell.2020.02.058; @doi:10/cf8chz; @doi:10.1016/j.antiviral.2020.104792].
Similar to SARS-CoV-1, SARS-CoV-2 exhibits redundancy in which host proteases can cleave the S protein [@doi:10.1016/j.cell.2020.02.052].
Specifically, both transmembrane protease serine protease-2 (TMPRSS2) and cathepsins B/L have been shown to mediate SARS-CoV-2 S protein proteolytic priming, and small molecule inhibition of these enzymes fully inhibited viral entry _in vitro_ [@doi:10.1016/j.cell.2020.02.052; @doi:10.1038/s41467-020-15562-9].
Proteolytic priming prepares the S protein for fusion [@doi:10/cf8chz; @doi:10.1016/j.antiviral.2020.104792].
The two subunits remain bound by van der Waals forces, with the S1 subunit stabilizing the S2 subunit during the membrane fusion process [@doi:10.1016/j.cell.2020.02.058].
Electron microscopy suggests that in some coronaviruses, including SARS-CoV-1 and MERS-CoV, a six-helix bundle separates the two subunits in the postfusion conformation, and the unusual length of this bundle facilitates membrane fusion through the release of additional energy [@doi:10.1146/annurev-virology-110615-042301].
Cleavage at a second site within S2 by these same proteases activates _S_ for fusion by inducing conformational changes [@doi:10.1016/j.cell.2020.02.058].
The viral membrane can then fuse with the endosomal membrane to release the viral genome into the host cytoplasm.
Once the virus enters a host cell, the replicase gene is translated and assembled into the viral replicase complex.
This complex then synthesizes the double-stranded RNA (dsRNA) genome from the genomic ssRNA(+).
The dsRNA genome is transcribed and replicated to create viral mRNAs and new ssRNA(+) genomes [@doi:10.1007/978-1-4939-2438-7_1; @url:https://viralzone.expasy.org/30?outline=all_by_species].
From there, the virus can spread into other cells.
In this way, the genome of SARS-CoV-2 provides insight into the pathogenic behavior of the virus.

#### Immune Evasion Strategies

Research in other HCoV provides some indication of how SARS-CoV-2 infection proceeds in spite of the human immune response.
By infecting the epithelium, viruses such as SARS-CoV-1 are known to bypass the physical barriers, such as skin and mucus, that comprise the immune system's first line of defense [@doi:10.1038/mi.2015.127].
Once the virus infiltrates host cells, it is adept at evading detection.
CD163+ and CD68+ macrophage cells are especially crucial for the establishment of SARS-CoV-1 in the body [@doi:10.1038/mi.2015.127].
These cells most likely serve as viral reservoirs that help shield SARS-CoV-1 from the innate immune response.
According to a study on the viral dissemination of SARS-CoV-1 in Chinese macaques, viral RNA could be detected in some monocytes throughout the process of differentiation into dendritic cells [@doi:10.1038/mi.2015.127].
This lack of active viral replication allows SARS-CoV-1 to escape the innate immune response because reduced levels of detectable viral RNA allow the virus to avoid both natural killer cells and Toll-like receptors [@doi:10.1038/mi.2015.127].
Even during replication, SARS-CoV-1 is able to mask its dsRNA genome from detection by the immune system.
Although dsRNA is a pathogen-associated molecular pattern that would typically initiate a response from the innate immune system [@doi:10.3389/fimmu.2018.00829], _in vitro_ analysis of nidoviruses including SARS-CoV-1 suggests that these viruses can induce the development of double-membrane vesicles that protect the dsRNA signature from being detected by the host immune system [@doi:10.1128/jvi.02501-05].
This protective envelope can therefore insulate these coronaviruses from the innate immune system's detection mechanism [@doi:10.1016/j.jpha.2020.03.001].

HCoVs are also known to interfere with the host immune response, rather than just evade it.
For example, the virulence of SARS-CoV-2 is increased by nsp1, which can suppress host gene expression by stalling mRNA translation and inducing endonucleolytic cleavage and mRNA degradation [@doi:10.1126/science.abc8665].
SARS-CoV-1 also evades the immune response by interfering with type I IFN induction signaling, which is a mechanism that leads to cellular resistance to viral infections.
SARS-CoV-1 employs methods such as ubiquitination and degradation of RNA sensor adaptor molecules MAVS and TRAF3/6 [@doi:10.12932/AP-200220-0772].
Also, MERS-CoV downregulates antigen presentation via MHC class I and MHC class II, which leads to a reduction in T cell activation [@doi:10.12932/AP-200220-0772].
These evasion mechanisms, in turn, can facilitate systemic infection.
Coronaviruses such as SARS-CoV-1 are also able to evade the humoral immune response through other mechanisms, such as inhibiting certain cytokine pathways or down-regulating antigen presentation by the cells [@doi:10.1128/jvi.02501-05].

#### Host Cell Susceptibility

ACE2 and TMPRSS2 have been identified as the primary entry portal and as a critical protease, respectively, in facilitating the entry of SARS-CoV-1 and SARS-CoV-2 into a target cell [@doi:10.1038/nature02145; @doi:10.1126/science.abb2507; @doi:10.1128/JVI.01542-10; @doi:10.1016/j.cell.2020.02.052; @doi:10.1128/JVI.02232-10].
This finding has led to a hypothesized role for ACE2 and TMPRSS2 expression in determining which cells, tissues, and organs are most likely to be infected by SARS-CoV-2.
ACE2 is expressed in numerous organs, such as the heart, kidney, and intestine, but it is most prominently expressed in alveolar epithelial cells; this pattern of expression is expected to contribute to the virus' association with lung pathology [@doi:10.1101/2020.02.24.963348; @doi:10.1007/s00134-020-05985-9; @doi:10.1016/j.phrs.2020.104833] as well as that of SARS [@doi:10.1002/path.1570].
Clinical investigations of COVID-19 patients have detected SARS-CoV-2 transcripts in bronchoalveolar lavage fluid (BALF) (93% of specimens), sputum (72%), nasal swabs (63%), fibrobronchoscopy brush biopsies (46%), pharyngeal swabs (32%), feces (29%), and blood (1%) [@doi:10.1001/jama.2020.3786].
Two studies reported that SARS-CoV-2 could not be detected in urine specimens [@doi:10.1001/jama.2020.3786; @doi:10.1001/jama.2020.3204]; however, a third study identified four urine samples (out of 58) that were positive for SARS-CoV-2 nucleic acids [@doi:10.1097/CM9.0000000000000774].
Although respiratory failure remains the leading cause of death for COVID-19 patients [@doi:10.1111/his.14134], SARS-CoV-2 infection can damage many other organ systems including the heart [@doi:10.1001/jamacardio.2020.0950], kidneys [@doi:10.1038/s41585-020-0319-7; @doi:10.1186/s13054-020-02872-z], liver [@doi:10/ggpx6s], and gastrointestinal tract [@doi:10.1053/j.gastro.2020.02.055; @doi:10.1111/1751-2980.12851].
As it becomes clear that SARS-CoV-2 infection can damage multiple organs, the scientific community is pursuing multiple avenues of investigation in order to build a consensus about how the virus affects the human body.

### Clinical Presentation of COVID-19

SARS-CoV-2 pathogenesis is closely linked with the clinical presentation of the COVID-19 disease.
Reports have described diverse symptom profiles associated with COVID-19, with a great deal of variability both within and between institutions and regions.
A large study from Wuhan, China conducted early in the pandemic identified fever and cough as the two most common symptoms that patients reported at hospital admission [@doi:10.1056/NEJMoa2002032], while a retrospective study in China described the clinical presentations of patients infected with SARS-CoV-2 as including lower respiratory tract infection with fever, dry cough, and dyspnea (shortness of breath) [@doi:10/ggnxb3].
This study [@doi:10/ggnxb3] noted that upper respiratory tract symptoms were less common, suggesting that the virus preferentially targets cells located in the lower respiratory tract.
However, data from the New York City region [@doi:10.1001/jama.2020.6775; @doi:10.1056/NEJMc2010419] showed variable rates of fever as a presenting symptom, suggesting that symptoms may not be consistent across individuals.
For example, even within New York City, one study [@doi:10.1001/jama.2020.6775] identified low oxygen saturation (<90% without the use of supplemental oxygen or ventilation support) in 20.4% of patients upon presentation, with fever being present in 30.7%, while another study [51] reported cough (79.4%), fever (77.1%), and dyspnea (56.5%) as the as the most common presenting symptoms; both of these studies considered only hospitalized patients.
A later study reported radiographic findings such as ground-glass opacity and bilateral patchy shadowing in the lungs of many hospitalized patients, with most COVID-19 patients having lymphocytopenia, or low levels of lymphocytes (a type of white blood cell) [@doi:10.1056/NEJMoa2002032].
Patients may also experience loss of smell, myalgias (muscle aches), fatigue, or headache.
Gastrointestinal symptoms can also present [@doi:10.15585/mmwr.mm6928a2], and the CDC includes nausea and vomiting, as well congestion and runny nose, on its list of symptoms consistent with COVID-19 [@url:https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html].
A preprint using data from an app-based survey of 500,000 individuals in the US found that among those tested for SARS-CoV-2, a loss of taste or smell, fever, and a cough were significant predictors of a positive test result [@doi:10.1101/2020.06.09.20126813].
It is important to note that in this study, the predictive value of symptoms may be underestimated if they are not specific to COVID-19.
This underestimation could occur because the outcome measured was a positive, as opposed to a negative, COVID-19 test result, meaning an association would be more easily identified for symptoms that were primarily or exclusively found with COVID-19.
At the time the surveys were conducted, due to limits in US testing infrastructure, respondents typically needed to have some symptoms known to be specific to COVID-19 in order to qualify for testing.
Widespread testing of asymptomatic individuals may therefore provide additional insight into the range of symptoms associated with COVID-19.

Consistent with the wide range of symptoms observed and the pathogenic mechanisms described above, COVID-19 can affect diverse body systems in addition to causing respiratory problems [@doi:10.1038/s41591-020-0968-3].
For example, COVID-19 can lead to acute kidney injury, especially in patients with severe respiratory symptoms or certain preexisting conditions [@doi:10.1016/j.kint.2020.05.006].
It can also cause neurological complications [@doi:10.1016/j.bbi.2020.03.031; @doi:10/d259], potentially including stroke, seizures or meningitis [@doi:10.1002/jmv.26000; @doi:10.1002/ana.25807].
In fact, autopsy samples suggest that SARS-CoV-2 may be able to enter the central nervous system via the neural–mucosal interface [@doi:10.1038/s41593-020-00758-5].
COVID-19 has also been associated with an increased incidence of large vessel stroke, particularly in patients under the age of 40 [@doi:10.1056/NEJMc2009787], and other thrombotic events including pulmonary embolism and deep vein thrombosis [@doi:10.1016/j.thromres.2020.04.013].
The mechanism behind these complications has been suggested to be related to coagulopathy, with reports indicating the presence of antiphospholipid antibodies [@doi:10.1056/NEJMc2007575] and elevated levels of d-dimer and fibrinogen degradation products in deceased patients [@doi:10.1111/jth.14768].
Other viral infections have been associated with coagulation defects and changes to the coagulation cascade; notably, SARS was also found to lead to disseminated intravascular coagulation and was associated with both pulmonary embolism and deep vein thrombosis [@doi:10.1002/jmv.23354].
The mechanism behind these insults has been suggested to be related to inflammation-induced increases in the von Willebrand factor clotting protein, leading to a pro-coagulative state [@doi:10.1002/jmv.23354].
Abnormal clotting (thromboinflammation or coagulopathy) has been increasingly discussed recently as a possible key mechanism in many cases of severe COVID-19, and may be associated with the high d-dimer levels often observed in severe cases [@doi:10/ggvd74; @doi:10.1186/s13054-020-03060-9; @doi:10.1007/s11239-020-02134-3].
This excessive clotting in lung capillaries has been suggested to be related to a dysregulated activation of the complement system, part of the innate immune system [@doi:10.1172/jci.insight.140711; @doi:10.1172/JCI140183].

#### Cytokine Release Syndrome

Symptoms of a disease can be caused by a pathogen, but they can also be caused by the immune system's reaction to the pathogen.
A dysregulated immune response can cause significant damage to the host [@isbn:9780815332183; @isbn:9780071283663; @doi:10.1016/j.chom.2020.05.009].
The inflammatory response has received particular attention for its role in both a healthy response to infection and a pathogenic one.
Inflammation is one of the most visible components of the immune response, as it is responsible for the hallmarks of injury, such as pain, heat, and swelling [@doi:10.18632/oncotarget.23208].
In response to injury or to signaling by pattern recognition receptors indicating the detection of a molecular pattern associated with a pathogen or foreign body, the immune system stimulates leukocytes that travel to the site of the threat, where they then produce cytokines [@doi:10.18632/oncotarget.23208].
Cytokines are a diverse group of small proteins that play an important role in intercellular signaling [@doi:10.1128/MMBR.05015-11].
Cytokines can be both pro- and anti-inflammatory, which means they can either stimulate or inhibit the production of additional cytokines [@doi:10.1128/MMBR.05015-11; @doi:10.1097/AIA.0b013e318034194e].
Some notable pro-inflammatory cytokines include the interleukins IL-1&beta; and IL-6 and tumor necrosis factor &alpha; (TNF-&alpha;) [@doi:10.1097/AIA.0b013e318034194e].
Anti-inflammatory cytokines play an immunoregulatory role complementary to the cascading effect of pro-inflammatory cytokines [@doi:10.1128/MMBR.05015-11; @doi:10.1097/AIA.0b013e318034194e].
A number of interleukins and interferons play anti-inflammatory roles, and receptors or receptor antagonists for inflammatory cytokines are also important for regulating inflammation [@doi:10.1097/AIA.0b013e318034194e].
IL-10 is an anti-inflammatory cytokine of particular note because it regulates the expression of TNF-&alpha;, IL-1, and IL-6 [@doi:10.1097/AIA.0b013e318034194e].
When the pro- and anti-inflammatory responses are both commensurate with the threat posed, the immune system drives a shift back to homeostasis [@doi:10.1111/imr.12671].
However, when the responses are disproportionate, the cytokine response can become dysregulated.
Too low of an inflammatory response will not eliminate the immune threat [@doi:10.1111/imr.12671].
In contrast, if the response is dysregulated towards excessive pro-inflammatory cytokine activity, inflammation can cascade [@doi:10.1159/000087104] and cause cell damage, among other problems [@doi:10.18632/oncotarget.23208].
Elevated levels of inflammation over the long-term are associated with many chronic health conditions, including type 2 diabetes, dementia and Alzheimer's, and arthritis [@doi:10.1038/s41591-019-0675-0].
On a shorter timescale, dysregulated systemic inflammation can cause sepsis, which can lead to multi-organ failure and death [@doi:10.1128/MMBR.05015-11; @pmid:22142805].

Cytokines have been investigated for their role in the immune response to lung infections long before the COVID-19 pandemic.
Dysregulation of the inflammatory response, including elevated levels of pro-inflammatory cytokines, is found in patients with ARDS, which is a severe condition that can arise from pneumonia, SARS, and COVID-19 [@doi:10.1159/000087104].
One study of patients with and at risk for ARDS, specifically those who were intubated for medical ventilation, found that shortly after the onset of ARDS, anti-inflammatory cytokine concentration in BALF increased relative to the concentration of pro-inflammatory cytokines [@doi:10.1164/ajrccm.164.10.2104013].
The results suggest that an increase in pro-inflammatory cytokines such as IL-6 may signal the onset of ARDS, but recovery depends on an increased anti-inflammatory response [@doi:10.1164/ajrccm.164.10.2104013].
However, patients with severe ARDS were excluded from this study.
Acute phase response to an infection can also cause damage to the capillary endothelium, allowing leaks that disrupt the balance between pro-inflammatory cytokines and their regulators [@doi:10.1164/ajrccm.164.10.2104013].
Hyperactivity of the pro-inflammatory response due to lung infection is commonly associated with acute lung injury and more rarely with the more severe manifestation, ARDS [@doi:10.1128/MMBR.05015-11].
The heightened inflammatory response in the lungs can also serve as a source for systemic inflammation, or sepsis, and potentially multi-organ failure [@doi:10.1128/MMBR.05015-11].
The shift from local to systemic inflammation is a phenomenon often referred to broadly as a cytokine storm [@doi:10.1128/MMBR.05015-11] or, more precisely, as cytokine release syndrome [@doi:10.1186/s40425-018-0343-9].
Sepsis is a known possible complication of pneumonia, and in an analysis of over 1,400 US pneumonia patients, IL-6, tumor necrosis factor (TNF), and IL-10 were found to be elevated at intake in patients who developed severe sepsis and/or ultimately deceased [@doi:10.1001/archinte.167.15.1655].
However, unlike the study analyzing pro- and anti-inflammatory cytokines in ARDS patients [@doi:10.1164/ajrccm.164.10.2104013], this study reported that unbalanced pro-/anti-inflammatory cytokine profiles were rare.
This discrepancy could be related to the fact that the sepsis study measured only three cytokines.
Regardless of variation in the anti-inflammatory response, prior work has therefore made it clear that pulmonary infection and injury are associated with systemic inflammation and with sepsis.
While IL-6 is a biomarker sometimes used to assess cytokine storm activity in sepsis [@doi:10.1128/MMBR.05015-11], the relationship between cytokine profiles and the risks associated with sepsis may be more complex.
In fact, although IL-6 has traditionally been considered pro-inflammatory, its pleiotropic effects via both classical and trans-signaling allow it to play an integral role in both the inflammatory and anti-inflammatory responses [@doi:10.1016/j.bbamcr.2011.01.034], leading it to be associated with both healthy and pathological responses to viral threat [@doi:10.3389/fmicb.2019.01057].

The inflammatory response was identified early on as a potential driver of COVID-19 outcomes due to existing research in SARS and emerging research in COVID-19.
In addition to the known role of cytokines in ARDS and lung infection more broadly, immunohistological analysis at autopsy of patients deceased from SARS revealed that ACE2-expressing cells that were infected by SARS-CoV-1 showed elevated expression of IL-6, IL-1&beta;, and TNF-&alpha; [@doi:10.1002/path.2067].
Similarly, the introduction of the S protein from SARS-CoV-1 to mouse macrophages was found to increase production of IL-6 and TNF-&alpha; [@doi:10.1016/j.virusres.2007.02.007].
For SARS-CoV-2 infection leading to COVID-19, early reports described a cytokine storm syndrome-like response in patients with particularly severe infections [@doi:10.1101/2020.02.24.963348; @doi:10/ggnzmc; @doi:10.1016/j.immuni.2020.06.017].
Among patients hospitalized with COVID-19 in Wuhan, China, 112 out of 191 (59%) developed sepsis, including all 54 of the non-survivors [@doi:10/ggnxb3].
However, the argument has been made that while the cytokine levels observed in COVID-19 patients fall outside of the normal range, they are not as high as typically found in patients with ARDS [@doi:10.1001/jamainternmed.2020.3313].
Regardless, inflammation has received significant interest both in regards to the pathology of COVID-19 as well as potential avenues for treatment, as the relationship between the cytokine storm and the pathophysiology of COVID-19 has led to the suggestion that a number of immunomodulatory pharmaceutical interventions could hold therapeutic value for the treatment of COVID-19 [@doi:10.1016/j.jaut.2020.102452].<!-- TODO: [cite therapeutics section] -->

#### Pediatric Presentation

The presentation of COVID-19 infection can vary greatly among pediatric patients and, in some cases, manifests in distinct ways from COVID-19 in adults.
Evidence suggests that while children and adolescents tend to have mostly asymptomatic infections, those that are symptomatic typically exhibit a mild illness [@doi:10.1101/2020.06.25.20140178; @doi:10.1056/NEJMc2005073; @doi:10.1111/apa.15270; @doi:10.1126/science.abe5765].
One review examined symptoms reported in 17 studies of children infected with COVID-19 during the early months of the COVID-19 epidemic in China and one study from Singapore [@doi:10.1001/jamapediatrics.2020.1467].
In the more than a thousand cases described, the most common reports were for mild symptoms such as fever, dry cough, fatigue, nasal congestion and/or runny nose, while three children were reported to be asymptomatic.
Severe lower respiratory infection was described in only one of the pediatric cases reviewed.
Gastrointestinal symptoms such as vomiting or diarrhea were occasionally reported.
Radiologic findings were not always reported in the case studies reviewed, but when they were mentioned they included bronchial thickening, ground-glass opacities, and/or inflammatory lesions [@doi:10.1001/jamapediatrics.2020.1467].
Neurological symptoms have also been reported [@doi:10.1001/jamaneurol.2020.2687].

These analyses indicate that most pediatric cases of COVID-19 are not severe.
Indeed, it is estimated that less than 1% of pediatric cases result in critical illness [@doi:10.1056/NEJMc2007617; @doi:10.1111/apa.15270].
However, serious complications and, in rare cases, deaths have occurred [@doi:10.1016/j.eclinm.2020.100433].
Of particular interest, children have occasionally experienced a serious inflammatory syndrome, multisystem inflammatory syndrome in children (MIS-C), following COVID-19 infection.
This syndrome is similar in some respects to Kawasaki disease, including Kawasaki disease shock syndrome [@doi:10.1093/jpids/piaa069; @doi:10.1001/jama.2020.10369; @doi:10.1016/j.ajem.2020.05.117] and is thought to be a distinct clinical manifestation of SARS-CoV-2 due to its distinct cytokine profile and the presence of burr cells in peripheral blood smears [@doi:10.1172/JCI140970; @doi:10.1016/j.cell.2020.09.016].
MIS-C has been associated with heart failure in some cases [@doi:10.1161/CIRCULATIONAHA.120.048360].
One case study [@doi:10/gg4sd6] described an adult who appeared to show symptoms similar to MIS-C after exposure to COVID-19, but cautioned against broad conclusions; a second possible adult case has also been reported [@doi:10.1016/j.ajem.2020.06.053].
The presentation of SARS-CoV-2 infection is therefore likely to be largely distinct between adult and pediatric populations.

### Systems-Level Effects

Systems biology provides a cross-disciplinary analytical paradigm through which the host response to an infection can be analyzed.
This field integrates the "omics" fields (genomics, transcriptomics, proteomics, metabolomics, etc.) using bioinformatics and other computational approaches.
Over the last decade, systems biology approaches have been used widely to study the pathogenesis of diverse types of life-threatening acute and chronic infectious diseases [@doi:10.1038/s41576-020-0212-5].
Omics-based studies have also provided meaningful information regarding host immune responses and surrogate protein markers in several viral, bacterial and protozoan infections [@doi:10.1002/prca.201300074].
Though the complex pathogenesis and clinical manifestations of SARS-CoV-2 infection are not yet fully understood, omics technologies offer the opportunity for discovery-driven analysis of biological changes associated with SARS-CoV-2 infection.
For example, previous studies suggest that infection by coronaviruses, such as SARS-CoV-1 and MERS-CoV, as well as other viruses, is associated with the upregulation of ACE2.
In several preliminary assays and an analysis of microarray data, ACE2 expression was reported to be significantly upregulated following infection of human embryonic kidney cells and human airway epithelial cells [@doi:10.1101/2020.02.24.963348].
This study also reported that direct stimulation with inflammatory cytokines such as type I interferons (e.g., IFN&beta;) resulted in the upregulation of ACE2 in human bronchial epithelial cells, with treated groups showing four-fold higher ACE2 expression than control groups at 18 hours post-treatment [@doi:10.1101/2020.02.24.963348].
While it is still unclear whether SARS-CoV-2 facilitates the positive regulation of its own transmission between host cells, the host immune response itself likely plays a key role in mediating infection-associated pathologies.
For this reason, the application of omics technologies to the process of characterizing the host response is expected to provide novel insights into how hosts respond to SARS-CoV-2 infection and how these changes might influence COVID-19 outcomes.

#### Transcriptomics

In addition to the study described above [@doi:10.1101/2020.02.24.963348], two other studies have profiled expression following SARS-CoV-2 infection using human cell lines.
The first study [@doi:10.1016/j.cell.2020.04.026] compared transcriptional responses to SARS-CoV-2 and to other respiratory viruses, including MERS-CoV, SARS-CoV, *Human parainfluenza virus 3*, *Respiratory syncytial virus*, and *Influenza A virus*.
The responses of three human cell lines were analyzed: A549 (adenocarcinomic human alveolar basal epithelial cells), Calu-3 (human airway epithelial cells derived from human bronchial submucosal glands), and MRC-5 (human fetal lung fibroblast cells).
As the viral entry portal ACE2 has low expression in A549 cells, these cells were supplemented with adenovirus-based vectors expressing either mCherry (a fluorescent protein used as a control) or ACE2 (A549-ACE2).
The authors also measured host transcriptional responses to SARS-CoV-2 in primary normal human bronchial epithelial cells (HBEC or NHBE cells), nasal washes from an animal model (ferret), and lung samples from two COVID-19 patients.
The transcriptional response differed between the COVID-19 infected cells and the cells infected by other viruses, with changes in differential expression specific to each infection type.
In the hosts where SARS-CoV-2 was able to replicate efficiently, differential expression analysis revealed that the transcriptional response was significantly different from the response to all of the other viruses tested.
A unique pro-inflammatory cytokine signature associated with SARS-CoV-2 was present in cells exposed to both high and low doses of the virus, with the cytokines IL-6 and IL1RA uniquely elevated in response to SARS-CoV-2 relative to other viruses.
However, the A549-ACE2 cells showed significant IFN-I or IFN-III expression when exposed to high, but not low, doses of SARS-CoV-2.
This finding suggests that IFN induction is dependent on the extent of exposure.
Similarly, in cells from the NHBE line, ferrets, and COVID-19 patients, chemokine signaling was significantly enriched, but there was no significant induction of IFN-I or IFN-III.
Together, these results suggest that SARS-CoV-2 induces a limited antiviral state with low IFN-I or IFN-III expression and a moderate IFN-stimulated gene response, in contrast to other viruses.
Other respiratory viruses have been found to encode antagonists to the IFN response.
The analysis of SARS-CoV-2 suggested that this transcriptional state was specific to cells expressing ACE2, as it was not observed in cells lacking expression of this protein except with ACE2 supplementation and at very high (10-fold increase) level of SARS-CoV-2 exposure.
This hypothesis was further supported by a recent study [@doi:10.1016/j.celrep.2020.108185] that showed that the SARS-CoV-2 *ORF3b* gene suppresses IFNB1 promoter activity (IFN-I induction) more efficiently than the SARS-CoV-1 *ORF3b* gene.
Taken together, these findings suggest that a unique cytokine profile is associated with the response to the SARS-CoV-2 virus, and that this response differs depending on the extent of exposure.

Another study [@doi:10.1101/2020.05.05.079194] analyzed dynamic transcriptional responses to SARS-CoV-2 and SARS-CoV-1.
They characterized the response of three human cell lines, H1299 (human non-small cell lung carcinoma cell line), Calu-3, and Caco-2 (human epithelial colorectal adenocarcinoma cell line), at 4 to 36 hours post infection.
Using poly(A) bulk RNA-seq, the authors found negligible susceptibility of H1299 cells (< 0.08 viral read percentage of total reads) compared to Caco-2 and Calu-3 cells (>10% of viral reads).
This finding suggests that the risk of infection varies among cell types, and that cell type could influence which hosts are more or less susceptible.
Based on visual inspection of microscopy images alongside transcriptional profiling, the authors also showed distinct responses among the host cell lines evaluated.
In contrast to Caco-2, Calu-3 cells infected with SARS-CoV-2 showed signs of impaired growth and cell death at 24 hours post infection, as well as moderate IFN induction with a strong up-regulation of IFN-stimulated genes.
Interestingly, the results were similar to those reported in Calu-3 cells exposed to much higher levels of SARS-CoV-2 [@doi:10.1016/j.cell.2020.04.026], as described above.
This finding suggests that IFN induction in Calu-3 cells is not dependent on the level of exposure, in contrast to A549-ACE2 cells.
The discrepancy could be explained by the observations that Calu-3 cells are highly susceptible to SARS-CoV-2 and show rapid viral replication [@doi:10.1038/s41467-020-15562-9], whereas A549 cells are incompatible with SARS-CoV-2 infection [@doi:10.1101/2020.03.02.972935].
This discrepancy raises the concern that _in vitro_ models may vary in their similarity to the human response, underscoring the importance of follow-up studies in additional models.

#### Proteomics

One early proteomics study investigated changes associated with _in vitro_ SARS-CoV-2 infection using Caco-2 cells [@doi:10.1038/s41586-020-2332-7].
This study reported that SARS-CoV-2 induced alterations in multiple vital physiological pathways, including translation, splicing, carbon metabolism and nucleic acid metabolism in the host cells.
Another area of interest is whether SARS-CoV-2 is likely to induce similar changes to other HCoV.
For example, because of the high level of sequence homology between SARS-CoV-2 and SARS-CoV-1, it has been hypothesized that sera from convalescent SARS-CoV-1 patients might show some efficacy in cross-neutralizing SARS-CoV-2-S-driven entry [@doi:10.1016/j.cell.2020.02.052].
However, despite the high level of sequence homology, certain protein structures might be immunologically distinct, which would be likely to prohibit effective cross-neutralization across different SARS species [@doi:10.1101/2020.03.21.990770].
Consequently, proteomic analyses of SARS-CoV-1 might also provide some essential information regarding the new pathogen [@doi:10.1073/pnas.0407992101; @doi:10.1016/j.bbrc.2004.02.074].

Considering the paucity of omics-level big data sets for SARS-CoV-2 currently available, existing data hubs that contain information for other coronaviruses such as UniProt [@doi:10.1093/nar/gky1049], NCBI Genome Database [@url:https://www.ncbi.nlm.nih.gov/genome/], The Immune Epitope Database and Analysis Resource [@doi:10.1093/nar/gky1006], and The Virus Pathogen Resource [@doi:10.1093/nar/gkr859] will serve as useful resources for comparative bioinformatics research of SARS-CoV-2.
Using such databases, the systems-level reconstruction of protein-protein interaction networks will enable the generation of hypotheses about the mechanism of action of SARS-CoV-2 and suggest potential drug targets.
In an initial study [@doi:10.1101/2020.03.22.002386], 26 of the 29 SARS-CoV-2 proteins were cloned and expressed in HEK293T kidney cells, allowing for the identification of 332 high-confidence human proteins interacting with them.
Notably, this study suggested that SARS-CoV-2 interacts with innate immunity pathways.
Ranking pathogens by the similarity between their interactomes and that of SARS-CoV-2 suggested *West Nile virus*, *Mycobacterium tuberculosis*, and *human papillomavirus* infections as the top three hits.
Therefore, given the lung symptoms associated with COVID-19, the *Mycobacterium tuberculosis* host-pathogen interactome in particular might provide new insights to the mechanism of SARS-CoV-2 infection.
Additionally, it was suggested that the envelope protein, E, could disrupt host bromodomain-containing proteins, i.e., BRD2 and BRD4, that bind to histones, and the spike protein could likely intervene in viral fusion by modulating the GOLGA7-ZDHHC5 acyl-transferase complex to increase palmitoylation, which is a post-translational modification that affects how proteins interact with membranes [@doi:10.3389/fimmu.2017.02003].

Another study [@doi:10.1101/2020.03.31.019216] used patient-derived peripheral blood mononuclear cells to identify 251 host proteins targeted by SARS-CoV-2.
This study also reported that more than 200 host proteins were disrupted following infection.
In particular, a network analysis showed that nsp9 and nsp10 interacted with NF-Kappa-B-Repressing Factor, which encodes a transcriptional repressor that mediates repression of genes responsive to Nuclear Factor kappa-light-chain-enhancer of activated B-cells.
These genes are important to pro-, and potentially also anti-, inflammatory signaling [@doi:10.1101/cshperspect.a001651].
This finding could explain the exacerbation of the immune response that shapes the pathology and the high cytokine levels characteristic of COVID-19, possibly due to the chemotaxis of neutrophils mediated by IL-8 and IL-6.
Finally, it was suggested [@doi:10.1101/2020.04.09.033522] that the E protein of both SARS-CoV-1 and SARS-CoV-2 has a conserved Bcl-2 Homology 3-like motif, which could inhibit anti-apoptosis proteins, e.g., BCL2, and trigger the apoptosis of T cells.
Several compounds are known to disrupt the host-pathogen protein interactome, largely through the inhibition of host proteins.
Therefore, this research identifies candidate targets for intervention and suggests that drugs modulating protein-level interactions between virus and host could be relevant to treating COVID-19.
By revealing which genes are perturbed during SARS-CoV-2 infection, proteomics-based analyses can thus provide novel insights into host-virus interaction and serve to generate new avenues of investigation for therapeutics.

### Viral Virulence

Like that of SARS-CoV-1, the entry of SARS-CoV-2 into host cells is mediated by interactions between the viral spike glycoprotein, S, and human ACE2 (hACE2) [@doi:10.1126/science.1116480; @doi:10.1016/j.cell.2020.02.058; @doi:10.1126/science.abb2762; @doi:10.1038/s41586-020-2179-y; @doi:10.1101/2020.02.19.956235; @doi:10.1016/j.cell.2020.02.052; @doi:10.1016/j.cell.2020.03.045; @doi:10.1128/jvi.00127-20].
Differences in how the S proteins of the two viruses interact with hACE2 could partially account for the increased transmissibility of SARS-CoV-2.
Recent studies have reported conflicting binding constants for the S-hACE2 interaction, though they have agreed that the SARS-CoV-2 S protein binds with equal, if not greater, affinity than the SARS-CoV-1 S protein does [@doi:10.1016/j.cell.2020.02.058; @doi:10.1101/2020.02.19.956235; @doi:10.1126/science.abb2507].
The C-terminal domain of the SARS-CoV-2 S protein in particular was identified as the key region of the virus that interacts with hACE2, and the crystal structure of the C-terminal domain of the SARS-CoV-2 S protein in complex with hACE2 reveals stronger interaction and a higher affinity for receptor binding than that of SARS-CoV-1 [@doi:10.1016/j.cell.2020.03.045].
Among the 14 key binding residues identified in the SARS-CoV-1 S protein, eight are conserved in SARS-CoV-2, and the remaining six are semi-conservatively substituted, potentially explaining variation in binding affinity [@doi:10.1016/j.cell.2020.02.058; @doi:10.1101/2020.02.19.956235].
Recent crystal structures have shown that the receptor binding domain (RBD) of the SARS-CoV-2 S protein, like that of other coronaviruses, undergoes stochastic hinge-like movement that flips it from a “closed” conformation, in which key binding residues are hidden at the interface between protomers, to an “open” one [@doi:10.1016/j.cell.2020.02.058; @doi:10.1126/science.abb2507].
Because the RBD plays such a critical role in viral entry, blocking its interaction with ACE2 could represent a promising therapeutic approach.
Nevertheless, despite the high structural homology between the SARS-CoV-2 RBD and that of SARS-CoV-1, monoclonal antibodies targeting SARS-CoV-1 RBD failed to bind to SARS-CoV-2-RBD [@doi:10.1126/science.abb2507].
However, in early research, sera from convalescent SARS patients were found to inhibit SARS-CoV-2 viral entry _in vitro_, albeit with lower efficiency than it inhibited SARS-CoV-1 [@doi:10.1016/j.cell.2020.02.052].

Comparative genomic analysis reveals that several regions of the coronavirus genome are likely critical to virulence.
The S1 domain of the spike protein, which contains the receptor binding motif, evolves more rapidly than _S_'s S2 domain [@doi:10.3390/v4061011; @doi:10.1016/j.jmb.2020.04.009].
However, even within the S1 domain, some regions are more conserved than others, with the receptors in S1's N-terminal domain (S1-NTD) evolving more rapidly than those in its C-terminal domain (S1-CTD) [@doi:10.1016/j.jmb.2020.04.009].
Both S1-NTD and S1-CTD are involved in receptor binding and can function as RBDs to bind proteins and sugars [@doi:10.3390/v4061011], but RBDs in the S1-NTD typically bind to sugars, while those in the S1-CTD recognize protein receptors [@doi:10.1146/annurev-virology-110615-042301].
Viral receptors show higher affinity with protein receptors than sugar receptors [@doi:10.1146/annurev-virology-110615-042301], which suggests that positive selection on or relaxed conservation of the S1-NTD might reduce the risk of a deleterious mutation that would prevent binding.
The SARS-CoV-2 S protein also contains an RRAR furin recognition site at the S1/S2 junction [@doi:10.1016/j.cell.2020.02.058; @doi:10.1126/science.abb2507], setting it apart from both bat coronavirus RaTG13, with which it shares 96% genome sequence identity, and SARS-CoV-1 [@doi:10.1038/s41586-020-2012-7].
Such furin cleavage sites are commonly found in highly virulent influenza viruses, and as such may contribute to the heightened pathogenicity of SARS-CoV-2 [@doi:10/bvgh5b; @doi:10.1006/viro.1999.9716].
The ongoing evolution of the spike protein can be seen from the genomic data.
For example, the mutation D614G became dominant by the end of May 2020, soon after its initial appearance in mid-March [@doi:10.1016/j.cell.2020.06.043; @doi:10.1016/j.cell.2020.09.032], and a variant carrying two mutations (N501Y and 69–70del) that was first observed in the UK in October 2020 [@doi:10.1016/j.jinf.2020.12.024] has quickly spread around the world [@url:https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/; @doi:10.1101/2020.12.28.20248906].
Effective cell entry is a critical component to pathogenesis and therefore an important process to understand when examining possible therapeutics.

### Mechanism of Transmission

Once a human host is infected with a virus, person-to-person viral transmission can occur through several possible mechanisms.
The primary mechanisms associated with respiratory viruses are contact, droplet, and aerosol transmission [@doi:10.1097/QCO.0000000000000563].
Contact transmission can occur through either contact with a contagious person or contact with active viral particles on a contaminated surface [@pubmed:23771256].
This latter mode of transmission is also called fomite transmission [@url:https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions].
Viral particles can enter the body if they then come in contact with the oral, nasal, eye, or other mucus membranes [@pubmed:23771256].
Droplet transmission occurs when a contagious individual sneezes, coughs, or exhales and produces respiratory droplets that can contain a large number of viral particles [@pubmed:23771256].
Contact with these droplets can occur through direct exposure to the droplets, such as breathing in droplets produced by a sneeze [@pubmed:23771256].
The droplets can also potentially settle on a surface and contribute to fomite transmission [@pubmed:23771256].
Aerosol transmission refers to much smaller particles (less than 5 micrometers) that are also produced by sneezing, coughing, or exhaling [@doi:10.1097/QCO.0000000000000563; @pubmed:23771256].
The small size of these particles allows them to remain suspended over a longer period of time and potentially to be moved by air currents [@pubmed:23771256].
Additionally, viral particles deposited on surfaces via large respiratory droplets can also later be aerosolized [@pubmed:23771256].
Droplet and/or contact transmission are both well-accepted modes of transmission for many viruses associated with common human illnesses, including influenza and rhinovirus [@pubmed:23771256].
The extent to which aerosol transmission contributes to the spread of respiratory viruses is less clear.
In influenza A, for example, viral particles can be detected in aerosols produced by infected individuals, but the extent to which these particles drive the spread of influenza A infection remains under debate [@pubmed:23771256; @doi:10.1097/QCO.0000000000000563; @doi:10.3201/eid1301.061202; @doi:10.1038/s41598-019-38825-y; @doi:10.1093/femsre/fuv039].
Regardless of its role in the spread of influenza A, however, aerosol transmission likely played a role in outbreaks such as the 1918 Spanish Influenza (H1N1) and 2009 "swine flu" (pH1N1) [@doi:10.1093/femsre/fuv039].
Contact, droplet, and aerosol transmission are therefore all worth evaluating when considering possible modes of transmission for a respiratory virus like SARS-CoV-2.

All three of these mechanisms have been identified as possible contributors to the transmission of HCoVs [@pubmed:23771256], including the highly pathogenic coronaviruses SARS-CoV-1 and MERS-CoV [@doi:10.1016/B978-0-12-385885-6.00009-2; @doi:10.1038/nrmicro.2016.81].
Transmission of SARS-CoV-1 is thought to proceed primarily through droplet transmission, but aerosol transmission is also considered possible [@pubmed:23771256], and fomite transmission may have also played an important role in some outbreaks [@doi:10.1371/journal.pone.0181558].
Similarly, the primary mechanism of MERS transmission is thought to be droplets because inter-individual transmission appears to be associated with close interpersonal contact (e.g., household or healthcare settings), but aerosolized particles of the MERS virus have been reported to persist much more robustly than influenza A under a range of environmental conditions [@doi:10.2807/1560-7917.es2013.18.38.20590; @doi:10.1186/s12985-015-0439-5].
While droplet-based and contact transmission were initially put forward as the greatest concern for the spread of SARS-CoV-2 [@doi:10.1038/s41368-020-0075-9], as additional information has emerged, the possibility of aerosol transmission has also been raised [@doi:10.1126/science.abc6197; @doi:10.1056/NEJMc2004973; @doi:10.1093/cid/ciaa939].
For example, the detection of SARS-CoV-2 viral particles in air samples taken from hospitals treating COVID-19 patients led to the concern that the virus could be spreading via aerosols [@doi:10.1038/s41586-020-2271-3].
The stability of the virus both in aerosols and on a variety of surfaces appeared similar to that of SARS-CoV-1 [@doi:10.1056/NEJMc2004973].
However, while the possibility of aerosol transmission seems plausible, the evidence suggests that droplet transmission is the dominant mechanism driving the spread of the virus [@doi:10.1001/jama.2020.12458], and the risk of fomite transmission under real-world conditions is likely to be substantially lower than the conditions used for experimental analyses [@doi:10/gg6br7].
These mechanisms may differ in their relevance to different types of transmission events, such as transmission within households, nosocomial transmissions, and transmission in indoor versus outdoor spaces.

#### Symptoms and Viral Spread

Other aspects of pathogenesis are also important to understanding how the virus spreads, especially the relationship between symptoms, viral shedding, and contagiousness.
Symptoms associated with reported cases of COVID-19 range from mild to severe [@url:https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html], but some individuals who contract COVID-19 remain asymptomatic throughout the duration of the illness [@doi:10.1007/s11427-020-1661-4].
The incubation period, or the time period between exposure and the onset of symptoms, has been estimated at five to eight days, with means of 4.91 (95% confidence interval (CI) 4.35-5.69) and 7.54 (95% CI 6.76-8.56) reported in two different Asian cities and a median of 5 (IQR 1 to 6) reported in a small number of patients in a Beijing hospital [@doi:10.7554/eLife.57149; @doi:10.1164/rccm.202003-0524LE].
However, the exact relationship between contagiousness and viral shedding remains unclear.
Estimates suggest that viral shedding can, in some cases, begin as early as 12.3 days (95% CI 5.9-17.0) before the onset of symptoms, although this was found to be very rare, with less than 0.1% of transmission events occurring 7 or more days before symptom onset [@doi:10.1038/s41591-020-0869-5].
Transmissibility appeared to peak around the onset of symptoms (95% CI -0.9 - 0.9 days), and only 44% (95% CI 30–57%) of transmission events were estimated to occur from presymptomatic contacts [@doi:10.1038/s41591-020-0869-5].
As these trends became apparent, concerns arose due to the potential for individuals who did not yet show symptoms to transmit the virus [@url:https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html].
Recovered individuals may also be able to transmit the virus after their symptoms cease.
Estimates of the communicable period based on twenty-four individuals who tested positive for SARS-CoV-2 prior to or without developing symptoms estimated that individuals may be contagious for one to twenty-one days, but they note that this estimate may be low [@doi:10.1007/s11427-020-1661-4].
In an early study, viral nucleic acids were reported to remain at observable levels in the respiratory specimens of recovering hospitalized COVID-19 patients for a median of 20 days and with a maximum observed duration through 37 days, when data collection for the study ceased [@doi:10/ggnxb3].
As more estimates of the duration of viral shedding are released, they are beginning to converge around approximately three weeks from first positive PCR test and/or onset of symptoms (which, if present, are usually identified within three days of the initial PCR test).
For example, in later studies, viral shedding was reported for up to 28 days following symptom onset [@doi:10.1038/s41586-020-2196-x] and for one to 24 days from first positive PCR test, with a median of 12 days [@doi:10.1001/jama.2020.3204].
On the other hand, almost 70% of patients were reported to still have symptoms at the time that viral shedding ceased, although all symptoms reduced in prevalence between onset and cessation of viral shedding [@doi:10.1016/j.jcv.2020.104577].
The median time that elapsed between the onset of symptoms and cessation of viral RNA shedding was 23 days and between first positive PCR test and cessation of viral shedding was 17 days [@doi:10.1016/j.jcv.2020.104577].
The fact that this study reported symptom onset to predate the first positive PCR test by an average of three days, however, suggests that there may be some methodological differences between it and related studies.
Furthermore, an analysis of residents of a nursing home with a known SARS-CoV-2 case measured similar viral load in residents who were asymptomatic regardless of whether they later developed symptoms, and the load in the asymptomatic residents was comparable to that of residents who displayed either typical of atypical symptoms [@doi:10.1056/NEJMoa2008457].
Taken together, these results suggest that the presence or absence of symptoms are not reliable predictors of viral shedding or of SARS-CoV-2 status (e.g, [@doi:10.1001/jama.2020.6887]).
However, it should be noted that viral shedding is not necessarily a robust indicator of contagiousness.
The risk of spreading the infection was low after ten days from the onset of symptoms, as viral load in sputum was found to be unlikely to pose a significant risk based on efforts to culture samples _in vitro_ [@doi:10.1038/s41586-020-2196-x].
The relationship between symptoms, detectable levels of the virus, and risk of viral spread is therefore complex.

The extent to which asymptomatic or presymptomatic individuals are able to transmit SARS-CoV-2 has been a question of high scientific and community interest.
Early reports (February and March 2020) described transmission from presymptomatic SARS-CoV-2-positive individuals to close family contacts [@doi:10.1001/jama.2020.2565; @doi:10.1016/j.ijid.2020.03.027].
One of these reports [@doi:10.1016/j.ijid.2020.03.027] also included a description of an individual who tested positive for SARS-CoV-2 but never developed symptoms.
Later analyses also sought to estimate the proportion of infections that could be traced back to a presymptomatic or asymptomatic individual (e.g., [@doi:10.2139/ssrn.3678556]).
Estimates of the proportion of individuals with asymptomatic infections have varied widely.
The proportion of asymptomatic individuals on board the Diamond Princess cruise ship, which was the site of an early COVID-19 outbreak, was estimated at 17.9% [@doi:10.2807/1560-7917.ES.2020.25.10.2000180].
In contrast, a model using the prevalence of antibodies among residents of Wuhan, China estimated a much higher rate of asymptomatic cases, at approximately 7 in 8, or 87.5% [@doi:10.1093/pcmedi/pbaa032].
An analysis of the populations of care homes in London found that, among the residents (median age 85), the rate of asymptomatic infection was 43.8%, and among the caretakers (median age 47), the rate was 49.1% [@doi:10.1016/j.eclinm.2020.100533].
The duration of viral shedding may also be longer in individuals with asymptomatic cases of COVID-19 compared to those who do show symptoms [@doi:10.1038/s41591-020-0965-6].
As a result, the potential for individuals who do not know they have COVID-19 to spread the virus raises significant concerns.
In Singapore and Tianjin, two cities studied to estimate incubation period, an estimated 40-50% and 60-80% of cases, respectively, were considered to be caused by contact with asymptomatic individuals [@doi:10.7554/eLife.57149].
An analysis of viral spread in the Italian town of Vo', which was the site of an early COVID-19 outbreak, revealed that 42.5% of cases were asymptomatic and that the rate was similar across age groups [@doi:10.1038/s41586-020-2488-1].
The argument was thus made that the town's lockdown was imperative for controlling the spread of COVID-19 because it isolated asymptomatic individuals.
While more models are likely to emerge to better explore the effect of asymptomatic individuals on SARS-CoV-2 transmission, these results suggest that strategies for identifying and containing asymptomatic but contagious individuals are important for managing community spread.

#### Estimating the Fatality Rate

Estimating the occurrence of asymptomatic and mild COVID-19 cases is important to identifying the mortality rate associated with COVID-19.
The mortality rate of greatest interest would be the total number of fatalities as a fraction of the total number of people infected.
One commonly reported metric is the case fatality rate (CFR), which compares the number of COVID-19 related deaths to the number of confirmed or suspected cases.
However, in locations without universal testing protocols, it is impossible to identify all infected individuals because so many asymptomatic or mild cases go undetected.
Therefore, a more informative metric is the infection fatality rate (IFR), which compares the known deaths to the estimated number of cases.
It thus requires the same numerator as CFR, but divides by an approximation of the total number of cases rather than only the observed/suspected cases.
IFR varies regionally, with some locations observed to have IFRs as low as 0.17% while others are as high as 1.7% [@doi:10.1016/j.ijid.2020.09.1464].
Estimates of CFR at the national and continental level and IFR at the content level is maintained by the Centre for Evidence-Based Medicine [@url:https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/].
Several meta-analyses have also sought to estimate IFR at the global scale.
These estimates have varied; one peer-reviewed study aggregated data from 24 other studies and estimated IFR at 0.68% (95% CI 0.53%–0.82%), but a preprint that aggregated data from 139 countries calculated a global IFR of 1.04% (95% CI 0.77%-1.38%) when false negatives were considered in the model [@doi:10.1101/2020.05.11.20098780; @doi:10.1016/j.ijid.2020.09.1464]. 
A similar prevalence estimate was identified through a repeated cross-sectional serosurvey conducted in New York City that estimated the IFR as 0.97% [@doi:10.1038/s41586-020-2912-6].
Examination of serosurvey-based estimates of IFR identified convergence on a global IFR estimate of 0.60% (95% CI 0.42%–0.77%) [@doi:10.1016/j.ijid.2020.09.1464].
All of these studies note that IFR varies widely by location, and it is also expected to vary with demographic and health-related variables such as age, sex, prevalence of comorbidities, and access to healthcare and testing [@url:https://ourworldindata.org/covid-mortality-risk].
Estimates of infection rates are becoming more feasible as more data becomes available for modeling and will be bolstered as serological testing becomes more common and more widely available.

### Dynamics of Transmission

Disease spread dynamics can be estimated using R~0~, the basic reproduction number, and R~t~, the effective reproduction number.
Accurate estimates of both are crucial to understanding the dynamics of infection and to predicting the effects of different interventions.
R~0~ is the average number of new (secondary) infections caused by one infected person, assuming a wholly susceptible population [@doi:10.1111/j.1467-9574.1996.tb01482.x] and is one of the most important epidemiological parameters [@isbn:9780691116174].
A simple mechanistic model used to describe infectious disease dynamics is a susceptible-infected-recovered compartmental model [@doi:10.1098/rspa.1927.0118; @doi:10.1038/280361a0].
In this model, individuals move through three states: susceptible, infected, and recovered; two parameters, $\gamma$ and $\beta$, specify the rate at which the infectious recover, and the infection transmission rate, respectively, and R~0~ is estimated as the ratio of $\beta$ and $\gamma$ [@doi:10.1126/science.abb5659; @isbn:9780691116174].
A pathogen can invade a susceptible population only if R~0~ > 1 [@isbn:9780691116174; @isbn:9780199209996].
The spread of an infectious disease at a particular time t can be quantified by R~t~, the effective reproduction number, which assumes that part of the population has already recovered (and thus gained immunity to reinfection) or that mitigating interventions have been put into place.
For example, if only a fraction S~t~ of the population is still susceptible, R~t~ = S~t~ x R~0~.
When R~t~ is greater than 1, an epidemic grows (i.e., the proportion of the population that is infectious increases); when R~t~ is less than 1, the proportion of the population that is infectious decreases.
R~0~ and R~t~ can be estimated directly from epidemiological data or inferred using susceptible-infected-recovered-type models.
To accurately capture the dynamics of SARS-CoV-2, the addition of a fourth compartment, i.e. a susceptible-exposed-infectious-recovered model may be appropriate.

Estimates of R~0~ for COVID-19 lie in the range R~0~=1.4-6.5 [@doi:10/ggjvr7; @doi:10.1093/jtm/taaa021; @doi:10.1126/science.abb3221].
Variation in R~0~ is expected between different populations, and the estimated values of R~0~ discussed below are for specific populations in specific environments.
The different estimates of R~0~ should not necessarily be interpreted as a range of estimates of the same underlying parameter.
In one study of international cases, the predicted value was R~0~=1.7 [@doi:10.1101/2020.03.21.20040329].
In China (both Hubei province and nationwide), the value was predicted to lie in the range R~0~=2.0-3.6 [@doi:10.2139/ssrn.3524675; @doi:10.1101/2020.01.25.919787; @doi:10/ggjvr7].
Another estimate based on a cruise ship where an outbreak occurred predicted R~0~=2.28 [@doi:10.1016/j.ijid.2020.02.033].
Susceptible-exposed-infectious-recovered model-derived estimates of R~0~ range from 2.0 - 6.5 in China [@doi:10.3390/jcm9020462; @doi:10.1101/2020.01.27.20018952; @doi:10.1101/2020.01.23.916726; @doi:10.1101/2020.01.23.20018549] to R~0~=4.8 in France [@doi:10.1101/2020.03.22.20040915].
Using the same model as for the French population, a study estimated R~0~=2.6 in South Korea [@doi:10.1101/2020.03.22.20040915], which is consistent with other studies [@tag:Park2020_distancing].
From a meta-analysis of studies estimating R~0~, [@doi:10.1093/jtm/taaa021] the median R~0~ was estimated to be 2.79 (IQR 1.16) based on twelve studies published between January 1 and February 7, 2020.

Inference of the effective reproduction number can provide insight into how populations respond to an infection and the effectiveness of interventions.
In China, R~t~ was predicted to lie in the range 1.6-2.6 in January 2020, before travel restrictions [@doi:10/ggptcf].
R~t~ decreased from 2.35 one week before travel restrictions were imposed (January 23, 2020), to 1.05 one week after.
Using their model, the authors also estimated the probability of new outbreaks occurring.
Assuming individual-level variation in transmission comparable to that of MERS or SARS, the probability of a single individual exporting the virus and causing a large outbreak is 17-25%, and assuming variation like that of SARS and transmission patterns like those observed for COVID-19 in Wuhan, the probability of a large outbreak occurring after ≥4 infections exist at a new location is greater than 50%.
An independent study came to similar conclusions, finding R~t~=2.38 in the two-week period before January 23 with a decrease to R~t~ = 1.34 (using data from January 24 to February 3) or R~t~=0.98 (using data from January 24 to February 8) [@doi:10.1126/science.abb3221].
In South Korea, R~t~ was inferred for February through March 2020 in two cities, Daegu (the center of the outbreak) and Seoul [@tag:Park2020_distancing].
Metro data was also analyzed to estimate the effects of social distancing measures.
R~t~ decreased in Daegu from around 3 to <1 over the period that social distancing measures were introduced.
In Seoul, R~t~ decreased slightly, but remained close to 1 (and larger than R~t~ in Daegu).
These findings indicate that social distancing measures appeared to be effective in containing the infection in Daegu, but in Seoul, R~t~ remained above 1, meaning secondary outbreaks remained possible.
The study also shows the importance of region-specific analysis: the large decline in case load nationwide was mainly due to the Daegu region and could mask persistence of the epidemic in other regions, such as Seoul and Gyeonggi-do.
In Iran, estimates of R~t~ declined from 4.86 in the first week to 2.1 by the fourth week after the first cases were reported [@doi:10.1101/2020.03.20.20038422].
In Europe, analysis of 11 countries inferred the dynamics of R~t~ over a time range from the beginning of the outbreak until March 28, 2020, by which point most countries had implemented major interventions (such as stay-at-home orders, public gathering bans, and school closures) [@doi:10.25561/77731].
Across all countries, the mean R~t~ before interventions began was estimated as 3.87; R~t~ varied considerably, from below 3 in Norway to above 4.5 in Spain.
After interventions, R~t~ decreased by an average of 64% across all countries, with mean R~t~=1.43.
The lowest predicted value was 0.97 for Norway and the highest was 2.64 for Sweden, which could be related to the fact that Sweden did not implement social distancing measures on the same scale as other countries.
The study concludes that while large changes in R~t~ are observed, it is too early to tell whether the interventions put into place are sufficient to decrease R~t~ below 1.

More generally, population-level epidemic dynamics can be both observed and modeled [@doi:10.1126/science.abb5659].
Data and empirically determined biological mechanisms inform models, while models can be used to try to understand data and systems of interest or to make predictions about possible future dynamics, such as the estimation of capacity needs [@doi:10.1073/pnas.2004064117] or the comparison of predicted outcomes among prevention and control strategies [@doi:10/ggp3xq; @doi:10.1073/pnas.2004978117].
Many current efforts to model R~t~ have also led to tools that assist the visualization of estimates in real time or over recent intervals [@url:https://epiforecasts.io/covid; @url:https://rt.live].
These are valuable resources, yet it is also important to note that the estimates arise from models containing many assumptions and are dependent on the quality of the data they use, which varies widely by region.

### Molecular Signatures and Transmission

Genetic variation in SARS-CoV-2 has been used to elucidate patterns over time and space.
Mutations observed in individual SARS-CoV-2 genome sequences can be used to trace transmission patterns and have provided insights during outbreak investigations [@doi:10.1186/s12967-020-02344-6; @doi:10.1093/nsr/nwaa036; @doi:10.1016/j.meegid.2020.104351].
Similar mutations observed in several patients may indicate that the patients belong to the same transmission group.
The tracking of SARS-CoV-2 mutations is recognized as an essential tool for controlling future outbreaks and tracing the path of the spread of SARS-CoV-2.
Efforts vary widely by country: the UK has coordinated has coordinated a national database of viral genomes [@doi:10/d5mg]; no such coordination has been achieved in the USA.
Several studies used phylogenetic analysis to determine the source of local COVID-19 outbreaks in Connecticut (USA), [@doi:10.1016/j.cell.2020.04.021], the New York City area (USA) [@doi:10.1126/science.abc1917], and Iceland [@doi:10.1056/NEJMoa2006100].
There is an ongoing effort to collect SARS-CoV-2 genomes throughout the COVID-19 outbreak, and as of January 18, 2021 more than 381,000 genome sequences have been collected from patients.<!-- TODO: consider auto-updating this -->
The sequencing data can be found at GISAID [@https://www.gisaid.org/], NCBI [@https://www.ncbi.nlm.nih.gov/sars-cov-2/], and COVID-19 data portal [@https://www.covid19dataportal.org/].

### Conclusions

The novel coronavirus SARS-CoV-2 is the third HCoV to emerge in the 21st century, and research into previous HCoVs has provided a strong foundation for characterizing the pathogenesis and transmission of SARS-CoV-2.
Critical insights into how the virus interacts with human cells have been gained from previous research into HCoVs and other viral infections.
As with other HCoVs, the immune response to SARS-CoV-2 is likely driven by detection of its spike protein, which allows it to enter cells through ACE2.
Epithelial cells have also emerged as the major cellular target of the virus, contextualizing the respiratory and gastrointestinal symptoms that are frequently observed in COVID-19.
Many of the mechanisms that facilitate the pathogenesis of SARS-CoV-2 are currently under consideration as possible targets for the treatment or prevention of COVID-19.<!-- TODO: [cite therapeutics] -->
Research in other viruses also provides a foundation for understanding the transmission of SARS-CoV-2 among people and can therefore inform efforts to control the virus's spread.
The extent to which aerosol and fomite transmission contribute to the spread of SARS-CoV-2 remains a question: in general, much like SARS-CoV-1 and MERS-CoV, this virus seems to be spread primarily by droplet transmission.
Asymptomatic transmission was also a concern in the SARS outbreak of 2002-03 and, as in current pandemic, presented challenges for estimating rates of infection [@doi:10.1098/rstb.2004.1490].
However, in the current pandemic, we have been fortunate to be able to build on top of 18 years of SARS-CoV-1 research in order to rapidly ascertain the identity and behavior of the virus.

Even with the background obtained from research in SARS and MERS, COVID-19 has revealed itself to be a complex and difficult-to-characterize disease that has many possible presentations that vary with age.
Variability in presentation, including cases with no respiratory symptoms or with no symptoms altogether, were also reported during the SARS epidemic at the beginning of the 21st century [@doi:10.1098/rstb.2004.1490].
The variability of both which symptoms present and their severity have presented challenges for public health agencies seeking to provide clear recommendations regarding which symptoms indicate SARS-CoV-2 infection and should prompt isolation.
Asymptomatic cases add complexity both to efforts to estimate statistics such as R~0~ and R~t~, which are critical to understanding the transmission of the virus, and IFR, which is an important component of understanding its impact on a given population.
The development of diagnostic technologies over the course of the pandemic has facilitated more accurate identification, including of asymptomatic cases.<!-- TODO: [cite diagnostics] -->
As more cases have been diagnosed, the health conditions and patient characteristics associated with more severe infection have also become more clear, although there are likely to be significant sociocultural elements that also influence these outcomes.<!-- TODO: [cite equity section] -->
While many efforts have focused on adults, and especially older adults because of the susceptibility of this demographic, additional research is needed to understand the presentation of COVID-19 and MIS-C in pediatric patients.
As more information is uncovered about the pathogenesis of HCoV and SARS-CoV-2 specifically, the diverse symptomatology of COVID-19 has and likely will continue to conform with the ever-broadening understanding of how SARS-CoV-2 functions within a human host.

While the SARS-CoV-2 virus is very similar to other HCoV in several ways, including in its genomic structure and the structure of the virus itself, there are also some differences that may account for differences in the COVID-19 pandemic compared to the SARS and MERS epidemics of the past two decades.
The R~0~ of SARS-CoV-2 has been estimated to be similar to SARS-CoV-1 but much higher than that of MERS-CoV [@doi:10.1093/ajcp/aqaa029; @doi:10.1093/ajcp/aqaa029].
While the structures of the viruses are very similar, evolution among these species may account for differences in their transmissibility and virulence.
For example, the acquisition of a furin cleavage site the S1/S2 boundary within the SARS-CoV-2 S protein may be associated with increased virulence.
Additionally, concerns have been raised about the accumulation of mutations within the SARS-CoV-2 species itself, and whether these could influence virulence.<!-- TODO: [cite evolution] -->
The coming of age of genomic technologies has made these types of analyses feasible, and genomics research characterizing changes in SARS-CoV-2 along with temporal and spatial movement is likely to provide additional insights into whether within-species evolution influences the effect of the virus on the human host.
Additionally, the rapid development of sequencing technologies over the past decade has made it possible to rapidly characterize the host response to the virus.
For example, proteomics analysis of patient-derived cells revealed candidate genes whose regulation is altered by SARS-CoV-2 infection, suggesting possible approaches for pharmaceutical invention and providing insight into which systems are likely to be disrupted in COVID-19 [@doi:10.1101/2020.03.31.019216].
As more patient data becomes available, the biotechnological advances of the 2000s are expected to allow for more rapid identification of potential drug targets than was feasible during the SARS, or even MERS, pandemic.

Thus, though the COVID-19 crisis is still evolving, the insights acquired over the past 20 years of HCoV research have provided a solid foundation for understanding the SARS-CoV-2 virus and the disease it causes.
As the scientific community continues to respond to COVID-19 and to elucidate more of the relationships between viral pathogenesis, transmission, and symptomatology, and as more data about the regulatory shifts associated with COVID-19 become available, this understanding will no doubt continue to evolve and to reveal additional connections among virology, pathogenesis, and health.
As additional information becomes available, this review will be updated to reflect the changing state of research in this area.
At present, understanding the SARS-CoV-2 virus and its pathogenesis is critical to a holistic understanding of the COVID-19 pandemic.



## Evolutionary and Genomic Analysis of SARS-CoV-2

### Abstract

### Introduction

### Initial Characterization of SARS-CoV-2

The first genome sequence of the virus was released on January 3, 2020. 
It revealed that the cluster of pneumonia cases seen in Wuhan were caused by a novel coronavirus [@doi:10.46234/ccdcw2020.017].
Multiple research groups have drafted the genome sequence of SARS-CoV-2 based on sequences developed from clinical samples collected from the lower respiratory tract, namely bronchoalveolar lavage fluid (BALF), and the upper respiratory tract, in the form of throat and nasopharyngeal swabs [@doi:10.1038/s41586-020-2008-3; @doi:10.1038/s41586-020-2012-7; @doi:10/ggjr43].
Analysis of the SARS-CoV-2 genome revealed significant sequence homology with two coronaviruses known to infect humans, with about 79% identity to SARS-CoV-1 and 50% to MERS-CoV [@doi:10/ggjr43].
However, in this analysis, the highest degree of similarity was observed between SARS-CoV-2 and bat-derived SARS-like coronaviruses (bat-SL-CoVZC45 and bat-SL-CoVZXC21) [@doi:10/ggjr43].
Other analyses have reported even greater similarity between SARS-CoV-2 and the bat coronavirus BatCoV-RaTG13, with identity as high as 96.2% [@doi:10.1038/s41586-020-2012-7; @doi:10.1093/nsr/nwaa036], and the closely related pangolin coronavirus [@doi:10.1101/2020.02.19.950253].
This evidence therefore suggests the SARS-CoV-2 virus is the result of zoonotic transfer of a virus from bats to humans.
Nevertheless, some fragments between SARS-CoV-2 and RATG13 differ by up to 17%, suggesting a complex natural selection process during zoonotic transfer.
While the _S_ region is highly similar to that of viruses found in pangolins [@doi:10.1101/2020.02.19.950253], there is no consensus about the origin of _S_ in SARS-CoV-2, as it could potentially be the result either of recombination or coevolution [@doi:10.1093/nsr/nwaa036; @doi:10.1126/sciadv.abb9153].
Though the intermediate host serving as the source for the zoonotic introduction of SARS-CoV-2 to human populations has not yet been identified, the SARS-CoV-2 virus has been placed within the coronavirus phylogeny through comparative genomic analyses.
Genomic analyses and comparisons to other known coronaviruses suggest that SARS-CoV-2 is unlikely to have originated in a laboratory -- either purposely engineered and released, or escaped -- and instead evolved naturally in an animal host [@doi:10.1038/s41591-020-0820-9].
Indeed, the World Health Organization (WHO) have published their intentions to thoroughly investigate the origins of SARS-CoV-2 [@url:https://www.who.int/docs/default-source/coronaviruse/20200802-tors-chn-and-who-agreed-final-version.pdf?sfvrsn=5323728d_2&download=true].
While the position of the SARS-CoV-2 virus within the coronavirus phylogeny has been largely resolved, the functional consequences of molecular variation between this virus and other viruses, such as its bat and pangolin sister taxa or SARS-CoV-1, remain unknown [@doi:10.1038/s41591-020-0820-9, @doi:10.1038/s41586-020-2012-7].
Fortunately, the basic genome structure of coronaviruses is highly conserved, and insight into the mechanisms the virus uses to enter cells, replicate, and spread is available from prior research on coronaviruses, which has been instrumental in the mobilization of global research to understand the biology of SARS-CoV-2. 

Additionally, worldwide sequencing of viral samples has provided some preliminary insights into possible mechanisms of adaptation in the virus and the detection of novel variants, and omics-based analysis of patient samples has elucidated some of the biological changes the virus induces in its human hosts.

### Coronaviruses and Animal Hosts

Coronaviruses have long been known to infect animals and have been the subject of veterinary medical investigations and vaccine development efforts due to their effect on the health of companion and agricultural animals [@doi:10/ckfn8b].
<!-- TO DO: Expand on the relationship between coronaviruses and animals -- which taxa are most often affected? how severe are veterinary infections? how has vaccine development worked for these diseases?--> 

<!-- TO DO: Be care to check overlap between this section and 20.pharmaceuticals.md. Trim to address just the important information about human-coronavirus interactions that feeds into an evolutionary perspective of how these host/virus interactions evolve across taxa and over time -->
Most coronaviruses show little to no transmission in humans.
However, it is thought that approximately one-third of common cold infections are caused by four seasonal human coronaviruses (HCoV): _Human coronavirus 229E_ (HCoV-229E), _Human coronavirus NL63_ (HCoV-NL63), _Human coronavirus OC43_ (HCoV-OC43), and _Human coronavirus HKU1_ (HCoV-HKU1) [@doi:10.1038/s41579-018-0118-9; @doi:10.3390/diseases4030026; @doi:10.1016/j.jcv.2018.01.019].
The first HCoV were identified in the 1960s: HCoV-229E in 1965 [@doi:10.3181/00379727-121-30734] and HCoV-OC43 in 1967 [@doi:10.1073/pnas.57.4.933].
Both of these viruses typically cause cold-like symptoms, including upper and lower respiratory infections [@doi:10.1186/1743-422X-1-7; @pmid:20700397; @doi:10.1186/s40779-020-00279-z], but they have also been associated with gastrointestinal symptoms [@doi:10.1111/j.1440-1754.2007.01246.x].
Two additional HCoV were subsequently identified [@doi:10.1038/nm1024; @doi:10.1128/JVI.79.2.884-895.2005].
In 2003, HCoV-NL63 [@doi:10.1038/nm1024] was first identified in a 7-month-old infant and then in clinical specimens collected from seven additional patients, five of whom were infants younger than 1 year old and the remainder of whom were adults.
CoV-HKU1 was identified in samples collected from a 71-year-old pneumonia patient in 2004 and then found in samples collected from a second adult patient [@doi:10.1128/JVI.79.2.884-895.2005].
These viruses are associated with respiratory diseases of varying severity, ranging from common cold to severe pneumonia, with severe symptoms mostly observed in immunocompromised individuals [@doi:10.1086/377612], and also have gastrointestinal involvement in some cases [@doi:10.1111/j.1440-1754.2007.01246.x].
In addition to these relatively mild HCoV, however, highly pathogenic human coronaviruses have been identified, including _Severe acute respiratory syndrome-related coronavirus_ (SARS-CoV or SARS-CoV-1) and _Middle East respiratory syndrome-related coronavirus_ (MERS-CoV) [@doi:10.1038/nrmicro.2016.81; @doi:10.1038/s41579-018-0118-9; @doi:10.1016/bs.aivir.2018.01.001].

At the time that SARS-CoV-1 emerged in the early 2000s, no HCoV had been identified in almost 40 years [@doi:10.1038/nrmicro.2016.81].
The first case of SARS was reported in November 2002 in the Guangdong Province of China, and over the following month, the disease spread more widely within China and then into several countries across multiple continents [@doi:10.1093/ajcp/aqaa029; @doi:10.1038/nrmicro.2016.81].
Unlike previously identified HCoV, SARS was much more severe, with an estimated death rate of 9.5% [@doi:10.1093/ajcp/aqaa029].
It was also highly contagious via droplet transmission, with a basic reproduction number (R~0~) of 4 (i.e., each person infected was estimated to infect four other people) [@doi:10.1093/ajcp/aqaa029].
However, the identity of the virus behind the infection remained unknown until April of 2003, when the SARS-CoV-1 virus was identified through a worldwide scientific effort spearheaded by the WHO [@doi:10.1038/nrmicro.2016.81].
SARS-CoV-1 belonged to a distinct lineage from the two other HCoV known at the time [@doi:10.1093/ajcp/aqaa029].
By July 2003, the SARS outbreak was officially determined to be under control, with the success credited to infection management practices [@doi:10.1038/nrmicro.2016.81].
A decade later, a second outbreak of severe respiratory illness associated with a coronavirus emerged, this time in the Arabian Peninsula.
This disease, known as Middle East respiratory syndrome (MERS), was linked to another novel coronavirus, MERS-CoV.
The fatality rate associated with MERS is much higher than that of SARS, at almost 35%, but the disease is much less easily transmitted, with an R~0~ of 1 [@doi:10.1093/ajcp/aqaa029].
Although MERS is still circulating, its low reproduction number has allowed for its spread to be contained [@doi:10.1093/ajcp/aqaa029].
The COVID-19 pandemic is thus associated with the seventh HCoV to be identified and the fifth since the turn of the millennium, though additional HCoVs may be in circulation but remain undetected.

SARS-CoV-1 and MERS-CoV were ultimately managed largely through infection management practices (e.g., mask wearing) and properties of the virus itself (i.e., low rate of transmission), respectively [@doi:10.1038/nrmicro.2016.81; @doi:10.1093/ajcp/aqaa029].
Vaccines were not used to control either outbreak, although vaccine development programs were established for SARS-CoV-1 [@doi:10.3390/v11010059].
In general, care for SARS and MERS patients focuses on supportive care and symptom management [@doi:10.1093/ajcp/aqaa029].
Clinical treatments for SARS and MERS developed during the outbreaks generally do not have strong evidence supporting their use.
Common treatments included Ribavirin, an antiviral, often in combination with corticosteroids or sometimes interferon (IFN) medications, which would both be expected to have immunomodulatory effects [@doi:10.1038/nrmicro.2016.81].
However, retrospective and _in vitro_ analyses have reported inconclusive results of these treatments on SARS and the SARS-CoV-1 virus, respectively [@doi:10.1038/nrmicro.2016.81].
IFNs and Ribavirin have shown promise in _in vitro_ analyses of MERS, but their clinical effectiveness remains unknown [@doi:10.1038/nrmicro.2016.81].
Therefore, only limited strategies can be adopted for the pharmaceutical management of COVID-19 from previous severe HCoV infections.
Research in response to prior outbreaks of HCoV-borne infections, such as SARS and MERS, have, however, provided a strong foundation for hypotheses about the pathogenesis of SARS-CoV-2 as well as potential diagnostic and therapeutic approaches.

### Zoonotic Transfer of Coronaviruses

<!-- TO DO: How does zoonotic transfer happen? What role has this played in previous HCoV outbreaks? How do viruses evolve during host species changes?-->

### Evolution of the SARS-CoV-2 Virus

#### Emergence of SARS-CoV-2

<!-- TO DO: Which zoonotic viruses have been identified as likely relatives of SARS-CoV-2? How do we know this viral species evolved naturally (as opposed to the conspiracy theories? What differs between SARS-CoV-2 and its close relatives?-->

#### Evolution of SARS-CoV-2 Variants

Evolution in SARS-CoV-2 has also been observed over a short timescale.
After zoonotic transfer, SARS-CoV-2 continued evolving in the human population [@doi:10.1186/s12967-020-02344-6].
The SARS-CoV-2 mutation rate is moderate compared to other RNA viruses [@doi:10.1016/j.meegid.2020.104351], which likely restricts the pace of evolution in SARS-CoV-2.
Nevertheless, genomic analyses have yielded statistical evidence of ongoing evolution.
Initially, two known variants of the spike protein emerged that differed by a single amino acid at position 614 (G614 and D614), and there is evidence that G614 had become more prevalent than D614 by June 2020 [@doi:10.1016/j.cell.2020.06.043].
While there is a hypothesis that this genomic change increased the SARS-CoV-2 infectivity and virulence, this hypothesis has not yet been tested due to a lack of data [@doi:10.1016/j.cell.2020.06.040].
Another study [@doi:10.1016/j.meegid.2020.104351] identified 198 recurrent mutations in a dataset of 7,666 curated sequences.
This pattern of convergent evolution at some sites could indicate that certain mutations confer an adaptive advantage.
While it is evident that SARS-CoV-2 exhibits moderate potential for ongoing and future evolution, the relationship between mutations and pathogenicity is not yet known.
Additional data is needed in order to understand patterns of evolutionary change and whether they are likely to affect virulence.

Several factors could promote the evolution of SARS-CoV-2, including host immunodeficiency and transient exposure to antibodies directed against SARS-CoV-2 proteins. 
A single case study of SARS-CoV-2 infection in an immunocompromised female with chronic lymphocytic leukemia and hypogammaglobulinemia [@doi:10.1016/j.cell.2020.10.049] suggested that an accelerated evolution of the virus could occur in conditions of immunodeficiency. 
A first administration of convalescent plasma did not clear the virus, and an ensuing increase in the genomic diversity in the samples was observed, suggesting an accelerated evolution due to selection pressure. 
A second administration of convalescent plasma cleared the virus from the host 105 days after the initial diagnosis. 
However, throughout the duration of infection, the patient was asymptomatic but contagious.
A second single case study in a 45-year old male with antiphospholipid syndrome [@doi:10.1056/NEJMc2031364] confirmed the earlier results, providing evidence of persistent COVID-19 symptoms in an immunocompromised patient for 154 days following diagnosis, ultimately leading to the death of patient. 
The treatments administered included remdesivir and the Regeneron anti-spike protein antibody cocktail. 
Genomic analyses of the patient's nasopharyngeal swabs confirmed an accelerated evolution of the virus through mutations in the spike gene and the receptor-binding domain. 
In summary, these two case studies suggested an accelerated evolution and persistent shedding of the virus in conditions of immunodeficiency. 
In particular, the first case highlighted the role of convalescent plasma in creating escape variants. 
In fact, one study [@doi:10.1101/2020.12.28.424451] exposed the SARS-CoV-2 virus to convalescent plasma _in vitro_ repeatedly to see how much plasma was required to neutralize the virus.
The results of the first six exposures were similar, but they reported that after the seventh exposure (on day 45), the amount of plasma required began to increase.
In analyzing the viral variants present, they found that this viral escape was promoted by the sudden accumulation of mutations, especially in the receptor-binding domain (RBD) and N-terminal domain (NTD), that quickly rose in frequency.
By the thirteenth exposure (day 85), the virus had evolved three mutations and could not longer be neutralized by the plasma used.
Taken together, these observations suggest that evolutionary analyses of SARS-CoV-2 can provide crucial information about the conditions that promote resistance in SARS-CoV-2 and the kinetics of how resistance develops, information which will be important for understanding the implications of how vaccine regimens are designed and whether/when next-generation vaccines will be needed.

When variants occur, they can rise in frequency by chance or through an adaptive process that confers a competitive advantage to the virus.
Variants that had the D614G mutation in the spike glycoprotein seemed to spread faster. <!-- TO DO: add more history of this variant?-->
However, it has been suggested that the mutation rose in frequency due to early chance events rather than by adaptive events [@doi:10.1001/jama.2020.27124].
Another mutation, Y453F, that occurred in the receptor binding domain of _S_, was first detected in mink; however, the transmission to humans has been established.
In mink, this mutation conferred an advantage by increasing the affinity towards ACE2 [@doi:10.1126/science.abe5901].
Similarly, N501Y mutation induces an increased affinity towards human ACE2 and has been involved in the dominance of B.1.1.7 by outcompeting other variants [@doi:10.1101/2020.12.24.20248822].
Therefore, genomic surveillance is essential to prevent the emergence of super-spreaders [@doi:10.1126/science.abf2946].

Emerging methods are being applied to this problem in an effort to understand which mutations are most likely to be of significant concern.
Novel machine learning methods were developed to predict the mutations in the sequence that promote viral escape.
While they preserve the pathogenicity of the virus, escape mutations change the virus's sequence to evade detection by the immune system. 
By using tools from natural language processing (NLP), viral escape was modeled as an NLP problem [@doi:10.1126/science.abd7331] where a modification makes a sentence grammatically correct but semantically different.
Therefore, language models of viruses could predict mutations that change the presentation of the virus to the immune system but preserve its infectivity.

#### Variants of concern and variants under surveillance

Viral replication naturally leads to the occurrence of mutations, and thus to genetic variation [@doi:10.1038/s41564-020-0690-4].
The emergence of new genetic variants of SARS-CoV-2 has attracted significant media attention since the detection of a variant of concern (VOC), a distinct phylogenetic cluster referred to as B.1.1.7/VOC 202012/01.
While the B.1.1.7 lineage garnered attention in November 2020, two genomes of the lineage were detected as early as September 20th, 2020 from routine genomic data sampled in Kent (U.K.) by the COVID-19 Genomics UK Consortium (COG-UK). 
The following day, a second B.1.1.7 genome was reported in greater London [@url:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/947048/Technical_Briefing_VOC_SH_NJL2_SH2.pdf; @url:https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563; @doi:10.1101/2020.12.30.20249034; @doi:10.1001/jama.2020.27124]
Since then, B.1.1.7 has spread across the UK and internationally, and it has now been detected in at least 62 countries [@url:https://cov-lineages.org/global_report_B.1.1.7.html], despite several countries imposing travel restrictions on travelers from the UK. 
Of the twenty-three mutations that define B.1.1.7 from the original strain isolated in Wuhan (lineage A), fourteen are lineage-specific and three appear to be biologically consequential mutations associated with the spike protein, namely N501Y, P681H, and 69-70del [@url:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/947048/Technical_Briefing_VOC_SH_NJL2_SH2.pdf;  @url:https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563].
The latter is a 6-bp deletion that leads to the loss of two amino acids and has consequences for immune recognition; it may, in conjunction with N501Y, be responsible for the increased transmissibility of the B.1.1.7 VOC due to changes in the RBD that increase binding affinity with ACE2 [@url:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/947048/Technical_Briefing_VOC_SH_NJL2_SH2.pdf; @doi:10.1101/2020.12.14.422555]. 
B.1.1.7 has increased transmissibility by up to 56%, leading to an R~0~ of approximately 1.4.
While there is also the possibility that this VOC may be associated with increased disease severity, there is currently insufficient evidence to draw any conclusions [@url:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/955239/NERVTAG_paper_on_variant_of_concern__VOC__B.1.1.7.pdf; @doi:10.1101/2020.12.24.20248822; @doi:10.1101/2020.12.30.20249034; @url:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/952490/Variant_of_Concern_VOC_202012_01_Technical_Briefing_4_England.pdf].
Other variants also express the 69-70del mutation [@url:https://virological.org/t/identification-of-a-novel-sars-cov-2-spike-69-70-deletion-lineage-circulating-in-the-united-states/577; @doi:10.1101/2020.12.24.20248814], and public health officials in the United States and the UK have been able to use RT-PCR-based assays (ThermoFisher TaqPath COVID-19 assay) to identify sequences with this deletion because it occurs where the qPCR probe binds [@doi:10.1101/2020.12.30.20249034]. 
In the UK, B.1.1.7 is present in more than 97% of diagnostic tests that return negative for S-gene targets and positive for the other targets; thus, the frequency of S-gene target failure can be used as a proxy for the detection of B.1.1.7 [@url:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/947048/Technical_Briefing_VOC_SH_NJL2_SH2.pdf; https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950823/Variant_of_Concern_VOC_202012_01_Technical_Briefing_3_-_England.pdf]._
The FDA has highlighted that the performance of three diagnostic tests may be affected by the B.1.1.7 lineage because it could cause false negative tests [@url:https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2].

While B.1.1.7 is currently the main VOC, other genetic variants not designated VOCs have been detected, including B.1.351 (20H/501Y.V2) and P.1 (20J/501Y.V3), both of which emerged independently [@url:https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html].
B.1.351 was first detected in October 2020 in South Africa, was later detected in the EU on December 28th, 2020 and has now spread to at least 26 countries [@url:https://www.gov.za/speeches/minister-zweli-mkhize-confirms-8-725-more-cases-coronavirus-covid-19-18-dec-2020-0000; @url:https://cov-lineages.org/global_report_B.1.351.html; @url:https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592]. 
B.1.351 contains several mutations at the RBD including K417N, E484K, and N501Y.
While the biological significance of these mutations are still under investigation, it does appear that this lineage may be associated with increased transmissibility [@doi:10.1101/2020.12.21.20248640] due to the N501Y mutation [@doi:10.1101/2020.12.14.422555; @url:https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563].
The P.1 variant is a branch of the B.1.1.28 lineage that was first detected in Japan in samples obtained from four travelers from Brazil during a screening at a Tokyo airport on January 10, 2021 [@url:https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA-first-update.pdf].
Shortly thereafter, it was established that there was a concentration of cases of the P.1 variant in Manaus, in the Amazonas State, Brazil.
In a small number of samples (n=31) sequenced in Manaus, 42% were identified as the P.1 variant as early as mid-December, but the variant seemed to be absent in genome surveillance testing prior to December [@url:https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586].
To date, at least eight countries have detected the P.1 lineage [@url:https://cov-lineages.org/global_report_P.1.html].
While the majority of P.1 cases detected internationally have been linked to travel originating from Brazil, the UK has also reported evidence of community transmission detected via routine community sequencing [@url:https://cov-lineages.org/global_report_P.1.html; @url:https://www.reuters.com/article/us-health-coronavirus-britain-variants/uk-detects-77-cases-of-south-african-covid-variant-nine-of-brazilian-idUSKBN29T07P].  
P.1 has eight lineage-specific mutations along with three concerning spike protein mutations in the RBD, including K417T, E484K, and N501Y [@doi:10.1101/2020.12.21.20248640].
 
There have been multiple different SARS-CoV-2 lineages detected that have mostly been of no more clinical concern than the original devastating lineage originating in Wuhan [@url:https://cov-lineages.org/lineages.html].
However, the spotlight has been cast on other variants of unknown clinical relevance due to the increase of cases observed that have been associated with B.1.1.7 in particular.  
Although early in its ascendency, CAL.20C (B.1.429) is a SARS-CoV-2 variant that was detected in California, USA [@doi:10.1101/2021.01.18.21249786].
It was first detected in July 2020 but was not detected again until October 2020. 
In December 2020, CAL.20C accounted for ~24% of the total cases in Southern California and ~36% of total cases in the Los Angeles area. 
CAL.20C has now been detected in New York and Washington, D.C., and some cases have been reported outside the USA in Oceania [@doi:10.1101/2021.01.18.21249786].
This variant is characterized by five lineage-specific mutations (ORF1a: I4205V, ORF1b:D1183Y, S: S13I;W152C;L452R).
The latter spike mutation, L452R, is found in an area of the RBD known to resist monoclonal antibodies to the spike protein [@doi:10.1016/j.cell.2020.07.012], and it is hypothesized that this mutation may resist polyclonal sera in convalescent patients or in individuals post-vaccination [@doi:10.1101/2020.12.31.425021; @doi:10.1101/2021.01.18.21249786].
CAL.20C is not a designated VOC; however, further research is required to determine the implications of the mutations encoded in this genetic variant.  
Another notable variant has recently been discovered in 35 patients in a Bavarian hospital in Germany; however, the sequencing data has not been published to date and it remains to be determined whether this variant is of any further concern [@url:https://www.br.de/nachrichten/bayern/neue-coronavirus-mutation-35-faelle-in-garmisch-partenkirchen,SMQ1V6u].

There are several shared mutations and deletions between the three lineages, P.1, B.1.1.7, and B.1.315 and indeed other variants of SARS-CoV-2 that are under investigation [@url:https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586].
For example, N501Y, which appears to have occurred independently in each of the three lineages.  
E484K is present in both B.1.351 and P.1 [@url:https://cov-lineages.org/global_report.html].
The mutations N501Y and E484K are found in the RBD within the receptor-binding motif responsible for forming an interface with the ACE2 receptor, which seems to be consequential for ACE2 binding affinity [@doi:10.1016/j.cell.2020.08.012].
Indeed, N501Y is associated with increased virulence and infectivity in mouse models [@doi:10.1126/science.abc4730].
E484K has also been associated with evasion from neutralizing antibodies [@doi:10.1016/j.chom.2020.11.007; @doi:10.1101/2020.12.28.424451; @doi:10.1101/2020.12.31.425021].
The del69-70 (del:11288:9) is also shared between P.1 and B.1.1.7 and happens to be a common deletion found in the N terminal mutation of the spike protein. 
This deletion has also been associated with several RBD mutations [@doi:10.1101/2020.11.19.389916; @doi:10.1101/2020.12.14.422555; @url:https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563].
There is concern that mutations in the spike protein of variants may lead to clinical consequences for transmissibility, disease severity, re-infection, therapeutics, and vaccinations [@doi:10.1126/science.abg4312; @url:https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596; @doi:10.1101/2020.12.28.424451; @doi:10.1101/2020.12.31.425021; @doi:10.1038/d41586-021-00121-z; @doi:10.1126/science.abf9302; @doi:10.1126/science.371.6527.329]. 

Vaccine producers are working to determine whether the vaccines are still effective against the novel genetic variants.
Moderna recently published data for their mRNA-1273 vaccine that showed no significant impact of neutralization against the B.1.1.7 variant upon vaccination in humans and non-human primates. 
On the other hand, Moderna reported a reduced but significant neutralization against the B.1.351 variant upon vaccination [@doi:10.1101/2021.01.25.427948].
Indeed, Pfizer–BioNTech reported that sera from twenty participants vaccinated with the BNT162b COVID-19 vaccine in previous clinical trials [@doi:10.1056/NEJMoa2034577; @doi:10.1056/NEJMoa2027906] elicited equivalent neutralizing titers against isogenic Y501 SARS-CoV-2 on an N501Y genetic background _in vitro_ [@doi:10.1101/2021.01.07.425740].
Another study has reported that the plasma neutralizing activity against SARS-CoV-2 variants encoding the combination of K417N:E484K:N501Y or E484K or N501Y was variably and significantly reduced in the sera of twenty participants who received either the Pfizer–BioNTech BNT162b (n = 6) vaccine or the Moderna’s mRNA-1273 vaccine (n =14) [@doi:10.1101/2021.01.15.426911]. 
For now, the consensus appears to be that the FDA approved vaccines still seem to be effective against the genetic variants of SARS-CoV-2 and their accompanying mutations, albeit with a slightly lower neutralizing capacity [@doi:10.1073/pnas.2008281117; @doi:10.1101/2021.01.15.426911; @doi:10.1101/2021.01.07.425740; @doi:10.1101/2021.01.25.427948]. 
Further research is required to discern the clinical, prophylactic, and therapeutic consequences of these genetic SARS-CoV-2 variants as the pandemic evolves. 

### Conclusions

As of October 2020 the SARS-CoV-2 virus remains a serious worldwide threat.
The scientific community has responded by rapidly collecting and disseminating information about the SARS-CoV-2 virus and the associated illness, COVID-19.
The rapid identification of the genomic sequence of the virus allowed for early contextualization of SARS-CoV-2 among other known respiratory viruses.
The pathogen is a coronavirus that is closely related to SARS-CoV-1, which caused the SARS pandemics of the early 2000s.
Knowing the phylogenetic context and genomic sequence of the virus then allowed for rapid insights into its structure and pathogenesis.


## Diagnostics

### Abstract

### Introduction

Identifying individuals who have contracted COVID-19 is crucial to slowing down the global pandemic.
Given the high transmissibility of SARS-CoV-2, the development of reliable assays to detect SARS-CoV-2 infection even in asymptomatic carriers is vitally important.
For instance, the deployment of wide-scale diagnostic testing followed by the isolation of infected people has been a key factor in South Korea's successful strategy for controlling the spread of the virus.
Following the first release of the genetic sequence of the virus by Chinese officials on January 10, 2020, the first test was released about 13 days later [@doi:10.2807/1560-7917.ES.2020.25.3.2000045].
Diagnostic approaches utilizing a variety of methods are currently or have been developed.
There are two main classes of diagnostic tests: molecular tests, which can diagnose an active infection by identifying the presence of SARS-CoV-2, and serological tests, which can assess whether an individual was infected in the past via the presence or absence of antibodies against SARS-CoV-2.
Molecular tests are essential for identifying individuals for treatment and alerting their contacts to quarantine and be alert for possible symptoms.
While serological tests may be of interest to individuals who wish to confirm they were infected with SARS-CoV-2 in the past, their potential for false positives means that they are not currently recommended for this use.
However, serological tests provide population-level information for epidemiological analysis, as they can be used to estimate the extent of the infection in a given area.
Thus, they may be useful in efforts to better understand the percent of cases that manifest as severe versus mild and for guiding public health and economic decisions regarding resource allocation and counter-disease measures.

Understanding the fundamental organization of the human immune response to viral threats is critical to understanding the varied response to SARS-CoV-2.
The human immune system utilizes a variety of innate and adaptive responses to protect against the pathogens it encounters.
The innate immune system consists of barriers, such as the skin, mucous secretions, neutrophils, macrophages, and dendritic cells.
It also includes cell-surface receptors that can recognize the molecular patterns of pathogens.
The adaptive immune system utilizes antigen-specific receptors that are expressed on B and T lymphocytes.
These components of the immune system typically act together; the innate response acts first, and the adaptive response begins to act several days after initial infection following the clonal expansion of T and B cells [@doi:10.1016/j.jaci.2005.09.034].
After a virus enters into a host cell, its antigen is presented by major histocompatibility complex 1 (MHC 1) molecules and is then recognized by cytotoxic T lymphocytes.

In the case of COVID-19, there is also concern about the immune system becoming over-active.
One of the main immune responses contributing to the onset of acute respiratory distress syndrome (ARDS) in COVID-19 patients is cytokine storm syndrome (CSS), which causes an extreme inflammatory response due to a release of pro-inflammatory cytokines and chemokines by immune effector cells.
In addition to respiratory distress, this mechanism can lead to organ failure and death in severe COVID-19 cases [@doi:10.1016/j.jpha.2020.03.001].

### Molecular Tests

Molecular tests are used to identify distinct genomic subsequences of a viral molecule in a sample and thus to diagnose an active viral infection.
This first requires identifying which biospecimens are likely to contain the virus during infection and then acquiring these samples from the patient(s) to be tested.
Common sampling sources for molecular tests include nasopharyngeal cavity samples, such as throat wash and saliva [@doi:10/ggp4qx], and stool samples [@doi:10.1002/jmv.25742].
Once a sample is acquired from a patient, molecular testing will utilize a number of steps, described below, to analyze a sample and identify whether evidence of SARS-CoV-2 is present.
When testing for RNA viruses like SARS-CoV-2, pre-processing is necessary in order to create DNA from the RNA sample.
The DNA can then be amplified with PCR.
Some tests use the results of the PCR itself to determine whether the pathogen is present, but in other cases, it may be necessary to sequence the amplified DNA.
Sequencing requires an additional pre-processing step: library preparation.
Library preparation is the process of preparing the sample for sequencing, typically by fragmenting the sequences and adding adapters [@doi:10.1016/j.biotechadv.2020.107537].
In some cases, library preparation can involve other modifications of the sample, such as adding "barcoding" to identify a particular sample in the sequence data, which is useful for pooling samples from multiple sources.
There are different reagents used for library preparation that are specific to identifying one or more target sections with PCR [@doi:10.1021/acsnano.0c02624].
Sequential pattern matching is then used to identify unique subsequences of the virus that identify it in specific.
If sufficient subsequences are found, the test is considered positive.

#### RT-PCR

Real-Time Polymerase Chain Reaction (RT-PCR) tests determine whether a target is present by measuring the rate of amplification during PCR compared to a standard.
When the target is RNA, such as in the case of RNA viruses, the RNA must be converted into complementary DNA during pre-processing.
The Drosten Lab, from Germany, was the first lab to establish and validate a diagnostic test to detect SARS-CoV-2.
This test uses RT-PCR with reverse transcription [@doi:10.2807/1560-7917.ES.2020.25.3.2000045] to detect several regions of the viral genome: the _ORF1b_ of the RNA-dependent RNA polymerase (RdRP), the Envelope protein gene (_E_), and the Nucleocapsid protein gene (_N_).
In collaboration with several other labs in Europe and in China, the researchers confirmed the specificity of this test with respect to other coronaviruses against specimens from 297 patients infected with a broad range of respiratory agents.
Specifically this test utilizes two probes against RdRP, one of which is specific to SARS-CoV-2 [@doi:10.2807/1560-7917.ES.2020.25.3.2000045].
Importantly, this assay was not found to return false positive results.

#### qRT-PCR

Chinese researchers developed a quantitative real-time reverse transcription PCR (qRT-PCR) test to identify two gene regions of the viral genome, _ORF1b_ and _N_ [@doi:10.1093/clinchem/hvaa029].
This assay was tested on samples coming two COVID-19 patients and a panel of positive and negative controls consisting of RNA extracted from several cultured viruses.
The assay uses the _N_ gene to screen patients, while the _ORF1b_ gene region is used to confirm the infection [@doi:10.1093/clinchem/hvaa029].
In this case the test was designed to detect sequences conserved across sarbecoviruses, or viruses within the same subgenus as SARS-CoV-2.
Considering that SARS-CoV-1 and SARS-CoV-2 are the only sarbecoviruses currently known to infect humans, a positive test can be assumed to indicate that the patient is infected with SARS-CoV-2.
However, this test is not able to discriminate the genetics of viruses within the sarbecovirus clade.

##### dPCR

Digital PCR (dPCR) is a new generation of PCR technologies offering an alternative to traditional real-time quantitative PCR.
In dPCR, a sample is partitioned into thousands of compartments, such as nanodroplets (droplet dPCR or ddPCR) or nanowells, and a PCR reaction takes place in each compartment.
This design allows for a digital read-out where each partition is either positive or negative for the nucleic acid sequence being tested for, allowing for much higher throughput.
While dPCR equipment is not yet as common as that for RT-PCR, dPCR for DNA targets generally achieves higher sensitivity than other PCR technologies while maintaining high specificity, though sensitivity is slightly lower for RNA targets [@doi:10.3390/s18041271].
High sensitivity is particularly relevant for SARS-CoV-2 detection, since low viral load in clinical samples can lead to false negatives.
Suo et al. [@doi:10.1080/22221751.2020.1772678] performed a double-blind evaluation of ddPCR for SARS-CoV-2 detection on 57 samples, comprised by 43 samples from suspected positive patients and 14 from supposed convalescents, that had all tested negative for SARS-CoV-2 using RT-PCR.
Despite the initial negative results, 33 out of 35 (94.3%) patients were later clinically confirmed positive.
All of these individuals tested positive using ddPCR.
Additionally, of 14 supposed convalescents who had received two consecutive negative RT-PCR tests, nine (64.2%) tested positive for SARS-CoV-2 using ddPCR.
Two symptomatic patients tested negative with both RT-PCR and ddPCR, but were later clinically diagnosed positive, and 5 of the 14 suspected convalescents tested negative by ddPCR.
While this study did not provide a complete head-to-head comparison to RT-PCR in all aspects, e.g., no samples testing positive using RT-PCR were evaluated by ddPCR, the study shows the potential of dPCR for viral detection even in highly diluted samples.
In a second study, Dong et al. [@doi:10.1101/2020.03.14.20036129] compared the results of qRT-PCR and ddPCR testing for SARS-CoV-2 in 194 samples, including 103 samples from suspected patients, 75 from contacts and close contacts, and 16 from suspected convalescents.
Of the 103 suspected patient samples, 29 were reported as positive, 25 as negative, and 49 as suspected by qRT-PCR; all patients were later confirmed to be SARS-CoV-2 positive.
Of the qRT-PCR negative or suspected samples, a total of 61 (17 negative and 44 suspected) were later confirmed to be positive by ddPCR, improving the overall detection rate among these patients from 28.2% to 87.4%.
Of 75 patient samples from contacts and close contacts, 48 tested negative with both methods, and these patients were observed to remain healthy.
Within the remaining 27 patient samples, 10 tested positive, 1 negative, and 16 suspect with qRT-PCR.
Fifteen out of 16 suspect samples and the negative test results were overturned by ddPCR, decreasing the rate of suspect cases from 21% to 1%.
Importantly, all samples that tested positive using qRT-PCR also tested positive using ddPCR.
Among the 16 convalescent patients, qRT-PCR identified 12 as positive, three as suspect, and one as negative, but RT-dPCR identified all 16 as positive.
This evidence further indicates that the lower limit of detection made possible by ddPCR may be useful for identifying when COVID-19 patients are cleared of the virus.
Overall, these studies suggest that dPCR is a promising tool for overcoming the problem of false-negative SARS-CoV-2 testing.

#### Pooled and Automated PCR Testing

Due to limited supplies and the need for more tests, several labs have found ways to pool or otherwise strategically design tests to increase throughput.
The first such result came from Yelin et al. [@doi:10.1101/2020.03.26.20039438], who found they could pool up to 32 samples in a single qPCR run.
This was followed by larger-scale pooling with slightly different methods [@doi:10.1101/2020.04.02.022186].
Although these approaches are also PCR based, they allow for more rapid scaling and higher efficiency for testing than the initial PCR-based methods developed.

##### CRISPR-based Detection

Two CRISPR-associated nucleases, Cas12 and Cas13, have been used for nucleic acid detection.
Multiple assays exploiting these nucleases have emerged as potential diagnostic tools for the rapid detection of SARS-CoV-2 genetic material and therefore SARS-CoV-2 infection.
The SHERLOCK method (Specific High-sensitivity Enzymatic Reporter unLOCKing) from Sherlock Biosciences relies on Cas13a to discriminate between inputs that differ by a single nucleotide at very low concentrations [@doi:10.1126/science.aam9321].
The target RNA is amplified by RT-RPA and T7 transcription, and the amplified product activates Cas13a.
The nuclease then cleaves a reporter RNA, which liberates a fluorescent dye from a quencher.
Several groups have used the SHERLOCK method to detect SARS-CoV-2 viral RNA.
An early study reported that the method could detect 7.5 copies of viral RNA in all 10 replicates, 2.5 copies in 6 out of 10, and 1.25 copies in 2 out of 10 runs [@doi:10.1101/2020.02.22.20025460].
It also reported 100% specificity and sensitivity on 114 RNA samples from clinical respiratory samples (61 suspected cases, among which 52 were confirmed and nine were ruled out by metagenomic next-generation sequencing, 17 nCoV-/HCoV+ cases and 36 samples from healthy subjects), and a reaction turnaround time of 40 minutes.
A separate study screened four designs of SHERLOCK and extensively tested the best-performing assay.
They determined the limit of detection to be 10 copies/&mu;l using both fluorescent and lateral flow detection [@doi:10.1101/2020.02.26.967026].
Lateral flow test strips are simple to use and read, but there are limitations in terms of availability and cost per test.
Another group therefore proposed the CREST protocol (Cas13-based, Rugged, Equitable, Scalable Testing), which uses a P51 cardboard fluorescence visualizer, powered by a 9V battery, for the detection of Cas13 activity instead of immunochromatography [@doi:10.1101/2020.04.20.052159].
CREST can be run, from RNA sample to result, with no need for AC power or a dedicated facility, with minimal handling in approximately 2 hours.
Testing was performed on 14 nasopharyngeal swabs.
CREST picked up the same positives as the CDC-recommended TaqMan assay with the exception of one borderline sample that displayed low-quality RNA.

The DETECTR method (DNA Endonuclease-Targeted CRISPR Trans Reporter) from Mammoth Biosciences involves purification of RNA extracted from patient specimens, amplification of extracted RNAs by loop-mediated amplification, which is a rapid, isothermal nucleic acid amplification technique, and application of their Cas12-based technology.
In their assay, guide RNAs were designed to recognize portions of sequences corresponding to the SARS-CoV-2 genome, specifically the N2 and E regions [@doi:10.1038/s41587-020-0513-4].
In the presence of SARS-CoV-2 genetic material, sequence recognition by the guide RNAs results in double-stranded DNA cleavage by Cas12, as well as cleavage of a single-stranded DNA molecular beacon.
The cleavage of this molecular beacon acts as a colorimetric reporter that is subsequently read out in a lateral flow assay and indicates the positive presence of SARS-CoV-2 genetic material and therefore SARS-CoV-2 infection.
The 40-minute assay is considered positive if there is detection of both the E and N genes or presumptive positive if there is detection of either of them.
The assay had 95% positive predictive agreement and 100% negative predictive agreement with the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT–PCR assay.
The estimated limit of detection was 10 copies per &mu;l reaction, versus 1 copy per &mu;l reaction for the CDC assay.
These results have been confirmed by other DETECTR approaches.
Using RTRPA for amplification, another group detected 10 copies of synthetic SARS-CoV-2 RNA per &mu;l of input within 60 minutes of RNA sample preparation in a proof-of-principle evaluation [@doi:10.1101/2020.02.29.971127].
The DETECTR protocol was improved by combining RT-RPA and CRISPR-based detection in a one-pot reaction that incubates at a single temperature, and by using dual crRNAs (which increases sensitivity).
This new assay, known as All-In-One Dual CRISPR-Cas12a (AIOD-CRISPR), detected 4.6 copies of SARS-CoV-2 RNA per &mu;l of input in 40 minutes [@doi:10.1101/2020.03.19.998724].
Another single-tube, constant-temperature approach using Cas12b instead of Cas12a achieved a detection limit of 5 copies/&mu;l in 40-60 minutes [@doi:10.1101/2020.04.10.023358].
It was also reported that that electric field gradients can be used to control and accelerate CRISPR assays by co-focusing Cas12-gRNA, reporters, and target [@doi:10.1101/2020.05.21.109637].
The authors generated an appropriate electric field gradient using a selective ionic focusing technique known as isotachophoresis (ITP) implemented on a microfluidic chip.
They also used ITP for automated purification of target RNA from raw nasopharyngeal swab samples.
Combining this ITP purification with loop-mediated isothermal amplification, their ITP-enhanced assay to achieved detection of SARS-CoV-2 RNA (from raw sample to result) in 30 minutes.

There is an increasing body of evidence that CRISPR-based assays offer a practical solution for rapid, low-barrier testing in areas that are at greater risk of infection, such as airports and local community hospitals.
In the largest study to date, DETECTR was compared to qRT-PCR on 378 patient samples [@doi:10.1101/2020.07.27.20147249].
The authors reported a 95% reproducibility.
Both techniques were equally sensitive in detecting SARS-CoV-2.
Lateral flow strips showed a 100% correlation to the high-throughput DETECTR assay.
Importantly, DETECTR was 100% specific for SARS-CoV-2 and did not detect other human coronaviruses.

#### Limitations of Molecular Tests

Tests that identify SARS-CoV-2 using nucleic-acid-based technologies will identify only individuals with current infections and are not appropriate for identifying individuals who have recovered from a previous infection.
Within this category, different types of tests have different limitations.
For example, PCR-based test can be highly sensitive, but in high-throughput settings they can show several problems:

1. False-negative responses, which can present a significant problem to large-scale testing.
   To reduce occurrence of false negatives, correct execution of the analysis is crucial [@doi:10.1038/d41587-020-00002-2].
2. Uncertainty surrounding the SARS-CoV-2 viral shedding kinetics, which could affect the result of a test depending on when it was taken [@doi:10.1038/d41587-020-00002-2].
3. Type of specimen, as it is not clear which clinical samples are best for detecting the virus [@doi:10.1038/d41587-020-00002-2].
4. Expensive machinery, which might be present in major hospitals and/or diagnostic centers but is often not available to smaller facilities [@doi:10.1126/science.abb8400].
5. Timing of the test, which might take up to 4 days to return results [@doi:10.1126/science.abb8400].
6. The availability of supplies for testing, including swabs and testing media, has been limited [@doi:10.1128/JCM.00512-20].
7. Because the guide RNA can recognize other interspersed sequences on the patient’s genome, false positives and a loss of specificity can occur.

Similarly, in tests that use CRISPR, false positives can occur due to the specificity of the technique, as the guide RNA can recognize other interspersed sequences on the patient’s genome.
As noted above, false negatives are a significant concern for several reason.
Importantly, clinical reports indicate that it is imperative to exercise caution when interpreting the results of molecular tests for SARS-CoV-2 because negative results do not necessarily mean a patient is virus-free [@doi:10.1128/JCM.00297-20].

### Serological Tests

Although diagnostic tests based on the detection of genetic material can be quite sensitive, they cannot provide information about the extent of the disease over time.
Most importantly, they would not work on a patient who has fully recovered from the virus at the time of sample collection.
In this context, serological tests, which use serum to test for the presence of antibodies against SARS-CoV-2, are significantly more informative.
Additionally, serological tests can help scientists to understand why the disease has a different course among patients, as well as which strategies might work to manage the spread of the infection.
Furthermore, serological tests hold significant interest because of the possibility that they could provide information relevant to advancing economic recovery and allowing reopenings.
For instance, people that had developed antibodies might be able to return to work, assuming (still-unproven) protective immunity [@doi:10.1101/2020.04.14.20065771].
Some infectious agents can be controlled through "herd immunity", which is when a critical mass within the population acquires immunity through vaccination and/or infection, preventing an infectious agent from spreading widely.
A simple SIR model predicts that to achieve the required level of exposure for herd immunity to be effective, at least (1-(1/R0)) fraction of the population must be immune or, equivalently, less than (1/R0) fraction of the population susceptible [@isbn:9780199209996].
However, for SARS-CoV-2 and COVID-19, the R0 and mortality rates that have been observed suggest that relying on herd immunity without some combination of vaccines, proven treatment options, and strong non-pharmaceutical measures of prevention and control would likely result in a significant loss of life.

#### Sustained Immunity to COVID-19

In the process of mounting a response to a pathogen, the immune system produces antibodies specific to the pathogen.
Understanding the acquisition and retention of antibodies is important both to the diagnosis of prior (inactive) infections and to the development of vaccines.
The two immunoglobulin classes most pertinent to these goals are immunoglobulin M (IgM), which are the first antibodies produced in response to an infection, and immunoglobulin G (IgG), which are the most abundant antibodies found in the blood.
Following SARS infection, IgM and IgG antibodies were detected in the second week post-infection.
IgM titers peaked by the first month post-infection, and then declined to undetectable levels after day 180.
IgG titers peaked by day 60, and persisted in all donors through the two-year duration of study [@doi:10.1111/j.1440-1843.2006.00783.x].
A two-year longitudinal study following convalesced SARS patients with a mean age of 29 found that IgG antibodies were detectable in all 56 patients surveyed for at least 16 months, and remained detectable in all but 4 (11.8%) of patients through the full two-year study period [@doi:10.1086/500469].
These results suggest that immunity to SARS-CoV-1 is sustained for at least a year.

The persistence of antibodies to SARS-CoV-2 remains under investigation.
Circulating antibody titers to other coronaviruses have been reported to decline significantly after 1 year [@doi:10.1017/s0950268800048019].
Autopsies of lymph nodes and spleens from severe acute COVID-19 patients showed a loss of T follicular helper cells and germinal centers that may explain some of the impaired development of antibody responses [@doi:10.1016/j.cell.2020.08.025].
An early study (initially released on _medRxiv_ on February 25, 2020) presented a chemiluminescence immunoassay to a synthetic peptide derived from the amino acid sequence of the SARS-CoV-2 _S_ protein [@doi:10.1093/infdis/jiaa243].
This method was highly specific to SARS-CoV-2 and detected IgM in 57.2% and IgG in 71.4% and 57.2% of sera samples from 276 confirmed COVID-19 patients.
They reported that they could detect IgG within two days of the onset of fever and were not able to detect IgM any earlier, a pattern they compared to findings in MERS.
Since then, several trials have reported the potential protective effect of antibodies in convalescent plasma obtained from recovered COVID-19 patients to treat critically ill COVID-19 patients [@doi:10.1172/jci138745; @doi:10.1001/jama.2020.4783; @doi:10.1056/NEJMoa2031893].

<!--TODO: add https://www.nature.com/articles/s41591-020-0965-6#Sec9 and evalute reports of recurrence.-->
Evidence to date suggests that sustained immunity to SARS-CoV-2 occurs for a period of at least 6-8 months [@doi:10.3201/eid2703.204543; @doi:10.1126/science.abf4063; @pmid:33443036].
One study assessed sustained immunity using 245 blood samples from 188 COVID-19 positive patients  [@doi:10.1126/science.abf4063]. 
The samples were collected at various time points between 6 and 240 days post-symptom onset, meaning some patients were assessed longitudinally. 
Of the samples, 43 were collected at least 6 months after symptom onset.
After 1 month, 98% of patients were seropositive for Spike IgG. 
Moreover, Spike IgG titers were stable and heterogeneous among patients over a period of 6 to 8 months post-symptom onset, with 90% of subjects seropositive at 6 months.
Similarly, at 6 to 8 months 88% of patients were seropositive for receptor binding domain (RBD) IgG and 90% were seropositive for SARS-CoV-2 neutralizing antibodies.
Memory B cells and memory T cells were also measured.
SARS-CoV-2 Spike-specific memory B cell levels steadily rose over the first 120 days following symptom onset. 
RBD-specific memory B cells had been detected in COVID-19 patients 90 days post-symptom onset in previous studies [@doi:10.1016/j.cell.2020.11.029; @pmid:33443036], and this study confirms these finding and shows that these cells steadily increase over the 4-5 months post-symptom onset [@doi:10.1126/science.abf4063].
Likewise, nucleocapsid-specific memory B cells seem to follow a similar pattern [@doi:10.1126/science.abf4063].
SARS-CoV-2 memory CD8+ T cells were also detected in 70% of 169 COVID-19 patients after 1 month [@doi:10.1126/science.abf4063], which is consistent with previous research [@doi:10.1016/j.cell.2020.05.015].
However, SARS-CoV-2 memory CD8+ T cells were slightly decreased (50%) 6 months post-symptom onset. 
In this same subset of COVID-19 patients, 93% of subjects had detectable levels of SARS-CoV-2 memory CD4+ T cells, of which 42% had > 1% SARS-CoV-2-specific CD4+ T cells.
At 6 months, 92% of patients were positive for SARS-CoV-2 memory CD4+ T cells.
Indeed, the spike-specific memory CD4+ T cells abundance over time were similar to the overall SARS-CoV-2-specific CD4+ T cells [@doi:10.1126/science.abf4063].
T cell immunity to SARS-CoV-2 at 6-8 months post-symptom onset has also been confirmed by others [@doi:10.1101/2020.11.01.362319; @doi:10.1101/2020.12.08.416636].
In another study, T cell reactivity to SARS-CoV-2 epitopes was also detected in some individuals never before exposed to SARS-CoV-2. 
This indicates that there is potential for cross-reactive T cell recognition between SARS-CoV-2 and pre-existing circulating coronaviruses that are responsible for the “common cold” [@doi:10.1016/j.cell.2020.05.015], but further research is required.
There is concern that immunity may wane over time, as there several reported cases of reinfection have been confirmed via genomic analysis that revealed distinct variants of SARS-CoV-2 within a single patient [@doi:10/ghfgkt; @doi:10.1093/cid/ciaa1451; @doi:10.1093/cid/ciaa1275].
Further research is required to determine the full extent to which sustained immunity can be and is typically achieved following SARS-CoV-2 infection
Furthermore, it is unclear whether previous infection may carry repercussions in terms of disease severity for patients [@doi:10/fscx] and what implications the possibility of reinfection holds for vaccine development and the long-term efficacy of vaccines [@doi:10.1038/s41591-020-1121-z; @doi:10.3389/fimmu.2020.571481]. 

#### Current Approaches

Several countries are now focused on implementing antibody tests, and in the United States, the FDA recently approved a serological test by Cellex for use under emergency conditions [@url:https://www.fda.gov/media/136625/download].
Specifically, the Cellex qSARS-CoV-2 IgG/IgM Rapid Test is a chromatographic immunoassay designed to qualitatively detect IgM and IgG antibodies against SARS-CoV-2 in the plasma (from a blood sample) of patients suspected to have developed the SARS-CoV-2 infection [@url:https://www.fda.gov/media/136625/download].
Such tests illuminate the progression of viral disease, as IgM are the first antibodies produced by the body and indicate that the infection is active.
Once the body has responded to the infection, IgG are produced and gradually replace IgM, indicating that the body has developed immunogenic memory [@doi:10.1002/jmv.25820].
The test cassette contains a pad of SARS-CoV-2 antigens and a nitrocellulose strip with lines for each of IgG and IgM, as well as a control (goat IgG) [@url:https://www.fda.gov/media/136625/download].
In a specimen that contains antibodies against the SARS-CoV-2 antigen, the antibodies will bind to the strip and be captured by the IgM and/or IgG line(s), resulting in a change of color [@url:https://www.fda.gov/media/136625/download].
With this particular assay, results can be read within 15-20 minutes [@url:https://www.fda.gov/media/136625/download].
Other research groups, such as the Krammer lab of the Icahn School of Medicine at Mount Sinai, proposed an ELISA test that detects IgG and IgM that react against the receptor binding domain (RBD) of the spike proteins (S) of the virus [@doi:10.1101/2020.03.17.20037713].
The authors are now working to get the assay into clinical use [@url:https://www.livescience.com/coronavirus-tests-available.html].

#### Limitations of Serological Tests

Importantly, false-positives can occur due to the cross-reactivity with other antibodies according to the clinical condition of the patient [@url:https://www.fda.gov/media/136625/download].
Therefore, this test should be used in combination with RNA detection tests [@url:https://www.fda.gov/media/136625/download].
Due to the long incubation times and delayed immune responses of infected patients, serological tests are insufficiently sensitive for a diagnosis in the early stages of an infection.
The limitations due to timing make serological tests far less useful for enabling test-and-trace strategies.

### Possible Alternatives to Current Practices for Identifying Active Cases

Clinical symptoms are too similar to other types of pneumonia to be sufficient as a sole diagnostics criterion.
In addition, as noted above, identifying asymptomatic cases is critical.
Even among mildly symptomatic patients, a predictive model based on clinical symptoms had a sensitivity of only 56% and a specificity of 91% [@doi:10.2807/1560-7917.ES.2020.25.16.2000508].
More problematic is that clinical symptom-based tests are only able to identify already symptomatic cases, not presymptomatic or asymptomatic cases.
They may still be important for clinical practice, and for reducing tests needed for patients deemed unlikely to have COVID-19.

X-ray diagnostics have been reported to have high sensitivity but low specificity in some studies [@doi:10.1148/radiol.2020200642].
Other studies have shown that specificity varies between radiologists [@doi:10.1148/radiol.2020200823], though the sensitivity reported here was lower than that published in the previous paper.
However, preliminary machine-learning results have shown far higher sensitivity and specificity from analyzing chest X-rays than was possible with clinical examination [@doi:10.1007/s13246-020-00865-4].
X-ray tests with machine learning can potentially detect asymptomatic or presymptomatic infections that show lung manifestations.
This approach would still not recognize entirely asymptomatic cases.
Given the above, the widespread use of X-ray tests on otherwise healthy adults is likely inadvisable.

### Strategies and Considerations for Determining Whom to Test

Early in the COVID-19 pandemic, testing was typically limited to individuals considered high risk for developing serious illness [@url:https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html].
This approach often involved limiting testing to people with severe symptoms and people showing mild symptoms that had been in contact with a person who had tested positive.
Individuals who are asymptomatic (i.e., potential spreaders) and individuals who are able to recover at home are therefore often unaware of their status.
However, this method of testing administration misses a high proportion of infections and does not allow for test-and-trace methods to be used.
For instance, a recent study from Imperial College estimates that in Italy, the true number of infections was around 5.9 million in a total population ~60 million, compared to the 70,000 detected as of March 28th [@doi:10.25561/77731].
Another analysis, which examined New York state, indicated that as of May, 2020, approximately 300,000 cases had been reported in a total population of approximately 20 million [@url:https://www.governor.ny.gov/sites/governor.ny.gov/files/atoms/files/NYForwardReopeningGuide.pdf].
This corresponded to ~1.5% of the population, but ~12% of individuals sampled statewide were estimated as positive through antibody tests (along with indications of spatial heterogeneity at higher resolution) [@url:https://www.governor.ny.gov/sites/governor.ny.gov/files/atoms/files/NYForwardReopeningGuide.pdf].
Technological advancements that facilitate widespread, rapid testing will therefore improve the potential to accurately assess the rate of infection and aid in controlling the virus' spread.

### Conclusions

Major advancements have been made in identifying diagnostic approaches.
The development of diagnostic technologies have been rapid, beginning with the release of the SARS-CoV-2 viral genome sequence in January.
As of October 2020, a range of diagnostic tests have become available.
One class of tests uses PCR (RT-PCR or qRT-PCR) to assess the presence of SARS-CoV-2 RNA, while another typically uses ELISA to test for the presence of antibodies to SARS-CoV-2.
The former approach is useful for identifying active infections, while the latter measures hallmarks of the immune response and therefore can detect either active infections or immunity gained from prior infection.
Combining these tests leads to extremely accurate detection of SARS-CoV-2 infection (98.6%), but when used alone, PCR-based tests are recommended before 5.5 days after the onset of the illness and antibody tests after 5.5 days [@doi:10.1001/jama.2020.8259].
Other strategies for testing can also influence the tests' accuracy, such as the use of nasopharyngeal swabs versus BALF [@doi:10.1001/jama.2020.8259], which allow for trade-offs between patient's comfort and test sensitivity.
Additionally, technologies such as digital PCR may allow for scale-up in the throughput of diagnostic testing, facilitating widespread testing.
One major question that remains is whether people who recover from SARS-CoV-2 develop sustained immunity, and over what period this immunity is expected to last.
Some reports have suggested that some patients may develop COVID-19 reinfections (e.g., [@doi:10/ghfgkt]), but the rates of reinfection are currently unknown.
Serologic testing combined with PCR testing will be critical to confirming purported cases of reinfection and to identifying the duration over which immunity is retained and to understanding reinfection risks.


## Identification and Development of Prophylactics and Therapeutics for COVID-19 

### Abstract

The novel coronavirus SARS-CoV-2 emerged in late 2019 and went on to significantly impact most countries worldwide.
Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: SARS-CoV-1, a sister species that emerged in 2002, and MERS-CoV, which emerged in 2012.
Although both of these previous pandemics were rapidly controlled, no vaccines or robust therapeutic interventions were identified.
However, previous insights into the immune response to coronaviruses, many made in the context of better understanding SARS and MERS, have been beneficial in identifying approaches to the treatment and prophylaxis of COVID-19.
A number of potential therapeutics were rapidly identified, leading to a large number of clinical trials investigating a variety of possible therapeutic approaches being initiated early on in the pandemic.
As a result, by the end of 2020, a small number of therapeutics have been authorized by regulatory agencies such as the Food and Drugs Administration in the United States, and many more continue to be under investigation.
Here, we describe a range of approaches for the treatment of COVID-19, along with their proposed mechanisms of action and the current status of clinical investigation into each candidate.
The status of these investigations will continue to evolve, and this review will be updated as progress is made.

### Importance 

The COVID-19 pandemic is a rapidly evolving crisis.
When the worldwide scientific community shifted its focus onto the SARS-CoV-2 virus and the disease it causes, a large number of possible pharmaceutical approaches for treatment and prevention were proposed.
What is known about each of these potential interventions has evolved rapidly throughout 2020.
In March 2020, we began monitoring a range of candidates and have continued to update this manuscript as new information became available throughout 2020.
Some have been supported, others have been revealed to be unlikely to have any therapeutic benefits, and most require more data before a conclusion can be drawn.
This rapidly changing area of research provides important insight into how the ongoing pandemic can be managed and also demonstrates the power of interdisciplinary collaboration to rapidly understand a virus and match its characteristics with existing or novel pharmaceuticals.

### Introduction

The novel coronavirus _Severe acute respiratory syndrome-related coronavirus 2_ (SARS-CoV-2) emerged in late 2019 and quickly precipitated the worldwide spread of novel coronavirus disease 2019 (COVID-19), the disease caused by its infection.
COVID-19 is associated with symptoms ranging from none (asymptomatic) to mild to severe, with approximately 2% of patients dying from COVID-19-related complicates such as acute respiratory disease syndrome (ARDS) [cite pathogenesis/transmission].
The virus is likely spread between people primarily by droplets, with the role of contact and aerosol transmission still in question [@doi:10.1001/jama.2020.12458; @doi:10/gg6br7].
As a result, public health guidelines have been critical to efforts to control the spread of the virus.
However, as of December 2020, COVID-19 remains a significant worldwide concern (Figure @fig:csse-deaths), with cases in some places surging far above the numbers reported in early 2020.
Due to the continued threat of the virus and the severity of the disease, the identification and development of prophylactic and therapeutic interventions have emerged as significant international priorities.
Both approaches hold valuable potential for controlling the impact of the disease.
Prophylactics induce immunity to prevent an individual from contracting a disease whereas therapeutics treat a disease in individuals who have already been infected.
While vaccine development programs have produced a number of promising candidates, there is also an immediate need for treatments that palliate symptoms and prevent the most severe outcomes from infection.
Fortunately, prior developments during other recent pandemics, especially those caused by human coronaviruses (HCoV), has provided a number of hypotheses guiding a biomedical approach to the novel coronavirus infection.

2,268,797 COVID-19 deaths had been reported worldwide as of February 3, 2021 (Figure @fig:csse-deaths).

![
**Cumulative global COVID-19 deaths since January 22, 2020.**
Data are from the COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University [@https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series].
](https://github.com/greenelab/covid19-review/raw/f91dbd581fcd3ac53f8247db97e52c9c10bcebec/csse/csse-deaths.svg "Global COVID-19 deaths"){#fig:csse-deaths secno=1}

#### Lessons from Prior HCoV Outbreaks

SARS-CoV-2's rapid shift from an unknown virus to a significant worldwide threat closely parallels the emergence of _Severe acute respiratory syndrome-related coronavirus_ (SARS-CoV-1).
The first documented case of COVID-19 was reported in Wuhan, China in November 2019, and the disease quickly spread worldwide during the early months of 2020.
Similarly, the first case of SARS was reported in November 2002 in the Guangdong Province of China and spread within China and then into several countries across continents over the following months [@doi:10.1093/ajcp/aqaa029; @doi:10.1038/nrmicro.2016.81].
In fact, the virus causing COVID-19 was quickly identified through genome sequencing as a novel betacoronavirus closely related to SARS-CoV-1 @doi:10.46234/ccdcw2020.017].
There are other similarities but also some differences in characteristics of the two viruses relevant to their spread.
SARS infection is severe, with an estimated death rate of 9.5% [@doi:10.1093/ajcp/aqaa029], while estimates of the death rate associated with COVID-19 are much lower, at approximately 2% [cite pathogenesis/transmission section] .
SARS-CoV-1 is highly contagious via droplet transmission and has a basic reproduction number (R~0~) of 4 (i.e., each person infected was estimated to infect four other people) [@doi:10.1093/ajcp/aqaa029].
SARS-CoV-2 also appears to be spread primarily by droplet transmission [@doi:10.1001/jama.2020.12458; @doi:10/gg6br7], and most estimates of its R~0~ fall between 2.5 and 3 [cite transmission/pathogenesis].
Furthermore, the 17-year difference in the timing of these two outbreaks has led to some major differences in the tools available for the international community's response.
At the time that SARS-CoV-1 emerged, no new HCoV had been identified in almost 40 years [@doi:10.1038/nrmicro.2016.81].
The identity of the virus underlying the SARS disease remained unknown until April of 2003, when the SARS-CoV-1 virus was characterized through a worldwide scientific effort spearheaded by the WHO [@doi:10.1038/nrmicro.2016.81].
In contrast, the SARS-CoV-2 genomic sequence was released on January 3, 2020 [@doi:10.46234/ccdcw2020.017], only days after the international community became aware of the novel pneumonia-like illness now known as COVID-19.
While SARS-CoV-1 belonged to a distinct lineage from the two other HCoV known at the time of its discovery [@doi:10.1093/ajcp/aqaa029], SARS-CoV-2 is closely related to SARS-CoV-1 and a more distant relative of another HCoV characterized in 2012, _Middle East respiratory syndrome-related coronavirus_ [@doi:10/ggjr43; @doi:10.1056/NEJMoa1211721].
Thus, despite their phylogenetic similarity, the viruses have different characteristics relevant to their spread, and the SARS-CoV-2 virus emerged under very different circumstances than SARS-CoV-1 in terms of scientific knowledge about HCoV.

The trajectories of the pandemics associated with each of the viruses have also diverged significantly.
By July 2003, the SARS outbreak was officially determined to be under control, with the success credited to infection management practices such as mask wearing [@doi:10.1038/nrmicro.2016.81].
In contrast, MERS is still circulating and remains a concern because the fatality rate is very high at almost 35%, but the disease is much less easily transmitted, with an R~0~ of 1 [@doi:10.1093/ajcp/aqaa029].
The low R~0~ in combination with public health practices allowed for its spread to be contained [@doi:10.1093/ajcp/aqaa029].
Neither of these trajectories are comparable to that of SARS-CoV-2, which remains a serious threat worldwide a full year after the first known cases of COVID-19.
However, early results suggest that pharmaceutical interventions for COVID-19 may be more successful than previous efforts to develop prophylactics and therapeutics for SARS and MERS.
Vaccines were not used to control either virus, although vaccine development programs were established for SARS-CoV-1 [@doi:10.3390/v11010059].
Care for SARS and MERS patients prioritized supportive care and symptom management [@doi:10.1093/ajcp/aqaa029].
To the extent that clinical treatments for SARS and MERS were explored, there is generally a lack of evidence supporting their efficacy.
For example, Ribavirin is an antiviral that was often used in combination with corticosteroids and sometimes interferon (IFN) medications to treat SARS and MERS [@doi:10.1038/nrmicro.2016.81], but its effects have been found to be inconclusive in retrospective and _in vitro_ analyses of  SARS and the SARS-CoV-1 virus, respectively [@doi:10.1038/nrmicro.2016.81].
IFNs and Ribavirin have shown promise in _in vitro_ analyses of MERS, but their clinical effectiveness remains unknown [@doi:10.1038/nrmicro.2016.81].
Therefore, only limited pharmaceutical advances from prior HCoV outbreaks can be adopted to COVID-19.
Importantly, though, prior analyses of the virological and pathogenic properties of SARS-CoV-1 and MERS-CoV provide a strong foundation for the development of hypotheses about SARS-CoV-2 that have served to accelerated the development and identification of potential prophylactic and therapeutic approaches.

#### Therapeutic Approaches

Therapeutic approaches to the current pandemic can utilize two potential avenues: they can reduce the symptoms that are harmful to COVID-19 patients, or they can directly target the virus to hinder the spread of infection.
The goal of the former is to reduce the severity and risks of an active infection while for the latter, it is to inhibit the development of the virus once an individual is infected.
A variety of symptom profiles with a range of severity are associated with COVID-19, many of which are not life-threatening.
A study of COVID-19 patients in a hospital in Berlin, Germany found that the symptoms associated with the highest risk of death included infection-related symptoms, such as sepsis, respiratory symptoms such as ARDS, and cardiovascular failure or pulmonary embolism [@doi:10.1101/2020.06.15.20131540].
Therefore, therapeutics that reduce risk associated with these severe outcomes are of particular interest to reducing the pandemic death toll.
Therapeutics that directly target the virus itself typically fall into the broad category of antivirals.
Antiviral therapies hinder the spread of a virus within the host, rather than destroying existing copies of the virus, and these drugs can vary in their specificity to a narrow or broad range of viral targets.
For both categories, uncertainty often surrounds treatments' exact mechanisms of action, as most therapies have secondary or off-target effects.

In this review, we describe some treatments and prophylactics that have been considered for COVID-19 and classify them according to their biological properties, specifically whether they are biologics (produced from components of organisms) or small molecules.
Small molecule drugs include drugs targeted at viral particles, drugs targeted at host proteins, and broad spectrum pharmaceuticals, while biologics include antibodies and interferons.
A large number of clinical trials investigating a wide range of possible therapeutics and prophylactics for COVID-19 are currently in progress or have already been completed (Figure @fig:ebm-trials).
The purpose of this review is to critically appraise the literature surrounding a subset of clinical trials and to evaluate a range of approaches to repurpose existing or develop novel approaches to the prevention, mitigation, and treatment of coronavirus infections.
The identity of the virus underlying the SARS disease remained unknown until April of 2003, when the SARS-CoV-1 virus was characterized through a worldwide scientific effort spearheaded by the WHO [@doi:10.1038/nrmicro.2016.81].
In contrast, the SARS-CoV-2 genomic sequence was released on January 3, 2020 [@doi:10.46234/ccdcw2020.017], only days after the international community became aware of the novel pneumonia-like illness now known as COVID-19.
While SARS-CoV-1 belonged to a distinct lineage from the two other HCoV known at the time of its discovery [@doi:10.1093/ajcp/aqaa029], SARS-CoV-2 is closely related to SARS-CoV-1 and a more distant relative of another HCoV characterized in 2012, _Middle East respiratory syndrome-related coronavirus_ [@doi:10/ggjr43; @doi:10.1056/NEJMoa1211721].
Thus, despite their phylogenetic similarity, the viruses have different characteristics relevant to their spread, and the SARS-CoV-2 virus emerged under very different circumstances than SARS-CoV-1 in terms of scientific knowledge about HCoV.

![
**COVID-19 clinical trials.**
There are 6,417 COVID-19 clinical trials and 168 trials with results as of November 9, 2020.
The recruitment statuses and trial phases are shown only for trials in which the status or phase is recorded.
The study types include only types used in at least five trials.
The common interventions are all interventions used in at least ten trials.
Combinations of interventions, such as Hydroxychloroquine + Azithromycin, are tallied separately from the individual interventions.
Trials data are from the University of Oxford Evidence-Based Medicine Data Lab's COVID-19 TrialsTracker [@doi:10.5281/zenodo.3732709].
](https://github.com/greenelab/covid19-review/raw/f91dbd581fcd3ac53f8247db97e52c9c10bcebec/ebmdatalab/ebmdatalab-trials.svg "COVID-19 clinical trials"){#fig:ebm-trials secno=1}

### Small Molecule Drugs

Small molecules are synthesized compounds of low molecular weight, typically less than 1 kilodalton (kDa) [@url:https://www.nuventra.com/resources/blog/small-molecules-versus-biologics/].
Small-molecule pharmaceutical agents have been a backbone of drug development since the discovery of penicillin in the early twentieth century [@doi:10.1126/science.287.5460.1960].
It and other antibiotics have long been among the best known applications of small molecules to therapeutics, but biotechnological developments such as the prediction of protein-protein interactions have facilitated advances in precise targeting of specific structures using small molecules [@doi:10.1126/science.287.5460.1960].
Small molecule drugs today encompass a wide range of therapeutics beyond antibiotics, including antivirals, protein inhibitors, and many broad-spectrum pharmaceuticals.

#### Small Molecule Antivirals

Antiviral drugs against SARS-CoV-2 are designed to inhibit replication of a virus within an epithelial host cell.
This process requires inhibiting the replication cycle of a virus by disrupting one of six fundamental steps [@isbn:978-1405136457].
In the first step, the virus attaches to the host cell, which it next penetrates through endocytosis.
Then the virus undergoes uncoating, which is classically defined as the release of viral contents into the host cell, and next the viral genetic material enters the nucleus where it gets replicated during the biosynthesis stage.
During the assembly stage, viral proteins are translated, allowing new viral particles to be assembled, and during the final step, release, the new viruses are released into the extracellular environment.
Many antiviral drugs are designed to inhibit the replication of viral genetic material during the biosynthesis step.
Unlike DNA viruses, which can use the host enzymes to propagate themselves, RNA viruses like SARS-CoV-2 depend on their own polymerase, the RNA-dependent RNA polymerase (RdRP), for replication [@doi:10.1007/978-1-4939-2438-7; @doi:10.1002/jmv.25761].
Targeting RdRP is therefore an effective strategy for antivirals against RNA viruses and is the proposed mechanism underlying the treatment of SARS and MERS with Ribavirin [@doi:10.1080/17460441.2019.1581171].
However, although antivirals are designed to target a virus, they can also impact other processes in the host and may have unintended effects.

##### Nucleoside and Nucleotide Analogs

###### Favipiravir

Favipiravir (Avigan), also known as T-705, was discovered by Toyama Chemical Co., Ltd. [@url:https://www.drugbank.ca/drugs/DB12466].
The drug was found to be effective at blocking viral amplification in several influenza subtypes as well as other RNA viruses, such as _Flaviviridae_ and _Picornaviridae_, through a reduction in plaque formation [@doi:10.1128/AAC.46.4.977-981.2002] and viral replication in Madin-Darby Canine Kidney (MDCK) cells [@doi:10.1128/AAC.01051-06].
Furthermore, inoculation of mice with favipiravir was shown to increase survival of influenza infections [@doi:10.1128/AAC.46.4.977-981.2002; @doi:10.1128/AAC.01051-06].
In 2014, the drug was approved in Japan for the treatment of patients infected with influenza that was resistant to conventional treatments like neuraminidase inhibitors [@doi:10.2183/pjab.93.027].
Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) acts as a purine and purine nucleoside analogue that inhibits viral RNA polymerase in a dose-dependent manner across a range of RNA viruses, including Influenza virus [@doi:10.1128/AAC.49.3.981-986.2005; @doi:10.1128/AAC.01074-08; @doi:10.1128/AAC.00356-07; @doi:10.1016/j.bbrc.2012.07.034; @doi:10.1128/AAC.01219-10].
Nucleotides and nucleosides are the natural building blocks for RNA synthesis.
Because of this, modifications to nucleotides and nucleosides can disrupt key processes including replication [@doi:10.1016/j.antiviral.2018.04.004].
Biochemical experiments showed that favipiravir was recognized as a purine nucleoside analogue and incorporated into the viral RNA template.
A single incorporation does not influence RNA transcription; however, multiple events of incorporation lead to the arrest of RNA synthesis [@doi:10.1371/journal.pone.0068347].
Evidence for T-705 inhibiting viral RNA polymerase are based on time-of-drug addition studies that found that viral loads were reduced with the addition of favipiravir in early times post-infection [@doi:10.1128/AAC.49.3.981-986.2005; @doi:10.1016/j.bbrc.2012.07.034; @doi:10.1128/AAC.01219-10].

The effectiveness of favipiravir for treating patients with COVID-19 is currently under investigation.
An open-label, nonrandomized, before-after controlled study was recently conducted [@doi:10.1016/j.eng.2020.03.007].
The study included 80 COVID-19 patients (35 treated with favipiravir, 45 control) from the isolation ward of the National Clinical Research Center for Infectious Diseases (The Third People’s Hospital of Shenzhen), Shenzhen, China.
The patients in the control group were treated with other antivirals, such as lopinavir and ritonavir.
It should be noted that subsequent, large-scale analyses, the WHO Solidarity trial and the RECOVERY trial, identified no effect of lopinavir or of a lopinavir-ritonavir combination, respectively, on the metrics of COVID-19-related mortality that each assessed [@doi:10.1056/NEJMoa2023184; @doi:10/fnx2; @doi:10.1056/NEJMe2034294].
Treatment was applied on days 2-14; treatment stopped either when viral clearance was confirmed or at day 14.
The efficacy of the treatment was measured by 1) the time until viral clearance using Kaplan-Meier survival curves, and 2) the improvement rate of chest computed tomography (CT) scans on day 14 after treatment.
The study found that favipiravir increased the speed of recovery, measured as viral clearance from the patient by RT-PCR, with patients receiving favipiravir recovering in  4 days compared to 11 days for patients receiving antivirals such as lopinavir and ritonavir.
Additionally, the lung CT scans of patients treated with favipiravir showed significantly higher improvement rates (91%) on day 14 compared to control patients (62%).
However, there were adverse side effects in 4 (11%) favipiravir-treated patients and 25 (56%) control patients.
The adverse side effects included diarrhea, vomiting, nausea, rash, and liver and kidney injury.
Overall, despite the study reporting clinical improvement in favipiravir-treated patients, due to some issues with study design, it cannot be determined whether treatment with favipiravir had an effect or whether these patients would have recovered regardless of any treatment.
For example, despite the significant differences observed between the two treatment groups, follow-up analysis is necessary due to the small sample size.
The selection of patients did not take into consideration important factors such as previous clinical conditions or sex, and there was no age categorization.
The study was neither randomized nor blinded, and the baseline control group was another antiviral instead of a placebo.
Additionally, it should be noted that this study was temporarily retracted and then restored without an explanation [@url:https://retractionwatch.com/retracted-coronavirus-covid-19-papers/].

In late 2020 and early 2021, the first randomized controlled trials of favipiravir for the treatment of COVID-19 released results [@doi:10.1016/j.ejps.2020.105631; @doi:10.1007/s00705-021-04956-9; @doi:10.1093/cid/ciaa1176].
The first [@doi:10.1016/j.ejps.2020.105631] used a randomized, controlled, open-label design to compare two drugs, favipiravir and baloxavir marboxil, to SOC alone.
Here, SOC included antivirals such as lopinavir/ritonavir and was administered to all patients.
The primary endpoint analyzed was viral clearance at day 14.
The sample size for this study was very small, with 29 total patients enrolled, and no significant effect of the treatments was found for the primary or any of the secondary outcomes analyzed, which included mortality.
The second study was larger, with 96 patients enrolled, and also utilized a randomized design.
This study enrolled only patients with mild to moderate symptoms and randomized them into two groups: one receiving CQ in addition to SOC, and the other receiving favipiravir in addition to SOC.
This study reported a non-significant trend for patients receiving favipiravir to have a shorter hospital stay and less likelihood of progressing to mechanical ventilation or to an oxygen saturation < 90%.
However, given the fact that favipiravir was being compared to CQ, which is now widely understood to be ineffective for treating COVID-19, these results do not suggest that favipiravir was likely to have had a strong effect on these outcomes. 
On the other hand, another trial of 60 patients reported a significant effect of favipiravir on viral clearance at four days (a secondary endpoint), but not at 10 days (the primary endpoint) [@doi:10.1093/cid/ciaa1176].
This study, as well as a prior study of favipiravir [@doi:10/ftgm], also reported that the drug was generally well-tolerated.
Thus, in combination, these small studies suggest that the effects of favipiravir as a treatment for COVID-19 cannot be determined based on the available evidence, but additionally, none raise major concerns about the safety profile of the drug.

###### Remdesivir

Remdesivir (GS-5734) is an intravenous antiviral that was developed by Gilead Sciences to treat Ebola Virus Disease (EVD).
At the outset of the COVID-19 pandemic, it did not have any have any FDA-approved use.
However, on May 1, 2020, the FDA issued an Emergency Use Authorization (EUA) for remdesivir for the treatment of hospitalized COVID-19 patients [@url:https://www.fda.gov/media/137564/download].
The EUA was based on information from two clinical trials, NCT04280705 and NCT04292899 [@clinicaltrials:NCT04292899; @clinicaltrials:NCT04280705; @doi:10.1056/NEJMoa2007764; @doi:10.1056/NEJMoa2007016].
Remdesivir is metabolized to GS-441524, an adenosine analog that inhibits a broad range of polymerases and then evades exonuclease repair, causing chain termination [@doi:10.1074/jbc.AC120.013056; @doi:10.1128/mBio.00221-18; @doi:10.1038/s41422-020-0282-0].
A clinical trial in the Democratic Republic of Congo found some evidence of effectiveness against EVD, but two antibody preparations were found to be more effective, and remdesivir was not pursued [@doi:10.1056/NEJMoa1910993].
Although it was developed against EVD, remdesivir also inhibits polymerase and replication of the coronaviruses MERS-CoV and SARS-CoV-1 in cell culture assays with submicromolar IC50s [@doi:10.1126/scitranslmed.aal3653].
It has also been found to inhibit SARS-CoV-2, showing synergy with chloroquine _in vitro_ [@doi:10.1038/s41422-020-0282-0].
The effectiveness of remdesivir for treating patients with COVID-19 is currently under investigation.

Remdesivir was first used on some COVID-19 patients under compassionate use guidelines [@doi:10.1126/science.abb7243, @doi:10.1056/NEJMoa2001191; @doi:10.1101/2020.03.09.20032896].
All were in late stages of COVID-19 infection, and these reports were inconclusive about the drug's efficacy.
Gilead Sciences, the maker of remdesivir, led a recent publication that reported outcomes for compassionate use of the drug in 61 patients hospitalized with confirmed COVID-19.
Here, 200 mg of remdesivir was administered intravenously on day 1, followed by a further 100 mg/day for 9 days [@doi:10.1056/NEJMoa2007016].
There were significant issues with the study design, or lack thereof.
There was no randomized control group.
The inclusion criteria were variable: some patients only required low doses of oxygen, while others required ventilation.
The study included many sites, potentially with variable inclusion criteria and treatment protocols.
The patients analyzed had mixed demographics.
There was a short follow-up period of investigation.
Some patients worsened, some patients died, and eight were excluded from the analysis mainly due to missing post-baseline information; thus, their health is unaccounted for.
Therefore, even though the study reported clinical improvement in 68% of the 53 patients ultimately evaluated, due to the significant issues with study design, it could not be determined whether treatment with remdesivir had an effect or whether these patients would have recovered regardless of treatment.
Another study comparing 5- and 10-day treatment regimens reported similar results but was also limited because of the lack of a placebo control [@doi:10.1056/NEJMoa2015301].
The study did not alter our understanding of the efficacy of remdesivir in treating COVID-19, but the encouraging results provided motivation for placebo-controlled studies.

Remdesivir was later tested in a double-blind placebo-controlled phase 3 clinical trial performed at 60 trial sites, 45 of which were in the United states [@doi:10.1056/NEJMoa2007764; @clinicaltrials:NCT04280705].
The trial recruited 1,062 patients and randomly assigned them to placebo treatment or treatment with remdesivir.
Patients were stratified for randomization based on site and the severity of disease presentation at baseline [@doi:10.1056/NEJMoa2007764].
The treatment was 200 mg on day 1, followed by 100 mg on days 2 through 10.
Data was analyzed from a total of 1,059 patients who completed the 29 day course of the trial (517 assigned to remdesivir and 508 to placebo) [@doi:10.1056/NEJMoa2007764].
The two groups were well matched demographically and clinically at baseline.
Those who received remdesivir had a median recovery time of 10 days, as compared with 15 days in those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; _p_ < 0.001).
The Kaplan-Meier estimates of mortality by 14 days were 6.7% with remdesivir and 11.9% with placebo, with a hazard ratio (HR) for death of 0.55 and a 95% CI of 0.36 to 0.83, and at day 29, remdesivir corresponded to 11.4% and the placebo to 15.2% (HR: 0.73; 95% CI: 0.52 to 1.03).
Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients in the placebo group (31.6%).
This study also reported an association between remdesivir administration and both clinical improvement and a lack of progression to more invasive respiratory intervention in patients receiving non-invasive and invasive ventilation at randomization [@doi:10.1056/NEJMoa2007764].
Largely on the results of this trial, the FDA issued an Emergency Use Authorization (EUA) for remdesivir for the treatment of hospitalized COVID-19 patients.
Clinical trials are currently underway to evaluate the use of remdesivir to treat COVID-19 patients at both early and late stages of infection and in combinations with other drugs (Figure @fig:ebm-trials).
These trials include [@doi:10.1038/s41422-020-0282-0; @clinicaltrials:NCT04292730; @url:https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR; @clinicaltrials:NCT04252664; @clinicaltrials:NCT04257656].
As of October 22, 2020, remdesivir received FDA approval based on three clinical trials [@url:https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19].

However, results suggesting no effect of remdesivir on survival were reported by the WHO Solidarity trial [@doi:10.1056/NEJMoa2023184].
This large-scale, open-label trial enrolled 11,330 adult in-patients at 405 hospitals in 30 countries around the world [@doi:10.1056/NEJMoa2023184].
Patients were randomized in equal proportions into four experimental and a control conditions, corresponding to four candidate treatments for COVID-19 and SOC, respectively; no placebo was administered.
The 2750 patients in the remdesivir group were administered 200 mg intravenously on the first day and 100 mg on each subsequent day until day 10 and assess for in-hospital death (primary endpoint), duration of hospitalization, and progression to mechanical ventilation.
There were also 2708 control patients who would have been eligible and able to receive remdesivir were they not assigned to the control group.
A total of 604 patients among these two cohorts deceased during initial hospitalization.
The rate ratio of death between these two groups was therefore not significant (_p_ = 0.50), suggesting that the administration of remdesivir did not affect survival.
The two secondary analyses similarly did not find any effect of remdesivir.
Additionally, the authors compared data from their study with data from three other studies of remdesivir (including [@doi:10.1056/NEJMoa2007764]) stratified by supplemental oxygen status.
The adjusted rate ratio for death based on this meta-analysis was 0.91.
These results thus do not support the previous findings that remdesivir reduced median recovery time and mortality risk in COVID-19 patients.

In response to the results of the Solidarity trial, Gilead, which manufactures remdesivir under the name Veklury^R, released a statement pointing to the fact that the Solidarity trial was not placebo-controlled or double-blind and at the time of the statement had not been peer reviewed [@url:https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-solidarity-trial]; these sentiments have been echoed elsewhere [@doi:10.1093/eurheartj/ehaa934].
Other critiques of this study have noted that antivirals are not typically targeted at patients with severe illness, and therefore remdesivir could be more beneficial for patients with mild rather than severe cases [@url:https://www.sciencemag.org/news/2020/10/very-very-bad-look-remdesivir-first-fda-approved-covid-19-drug; @doi:10.1056/NEJMe2034294].
However, the publication associated with the trial sponsored by Gilead did suggest an effect of remdesivir on patients with severe disease, identifying an 11 versus 18 day recovery period (rate ratio for recovery: 1.31, 95% CI 1.12 to 1.52), although the results of a significance test were not provided [@doi:10.1056/NEJMoa2007764].
Additionally, a smaller analysis comparing treatment with remdesivir to standard of care in patients with moderate COVID-19 reported a small effect size, corresponding to minimal differences between these groups at day 11 [@doi:10.1001/jama.2020.16349].
Therefore, some of the findings from this trial do seem to contradict the findings of the Solidarity trial.
On the other hand, only 62% of patients in the Solidarity trial were randomized on the day of admission or one day afterwards [@doi:10.1056/NEJMoa2023184], and differences in disease progression may influence the effect of remdesivir [@doi:10.1056/NEJMe2034294], so there could be be additional confounding factors in one or both trials.
The broad international nature of the Solidarity clinical trial, which included countries with a wide range of economic profiles and a variety of healthcare systems, provides a much-needed global perspective in a pandemic [@doi:10.1056/NEJMe2034294].
Despite the findings of the Solidarity trial, remdesivir remains available for the treatment of COVID-19 in many places.
Follow-up studies are needed and in many cases are underway to further investigate remdesivir-related outcomes, with possibilities including combinations of remdesivir with other drugs such as baricitinib, which is an inhibitor of Janus kinase 1 and 2 [@doi:10.1056/NEJMoa2031994].
Similarly, the extent to which the remdesivir dosing regimen could influence outcomes is still under consideration.
A randomized, open-label trial compared the effect of remdesivir on 397 patients with severe COVID-19 over 5 versus 10 days [@doi:10.1056/NEJMoa2015301; @ClinicalTrials:NCT04292899].
Patients in the two groups were administered 200 mg of remdesivir intravenously on the first day, followed by 100 mg on the subsequent four or nine days, respectively.
The two groups differed significantly in their clinical status, with patients assigned to the 10-day group having more severe illness.
This study also differed from most because it included not only adults, but also pediatric patients as young as 12 years old.
This study found no significant differences across several outcomes for patients receiving a 5-day or 10-day course, when correcting for baseline clinical status.
They did find evidence suggesting that the 10-day course might reduce mortality in the most severe patients at day 14, but the representation of this group in the study population was too low to justify any conclusions [@doi:10.1056/NEJMoa2015301].
Thus, additional research is also required to determine whether the dosage and duration of remdesivir administration influences outcomes.

In summary, remdesivir is a first in class drug due to its FDA approval.
Early investigations of this drug establish proof of principle that drugs targeting the virus can benefit COVID-19 patients.
It also shows proof of principle that SARS-CoV-2 can be targeted at the level of viral replication, since remdesivir targets the viral RNA polymerase at high potency.
Moreover, one of the most successful strategies for developing therapeutics for viral diseases is to target the viral replication machinery, which are typically virally encoded polymerases.
Small molecule drugs targeting viral polymerases are the backbones of treatments for other viral diseases including HIV and Herpes.
Notably, the HIV and herpes polymerases are a reverse transcriptase and a DNA polymerase, respectively, whereas SARS-CoV-2 encodes an RdRP, so most of the commonly used polymerase inhibitors are not likely to be active against SARS-CoV-2.
In clinical use, polymerase inhibitors show short term benefits for HIV patients but for long term benefits they must be part of combination regimens.
They are typically combined with protease inhibitors, integrase inhibitors, and even other polymerase inhibitors.
Additional clinical trials of remdesivir in different patient pools and in combination with other therapies will refine its use in the clinic.

##### Protease Inhibitors

Several studies showed that viral proteases play an important role in the life cycle of viruses, including coronaviruses, by modulating the cleavage of viral polyprotein precursors [@doi:10.2174/138161207780162971].
Several FDA-approved drugs target proteases, including lopinavir and ritonavir for HIV infection and simeprevir for hepatitis C virus infection.
In particular, serine protease inhibitors were suggested for the treatment of SARS and MERS viruses [@doi:10.1016/j.antiviral.2015.01.011].
Recently, a study [@doi:10.1016/j.cell.2020.02.052] suggested that camostat mesylate, an FDA-approved protease inhibitor (PI) could block the entry of SARS-CoV-2 into lung cells _in vitro_.
However, to test the efficacy of PIs in patients, randomized clinical trials will need to be conducted on patients and healthy volunteers.
Investigation of possible PIs that would work against SARS-CoV-2 has been driven by computational predictions, leading to the computer-aided design of a Michael acceptor inhibitor, N3, to target a protease critical to SARS-CoV-2 replication.

Discovery of the N3 mechanism arose from interest in the two polyproteins encoded by the SARS-CoV-2 replicase gene, pp1a and pp1ab, that are critical for viral replication and transcription [@doi:10.1038/s41586-020-2223-y].
These polyproteins must undergo proteolytic processing. 
This processing is usually conducted by Mpro, a 33.8-kDa SARS-CoV-2 protease that is therefore fundamental to viral replication and transcription.
N3 was designed computationally [@doi:10.1371/journal.pbio.0030324] to bind in the substrate binding pocket of the Mpro protease of SARS-like coronaviruses [@doi:10.1007/s13238-013-2841-3], therefore inhibiting proteolytic processing.
Subsequently, the structure of N3-bound SARS-CoV-2 Mpro was solved [@doi:10.1038/s41586-020-2223-y], confirming the computational prediction.
N3 was tested _in vitro_ on SARS-CoV-2-infected Vero cells, which belong to a line of cells established from the kidney epithelial cells of an African green monkey, and was found to inhibit SARS-CoV-2 [@doi:10.1038/s41586-020-2223-y].

Although N3 is a strong inhibitor of SARS-CoV-2 _in vitro_, its safety and efficacy still need to be tested in healthy volunteers and patients.
After the design and confirmation of N3 as a highly potent Michael acceptor inhibitor and the identification of Mpro's structure [@doi:10.1038/s41586-020-2223-y; @doi:10.1126/science.abb3405], 10,000 compounds were screened for their _in vitro_ anti-Mpro activity.
The six leads that were identified were ebselen, disulfiram, tideglusib, carmofur, and PX-12.
_In vitro_ analysis revealed that Ebselen had the strongest potency in reducing the viral load in SARS-CoV-2-infected Vero cells [@doi:10.1038/s41586-020-2223-y].
Ebselen is an organoselenium compound with anti-inflammatory and antioxidant properties [@doi:10.1007/s11033-014-3417-x] 
It has been proposed as a possible treatment for conditions ranging from bipolar disorder to diabetes to heart disease [@doi:10.1007/s11033-014-3417-x], and a preliminary investigation of ebselen as a treatment for noise-induced hearing loss provided promising reports of its safety [@doi:10/gbwnbv].
For COVID-19, the NSP5 in SARS-CoV-2 contains a cysteine at the active site of Mpro, and ebselen is able to inactivate the protease by bonding covalently with this cysteine to form a selenosulfide [@doi:10.1007/s11033-014-3417-x; @doi:10.1016/j.freeradbiomed.2020.06.032].
Interestingly there has been some argument that selenium deficiency may be associated with more severe COVID-19 outcomes [@doi:10.3390/nu12072098; @doi:10.1017/S0007114520003128; @doi:10.1016/j.redox.2020.101715], possibly indicating that its antioxidative properties are protective [@doi:10.1016/j.freeradbiomed.2020.06.032].
On the other hand, ebselen and the other compounds identified are likely to be promiscuous binders, which could diminish their therapeutic potential [@doi:10.1038/s41586-020-2223-y].
While there is clear computational and _in vitro_ support for ebselen's potential as a COVID-19 therapeutic, results from clinical trials are not yet available for this compound.

In summary, N3 is a computationally designed molecule that inhibits the viral transcription through inhibiting Mpro.
Ebselen is both a strong Mpro inhibitor and strong inhibitor of viral replication _in vitro_ that was found to reduce SARS-CoV-2 viral load even more effectively than N3.
Ebselen is a very promising compound since its safety has been demonstrated in other indications.
However, Ebselen is likely a false positive since it is a promiscuous compound that can have many targets [@doi:10.1039/c8cc04258f].
Therefore, compounds with higher specificity may be required to effectively translate to clinical trials.

<!--##### Molecules Targeting the Viral Envelope-->
#### Broad-Spectrum Pharmaceuticals

When a virus enters a host, the host becomes the virus' environment.
Therefore, the state of the host can also influence the virus's ability to replicate and spread.
Traditionally, viral targets have been favored for pharmaceutical interventions because altering host processes is likely to be less specific than targeting the virus directly [@doi:10.1016/j.antiviral.2013.03.020].
On the other hand, targeting the host offers potential for a complementary strategy to antivirals that could broadly limit the ability of viruses to replicate [@doi:10.1016/j.antiviral.2013.03.020].
As a result, therapeutic approaches that target host proteins have become an area of interest for SARS-CoV-2.
Viral entry receptors in particular have emerged as a target of interest.
Entry of SARS-CoV-2 into the cell depends on binding to the Angiotensin-converting enzyme 2 (ACE2) receptor, which is catalyzed by the enzyme encoded by _TMPRSS2_ [@doi:10.1016/j.cell.2020.02.052].
In principle, drugs that reduce the expression of these proteins or sterically hinder viral interactions with them might reduce viral entry into cells.

Due to the urgent nature of the COVID-19 pandemic, many of the pharmaceutical agents that have been widely publicized as having possible therapeutic or prophylactic effects are broad-spectrum pharmaceuticals that pre-date the COVID-19 pandemic.
These treatments are not specifically targeted at the virus itself or at the host receptors it relies on, but rather induce broad shifts in host biology that are hypothesized to be potential inhibitors of the virus.
In most cases, interest in particular candidate medications arises because they are already available for other purposes.
However, the fact that the targets of these agents are non-specific means that the mechanism of action can appear to be relevant to COVID-19 without a therapeutic or prophylactic effect being observed in rigorous testing.
This category of drugs has also received significant attention from the media and general public, often before rigorous testing has been able to determine their effectiveness against SARS-CoV-2.

##### ACEi and ARB

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are among today's most commonly prescribed medications [@url:https://clincalc.com/DrugStats/Drugs/Lisinopril; @doi:10.1056/NEJMp1901657].
In the United States, for example, they are prescribed well over 100,000,000 times annually.
Data from some animal models suggest that several, but not all, ACE inhibitors and several ARBs increase ACE2 expression in the cells of some organs [@doi:10.1093/cvr/cvaa097].
Clinical studies have not established whether plasma ACE2 expression is increased in humans treated with these medications [@doi:10.1093/europace/euw246].
While randomized clinical trials are ongoing, a variety of observational studies have examined the relationship between exposure to ACE inhibitors or ARBs and outcomes in patients with COVID-19.
An observational study of the association of exposure to ACE inhibitors or ARB with outcomes in COVID-19 was retracted from the _New England Journal of Medicine_ [@doi:10.1056/NEJMoa2007621].
Moreover, because observational studies are subject to confounding, randomized controlled trials are the standard means of assessing the effects of medications, and the findings of the various observational studies bearing on this topic cannot be interpreted as indicating a protective effect of the drug [@doi:10.1161/CIRCRESAHA.120.317205; @doi:10.2215/CJN.03530320].
Several clinical trials testing the effects of ACE inhibitors or ARBs on COVID-19 outcomes are ongoing [@clinicaltrials:NCT04338009; @clinicaltrials:NCT04353596; @clinicaltrials:NCT04311177; @clinicaltrials:NCT04312009; @clinicaltrials:NCT04330300; @clinicaltrials:NCT04366050].
These studies of randomized intervention will provide important data for understanding whether exposure to ACEis or ARBs is associated with COVID-19 outcomes.
Additional information about ACE2, observational studies of ACE inhibitors and ARBs in COVID-19, and clinical trials on this topic have been summarized [@url:http://www.nephjc.com/news/covidace2].

##### Hydroxychloroquine and Chloroquine

Chloroquine (CQ) and hydroxychloroquine (HCQ) are lysosomotropic agents, meaning they are weak bases that can pass through the plasma membrane.
Both drugs increase cellular pH by accumulating in their protonated form inside lysosomes [@doi:10.1186/1743-422X-8-163; @doi:10.1111/j.1529-8019.2007.00131.x].
This shift in pH inhibits the breakdown of proteins and peptides by the lysosomes during the process of proteolysis [@doi:10.1111/j.1529-8019.2007.00131.x].
A number of mechanisms have been proposed through which these drugs could influence the immune response to pathogen challenge.
For example, CQ/HCQ can interfere with digestion of antigens within the lysosome and inhibit CD4 T-cell stimulation while promoting the stimulation of CD8 T-cells [@doi:10.1111/j.1529-8019.2007.00131.x].
CQ/HCQ can also decrease the production of certain key cytokines involved in the immune response, including interleukin-6 (IL-6), and inhibit the stimulation of toll-like receptors (TLR) and TLR signaling [@doi:10.1111/j.1529-8019.2007.00131.x].
The drugs also have anti-inflammatory and photoprotective effects and may also affect rates of cell death, blood clotting, glucose tolerance, and cholesterol levels [@doi:10.1111/j.1529-8019.2007.00131.x].

Interest in CQ and HCQ for treating COVID-19 was catalyzed by a mechanism observed in _in vitro_ studies of both SARS-CoV-1 and SARS-CoV-2.
In one study, CQ inhibited viral entry of SARS-CoV-1 into Vero E6 cells, a cell line that was derived from Vero cells in 1968, through the elevation of endosomal pH and the terminal glycosylation of the cellular entry receptor, ACE2 [@doi:10.1186/1743-422X-2-69].
Increased pH within the cell, as discussed above, inhibits proteolysis, and terminal glycosylation of ACE2 is thought to interfere with virus-receptor binding.
An _in vitro_ study of SARS-CoV-2 infection of Vero cells found both HCQ and CQ to be effective in inhibiting viral replication, with HCQ being more potent [@doi:10.1093/cid/ciaa237].
Additionally, an early case study of three COVID-19 patients reported the presence of antiphospholipid antibodies in all three patients [@doi:10.1056/NEJMc2007575].
Antiphospholipid antibodies are central to the diagnosis of the antiphospholipid syndrome, a disorder that HCQ has often been used to treat [@doi:10.1182/blood.V128.22.5023.5023; @doi:10.1016/j.autrev.2014.01.053; @doi:10.1182/asheducation-2016.1.714].
Because the 90% effective concentration (EC~90~) of CQ in Vero E6 cells (6.90 μM) can be achieved in and tolerated by rheumatoid arthritis patients, it was hypothesized that it might also be possible to achieve the effective concentration in COVID-19 patients [@doi:10.1093/jac/dkaa114].
Additionally, HCQ has been found to be effective in treating HIV [@doi:10/cq2hx9] and chronic Hepatitis C [@doi:10.1002/jmv.24575].
Together, these studies triggered initial enthusiasm about the therapeutic potential for HCQ and CQ against COVID-19.
HCQ/CQ has been proposed both as a treatment for COVID-19 and a prophylaxis against SARS-CoV-2 exposure.
HCQ/CQ are sometimes administered with azithromycin (AZ) and/or zinc supplementation.
<!--
rishirajgoel to add text on Azithromycin
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262884/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918160/
https://www.ncbi.nlm.nih.gov/pubmed/28099856
https://www.ncbi.nlm.nih.gov/pubmed/27911847
-->

###### Therapeutic Administration of HCQ/CQ

The initial study evaluating HCQ as a treatment for COVID-19 patients was published on March 20, 2020 by Gautret et al. [@doi:10.1016/j.ijantimicag.2020.105949].
This non-randomized, non-blinded, non-placebo clinical trial compared HCQ to standard of care (SOC) in 42 hospitalized patients in southern France.
They reported that patients who received HCQ showed higher rates of virological clearance by nasopharyngeal swab on Days 3-6 when compared to standard care.
This study also treated six patients with both HCQ + AZ and found this combination therapy to be more effective than HCQ alone.
However, the design and analyses used showed weaknesses that severely limit interpretability of results, including the lack of randomization, lack of blinding, lack of placebo, lack of Intention-To-Treat analysis, lack of correction for sequential multiple comparisons, trial arms entirely confounded by hospital, false negatives in outcome measurements, lack of trial pre-registration, and small sample size.
Two of these weaknesses are due to inappropriate data analysis and can therefore be corrected _post hoc_ by recalculating the p-values (lack of Intention-To-Treat analysis and multiple comparisons).
However, all other weaknesses are fundamental design flaws and cannot be corrected for.
Thus, conclusions cannot be generalized outside of the study.
The International Society of Antimicrobial Chemotherapy, the scientific organization that publishes _International Journal of Antimicrobial Agents_ where the article appeared, has announced that the article does not meet its expected standard for publications [@url:https://www.isac.world/news-and-publications/official-isac-statement], although it has not been officially retracted.
Because of the preliminary data presented in this study, the use of HCQ in COVID-19 treatment was subsequently explored by other researchers.
About one week later, a follow-up case study reported that 11 consecutive patients were treated with HCQ + AZ using the same dosing regimen [@doi:10.1016/j.medmal.2020.03.006].
One patient died, two were transferred to the ICU, and one developed a prolonged QT interval, leading to discontinuation of HCQ + AZ.
As in the Gautret et al. study, the outcome assessed was virological clearance at Day 6 post-treatment, as measured in nasopharyngeal swabs.
Of the ten living patients on Day 6, eight remained positive for SARS-CoV-2 RNA.
Like in the original study, interpretability was severely limited by the lack of a comparison group and the small sample size.
However, these results stand in contrast to the claims by Gautret et al. that all six patients treated with HCQ + AZ tested negative for SARS-CoV-2 RNA by Day 6 post-treatment.
This case study illustrated the need for further investigation using robust study design to evaluate the efficacy of HCQ and/or CQ.

On April 10, 2020, a randomized, non-placebo trial of 62 COVID-19 patients at the Renmin Hospital of Wuhan University was released [@doi:10.1101/2020.03.22.20040758].
This study investigated whether HCQ decreased time to fever break or time to cough relief when compared to SOC [@doi:10.1101/2020.03.22.20040758].
This trial found HCQ decreased both average time to fever break and average time to cough relief, defined as mild or no cough.
While this study improved on some of the methodological flaws in Gautret et al. by randomizing patients, it also had several flaws in trial design and data analysis that prevent generalization of the results.
These weaknesses include the lack of placebo, lack of correction for multiple primary outcomes, inappropriate choice of outcomes, lack of sufficient detail to understand analysis, drastic disparities between pre-registration and published protocol, and small sample size.
The choice of outcomes may be inappropriate as both fevers and cough may break periodically without resolution of illness.
Additionally, for these outcomes, the authors reported that 23 of 62 patients did not have a fever and 25 of 62 patients did not have a cough at the start of the study, but the authors failed to describe how these patients were included in a study assessing time to fever break and time to cough relief.
It is important to note here that the authors claimed "neither the research performers nor the patients were aware of the treatment assignments."
This blinding seems impossible in a non-placebo trial because at the very least, providers would know whether they were administering a medication or not, and this knowledge could lead to systematic differences in the administration of care.
Correction for multiple primary outcomes can be adjusted _post hoc_ by recalculating p-values, but all of the other issues were design and statistical weaknesses that cannot be corrected for.
Additionally, the observation of drastic disparities between pre-registration and published protocol could indicate p-hacking [@doi:10.1371/journal.pbio.1002106].
The design limitations mean that the conclusions cannot be generalized outside of the study.
A second randomized trial, conducted by the Shanghai Public Health Clinical Center, analyzed whether HCQ increased rates of virological clearance at day 7 in respiratory pharyngeal swabs compared to standard care [@doi:10/drbx].
This trial was published in Chinese along with an abstract in English, and only the English abstract was read and interpreted for this review.
The trial found comparable outcomes in virological clearance rate, time to virological clearance, and time to body temperature normalization between the treatment and control groups.
A known weakness is small sample size, with only 30 patients enrolled and 15 in each arm.
This problem suggests the study is underpowered to detect potentially useful differences and precludes interpretation of results.
Additionally, because only the abstract could be read, other design and analysis issues could be present.
Thus, though these studies added randomization to their assessment of HCQ, their conclusions should be interpreted very cautiously.
These two studies assessed different outcomes and reached differing conclusions about the efficacy of HCQ for treating COVID-19; the designs of both studies, especially with respect to sample size, meant that no general conclusions can be made about the efficacy of the drug.

Several widely reported studies on HCQ have issues with data integrity and/or provenance.
A Letter to the Editor published in _BioScience Trends_ on March 16, 2020 claimed that numerous clinical trials have shown that HCQ is superior to control treatment in inhibiting the exacerbation of COVID-19 pneumonia [@doi:10.5582/bst.2020.01047].
This letter has been cited by numerous primary literature, review articles, and media alike [@doi:10.7150/ijbs.45498; @doi:10.7150/ijbs.45053].
However, the letter referred to 15 pre-registration identifiers from the Chinese Clinical Trial Registry.
When these identifiers are followed back to the registry, most trials claim they are not yet recruiting patients or are currently recruiting patients.
For all of these 15 identifiers, no data uploads or links to publications could be located on the pre-registrations.
At the very least, the lack of availability of the primary data means the claim that HCQ is efficacious against COVID-19 pneumonia cannot be verified.
Similarly, a recent multinational registry analysis [@doi:10/ggwzsb] analyzed the efficacy of CQ and HCQ with and without a macrolide, which is a class of antibiotics that includes Azithromycin, for the treatment of COVID-19.
The study observed 96,032 patients split into a control and four treatment conditions (CQ with and without a macrolide; HCQ with and without a macrolide).
They concluded that treatment with CQ and HCQ was associated with increased risk of _de novo_ ventricular arrhythmia during hospitalization.
However, this study has since been retracted by _The Lancet_ due to an inability to validate the data used [@doi:10/ggzqng].
These studies demonstrate that increased skepticism in evaluation of the HCQ/CQ and COVID-19 literature may be warranted, possible because of the significant attention HCQ and CQ have received as possible treatments for COVID-19 and the politicization of these drugs.

Despite the fact that the study suggesting that CQ/HCQ increased risk of ventricular arrhythmia in COVID-19 patients has now been retracted, previous studies have identified risks associated with HCQ/CQ.
A patient with systemic lupus erythematosus developed a prolonged QT interval that was likely exacerbated by use of HCQ in combination with renal failure [@doi:10.1155/2016/4626279].
A prolonged QT interval is associated with ventricular arrhythmia [@doi:10.1016/j.hrthm.2008.05.008].
Furthermore, a separate study [@doi:10.1101/2020.04.08.20054551] investigated the safety associated with the use of HCQ with and without macrolides between 2000 and 2020.
The study involved 900,000 cases treated with HCQ and 300,000 cases treated with HCQ + AZ.
The results indicated that short-term use of HCQ was not associated with additional risk, but that HCQ + AZ was associated with an enhanced risk of cardiovascular complications (15-20% increased risk of chest pain) and a two-fold increased risk of mortality.
Therefore, whether studies utilize HCQ alone or HCQ in combination with a macrolide may be an important consideration in assessing risk.
As results from initial investigations of these drug combinations have emerged, concerns about the efficacy and risks of treating COVID-19 with HCQ and CQ has led to the removal of CQ/HCQ from SOC practices in several countries [@doi:10.1101/2020.04.07.20056424; @url:https://www.cnn.com/2020/04/13/health/chloroquine-risks-coronavirus-treatment-trials-study/index.html].
As of May 25, 2020, WHO had suspended administration of HCQ as part of the worldwide Solidarity Trial [@raw:WHO_briefing_2020_5_25], and later the final results of this large-scale trial that compared 947 patients administered HCQ to 906 controls revealed no effect on the primary outcome, mortality during hospitalization (rate ratio: 1.19; P=0.23)

As additional research has emerged, HCQ/CQ have increasingly been demonstrated to be ineffective against COVID-19 and to carry a number of significant side effects.
A randomized, open-label, non-placebo trial of 150 COVID-19 patients was conducted in parallel at 16 government-designated COVID-19 centers in China to assess the safety and efficacy of HCQ [@doi:10.1101/2020.04.10.20060558].
The trial compared treatment with HCQ in conjunction with SOC to SOC alone in 150 infected patients who were assigned randomly to the two groups (75 per group).
The primary endpoint of the study was the negative conversion rate of SARS-CoV-2 in 28 days, and the investigators found no difference in this parameter between the groups.
The secondary endpoints were an amelioration of the symptoms of the disease such as axillary temperature ≤36.6°C, SpO2 >94% on room air, and disappearance of symptoms like shortness of breath, cough, and sore throat.
The median time to symptom alleviation was similar across different conditions (19 days in HCQ+SOC vs. 21 days in SOC).
Additionally, 30% of the patients receiving SOC+HCQ reported adverse outcomes compared to 8.8% of patients receiving only SOC, with the most common adverse outcome in the SOC+HCQ group being diarrhea (10% vs. 0% in the SOC group, p=0.004).
However, there are several factors that limit the interpretability of this study.
Most of the enrolled patients had mild-to-moderate symptoms (98%), and the average age was 46.
SOC in this study included the use of antivirals (Lopinavir-Ritonavir, Arbidol, Oseltamivir, Virazole, Entecavir, Ganciclovir, and Interferon alfa), which appeared to introduce confounding effects.
Thus, to isolate the effect of HCQ, SOC would need to exclude the use of antivirals.
In this trial, the samples used to test for the presence of the SARS-CoV-2 virus were collected from the upper respiratory tract, and the authors indicated that the use of upper respiratory samples may have introduced false negatives (e.g., [@doi:10.1001/jama.2020.3786]).
Another limitation of the study that the authors acknowledge was that the HCQ treatment began, on average, at a 16-day delay from the symptom onset.
The fact that this study was open-label and lacked a placebo limits interpretation, and additional analysis is required to determine whether HCQ reduces inflammatory response.
Therefore, despite some potential areas of investigation identified in _post hoc_ analysis, this study cannot be interpreted as providing support for HCQ as a therapeutic against COVID-19.

Additional evidence comes from a retrospective analysis [@doi:10.1101/2020.04.16.20065920] that examined data from 368 COVID-19 patients across all United States Veteran Health Administration medical centers.
The study retrospectively investigated the effect of the administration of HCQ (n=97), HCQ + AZ (n=113), and no HCQ (n=158) on 368 patients.
The primary outcomes assessed were death and the need for mechanical ventilation.
Standard supportive care was rendered to all patients.
Due to the low representation of women (N=17) in the available data, the study included only men, and the median age was 65 years.
The rate of death in the HCQ-only treatment condition was 27.8% and in the HCQ + AZ treatment condition, it was 22.1%.
In comparison to the 14.1% rate of death in the no-HCQ cohort, these data indicated a statistically significant elevation in the risk of death for the HCQ-only group compared to the no-HCQ group (adjusted HR: 2.61, p=0.03), but not for the HCQ + AZ group compared to the no-HCQ group (adjusted HR: 1.14; p=0.72).
Further, the risk of ventilation was similar across all three groups (adjusted HR: 1.43, p=0.48 (HCQ) and 0.43, p=0.09 (HCQ + AZ) compared to no HCQ).
The study thus showed evidence of an association between increased mortality and HCQ in this cohort of COVID-19 patients but no change in rates of mechanical ventilation among the treatment conditions.
The study had a few limitations: it was not randomized, and the baseline vital signs, laboratory tests, and prescription drug use were significantly different among the three groups.
All of these factors could potentially influence treatment outcome.
Furthermore, the authors acknowledge that the effect of the drugs might be different in females and pediatric subjects, since these subjects were not part of the study.
The reported result that HCQ + AZ is safer than HCQ contradicts the findings of the previous large-scale analysis of twenty years of records that found HCQ + AZ to be more frequently associated with cardiac arrhythmia than HCQ alone [@doi:10.1101/2020.04.08.20054551]; whether this discrepancy is caused by the pathology of COVID-19, is influenced by age or sex, or is a statistical artifact is not presently known.

Finally, findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial were released on October 8, 2020.
This study used a randomized, open-label design to study the effects of HCQ compared to standard care at 176 hospitals in the United Kingdom [@doi:10.1056/NEJMoa2022926].
This large study enrolled 11,197 hospitalized patients whose physicians believed it would not harm them to participate.
Patients were randomized into either the control group or one of the treatment arms, with twice as many patients enrolled in the control group as any treatment group.
Of the patients eligible to receive HCQ, 1,561 were randomized into the HCQ arm while 3,155 were randomized into the control arm.
The demographics of the HCQ and control groups were similar in terms of average age (65 years), proportion female (approximately 38%), ethnic make-up (73% versus 76% white), and prevalence of pre-existing conditions (56% versus 57% overall).
In the HCQ arm of the study, patients received 800 mg at baseline and again after 6 hours, then 400 mg at 12 hours and every subsequent 12 hours.
The primary outcome analyzed was all-cause mortality, and patient vital statistics were reported by physicians upon discharge or death, or else at 28 days following HCQ administration if they remained hospitalized.
The secondary outcome assessed was the combined risk of progression to invasive mechanical ventilation or death within 28 days.
By the advice of an external data monitoring committee, the HCQ arm of the study was reviewed early, leading to it being closed due a lack of support for HCQ as a treatment for COVID-19.
Patients who received HCQ had a longer duration of hospitalization than patients receiving usual care, were less likely to be discharged alive within 28 days, and were more likely to progress to mechanical ventilation.
This large-scale study thus builds upon studies in the United States and China to suggest that HCQ is not an effective treatment, and in fact may negatively impact COVID-19 patients due to its side effects.
The rates of COVID-19-related reported in the RECOVERY trial did not differ between the control and HCQ arms, but patients receiving HCQ were more likely to die due to cardiac events.
Therefore, though none of the studies have been blinded, taken together it becomes clear that all of the available evidence points to significant concerns about the administration of HCQ to hospitalized COVID-19 patients, without providing any support for its efficacy.

###### HCQ for the Treatment of Mild Cases

One additional possible therapeutic application considered was the treatment of mild COVID-19 cases in otherwise healthy individuals.
This possibility was assessed in a randomized, open-label, multi-center analysis conducted in Catalonia (Spain) [@doi:10.1093/cid/ciaa1009].
This analysis enrolled adults 18 and older who had been experiencing mild symptoms of COVID-19 for fewer than five days.
Participants were randomized into an HCQ arm (N=136) and a control arm (N=157), and those in the treatment arm were administered 800 mg of HCQ on the first day of treatment followed by 400 mg on each of the subsequent six days.
The primary outcome assessed was viral clearance at days 3 and 7 following the onset of treatment, and secondary outcomes were clinical progression and time to complete resolution of symptoms.
They found no significant differences between the two groups.
This study thus suggests that HCQ does not improve recovery from COVID-19, even in otherwise healthy adult patients with mild symptoms.

###### Prophylactic Administration of HCQ

An initial study of the possible prophylactic application of HCQ utilized a randomized, double-blind, placebo-controlled design to analyze the administration of HCQ prophylactically [@doi:10.1056/NEJMoa2016638].
Asymptomatic adults in the United States and Canada who had been exposed to SARS-CoV-2 within the past four days were enrolled in an online study to see whether administration of HCQ over five days would influence the probability of developing COVID-19 symptoms over a 14-day period.
Of the participants, 414 received HCQ and 407 received a placebo.
The participants averaged 40 years of age and 51.6% were women.
They found no significant difference in the rate of symptomatic illness between the two groups (11.8% HCQ, 14.3% placebo, p=0.35).
The HCQ condition was associated with side effects, with 40.1% of patients reporting side effects compared to 16.8% in the control group (p<0.001).
However, likely due to the high enrollment of healthcare workers (66% of participants) and the well-known side effects associated with HCQ, a large number of participants were able to correctly identify whether they were receiving HCQ or a placebo (46.5% and 35.7%, respectively).
Furthermore, due to a lack of availability of diagnostic testing, only 20 of the 107 cases were confirmed with a PCR-based test to be positive for SARS-CoV-2.
The rest were categorized as "probable" or "possible" cases by a panel of four physicians who were blind to the treatment status.
One possible confounder is that a patient presenting one or more symptoms, which included diarrhea, was defined as a "possible" case, but diarrhea is also a common side effect of HCQ.
Additionally, four of the twenty PCR-confirmed cases did not develop symptoms until after the observation period had completed, suggesting that the 14-day trial period may not have been long enough or that some participants also encountered secondary exposure events.
Finally, in addition to the young age of the participants in this study, which ranged from 32 to 51, there were possible impediments to generalization introduced by the selection process, as 2,237 patients who were eligible but had already developed symptoms by day 4 were enrolled in a separate study.
It is therefore likely that asymptomatic cases were over-represented in this sample, which would not have been detected based on the diagnostic criteria used.
Therefore, while this study does represent the first effort to conduct a randomized, double-blind, placebo-controlled investigation of HCQ's effect on COVID-19 symptoms in a large sample, the lack of PCR tests and several other design flaws significantly impede interpretation of the results.
However, in line with the results from therapeutic studies, there is no evidence that HCQ provides protection against COVID-19.

A second study [@doi:10.1001/jamainternmed.2020.6319] examined the effect of administering HCQ to healthcare workers as a pre-exposure prophylactic.
The primary outcome assessed was the conversion from SARS-CoV-2 negative to SARS-CoV-2 positive status over the 8 week study period.
This study was also randomized, double-blind, and placebo-controlled and sought to address some of the limitations of the first prophylactic study.
They aimed to enroll 200 healthcare workers, preferentially those working with COVID-19 patients, at two hospitals within the University of Pennsylvania hospital system in Philadelphia, PA.
Participants were randomized 1:1 to receive either 600 mg of HCQ daily or a placebo, and their SARS-CoV-2 infection status and antibody status were assessed using RT-PCR and serological testing, respectively, at baseline, 4 weeks, and 8 weeks following the beginning of the treatment period.
The statistical design of the study accounted for interim analyses at 50 and 100 participants in case efficacy or futility of HCQ for prophylaxis became clear earlier than completion of enrollment.
The 139 individuals enrolled comprised a study population that was fairly young (average age 33) and made of largely of people who were white, women, and without pre-existing conditions.
At the second interim analysis, more individuals in the treatment group than the control group had contracted COVID-19 (4 versus 3), causing the estimate z-score to fall below the pre-established threshold for futility.
As a result, the trial was terminated early, offering additional evidence against the use of HCQ for prophylaxis.

###### Summary of HCQ/CQ Research Findings

Early _in vitro_ evidence indicated that HCQ could be an effective therapeutic against SARS-CoV-2 and COVID-19, leading to early interest in its potential as both a therapeutic and prophylaxis.
Initially it was hypothesized that CQ/HCQ might be effective against SARS-CoV-2, especially since CQ and HCQ have both been found to inhibit the expression of CD154 in T-cells and to reduce TLR signaling that leads to the production of pro-inflammatory cytokines [@doi:10.1038/s41584-020-0372-x].
Clinical trials for COVID-19 have more often used HCQ rather than CQ because it offers the advantages of being cheaper and having fewer side effects than CQ.
However, a large analysis of patients receiving HCQ from January 2000 through March 2020 reported that the combination of HCQ and azithromycin, but not other macrolides, was associated with an elevated risk of cardiovascular complications and mortality.
Multiple clinical studies have already been carried out to assess HCQ as a therapeutic agent for COVID-19, and many more are in progress.
To date, none of these studies have used randomized, double-blind, placebo-controlled designs with a large sample size, which would be the gold standard.
Despite the design limitations (which would be more likely to produce false positives than false negatives), initial optimism about HCQ has not been substantiated by these studies.
The most methodologically rigorous HCQ-focused analysis to date [@doi:10.1056/NEJMoa2016638] evaluated the prophylactic potential of HCQ and found no significant differences between the treatment and control groups, and the WHO's global Solidarity trial  similarly reported no effect of HCQ on mortality.
Thus, HCQ/CQ are not likely to be effective therapeutic or prophylactic agents against COVID-19.
Additionally, one study identified an increased risk of mortality in older men receiving HCQ, and administration of HCQ and HCQ+AZ did not decrease the use of mechanical ventilation in these patients [@doi:10.1101/2020.04.16.20065920].
HCQ use for COVID-19 could also lead to shortages for anti-malarial or anti-rheumatic use, where it has been definitively proven to be effective.
Despite significant attention, these drugs appear to be ineffective against COVID-19.
Several countries have now removed CQ from their SOC for COVID-19 due to the lack of evidence of efficacy and the frequency of adverse effects.

##### Dexamethasone

Dexamethasone (9α-fluoro-16α-methylprednisolone) is a synthetic corticosteroid that binds to glucocorticoid receptors [@doi:10.1021/cr068203e; @url:https://www.cebm.net/covid-19/dexamethasone/].
It was first synthesized in the late 1950s as an anti-inflammatory and has been used to treat rheumatoid arthritis and other inflammatory conditions [@doi:10.1021/ja01545a061; @doi:10.1001/jama.1960.03030070009002].
Steroids such as dexamethasone are widely available and affordable, and they are often used to treat community-acquired pneumonia [@doi:10.1038/s41392-020-0127-9].
A clinical trial that began in 2012 recently reported that dexamethasone may improve outcomes for patients with ARDS [@doi:10/ggpxzc].
However, meta-analysis of a small amount of available data regarding the use of dexamethasone to treat SARS suggested that it may, in fact, be associated with patient harm [@doi:10/ggks86], although these findings may have been biased by the fact that all of the studies examined were observational and a large number of inconclusive studies were not included [@doi:10/ggq356].
Dexamethasone works as an anti-inflammatory by binding to glucocorticoid receptors with higher affinity than endogenous cortisol [@doi:10.1016/B978-0-323-48110-6.00034-X].
In order to understand how dexamethasone works to reduce inflammation, it is necessary to consider the stress response more broadly.
In response to stress, corticotropin‐releasing hormone stimulates the release of neurotransmitters known as catecholamines, such as epinephrine, and steroid hormones known as glucocorticoids, such as cortisol [@doi:10.1016/j.cyto.2015.01.008; @doi:10.1111/j.1749-6632.2002.tb04229.x].
While catecholamines are often associated with the fight-or-flight response, the specific role that glucocorticoids play is less clear, although they are thought to be important to restoring homeostasis [@doi:10.1159/000054578].
Immune challenge is a stressor that is known to interact closely with the stress response.
The immune system can therefore interact with the central nervous system; for example, macrophages can both respond to and produce catecholamines [@doi:10.1016/j.cyto.2015.01.008].
Additionally, the production of both catecholamines and glucocorticoids is associated with inhibition of proinflammatory cytokines such as IL-6, IL-12, and tumor necrosis factor-α (TNF‐α) and the stimulation of anti-inflammatory cytokines such as IL-10, meaning that the stress response can regulate inflammatory immune activity [@doi:10.1111/j.1749-6632.2002.tb04229.x].
Administration of dexamethasone has been found to correspond to dose-dependent inhibition of IL-12 production, but not to affect IL-10 [@PMID:8902882]; the fact that this relationship could be disrupted by administration of a glucocorticoid-receptor antagonist suggests that it is regulated by the receptor itself [@PMID:8902882]. <!-- Note: waiting for full text of this paper, this is based on abstract and citations-->
Thus, the administration of dexamethasone for COVID-19 is likely to simulate the release of glucocorticoids endogenously during stress, resulting in binding of the synthetic steroid to the glucocorticoid receptor and the associated inhibition of the production of proinflammatory cytokines.
In this model, dexamethasone reduces inflammation by stimulating the mechanism that reduces inflammation following a threat such as immune challenge.
Immunosuppressive drugs such as steroids are typically contraindicated in the setting of infection [@doi:10.1177/2040622313485275], but because COVID-19 results in hyperinflammation that appears to contribute to mortality via lung damage, immunosuppression may be a helpful approach to treatment [@doi:10/ggnzmc].
The decision of whether and/or when to counter hyperinflammation with immunosuppression in the setting of COVID-19 was an area of intense debate, as the risks of inhibiting antiviral immunity needed to be weighed against the beneficial anti-inflammatory effects [@doi:10/ggq8hs].
As a result, guidelines early in the pandemic typically recommended avoiding treating COVID-19 patients with corticosteroids such as dexamethasone [@doi:10/ggks86].

The application of dexamethasone for the treatment of COVID-19 was evaluated as part of the multi-site RECOVERY trial in the United Kingdom [@doi:10.1101/2020.06.22.20137273].
Over 6,000 hospitalized COVID-19 patients were assigned into standard care or treatment (dexamethasone) arms of the trial with a 2:1 ratio.
At the time of randomization, some patients were ventilated (16%), others were on non-invasive oxygen (60%), and others were breathing independently (24%).
Patients in the treatment arm were administered dexamethasone either orally or intravenously at 6 mg per day for up to 10 days.
The primary end-point was the patient's status at 28-days post-randomization (mortality, discharge, or continued hospitalization), and secondary outcomes analyzed included the progression to invasive mechanical ventilation over the same period.
The 28-day mortality rate was found to be lower in the treatment group than in the standard care group (21.6% vs 24.6%, p <0.001).
However, this finding was driven by differences in mortality among patients who were receiving mechanical ventilation or supplementary oxygen at the start of the study.
The report indicated that dexamethasone reduced 28-day mortality relative to standard care in patients who were ventilated (29.3% vs. 41.4%) and among those who were receiving oxygen supplementation (23.3% vs. 26.2%) at randomization, but not in patients who were breathing independently (17.8% vs. 14.0%).
One possible confounder is that patients receiving mechanical ventilation tended to be younger than patients who were not receiving respiratory support (by 10 years on average) and to have had symptoms for a longer period.
However, adjusting for age did not change their conclusions, although the duration of symptoms was found to be significantly associated with the effect of dexamethasone administration.
These findings also suggested that dexamethasone may have reduced progression to mechanical ventilation, especially among patients who were receiving oxygen support at randomization.
Thus, this large, randomized, and multi-site, albeit not placebo-controlled, study suggests that administration of dexamethasone to patients who are unable to breathe independently may significantly improve survival outcomes.
Additionally, dexamethasone is a widely available and affordable medication, raising the hope that it could be made available to COVID-19 patients globally.

The results of the RECOVERY trial's analysis of dexamethasone suggest that this therapeutic is effective primarily in  patients who had been experiencing symptoms for at least seven days and patients who were not breathing independently [@doi:10.1056/NEJMoa2021436].
Thus, it seems likely that dexamethasone is useful for treating inflammation associated with immunopathy or cytokine release syndrome.
In fact, corticosteroids such as dexamethasone are sometimes used to treat CRS [@doi:10.1182/blood-2014-05-552729].
It is not surprising that administration of an immunosuppressant would be most beneficial when the immune system was dysregulated towards inflammation.
However, it is also unsurprising that care must be taken in administering an immunosuppressant to patients fighting a viral infection.
In particular, the concern has been raised that treatment with dexamethasone might increase patient susceptibility to concurrent (e.g., nosocomial) infections [@doi:10.23812/20-EDITORIAL_1-5].
Additionally, the drug could potentially slow viral clearance and inhibit patients' ability to develop antibodies to SARS-CoV-2 [@doi:10.23812/20-EDITORIAL_1-5; @doi:10/ggks86]. 
Furthermore, dexamethasone has been associated with side effects that include psychosis, glucocorticoid-induced diabetes, and avascular necrosis [@doi:10/ggks86], and the RECOVERY trial did not report outcomes with enough detail to be able to determine whether they observed similar complications.
However, since these results were released, strategies have been proposed for administering dexamethasone alongside more targeted treatments to minimize the likelihood of negative side effects [@doi:10.23812/20-EDITORIAL_1-5].
Given the available evidence, dexamethasone is currently the most promising treatment for severe COVID-19.

### Biologics

Biologics are produced from components of living organisms or viruses.
They include treatments such as humanized monoclonal antibodies (mAb) tocilizumab (TCZ), and neutralizing antibodies (nAbs), and can also include prophylactics such as vaccines.
Historically produced from animal tissue, biologics have become increasingly feasible to produce as recombinant DNA technologies have advanced [@doi:10.1016/j.copbio.2009.10.006].
Often, they are glycoproteins or peptides [@doi:10.2174/138920006774832604], but whole viruses can also be used therapeutically or prophylactically, not only for vaccines but also as vectors for gene therapy or therapeutic proteins or for oncolytic virotherapy [@doi:10.3390/jcm9040972].
They are typically catabolized by the body to their amino acid components [@doi:10.2174/138920006774832604].
There are many differences on the development side between biologics and synthesized pharmaceuticals, such as small molecule drugs.
Biologics are typically orders of magnitude larger than small molecule drugs and their physiochemical properties are often much less understood [@doi:10.2174/138920006774832604].
They are often heat sensitive, and their toxicity can vary, as it is not directly associated with the primary effects of the drug [@doi:10.2174/138920006774832604].
However, this class includes some extremely significant medical breakthroughs, including insulin for the management of diabetes and the smallpox vaccine.
As a result, it is another possible avenue through which the pharmacological management of SARS-CoV-2 infection can be explored. 

#### Tocilizumab

TCZ is a receptor antibody that was developed to manage chronic inflammation caused by the continuous synthesis of the cytokine IL-6 [@doi:10.1101/cshperspect.a016295].
IL-6 is a pro-inflammatory cytokine belonging to the interleukin family, which is comprised by immune system regulators that are primarily responsible for immune cell differentiation.
Often used to treat conditions such as rheumatoid arthritis [@doi:10.1101/cshperspect.a016295], TCZ has become a pharmaceutical of interest for the treatment of COVID-19 because of the role IL-6 plays in this disease. 
While secretion of IL-6 can be associated with chronic conditions, it is a key player in the innate immune response and is secreted by macrophages in response to the detection of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [@doi:10.1101/cshperspect.a016295].
An analysis of 191 in-patients at two Wuhan hospitals revealed that blood concentrations of IL-6 differed between patients who did and did not recover from COVID-19.
Patients who ultimately deceased had higher IL-6 levels at admission than those who recovered [@doi:10/ggnxb3].
Additionally, IL-6 levels remained higher throughout the course of hospitalization in the patients who ultimately deceased [@doi:10/ggnxb3].
This finding provided some early evidence that COVID-19 deaths may be induced by the hyperactive immune response, often referred to as cytokine release syndrome (CRS) or cytokine storm syndrome (CSS), as IL-6 plays a key role in this response [@doi:10.1128/mmbr.05015-11].
In this context, the observation of elevated IL-6 in patients who died may reflect an over-production of proinflammatory interleukins, suggesting that TCZ may palliate some of the most severe symptoms of COVID-19 associated with increased cytokine production.

Human IL-6 is a 26-kDa glycoprotein that consists of 184 amino acids and contains two potential N-glycosylation sites and four cysteine residues. 
It binds to a type I cytokine receptor (IL-6Rα or glycoprotein 80) that exists in both membrane-bound (IL-6Rα) and soluble (sIL-6Rα) forms [@doi:10.3389/fimmu.2016.00604].
It is not the binding of IL-6 to the receptor that initiates pro- and/or anti-inflammatory signaling, but rather the binding of the complex to another subunit, known as IL-6Rβ or glycoprotein 130 (gp13) [@doi:10.7150/ijbs.4989; @doi:10.3389/fimmu.2016.00604].
Unlike membrane-bound IL-6Rα, which is only found on hepatocytes and some types of leukocytes, gp130 is found on most cells [@doi:10.1007/s00430-006-0019-9].
When IL-6 binds to sIL-6Rα, the complex can then bind to a gp130 protein on any cell [@doi:10.1007/s00430-006-0019-9].
The binding of IL-6 to IL-6Rα is termed classical signaling, while its binding to sIL-6Rα is termed trans-signaling [@doi:10.1016/j.cytogfr.2012.04.001; @doi:10.1042/bj3000281; @doi:10.1007/s00430-006-0019-9].
These two signaling processes are thought to play different roles in health and illness.
For example, trans-signaling may play a role in the proliferation of mucosal T-helper TH2 cells associated with asthma, while an earlier step in this proliferation process may be regulated by classical signaling [@doi:10.1007/s00430-006-0019-9].
Similarly, IL-6 is known to play a role in Crohn's Disease via trans-, but not classical, signaling [@doi:10.1007/s00430-006-0019-9].
Both classical and trans-signaling can occur through three independent pathways: the Janus-activated kinase-STAT3 pathway, the Ras/Mitogen-Activated Protein Kinases (MAPK) pathway and the Phosphoinositol-3 Kinase/Akt pathway [@doi:10.3389/fimmu.2016.00604].
These signaling pathways are involved in a variety of different functions, including cell type differentiation, immunoglobulin synthesis, and cellular survival signaling pathways, respectively [@doi:10.3389/fimmu.2016.00604].
The ultimate result of the IL-6 cascade is to direct transcriptional activity of various promoters of pro-inflammatory cytokines, such as IL-1, TFN, and even IL-6 itself, through the activity of NF-κB [@doi:10.3389/fimmu.2016.00604].
IL-6 synthesis is tightly regulated both transcriptionally and post-transcriptionally, and it has been shown that viral proteins can enhance transcription of the IL-6 gene by strengthening the DNA-binding activity between several transcription factors and IL-6 gene-cis-regulatory elements [@doi:10.2492/inflammregen.33.054].
Therefore, drugs inhibiting the binding of IL-6 to IL-6Rα or sIL-6Rα are of interest for combating the hyperactive inflammatory response characteristic of CRS and CSS.
TCZ is a humanized monoclonal antibody that binds both to the insoluble and soluble receptor of IL-6, providing de facto inhibition of the IL-6 immune cascade.

Tocilizumab is being administered either as an intervention or as concomitant medication in 84 COVID-19 clinical trials (Figure @fig:ebm-trials).
No randomized, placebo-controlled studies of TCZ have currently released results.
Therefore, no conclusions can be drawn about its efficacy for the treatment of COVID-19.
However, early interest in TCZ as a possible treatment for COVID-19 emerged from a very small retrospective study in China that examined 20 patients with severe symptoms in early February 2020 and reported rapid improvement in symptoms following treatment with TCZ [@doi:10.1073/pnas.2005615117].
Subsequently, a number of retrospective studies have been conducted in several countries.
Many studies use a retrospective, observational design, where they compare outcomes for COVID-19 patients who received TCZ to those who did not over a set period of time.
For example, one of the largest retrospective, observational analysis released to date [@doi:10/d2pk] compared the rates at which patients who received TCZ deceased or progressed to invasive medical ventilation over a 14-day period compared to patients receiving only SOC.
Under this definition, SOC could include other drugs such as HCQ, azithromycin, lopinavir-ritonavir or darunavir-cobicistat, or heparin.
While this study was not randomized, a subset of patients who were eligible to receive TCZ were unable to obtain it due to shortages; however, these groups were not directly compared in the analysis.
After adjusting for variables such as age, sex, and SOFA score, they found that patients treated with TCZ were less likely to progress to invasive medical ventilation and/or death (adjusted HR = 0.61, CI 0.40-0.92, p=0.020), although analysis of death and ventilation separately suggests that this effect may have been driven by differences in the death rate (20% of control versus 7% of TCZ-treated patients).
They reported particular benefits for patients whose PaO~2~/FiO~2~ ratio, also known as the Horowitz Index for Lung Function, fell below a 150 mm Hg threshold.
They found no differences between groups administered subcutaneous versus intravenous TCZ.

Another retrospective observational analysis of interest examined the charts of patients at a hospital in Connecticut, USA where 64% of all 239 COVID-19 patients in the study period were administered TCZ based on assignment by a standardized algorithm [@doi:10.1016/j.chest.2020.06.006].
They found that TCZ administration was associated with more similar rates of survivorship in patients with severe versus nonsevere COVID-19 at intake, defined based on the amount of supplemental oxygen needed.
They therefore proposed that their algorithm was able to identify patients presenting with or likely to develop CRS as good candidates for TCZ.
This study also reported higher survivorship in Black and Hispanic patients compared to white patients when adjusted for age.
The major limitation with interpretation for these studies is that there may be clinical characteristics that influenced medical practitioners decisions to administer TCZ to some patients and not others.
One interesting example therefore comes from an analysis of patients at a single hospital in Brescia, Italy, where TCZ was not available for a period of time [@doi:10.1016/j.ejim.2020.05.009].
This study compared COVID-19 patients admitted to the hospital before and after March 13, 2020, when the hospital received TCZ.
Therefore, patients who would have been eligible for TCZ prior to this arbitrary date did not receive it as treatment, making this retrospective analysis something of a natural experiment.
Despite this design, demographic factors did not appear to be consistent between the two groups, and the average age of the control group was older than the TCZ group.
The control group also had a higher percentage of males and a higher incidence of comorbidities such as diabetes and heart disease.
All the same, the multivariate HR, which adjusted for these clinical and demographic factors, found a significant difference between survival in the two groups (HR=0.035, CI=0.004-0.347, p = 0.004).
They reported improvement of survival outcomes after the addition of TCZ to their SOC regime, with 11 of 23 patients (47.8%) admitted prior to March 13th dying compared to 2 of 62 (3.2%) admitted afterwards.
They also reported a reduced progression to mechanical ventilation in the TCZ group.
However, this study also holds a significant limitation: the time delay between the two groups means that knowledge about how to treat the disease likely improved over this timeframe as well.
All the same, the results of these observational retrospective studies provide support for TCZ as a pharmaceutical of interest for follow-up in clinical trials. 

In addition to the retrospective observational studies, other analysis have utilized a retrospective case-control design to match pairs of patients with similar baseline characteristics, only one of whom received TCZ for COVID-19.
In one such study, TCZ was significantly associated with a reduced risk of progression to ICU admission or death [@doi:10.1016/j.medmal.2020.05.001].
This study examined only 20 patients treated with TCZ (all but one of the patients treated with TCZ in the hospital during the study period) and compared them to 25 patients receiving SOC.
For the combined primary endpoint of death and/or ICU admission, only 25% of patients receiving TCZ progressed to an endpoint compared to 72% in the SOC group (p = 0.002, presumably based on a chi-square test based on the information provided in the text). 
When the two endpoints were examined separately, progression to invasive medical ventilation remained significant (32% SOC compared to 0% TCZ, p = 0.006) but not for mortality (48% SOC compared to 25% TCZ, p = 0.066).
In contrast, a study that compared 96 patients treated with TCZ to 97 patients treated with SOC only in New York City found that differences in mortality did not differ between the two groups, but that this difference did become significant when intubated patients were excluded from the analysis [@doi:10.1093/qjmed/hcaa206].
Taken together, these findings suggest that future clinical trials of TCZ may want to include intubation as an endpoint.
However, these studies should be approached with caution, not only because of the small number of patients enrolled and the retrospective design, but also because they performed a large number of statistical tests and did not account for multiple hypothesis testing.
These last findings highlight the need to search for a balance between impairing a harmful immune response, such as the one generated during CRS and CSS, and preventing the worsening of the clinical picture of the patients by potential new viral infections.

Though data about TCZ for COVID-19 is still only just emerging, some meta-analyses and systematic reviews have investigated the available data.
One meta-analysis [@doi:10.2139/ssrn.3642653] evaluated 19 studies published or released as preprints prior to July 1, 2020 and found that the overall trends supportive of the frequent conclusion that TCZ does improve survivorship, with a significant HR of 0.41.
This trend improved when they excluded studies that administered a steroid alongside TCZ, with a significant HR of 0.04.
They also found some evidence for reduced IMV or ICU admission, but only when excluding all studies except a small number reporting estimates that were adjusted for possible bias introduced by the challenges of stringency during the enrollment process.
A systematic analysis of nine case-control studies estimated a HR of 0.482, which was also significant [@doi:10.1101/2020.07.10.20150938]. 
Although these estimates are similar, it is important to note that they are drawing from the same literature and are therefore likely to be affected by the same biases in publication.
A second systematic review of studies investigating TCZ treatment for COVID-19 analyzed 31 studies that had been published or released as pre-prints and reported that none carried a low risk of bias (RoB) [@doi:10.1016/j.pulmoe.2020.07.003].
Therefore, the present evidence is not likely to be sufficient for conclusions about the efficacy of TCZ.

Additionally, there are possible risks associated with the administration of TCZ for COVID-19.
TCZ has been used for over a decade to treat rheumatoid arthritis [@doi:10.1177/1759720X18798462], and a recent study found the drug to be safe for pregnant and breastfeeding women [@doi:10.1093/rheumatology/kez100].
However, TCZ may increase the risk of developing infections [@doi:10.1177/1759720X18798462], and rheumatoid arthritis patients with chronic hepatitis B infections had a high risk of hepatitis B virus reactivation when TCZ was administered in combination with other RA drugs [@doi:10.1111/1756-185X.13010].
As a result, TCZ is contraindicated in patients with active infections such as tuberculosis [@doi:10.1186/s12967-020-02339-3].
Previous studies have investigated, with varying results, a possible increased risk of infection in rheumatoid arthritis patients administered TCZ [@doi:10.1093/rheumatology/keq343; @doi:10.1136/annrheumdis-2018-214367], although another study reported that the incidence rate of infections was higher in clinical practice rheumatoid arthritis patients treated with TCZ than in the rates reported by clinical trials [@doi:10.1093/rheumatology/ker223].
In the investigation of 544 Italian COVID-19 patients, the group treated with TCZ was found to be more likely to develop secondary infections, with 24% compared to 4% in the control group [@doi:10/d2pk].
Reactivation of hepatitis B and herpes simplex virus 1 was also reported in a small number of patients in this study, all of whom were receiving TCZ.
A July 2020 case report described negative outcomes of two COVID-19 patients after receiving TCZ, including one death; however, both patients were intubated and had entered septic shock prior to receiving TCZ [@doi:10.1016/j.chest.2020.04.024], likely indicating a severe level of cytokine production.
Additionally, D-dimer and sIL2R levels were reported by one study to increase in patients treated with TCZ, which raised concerns because of the potential association between elevated D-dimer levels and thrombosis and between sIL2R and diseases where T-cell regulation is compromised [@doi:10.1016/j.chest.2020.06.006]. 
An increased risk of bacterial infection was also identified in a systematic review of the literature, based on the unadjusted estimates reported [@doi:10.2139/ssrn.3642653].
In summary, TCZ administration to COVID-19 patients is not without risks, may introduce additional risk of developing secondary infections, and should be approached especially cautiously for patients who have latent viral infections.

In summary, approximately 25% of coronavirus patients develop ARDS, which is caused by an excessive early response of the immune system which can be a component of cytokine release syndrome [@doi:10.1016/j.chest.2020.06.006] and cytokine storm syndrome [@doi:10.1186/s12967-020-02339-3].
This overwhelming inflammation is triggered by IL-6.
TCZ is an inhibitor of IL-6 and therefore may be able to neutralize the inflammatory pathway that leads to the cytokine storm.
While the mechanism suggests TCZ may be beneficial for the treatment of COVID-19 patients experiencing excessive immune activity, no randomized controlled trials are available assessing its effect.
However, small initial studies have found preliminary indications that TCZ may reduce progression to invasive medical ventilation and/or death.
It should be noted that SOC varied widely across retrospective studies, with one study administering HCQ, lopinavir-ritonavir, antibiotics, and/or heparin as part of standard care.
Interest in TCZ as a treatment for COVID-19 was supported by two meta-analyses that converged on a HR estimate of approximately 0.45 [@doi:10.1101/2020.07.10.20150938; @doi:10.2139/ssrn.3642653], but a third meta-analysis found that all of the available literature carries a risk of bias, with even the largest available TCZ studies to date carrying a moderate risk of bias under the ROBINS-I criteria [@doi:10.1016/j.pulmoe.2020.07.003].
Additionally, different studies used different dosages, number of doses, and methods of administration; ongoing research may be needed to optimize administration of TCZ [@doi:10.1016/j.jcv.2020.104443], although similar results were reported by one study for intravenous and subcutaneous administration [@doi:10/d2pk].
Clinical trials that are in progress are likely to provide additional insight into the effectiveness of this drug for the treatment of COVID-19 along with how it should be administered.

#### Neutralizing Antibodies

Monoclonal antibodies have revolutionized the way we treat human diseases.
They have become some of the best-selling drugs in the pharmaceutical market in recent years [@doi:10.1186/s12929-019-0592-z].
There are currently 79 FDA approved mAbs on the market including antibodies for viral infections (e.g. Ibalizumab for HIV and Palivizumab for RSV) [@doi:10.1186/s12929-019-0592-z; @doi:10.1146/annurev-immunol-032712-095916].
Virus-specific neutralizing antibodies commonly target viral surface glycoproteins or host structures, thereby inhibiting viral entry through receptor binding interference [@doi:10.3389/fmicb.2017.02323; @doi:10.1080/21645515.2017.1337614].
This section discusses current efforts in developing neutralizing antibodies against SARS-CoV-2 and how expertise gained from previous approaches for MERS-CoV and SARS-CoV-1 may benefit antibody development.

##### Spike (S) Neutralizing Antibody

During the first SARS epidemic in 2002, nAbs were found in SARS-CoV-1-infected patients [@doi:10.1111/j.1469-0691.2004.01009.x;@doi:10.1086/423286].
Several studies following up on these findings identified various S-glycoprotein epitopes as the major targets of neutralizing antibodies against SARS-CoV-1 [@doi:10.1517/14712590902763755].
The passive transfer of immune serum containing nAbs from SARS-CoV-1-infected mice resulted in protection of naïve mice from viral lower respiratory tract infection upon intranasal challenge [@doi:10.1128/jvi.78.7.3572-3577.2004].
Similarly, a meta-analysis suggested that administration of plasma from recovered SARS-CoV-1 patients reduced mortality upon SARS-CoV-1 infection [@doi:10.1093/infdis/jiu396].
Similar results were observed in MERS-CoV infection during the second coronavirus-related epidemic of the 21st century.
In these cases, neutralizing antibodies were identified against various epitopes of the receptor binding domain (RBD) of the S glycoprotein [@doi:10.1073/pnas.1402074111; @doi:10.1128/JVI.00912-14].
Coronaviruses use trimeric spike (S) glycoproteins on their surface to bind to host cell receptors, such as ACE2, allowing for cell entry [@doi:10.1016/j.cell.2020.02.052; @doi:10.1016/j.cell.2020.02.058].
Each S glycoprotein protomer is comprised of an S1 domain, also called the RBD, and an S2 domain.
The S1 domain binds to host cell receptors while the S2 domain facilitates the fusion between the viral envelope and host cell membranes [@doi:10.1517/14712590902763755].
Although targeting of the host cell receptor ACE2 shows efficacy in inhibiting SARS-CoV-2 infection [@doi:10.1038/nature02145], given the physiological relevance of ACE2 [@doi:10/bsbp49], it would be favorable to target virus-specific structures rather than host receptors.
This forms the rationale of developing neutralizing antibodies against the S glycoprotein, disrupting its interaction with ACE2 and other receptors and thereby inhibiting viral entry.

The first human neutralizing antibody against SARS-CoV-2 targeting the trimeric spike (S) glycoproteins was developed using hybridoma technology [@doi:10.1101/2020.03.11.987958], where antibody-producing B-cells developed by mice can be inserted into myeloma cells to produce a hybrid cell line (the hybridoma) that is grown in culture.
The 47D11 clone was able to cross-neutralize SARS-CoV-1 and SARS-CoV-2 by a mechanism that is different from receptor binding interference.
The exact mechanism of how this clone neutralizes SARS-CoV-2 and inhibits infection _in vitro_ remains unknown, but a potential mechanism might be antibody-induced destabilization of the membrane prefusion structure [@doi:10.1101/2020.03.11.987958; @doi:10.1016/j.cell.2018.12.028].
The ability of this antibody to prevent infection at a feasible dose needs to be validated _in vivo_, especially since _in vitro_ neutralization effects have been shown to not be reflective of _in vivo_ efficacy [@doi:10.1128/JVI.01603-17].
Only a week later, a different group successfully isolated multiple nAbs targeting the RBD of the S glycoprotein from blood samples taken from COVID-19 patients in China [@doi:10.1101/2020.03.21.990770].
Interestingly, the patient-isolated antibodies did not cross-react with RBDs from SARS-CoV-1 and MERS-CoV, although cross-reactivity to the trimeric spike proteins of SARS-CoV-1 and MERS-CoV was observed.
This finding suggests that the RBDs between the three coronavirus species are immunologically distinct and that the isolated nAbs targeting the RBD of SARS-CoV-2 are species specific.
While this specificity is desirable, it also raises the question of whether these antibodies are more susceptible to viral escape mechanisms.
Viral escape is a common resistance mechanism to nAb therapy due to selective pressure from neutralizing antibodies [@doi:10.2217/imt.15.33; @doi:10.1126/science.1213256].
For HIV, broadly neutralizing antibodies (bnAbs) targeting the CD4 binding site (CD4bs) show greater neutralization breadth than monoclonal antibodies, which target only specific HIV strains [@doi:10.1016/j.molmed.2019.01.007].
For MERS-CoV, a combination of multiple neutralizing antibodies targeting different antigenic sites prevented neutralization escape [@doi:10.1128/JVI.02002-17].
It was found that the different antibody isolates did not target the same epitopes, suggesting that using them in combination might produce a synergistic effect that prevents viral escape [@doi:10.1101/2020.03.21.990770].
It was also demonstrated that binding affinity of the antibodies does not reflect their capability to compete with ACE2 binding.
Furthermore, no conclusions about correlations between the severity of disease and the ability to produce neutralizing antibodies can be drawn at this point.
Rather, higher neutralizing antibody titers were more frequently found in patients with severe disease.
Correspondingly, higher levels of anti-spike IgG were observed in patients that deceased from infection compared to patient that recovered [@doi:10.1172/jci.insight.123158].

Results from the SARS and MERS epidemics thus provide valuable lessons for the design of neutralizing antibodies for the current outbreak.
The findings for SARS-CoV-1 and MERS-CoV can aid in identifying which structures constitute suitable targets for nAbs, despite the fact that the RBD appears to be distinct between the three coronavirus species.
These studies also suggest that a combination of nAbs targeting distinct antigens might be necessary to provide protection [@doi:10.1128/JVI.02002-17].
The biggest challenge remains identifying antibodies that not only bind to their target, but also prove to be beneficial for disease management.
On that note, a recently published study indicates that anti-spike antibodies could make the disease worse rather than eliminating the virus [@doi:10.1172/jci.insight.123158].
These findings underscores our current lack of understanding the full immune response to SARS-CoV-2.

#### Interferons

IFNs are a family of cytokines critical to activating the innate immune system response against viral infections.
Interferons are classified into three categories based on their receptor specificity: types I, II and III [@doi:10.1128/mmbr.05015-11].
Specifically, IFNs I (IFN-𝛼 and 𝛽) and II (IFN-𝛾) induce the expression of antiviral proteins that bring the viral RNA to degradation [@doi:10.1016/j.jcv.2003.11.013].
Among these IFNs, IFN-𝛽 has already been found to strongly inhibit the replication of other coronaviruses, such as SARS-CoV-1, in cell culture, while IFN-𝛼 and 𝛾 were shown to be less effective in this context [@doi:10.1016/j.jcv.2003.11.013].
There is evidence that patients with higher susceptibility to ARDS indeed show deficiency in IFN-𝛽.
For instance, infection with other coronaviruses impairs IFN-𝛽 expression and synthesis, allowing the virus to escape the innate immune response [@doi:10.1016/j.virusres.2014.07.024].
On March 18 2020, Synairgen plc received approval to start a phase II trial for SNG001, an IFN-𝛽-1a formulation to be delivered to the lungs via inhalation.
SNG001 was already shown to be effective in reducing viral load in an _in vivo_ model of swine flu and _in vitro_ models of other coronavirus infections [@synairgen-SNG001].
In July, a press release from Synairgen stated that SNG001 reduced progression to ventilation in a double-blind, placebo-controlled, multi-center study of 101 patients with an average age in the late 50s [@url:https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf].
They also reported that patients in the treatment group showed greater recovery and lower breathlessness.
However, given that this information was released in a press release rather than in a manuscript and thus cannot be thoroughly reviewed, these findings should be considered preliminary.
Additionally, the WHO Solidarity trial reported no significant effect of IFN-𝛽1a on patient survival during hospitalization [@doi:10.1056/NEJMoa2023184].

### Discussion

With the emergence of the COVID-19 pandemic caused by the coronavirus SARS-CoV-2, the development and/or identification of therapeutic and prophylactic interventions became an issue of international urgency.
In previous outbreaks of HCoV, namely SARS and MERS, the development of these interventions was very limited.
As research has progressed, several potential approaches to treatment have emerged (Figure @fig:therapeutics)..
Most notably, remdesivir has been approved by the FDA for the treatment of COVID-19, and dexamethasone, which was approved by the FDA in 1958, has been found to improve outcomes for patients with severe COVID-19.
Other potential therapies are being still being explored and require additional data (Figure @fig:ebm-trials).
As more evidence becomes available, the potential for existing and novel therapies to improve outcomes for COVID-19 patients will become better understood.

![
**Mechanism of Action for Potential Therapeutics**
Potential therapeutics currently being studied target the SARS-CoV-2 or modify the host environment through many different mechanisms.
Here, the relationship between the virus and several therapeutics described above are visualized.
](images/N001-LifeCyclePlusDrugs.png){#fig:therapeutics secno=1}

Insights into the pathogenesis and immune response to SARS-CoV-2 have also provided some insights into prophylactics <~--TO DO: cite preprint of pathogenesis-->.
Insights from the immune response to SARS-CoV-2 have also guided the identification of potential therapeutics.
As cases have become better characterized, it has become evident that many patients experience an initial immune response to the virus that is typically characterized by fever, cough, dyspnea, and related symptoms.
However, the most serious concern is cytokine release syndrome, when the body's immune response becomes dysregulated, resulting in an extreme inflammatory response.
The RECOVERY trial, a large-scale, multi-arm trial enrolling about 15% of all COVID-19 patients in the United Kingdom, was the first to identify that the widely available steroid dexamethasone seems to be beneficial for patients suffering from this immune dysregulation [@doi:10.1101/2020.06.22.20137273].
The results of efforts to identify therapeutic treatments to treat patients early in the course of infection have been more ambiguous.
Early interest in the drugs hydroxychloroquine and chloroquine yielded no promising results from studies with robust experimental designs.
On the other hand, the experimental drug remdesivir, which was developed for Ebola, has received enough support from early analyses to receive FDA approval, but results have been mixed.
The potential for other drugs, such as tocilizumab, to reduce recovery time remains unclear, but some early results were promising.

One concern is that the presentation of COVID-19 appears to be heterogeneous across the lifespan.
Many adult cases, especially in younger adults, present with mild symptoms or even asymptomatically, while others, especially in older adults, can be severe or fatal.
In children, the SARS-CoV-2 virus can present as two distinct diseases, COVID-19 or MIS-C.
The therapeutics and prophylactics discussed here were all tested in adults, and additional research is needed to identify therapeutics that address the symptoms characteristic of pediatric COVID-19 and MIS-C cases.

#### Potential Avenues of Interest for Therapeutic Development

Given what is currently known about these therapeutics for COVID-19, a number of related therapies beyond those explored above may also prove to be of interest.
For example, the demonstrated benefit of dexamethasone and the ongoing potential of tocilizumab for treatment of COVID-19 suggests that other anti-inflammatory agents might also hold value for the treatment of COVID-19.
Given that current evidence about treating COVID-19 with dexamethasone suggests that the need to curtail the cytokine storm inflammatory response to the virus can transcend the risks of immunosuppression, exploration of more anti-inflammatory agents may be warranted.
While dexamethasone is considered widely available and generally affordable, the high costs of biologics such as tocilizumab therapy may present obstacles to wide-scale distribution of this drug if it proves of value.
At the doses used for rheumatoid arthritis patients, the cost for tocilizumab ranges from $179.20 to $896 per dose for the IV form and $355 for the pre-filled syringe [@url:https://www.ncbi.nlm.nih.gov/books/NBK349513/table/T43/].
There are several anti-inflammatory agents used for the treatment of autoimmune diseases that may also be able to counter the effects of the cytokine storm induced by the virus, some of which, such as cyclosporine, are likely to be more cost-effective and readily available than biologics [@url:https://escholarship.umassmed.edu/meyers_pp/385].
While tocilizumab targets IL-6, several other inflammatory markers could be potential targets, including TNF-alpha.
Inhibition of TNF-alpha by an inhibitor such as Etanercept has been previously suggested for treatment of SARS-CoV-1 [@doi:10.1185/030079903125002757] and may be relevant for SARS-CoV-2 as well.
Another anti-IL-6 antibody, sarilumab, is also being investigated [@url:http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19; @clinicaltrials:NCT04327388].
Baricitinib and other small molecule inhibitors of the Janus-activated kinase pathway also curtail the inflammatory response and have been suggested as potential options for SARS-CoV-2 infections [@doi:10/dph5].
Baricitinib in particular may be able to reduce the ability of SARS-CoV-2 to infect lung cells [@doi:10/ggnrsx].
Clinical trials studying baricitinib in COVID-19 have already begun in the US and in Italy [@url:https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testing-therapies-covid-19; @clinicaltrials:NCT04320277].
Identification and targeting of further inflammatory markers that are relevant in SARS-CoV-2 infection may be of value for curtailing the inflammatory response and lung damage.

In addition to immunosuppressive treatments that are most beneficial late in disease progression, much research is focused on identifying treatments would be likely to benefit early-stage patients.
For example, although studies of hydroxychloroquine have not supported the early theory-driven interest in this antiviral treatment, alternative compounds with related mechanisms may still have potential.
Hydroxyferroquine derivatives of HCQ have been described as a class of bioorganometallic compounds that exert antiviral effects with some selectivity for SARS-CoV-1 _in vitro_ [@doi:10.1021/jm0601856].
Future work could explore whether such compounds exert antiviral effects against SARS-CoV-2 and whether they would be safer for use in COVID-19.
Another potential approach is the development of antivirals, which could be broad-spectrum, specific to coronaviruses, or targeted to SARS-CoV-2.
Development of new antivirals is complicated by the fact that none have yet been approved for human coronaviruses.
Intriguing new options are emerging, however.
Beta-D-N4-hydroxycytidine (NHC) is an orally bioavailable ribonucleotide analog showing broad-spectrum activity against RNA viruses, which may inhibit SARS-CoV-2 replication _in vitro_ and _in vivo_ in mouse models of HCoVs [@doi:10.1126/scitranslmed.abb5883].
A range of other antivirals are also in development.
Development of antivirals will be further facilitated as research reveals more information about the interaction of SARS-CoV-2 with the host cell and host cell genome, mechanisms of viral replication, mechanisms of viral assembly, and mechanisms of viral release to other cells; this can allow researchers to target specific stages and structures of the viral life cycle.
Finally, antibodies against viruses, also known as antiviral monoclonal antibodies, could be an alternative as well and are described in detail in an above section.
The goal of antiviral antibodies is to neutralize viruses through either cell-killing activity or blocking of viral replication [@doi:10.1016/j.tim.2015.07.005].
They may also engage the host immune response, encouraging the immune system to hone in on the virus.
Given the cytokine storm that results from immune system activation in response to the virus, which has been implicated in worsening of the disease, a neutralizing antibody (nAb) may be preferable.
Upcoming work may explore the specificity of nAbs for their target, mechanisms by which the nAbs impede the virus, and improvements to antibody structure that may enhance the ability of the antibody to block viral activity.

Some research is also investigating potential therapeutics and prophylactics that would interact with components of the innate immune response.
For example, there are a variety of TLRs, PRRs that recognize PAMPs and DAMPs.
TLRs form a part of innate immune recognition and can more generally contribute to promoting both innate and adaptive responses [@ISBN:9780815332183].
In mouse models, poly(I:C) and CpG, which are agonists of toll-like receptors TLR3 and TLR9, respectively, showed protective effects when administered prior to SARS-CoV-1 infection [@doi:10.1128/JVI.01410-12].
Therefore, TLR agonists hold some potential for broad-spectrum prophylaxis.

Given that a large number of clinical trials are currently in progress, more information about the potential of these and other therapeutics should become available over time.
This information, combined with advances in understanding the molecular structure and viral pathogenesis of SARS-CoV-2, may lead to a more complete understanding of how the virus affects the human host and what strategies can improve outcomes.
To date, investigations of potential therapeutics for COVID-19 have focused primarily on repurposing existing drugs.
This approach is necessary given the urgency of the situation as well as the extensive time required for developing and testing new therapies.
However, in the long-term, new drugs specific for treatment of COVID-19 may also enter development.
Development of novel drugs is likely to be guided by what is known about the pathogenesis and molecular structure of SARS-CoV-2.
For example, understanding the various structural components of SARS-CoV-2 may allow for the development of small molecule inhibitors of those components.
Currently, crystal structures of the SARS-CoV-2 main protease have recently been resolved [@doi:10.1038/s41586-020-2223-y; @url:https://www.diamond.ac.uk/covid-19/for-scientists/Main-protease-structure-and-XChem.html], and efforts are already in place to perform screens for small molecule inhibitors of the main protease, which have yielded potential hits [@doi:10.1038/s41586-020-2223-y].
Much work remains to be done to determine further crystal structures of other viral components, understand the relative utility of targeting different viral components, perform additional small molecule inhibitor screens, and determine the safety and efficacy of the potential inhibitors.
While still nascent, work in this area is promising.
Over the longer term, this approach and others may lead to the development of novel therapeutics specifically for COVID-19 and SARS-CoV-2.

#### Conclusions of the Present Analysis

Due to the large number of clinical trials currently under examination (Figure @fig:ebm-trials), not all candidates are examined here.
Instead, this review seeks to provide an overview of the range of mechanisms that have been explored and to examine some prominent candidates in the context of the pathogenesis of and immune response to SARS-CoV-2.
As more research becomes available, this review will be updated to include additional therapeutics that emerge and to include new findings that are released about those discussed here.
While no therapeutics or vaccines were developed for SARS-CoV-1 or MERS-CoV, the current state of COVID-19 research suggests that the body of literature produced before and after the emergence of these viruses has prepared the biomedical community for a rapid response to novel HCoV like SARS-CoV-2.
As the COVID-19 pandemic continues to be a topic of significant worldwide concern, more information is expected to become available about pharmaceutical mechanisms that can be used to combat this, and possibly other, HCoV.
These advances therefore not only benefit the international community's ability to respond to the current crisis, but are also likely to shape responses to future viral threats.


## Dietary Supplements and Nutraceuticals Under Investigation for COVID-19 Prevention and Treatment

### Abstract

Coronavirus disease 2019 (COVID-19) has caused global disruption and a significant loss of life.
Existing treatments that can be repurposed as prophylactic and therapeutic agents could reduce the pandemic's devastation.
Emerging evidence of potential applications in other therapeutic contexts has led to the investigation of dietary supplements and nutraceuticals for COVID-19.
Such products include vitamin C, vitamin D, omega 3 polyunsaturated fatty acids, probiotics, and zinc, all of which are currently under clinical investigation.
In this review, we critically appraise the evidence surrounding dietary supplements and nutraceuticals for the prophylaxis and treatment of COVID-19.
Overall, further study is required before evidence-based recommendations can be formulated, but nutritional status plays a significant role in patient outcomes, and these products could help alleviate deficiencies. 
For example, evidence indicates that vitamin D deficiency may be associated with greater incidence of infection and severity of COVID-19, suggesting that vitamin D supplementation may hold prophylactic or therapeutic value.
A growing number of scientific organizations are now considering recommending vitamin D supplementation to those at high risk of COVID-19.
Because research in vitamin D and other nutraceuticals and supplements is preliminary, here we evaluate the extent to which these nutraceutical and dietary supplements hold potential in the COVID-19 crisis.

### Importance

Sales of dietary supplements and nutraceuticals have increased during the pandemic due to their perceived "immune-boosting" effects.
However, little is known about the efficacy of these dietary supplements and nutraceuticals against the novel coronavirus (SARS-CoV-2) or the disease it causes, COVID-19.
This review provides a critical overview of the potential prophylactic and therapeutic value of various dietary supplements and nutraceuticals from the evidence available to date.
These include vitamin C, vitamin D, and zinc, which are often perceived by the public as treating respiratory infections or supporting immune health.
Consumers need to be aware of misinformation and false promises surrounding some supplements, which may be subject to limited regulation by authorities.
However, considerably more research is required to determine whether dietary supplements and nutraceuticals exhibit prophylactic and therapeutic value against SARS-CoV-2 infection and COVID-19.
This review provides perspective on which nutraceuticals and supplements are involved in biological processes that are relevant to recovery from or prevention of COVID-19.

### Introduction

The year 2020 saw scientists and the medical community scrambling to repurpose or discover novel host-directed therapies against the coronavirus diseases 2019 (COVID-19) pandemic caused by the spread of the novel _Severe acute respiratory syndrome-related coronavirus 2_ (SARS-CoV-2).
This rapid effort led to the identification of some promising pharmaceutical therapies for hospitalized patients, such as remdesivir and dexamethasone.
Furthermore, most societies have adopted non-pharmacological preventative measures such as utilizing public health strategies that reduce the transmission of SARS-CoV-2.
However, during this time, many individuals sought additional protections via the consumption of various dietary supplements and nutraceuticals that they believed to confer beneficial effects.
While a patient's nutritional status does seem to play a role in COVID-19 susceptibility and outcomes [@doi:10.3390/nu12051466; @doi:10.1101/2020.10.19.20214395; @doi:10.1093/advances/nmaa125; @doi:10.1016/j.ijid.2020.08.018; @doi:10.3390/nu12041181], the beginning of the pandemic saw sales of vitamins and other supplements to soar despite a lack of any evidence supporting their use against COVID-19.
In the United States, for example, dietary supplement and nutraceutical sales have shown modest annual growth in recent years (approximately 5%, or a $345 million increase in 2019), but during the six-week period preceding April 5, 2020, they increased by 44% ($435 million) relative to the same period in 2019 [@url:https://www.nutritionaloutlook.com/view/peak-dietary-supplement-sales-leveling-during-covid-19-pandemic-growth-still-remains-strong].
While growth subsequently leveled off, sales continued to boom, with a further 16% ($151 million) increase during the six weeks preceding May 17, 2020 relative to 2019 [@url:https://www.nutritionaloutlook.com/view/peak-dietary-supplement-sales-leveling-during-covid-19-pandemic-growth-still-remains-strong].
In France, New Zealand, India, and China, similar trends in sales were reported [@doi:10.3390/nu12061699; @url:https://www.nutraingredients-asia.com/Article/2020/07/06/Lockdown-impact-Grocery-stores-bolstered-NZ-supplements-sales-as-pharmacies-slumped; @url:https://www.nutritioninsight.com/news/covid-19-temporarily-bolsters-european-interest-in-supplements.html; @url:https://www.nutraingredients.com/Article/2020/07/21/India-s-immune-health-surge-Nation-leads-APAC-in-number-of-new-product-launches-new-data].
The increase in sales was driven by a consumer perception that dietary supplements and nutraceuticals would protect consumers from infection and/or mitigate the impact of infection due to the various "immune-boosting" claims of these products [@doi:10.1016/j.tifs.2020.09.001; @url:https://kerry.com/insights/kerrydigest/2020/5-food-and-beverage-trends-in-europe-during-covid-19].

Due to the significant interest from the general public in dietary additives, whether and to what extent nutraceuticals or dietary supplements can provide any prophylactic or therapeutic benefit remains a topic of interest for the scientific community.
Nutraceuticals and dietary supplements are related but distinct non-pharmaceutical products.
Nutraceuticals are classified as supplements with health benefits beyond their basic nutritional value [@doi:10.1080/10408390902841529; @doi:10.1038/nrcardio.2016.103].
The key difference between a dietary supplement and a nutraceutical is that nutraceuticals should not only supplement the diet, but also aid in the prophylaxis and/or treatment of a disorder or disease [@doi:10.1208/ps050325].
However, dietary supplements and nutraceuticals, unlike pharmaceuticals, are not subject to the same regulatory protocols that protect consumers of medicines.
Indeed, nutraceuticals do not entirely fall under the responsibility of the Food and Drug Administration (FDA), but they are monitored as dietary supplements according to the Dietary Supplement, Health and Education Act 1994 (DSHEA) [@url:https://ods.od.nih.gov/About/DSHEA_Wording.aspx] and the Food and Drug Administration Modernization Act 1997 (FDAMA) [@url:https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-administration-modernization-act-fdama-1997].
Due to increases in sales of dietary supplements and nutraceuticals, in 1996 the FDA established the Office of Dietary Supplement Programs (ODSP) to increase surveillance.
Novel products or nutraceuticals must now submit a new dietary ingredient notification to the ODSP for review.
There are significant concerns that these legislations do not adequately protect the consumer as they ascribe responsibility to the manufacturers to ensure the safety of the product before manufacturing or marketing [@doi:10.1080/17512433.2018.1464911].
Manufacturers are not required to register or even seek approval from the FDA to produce or sell food supplements or nutraceuticals.
Health or nutrient content claims for labeling purposes are approved based on an authoritative statement from the Academy of Sciences or relevant federal authorities once the FDA has been notified and on the basis that the information is known to be true and not deceptive [@doi:10.1080/17512433.2018.1464911].
Therefore, there is often a gap between perceptions by the American public about a nutraceutical or dietary supplement and the actual clinical evidence surrounding its effects.

Despite differences in regulations, similar challenges exist outside of the United States.
In Europe, where the safety of supplements are monitored by the European Union (EU) under Directive 2002/46/EC [@url:https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32002L0046].
However, nutraceuticals are not directly mentioned.
Consequently, nutraceuticals can be generally described as either a medicinal product under Directive 2004/27/EC [@url:https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32004L0027] or as a 'foodstuff' under Directive 2002/46/EC of the European council.
In order to synchronize the various existing legislations, Regulation EC 1924/2006 on nutrition and health claims was put into effect to assure customers of safety and efficacy of products and to deliver understandable information to consumers.
However, specific legislation for nutraceuticals is still elusive.
Health claims are permitted on a product label only following compliance and authorization according to the European Food Safety Authority (EFSA) guidelines on nutrition and health claims [@url:https://ec.europa.eu/food/safety/labelling_nutrition/claims/register/public].
EFSA does not currently distinguish between food supplements and nutraceuticals for health claim applications of new products, as claim authorization is dependent on the availability of clinical data in order to substantiate efficacy [@doi:10.1111/bcp.13496].
These guidelines seem to provide more protection to consumers than the FDA regulations but potentially at the cost of innovation in the sector [@doi:10.1080/09637486.2016.1212816].
The situation becomes even more complicated when comparing regulations at a global level, as countries such as China and India have existing regulatory frameworks for traditional medicines and phytomedicines not commonly consumed in Western society [@doi:10.3390/nu10010041].
Currently, there is debate among scientists and regulatory authorities surrounding the development of a widespread regulatory framework to deal with the challenges of safety and health claim substantiation for nutraceuticals [@doi:10.1111/bcp.13496; @doi:10.1080/17512433.2018.1464911], as these products do not necessarily follow the same rigorous clinical trial frameworks used to approve the use of pharmaceuticals.
Such regulatory disparities have been highlighted by the pandemic, as many individuals and companies have attempted to profit from the vulnerabilities of others by overstating claims in relation to the treatment of COVID-19 using supplements and nutraceuticals.
The FDA has written several letters to prevent companies marketing or selling products based on false hyperbolic promises about preventing SARS-CoV-2 infection or treating COVID-19 [@url:https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/noetic-nutraceuticals-607572-05152020; @url:https://beta.regulations.gov/document/FDA-2020-S-0023-0068; @url:https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/spartan-enterprises-inc-dba-watershed-wellness-center-610876-10302020].
These letters came in response to efforts to market nutraceutical prophylactics against COVID-19, some of which charged the consumer as much as $23,000 [@url:https://www.ftc.gov/news-events/press-releases/2020/07/ftc-sues-california-marketer-23000-covid-19-treatment-plan].
There have even been some incidents highlighted in the media because of their potentially life threatening consequences; for example, the use of oleandrin was touted as a potential "cure" by individuals close to the former President of the United States despite its high toxicity [@url:https://cen.acs.org/biological-chemistry/natural-products/oleandrin-compound-touted-possible-COVID/98/web/2020/08].
Thus, heterogeneous and at times relaxed regulatory standards have permitted high-profile cases of the sale of nutraceuticals and dietary supplements that are purported to provide protection against COVID-19, despite a lack of research into these compounds.

Notwithstanding the issues of poor safety, efficacy, and regulatory oversight, some dietary supplements and nutraceuticals have exhibited therapeutic and prophylactic potential.
Some have been linked with reduced immunopathology, antiviral and anti-inflammatory activities, or even the prevention of acute respiratory distress syndrome (ARDS) [@doi:10/ggkd3b; @doi:10.1016/j.tifs.2020.09.001; @doi:10.3390/nu12061718].
A host of potential candidates have been highlighted in the literature that target various aspects of the COVID-19 viral pathology, while others are thought to prime the host immune system.
These candidates include vitamins and minerals along with extracts and omega-3 polyunsaturated fatty acids (n-3 PUFA) [@doi:10.1002/jmv.25707].
_In vitro_ and _in vivo_ studies suggest that nutraceuticals containing phycocyanobilin, N-acetylcysteine, glucosamine, selenium or phase 2 inductive nutraceuticals (e.g. ferulic acid, lipoic acid, or sulforaphane) can prevent or modulate RNA virus infections via amplification of the signaling activity of mitochondrial antiviral-signaling protein (MAVS) and activation of Toll-like receptor 7 [@doi:10.1016/j.pcad.2020.02.007].
While promising, further animal and human studies are required to assess the therapeutic potential of these various nutrients and nutraceuticals against COVID-19.
For the purpose of this review, we have highlighted some of the main dietary supplements and nutraceuticals that are currently under investigation for their potential prophylactic and therapeutic applications.
These include n-3 PUFA, zinc, vitamins C and D, and probiotics.

### n-3 PUFA

One category of supplements that has been explored for beneficial effects against various viral infections are the n-3 PUFAs [@doi:10.1002/jmv.25707], commonly referred to as omega-3 fatty acids, which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
EPA and DHA intake can come from a diet high in fish or through dietary supplementation with fish oils or purified oils [@doi:10.1039/c9fo01742a].
Other, more sustainable sources of EPA and DHA include algae [@doi:10.3389/fphys.2020.00752; @doi:10.3390/fermentation4020046], which can also be exploited for their rich abundance of other bioactive compounds such as angiotensin converting enzyme inhibitor peptides and antiviral agents including phycobiliproteins, sulfated polysaccharides, and calcium-spirulan [@doi:10.1016/j.nut.2020.111089].
n-3 PUFAs have been investigated for many years for their therapeutic potential [@doi:10.1007/bf03257413].
Supplementation with fish oils is generally well tolerated [@doi:10.1007/bf03257413], and intake of n-3 PUFAs through dietary sources or supplementation is specifically encouraged for vulnerable groups such as pregnant and lactating women [@url:https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2017/01/update-on-seafood-consumption-during-pregnancy; @pmc:PMC2621042].
As a result, these well-established compounds have drawn significant interest for their potential immune effects and therapeutic potential.

Particular interest has arisen in n-3 PUFAs as potential therapeutics against diseases associated with inflammation.
n-3 PUFAs have been found to mediate inflammation by influencing processes such as leukocyte chemotaxis, adhesion molecule expression, and the production of eicosanoids [@doi:10.1111/j.1365-2125.2012.04374.x; @doi:10.1016/j.bbalip.2014.08.010].
This and other evidence indicates that n-3 PUFAs may have the capacity to modulate the adaptive immune response [@doi:10.1111/j.1365-2125.2012.04374.x; @doi:10.1039/c9fo01742a; @doi:10.1038/nrcardio.2016.103]; for example, they have been found to influence antigen presentation and the production of CD4(+) Th1 cells, among other relevant effects [@doi:10.1016/j.ejphar.2015.03.100].
Certainly, preliminary evidence from banked blood samples from 100 COVID-19 patients suggests that patients with a higher omega-3 index, a measure of n-3 and n-6 fatty acids in red blood cells, had a lower risk of death due to COVID-19 [@doi:10.1016/j.plefa.2021.102250].
Interest has also arisen as to whether nutritional status related to n-3 PUFAs can also affect inflammation associated with severe disease, such as ARDS or sepsis [@doi:10.1007/s11745-016-4129-x; @doi:10.1016/j.nut.2019.02.016].
ARDS and sepsis hold particular concern in the treatment of severe COVID-19; an analysis of 82 deceased COVID-19 patients in Wuhan during January to February 2020 reported that respiratory failure (associated with ARDS) was the cause of death in 69.5% of cases, and sepsis or multi-organ failure accounted for 28.0% of deaths [@doi:10.1371/journal.pone.0235458].
Research in ARDS prior to current pandemic suggests that n-3 PUFAs may hold some therapeutic potential.
One study randomized 16 consecutive ARDS patients to receive either a fish oil-enriched lipid emulsion or a control lipid emulsion (comprised of 100% long-chain triglycerides) under a double-blinded design [@doi:10.1186/1743-7075-8-22].
They reported a statistically significant reduction in leukotriene B4 levels in the group receiving the fish oil-enriched emulsion, suggesting that the fish oil supplementation may have reduced inflammation.
However, they also reported that most of their tests were not statistically significant, and therefore it seems that additional research using larger sample sizes is required.
A recent meta-analysis of 10 randomized controlled trials (RCTs) examining the effects of n-3 PUFAs on ARDS patients did not find evidence of any effect on mortality, although the effect on secondary outcomes could not be determined due to a low quality of evidence [@doi:10.4187/respcare.06965].
However, another meta-analysis that examined 24 RCTs studying the effects of n-3 fatty acids on sepsis, including ARDS-induced sepsis, did find support for an effect on mortality when n-3 fatty acids were administered via enteral nutrition, although a paucity of high-quality evidence again limited conclusions [@doi:10.1186/s12937-018-0356-8].
Therefore, despite theoretical support for an immunomodulatory effect of n-3 PUFAs in COVID-19, evidence from existing RCTs is insufficient to determine whether supplementation offers an advantage in a clinical setting that would be relevant to COVID-19.

Another potential mechanism that has led to interest in n-3 PUFAs as protective against viral infections including COVID-19 is its potential as a precursor molecule for the biosynthesis of endogenous specialized proresolving mediators (SPM), such as protectins and resolvins, that actively resolve inflammation and infection [@doi:10.1016/j.immuni.2014.02.009].
SPM have exhibited beneficial effects against a variety of lung infections, including some caused by RNA viruses [@doi:10.1038/nri.2015.4; @doi:10.1002/biof.1691].
Indeed, protectin D1 has been shown to increase survival from H1N1 viral infection in mice by affecting the viral replication machinery [@doi:10.1016/j.cell.2013.02.027].
Several mechanisms for SPM have been proposed, including preventing the release of pro-inflammatory cytokines and chemokines or increasing phagocytosis of cellular debris by macrophages [@doi:10.1038/nature13479].
In influenza, SPM promote antiviral B lymphocytic activities [@doi:10.4049/jimmunol.1302795], and protectin D1 has been shown to increase survival from H1N1 viral infection in mice by affecting the viral replication machinery [@doi:10.1016/j.cell.2013.02.027].
It has thus been hypothesized that SPM could aid in the resolution of the cytokine storm and pulmonary inflammation associated with COVID-19 [@doi:10.1007/s10555-020-09889-4; @doi:10.1016/j.mehy.2020.110340].
Another theory is that some comorbidities, such as obesity, could lead to deficiencies of SPM, which could in turn be related to the occurrence of adverse outcomes for COVID-19 [@doi:10.3389/fimmu.2020.01997].
However, not all studies are in agreement that n-3 PUFAs or their resulting SPM are effective against infections [@doi:10.3945/jn.109.108027].
At a minimum, the effectiveness of n-3 PUFAs against infections would be dependent on the dosage, timing, and the specific pathogens responsible [@doi:10.1016/j.jinf.2016.10.001].
On another level, there is still the question of whether fish oils can raise the levels of SPM levels upon ingestion and in response to acute inflammation in humans [@doi:10.1194/jlr.M060392].
Currently, Karolinska University Hospital is running a trial that will measure the levels of SPM as a secondary outcome following intravenous supplementation of n-3 PUFAs in hospitalized COVID-19 patients to determine whether n-3 PUFAs provides therapeutic value [@clinicaltrials:NCT04647604; @doi:10.3389/fphys.2020.624657].
Therefore, while this mechanism provides theoretical support for a role for n-3 PUFAs against COVID-19, experimental support is still needed.

A third possible mechanism by which n-3 PUFAs could benefit COVID-19 patients arises from the fact that some COVID-19 patients, particularly those with comorbidities, are at a significant risk of thrombotic complications including arterial and venous thrombosis [@doi:10.1182/blood.2020006000; @doi:10.1007/s11239-020-02134-3].
Therefore, the use of prophylactic and therapeutic anticoagulants and antithrombotic agents is under consideration [@doi:10.1016/j.jacc.2020.04.031; @doi:10.3389/fnut.2020.583080].
Considering that there is significant evidence that n-3 fatty acids and other fish oil-derived lipids possess antithrombotic properties and anti-inflammatory properties [@doi:10.1016/j.prostaglandins.2018.09.005; @doi:10.1016/j.blre.2020.100694; @doi:10.1039/C9FO01742A], they may have therapeutic value against the prothrombotic complications of COVID-19.
In particular, concerns have been raised within the medical community about using investigational therapeutics on COVID-19 patients who are already on antiplatelet therapies due to pre-existing comorbidities because the introduction of such therapeutics could lead to issues with dosing and drug choice and/or negative drug-drug interactions [@doi:10.1016/j.jacc.2020.04.031].
In such cases, dietary sources of n-3 fatty acids or other nutraceuticals with antiplatelet activities could hold particular value for reducing the risk of thrombotic complications in patients already receiving pharmaceutical antiplatelet therapies.
A new clinical trial [@clinicaltrials:NCT04412018] is currently recruiting COVID-19 positive patients to investigate the anti-inflammatory activity of a recently developed, highly purified nutraceutical derivative of EPA known as icosapent ethyl (Vascepa^TM^) [@doi:10.1056/NEJMoa1812792].
Other randomized controlled trials that are in the preparatory stages intend to investigate the administration of EPA and other bioactive compounds to COVID-19 positive patients in order to observe whether anti-inflammatory effects or disease state improvements occur [@clinicaltrials:NCT04335032; @clinicaltrials:NCT04323228].
Finally, while there have been studies investigating the therapeutic value of n-3 fatty acids against ARDS in humans, there is still limited evidence of their effectiveness [@doi:10.3390/ijms21093104].
It should be noted that the overall lack of human studies in this area means there is limited evidence as to whether these supplements could affect COVID-19 infection.
Consequently, the clinical trials that are underway and those that have been proposed will provide valuable insight into whether the anti-inflammatory potential of n-3 PUFAs and their derivatives can be beneficial to the treatment of COVID-19.
All the same, while the evidence is not present to draw conclusions about whether n-3 PUFAs will be useful in treating COVID-19, there is likely little harm associated with a diet rich in fish oils, and interest in n-3 PUFA supplementation by the general public is unlikely to have negative effects.

### Zinc

Zinc is nutrient supplement that may exhibit some benefits against RNA viral infections.
Zinc is a trace metal obtained from dietary sources or supplementation and is important for the maintenance of immune cells involved in adaptive and innate immunity [@doi:10.1016/j.abb.2016.03.022].
Supplements can be administered orally as a tablet or as a lozenge and are available in many forms, such as zinc picolinate, zinc acetate, and zinc citrate.
Zinc is also available from dietary sources including meat, seafood, nuts, seeds, legumes, and dairy.
The role of zinc in immune function has been extensively reviewed [@doi:10.1016/j.abb.2016.03.022].
Zinc is an important signaling molecule, and zinc levels can alter host defense systems.
In inflammatory situations such as an infection, zinc can regulate leukocyte immune responses and activate the nuclear factor kappa-light-chain-enhancer of activated B cells, thus altering cytokine production [@doi:10.4049/jimmunol.179.6.4180; @doi:10.1067/mlc.2001.118108].
In particular, zinc supplementation can increase natural killer cell levels, which are important cells for host defense against viral infections [@doi:10.1126/science.1198687; @doi:10.1016/j.abb.2016.03.022].
As a result of these immune-related functions, zinc is also under consideration for possible benefits against COVID-19.

Adequate zinc intake has been associated with reduced incidence of infection [@doi:10.1093/ajcn/85.3.837] and antiviral immunity [@doi:10.1093/advances/nmz013].
A randomized, double-blind, placebo-controlled trial that administered zinc supplementation to elderly subjects over the course of a year found zinc deficiency to be associated with increased susceptibility to infection and that zinc deficiency could be prevented through supplementation [@doi:10.1093/ajcn/85.3.837].
Clinical trial data supports the utility of zinc to diminish the duration and severity of symptoms associated with common colds when it is provided within 24 hours of the onset of symptoms [@doi:10.1331/1544-3191.44.5.594.Hulisz; @doi:10.2174/1874306401105010051].
An observational study showed that COVID-19 patients had significantly lower zinc levels in comparison to healthy controls and that zinc-deficient COVID-19 patients (those with levels less than 80 μg/dl) tended to have more complications (70.4% vs 30.0%, _p_ = 0.009) and potentially prolonged hospital stays (7.9 vs 5.7 days, _p_ = 0.048) relative to patients who were not zinc deficient [@doi:10.1016/j.ijid.2020.09.014].
In coronaviruses specifically, _in vitro_ evidence has demonstrated that the combination of zinc (Zn^2+^) and zinc ionophores (pyrithione) can interrupt the replication mechanisms of SARS-CoV-GFP (a fluorescently tagged SARS-CoV-1) and a variety of other RNA viruses [@doi:10.1371/journal.ppat.1001176; @doi:10.1016/j.antiviral.2014.12.015].
Currently, there are over twenty clinical trials registered with the intention to use zinc in a preventative or therapeutic manner for COVID-19.
However, many of these trials proposed the use of zinc in conjunction with hydroxychloroquine and azithromycin [@clinicaltrials:NCT04370782; @clinicaltrials:NCT04377646; @clinicaltrials:NCT04395768; @clinicaltrials:NCT04373733], and it is not known how the lack of evidence supporting the use of hydroxychloroquine will affect investigation of zinc.
One retrospective observational study of New York University Langone hospitals in New York compared outcomes among hospitalized COVID-19 patients administered hydroxychloroquine and azithromycin with zinc sulfate (n = 411) versus hydroxychloroquine and azithromycin alone (n = 521).
Notably, zinc is the only treatment that was used in this trial that is still under consideration as a therapeutic agent due to to the lack of efficacy and potential adverse events associated with hydroxychloroquine and azithromycin against COVID-19 [@doi:10.1056/NEJMoa2019014; @doi:10.1371/journal.pone.0244778; @doi:10.1016/j.cmi.2020.08.022].
While the addition of zinc sulfate did not affect the duration of hospitalization, the length of ICU stays or patient ventilation duration, univariate analyses indicated that zinc did increase the frequency of patients discharged and decreased the requirement for ventilation, referrals to the ICU, mortality [@doi:10.1099/jmm.0.001250].
However, a smaller retrospective study at Hoboken University Medical Center New Jersey failed to find an association between zinc supplementation and survival of hospitalized patients [@doi:10.1016/j.chest.2020.06.082].
Therefore, whether zinc contributes to COVID-19 recovery remains unclear.
Other trials are now investigating zinc in conjunction with other supplements such as vitamin C or n-3 PUFA [@clinicaltrials:NCT04342728; @clinicaltrials:NCT04323228].
Though there is, overall, encouraging data for zinc supplementation against the common cold and viral infections, there is currently limited evidence to suggest zinc supplementation has any beneficial effects against the current novel COVID-19; thus, the clinical trials that are currently underway will provide vital information on the efficacious use of zinc in COVID-19 prevention and/or treatment.
However, given the limited risk and the potential association between zinc deficiency and illness, maintaining a healthy diet to ensure an adequate zinc status may be advisable for individuals seeking to reduce their likelihood of infection.

### Vitamin C

Vitamins B, C, D, and E have also been suggested as potential nutrient supplement interventions for COVID-19 [@doi:10.1002/jmv.25707; @doi:10.20944/preprints202003.0347.v1].
In particular vitamin C has been proposed as a potential therapeutic agent against COVID-19 due to its long history of use against the common cold and other respiratory infections [@doi:10.3389/fimmu.2020.574029; @doi:10.3390/nu12113286].
Vitamin C can be obtained via dietary sources such as fruits and vegetables or via supplementation.
Vitamin C plays a significant role in promoting immune function due to its effects on various immune cells.
It affects inflammation by modulating cytokine production, decreasing histamine levels, enhancing the differentiation and proliferation of T- and B-lymphocytes, increasing antibody levels, and protecting against the negative effects of reactive oxygen species, among other effects related to COVID-19 pathology [@doi:10.1155/2014/426740; @doi:10.1007/s00210-013-0880-1; @doi:10.3390/nu9111211].
Vitamin C is utilized by the body during viral infections, as evinced by lower concentrations in leukocytes and lower concentrations of urinary vitamin C.
Post-infection, these levels return to baseline ranges [@doi:10.1177/003693307301800102; @doi:10.1111/j.1749-6632.1975.tb29312.x; @doi:10/fd22sv; @doi:10.3390/nu9040339; @doi:10.1079/bjn19920004].
It has been shown that as little as 0.1 g/d of vitamin C can maintain normal plasma levels of vitamin C in healthy individuals, but higher doses of at least 1-3 g/d are required for critically ill patients in ICUs [@doi:10.3390/nu11040708].
Indeed, vitamin C deficiency appears to be common among COVID-19 patients [@doi:10.1016/j.medidd.2020.100064; @doi:10.1186/s13054-020-03249-y].
COVID-19 is also associated with the formation of microthrombi and coagulopathy [@doi:10.1172/JCI140183] that contribute to its characteristic lung pathology [@doi:10.1183/16000617.0240-2020], but these symptoms can be ameliorated by early infusions of vitamin C to inhibit endothelial surface P-selectin expression and platelet-endothelial adhesion [@doi:10.3390/antiox6030049].
Intravenous vitamin C also reduced D-dimer levels, which are notably elevated in COVID-19 patients [@doi:10.1186/s13054-020-03060-9; @doi:10/ggvd74], in a case study of 17 COVID-19 patients [@doi:10.1080/14787210.2020.1794819].
There is therefore preliminary evidence suggesting that vitamin C status and vitamin C administration may be relevant to COVID-19 outcomes.

Larger-scale studies of vitamin C, however, have provided mixed results.
A recent meta-analysis found consistent support for regular vitamin C supplementation reducing the duration of the common cold, but that supplementation with vitamin C (> 200 mg) failed to reduce the incidence of colds [@doi:10.1002/14651858.CD000980.pub4].
Individual studies have found Vitamin C to reduce the susceptibility of patients to lower respiratory tract infections, such as pneumonia [@doi:10.1097/00006454-199709000-00003].
Another meta-analysis demonstrated that in twelve trials, vitamin C supplementation reduced the length of stay of patients in intensive care units (ICUs) by 7.8% (95% CI: 4.2% to 11.2%; _p_ = 0.00003).
Furthermore, high doses (1-3 g/day) significantly reduced the length of an ICU stay by 8.6% in six trials (_p_ = 0.003).
Vitamin C also shortened the duration of mechanical ventilation by 18.2% in three trials in which patients required intervention for over 24 hours (95% CI 7.7% to 27%; p = 0.001) [@doi:10.3390/nu11040708].
Despite these findings, an RCT of 167 patients known as CITRUS ALI failed to show a benefit of a 96-hour infusion of vitamin C to treat ARDS [@doi:10.1001/jama.2019.11825].
Clinical trials specifically investigating vitamin C in the context of COVID-19 have now begun, as highlighted by Carr et al. [@doi:10.3390/nu12113286].
These trials intend to investigate the use of intravenous vitamin C in hospitalized COVID-19 patients.
The first trial to report initial results took place in Wuhan, China [@doi:10.1136/bmjopen-2020-039519].
These initial results indicated that the administration of 12 g/12 hr of intravenous vitamin C for 7 days in 56 critically ill COVID-19 patients resulted in a promising reduction of 28-day mortality (_p_ = 0.06) in univariate survival analysis [@doi:10.21203/rs.3.rs-52778/v2].
Indeed, the same study reported a significant decrease in IL-6 levels by day 7 of vitamin C infusion (_p_ = 0.04) [@doi:10.21203/rs.3.rs-52778/v1].
Additional studies that are being conducted in Canada, China, Iran, and the USA will provide additional insight into whether vitamin C supplementation affects COVID-19 outcomes on a larger scale.

Even though evidence supporting the use of vitamin C is beginning to emerge, we will not know how effective vitamin C is as a therapeutic for quite some time.
Currently (as of January 2021) over fifteen trials are registered with clinicaltrials.gov that are either recruiting, active or are currently in preparation.
When completed, these trials will provide crucial evidence on the efficacy of vitamin C as a therapeutic for COVID-19 infection.
However, the majority of supplementation studies investigate the intravenous infusion of vitamin C in severe patients.
Therefore, there is a lack of studies investigating the potential prophylactic administration of vitamin C via oral supplementation for healthy individuals or potentially asymptomatic SARS-CoV-2 positive patients.
Once again, vitamin C intake is part of a healthy diet and the vitamin likely presents minimal risk, but its potential prophylactic or therapeutic effects against COVID-19 are yet to be determined.
To maintain vitamin C status, it would be prudent for individuals to ensure that they consume the recommended dietary allowance of vitamin C to maintain a healthy immune system [@doi:10.3390/nu12051466].
The recommended dietary allowance according to the FDA is 75-90 mg/d, whereas EFSA recommends 110 mg/d [@doi:10.17226/9810].

### Vitamin D

Of all of the supplements currently under investigation, vitamin D has become a leading prophylactic and therapeutic candidate against SARS-CoV-2.
Vitamin D can modulate both the adaptive and innate immune system and is associated with various aspects of immune health and antiviral defense [@doi:10.3390/nu9070651; @doi:10.3390/ijms19082419; @doi:10.3390/nu12072097; @doi:10.1111/j.1365-2249.2009.04001.x; @doi:10.1016/j.ecl.2017.07.010].
Vitamin D can be sourced through diet or supplementation, but it is mainly biosynthesized by the body on exposure to ultraviolet light (UVB) from sunlight.
Vitamin D deficiency is associated with an increased susceptibility to infection [@doi:10.2310/JIM.0b013e31821b8755].
In particular, vitamin D deficient patients are at risk of developing acute respiratory infections [@doi:10.1016/j.jsbmb.2012.11.017] and ARDS [@doi:10.1016/j.jsbmb.2012.11.017].
1,25-dihydroxyvitamin D3 is the active form of vitamin D that is involved in adaptive and innate responses; however, due to its low concentration and a short half life of a few hours, vitamin D levels are typically measured by the longer lasting and more abundant precursor 25-hydroxyvitamin D.
The vitamin D receptor is expressed in various immune cells, and vitamin D is an immunomodulator of antigen presenting cells, dendritic cells, macrophages, monocytes, and T- and B-lymphocytes [@doi:10.2310/JIM.0b013e31821b8755; @doi:10.1016/j.coph.2010.04.001].
Due to its potential immunomodulating properties, vitamin D supplementation may be advantageous to maintain a healthy immune system.

Early in the pandemic it was postulated that an individual’s vitamin D status could significantly affect their risk of developing COVID-19 [@doi:10.3390/nu12040988].
This hypothesis was derived from the fact that the current pandemic emerged in Wuhan China during winter, when 25-hydroxyvitamin D concentrations are at their lowest due to a lack of sunlight, whereas in the Southern Hemisphere, where it was nearing the end of the summer and higher 25-hydroxyvitamin D concentrations would be higher, the number of cases was low.
This led researchers to question whether there was a seasonal component to the SARS-CoV-2 pandemic and whether vitamin D levels might play a role [@doi:10.3390/nu12040988; @doi:10.1111/joim.13149; @doi:10.1016/j.ajic.2020.06.193; @doi:10.1111/apt.15777].
Though it is assumed that COVID-19 is seasonal, multiple other factors that can affect vitamin D levels should also be considered.
These factors include an individual’s nutritional status, their age, their occupation, skin pigmentation, potential comorbidities, and the variation of exposure to sunlight due to latitude amongst others.
Indeed, it has been estimated that each degree of latitude north of 28 degrees corresponded to a 4.4% increase of COVID-19 mortality, indirectly linking a persons vitamin D levels via exposure to UVB light to COVID-19 mortality [@doi:10.1111/joim.13149].

As the pandemic has evolved, additional research of varying quality has investigated some of the potential links identified early in the pandemic [@doi:10.3390/nu12040988] between vitamin D and COVID-19.
Indeed, studies are beginning to investigate whether there is any prophylactic and/or therapeutic relationship between vitamin D and COVID-19.
A study in Switzerland demonstrated that 27 SARS-CoV-2 positive patients exhibited 25-hydroxyvitamin D plasma concentrations that were significantly lower (11.1 ng/ml) than those of SARS-CoV-2 negative patients (24.6 ng/ml; _p_ = 0.004), an association that held when stratifying patients greater than 70 years old [@doi:10.3390/nu12051359].
These findings seem to be supported by a Belgian observational study of 186 SARS-CoV-2 positive patients exhibiting symptoms of pneumonia, where 25-hydroxyvitamin D plasma concentrations were measured and CT scans of the lungs were obtained upon hospitalization [@doi:10.1101/2020.05.01.20079376].
A significant difference in 25-hydroxyvitamin D levels was observed between the SARS-CoV-2 patients and 2,717 season-matched diseased controls.
Both female and male patients possessed lower median 25-hydroxyvitamin D concentrations than the control group as a whole (18.6 ng/ml versus 21.5 ng/ml; _p_ = 0.0016) and a higher rate of vitamin D deficiency (58.6% versus 42.5%).
However, when comparisons were stratified by sex, evidence of sexual dimorphism became apparent, as female patients had equivalent levels of 25-hydroxyvitamin D to females in the control group, whereas male patients were deficient in 25-hydroxyvitamin D relative to male controls (67% versus 49%; _p_ = 0.0006).
Notably, vitamin D deficiency was progressively lower in males with advancing radiological disease stages (_p_ = 0.001).
These studies are supported by several others that indicate that vitamin D status may be an independent risk factor for the severity of COVID-19 [@doi:10.1371/journal.pone.0239799; @doi:10.1016/j.jiph.2020.06.021; @doi:10.1111/febs.15495; @doi:10.1001/jamanetworkopen.2020.19722] and in COVID-19 patients relative to population-based controls [@doi:10.1210/clinem/dgaa733].
Indeed, serum concentrations of 25-hydroxyvitamin D above 30 ng/ml, which indicate vitamin D sufficiency, seems to be associated with a reduction in serum C-reactive protein, an inflammatory marker, along with increased lymphocyte levels, which suggests that vitamin D levels may modulate the immune response by reducing risk for cytokine storm in response to SARS-CoV-2 infection [@doi:10.1210/clinem/dgaa733].
A study in India determined that COVID-19 fatality was higher in patients with severe COVID-19 and low serum 25-hydroxyvitamin D (mean level 6.2 ng/ml; 97% vitamin D deficient) levels versus asymptomatic non-severe patients with higher levels of vitamin D (mean level 27.9 ng/ml; 33% vitamin D deficient) [@doi:10.1038/s41598-020-77093-z].
In the same study, vitamin D deficiency was associated with higher levels of inflammatory markers including IL-6, ferritin, and tumor necrosis factor &alpha;.
Collectively, these studies add to a multitude of observational studies reporting potential associations between low levels of 25-hydroxyvitamin D and COVID-19 incidence and severity [@doi:10.3390/nu12051359; @doi:10.3390/nu12123773; @doi:10.1007/s40618-020-01370-x; @doi:10.1210/clinem/dgaa733; @doi:10.3390/nu12092757; @doi:10.3390/nu12092775; @doi:10.1080/07315724.2020.1826005; @doi:10.1001/jamanetworkopen.2020.19722; @doi:10.1016/j.intimp.2020.107001; @doi:10.1093/jn/nxaa332].

Despite the large number of studies establishing a link between vitamin D status and COVID-19 severity, an examination of data from the UK Biobank did not support this thesis [@doi:10.1016/j.dsx.2020.04.050; @doi:10.1007/s00394-020-02372-4].
These analyses examined 25-hydroxyvitamin D concentrations alongside SARS-CoV-2 positivity and COVID-19 mortality in over 340,000 UK Biobank participants.
However, these studies have caused considerable debate that will likely be settled following further studies [@doi:10.1111/cen.14276; @doi:10.1016/j.dsx.2020.05.046].
Overall, while the evidence suggests that there is likely an association between low serum 25-hydroxyvitamin D and COVID-19 incidence, these studies must be interpreted with caution, as there is the potential for reverse causality, bias, and other confounding factors including that vitamin D deficiency is also associated with numerous pre-existing conditions and risk factors that can increase the risk for severe COVID-19 [@doi:10.3390/nu12051466; @doi:10.1038/s41371-020-00398-z; @doi:10.1111/joim.13149; @doi:10.1007/s40520-020-01677-y].

While these studies inform us of the potential importance of vitamin D sufficiency and the risk of SARS-CoV-2 infection and severe COVID-19, they fail to conclusively determine whether vitamin D supplementation can therapeutically affect the clinical course of COVID-19.
In one study, 40 vitamin D deficient asymptomatic or mildly symptomatic participants patients were either randomized to receive 60,000 IU of cholecalciferol daily for at least 7 days (n = 16) or a placebo (n = 24) with a target serum 25-hydroxyvitamin D level >50 ng/ml.
At day 7, 10 patients achieved >50 ng/ml, followed by another 2 by day 14.
By the end of the study, the treatment group had a greater proportion of vitamin D-deficient participants that tested negative for SARS-CoV-2 RNA, and they had a significantly lower fibrinogen levels, potentially indicating a beneficial effect [@doi:10.1136/postgradmedj-2020-139065].
A pilot study in Spain determined that early administration of high dose calcifediol (~21,000 IU days 1-2 and ~11,000 IU days 3-7 of hospital admission) with hydroxychloroquine and azithromycin to 50 hospitalized COVID-19 patients significantly reduced ICU admissions and may have reduced disease severity versus hydroxychloroquine and azithromycin alone [@doi:10.1016/j.jsbmb.2020.105751].
Although this study received significant criticism from the National Institute for Health and Care Excellence (NICE) in the UK [@url:https://www.nice.org.uk/advice/es28/chapter/Key-messages], an independent follow-up statistical analysis supported the findings of the study with respect to the results of cholecalciferol treatment [@doi:10.1101/2020.11.08.20222638].
Another trial of 986 patients hospitalized for COVID-19 in three UK hospitals administered cholecalciferol supplementation (≥ 280,000 IU in a time period of 7 weeks) to 151 patients and found an association with a reduced risk of COVID-19 mortality, regardless of baseline 25-hydroxyvitamin D levels [@doi:10.3390/nu12123799].
However, a double-blind, randomized, placebo-controlled trial of 240 hospitalized COVID-19 patients in São Paulo, Brazil administered a single 200,000 IU oral dose of vitamin D.
While levels of 25-hydroxyvitamin D did increase from 21% to ~27% (_p_ = 0.001) and the supplementation was well tolerated, there was no reduction in the length of hospital stay or mortality and no change to any other relevant secondary outcomes [@doi:10.1101/2020.11.16.20232397].
These early findings are thus still inconclusive with regards to the therapeutic value of vitamin D supplementation.
However, other trials are underway, including one trial that is investigating the utility of vitamin D as an immune-modulating agent by monitoring whether administration of vitamin D precipitates an improvement of health status in non-severe symptomatic COVID-19 patients and whether vitamin D prevents patient deterioration [@clinicaltrials:NCT04334005].
Other trials are examining various factors including mortality, symptom recovery, severity of disease, rates of ventilation, inflammatory markers such as C-reactive protein and IL-6, blood cell counts, and the prophylactic capacity of vitamin D administration [@clinicaltrials:NCT04385940; @clinicaltrials:NCT04334005; @clinicaltrials:NCT04411446; @clinicaltrials:NCT04344041].
Concomitant administration of vitamin D with pharmaceuticals such as aspirin [@clinicaltrials:NCT04363840] and bioactive molecules such as resveratrol [@clinicaltrials:NCT04400890] are also under investigation.

The effectiveness of vitamin D supplementation against COVID-19 remains open for debate.
All the same, there is no doubt that vitamin D deficiency is a widespread issue and should be addressed not only because of its potential link to SARS-CoV-2 incidence [@doi:10.1530/eje-18-0736], but also due to its importance for overall health.
There is a possibility that safe exposure to sunlight could improve endogenous synthesis of vitamin D, potentially strengthening the immune system.
However, sun exposure is not sufficient on its own, particularly in the winter months.
Indeed, while the possible link between vitamin D status and COVID-19 is further investigated, preemptive supplementation of vitamin D and encouraging people to maintain a healthy diet for optimum vitamin D status is likely to raise serum levels of 25-hydroxyvitamin D while being unlikely to carry major health risks.
These principles seem to be the basis of a number of guidelines issued by some countries and scientific organizations that have advised supplementation of vitamin D during the pandemic.
The Académie Nationale de Médecine in France recommends rapid testing of 25-hydroxyvitamin D for people over 60 years old to identify those most at risk of vitamin D deficiency and advises them to obtain a bolus dose of 50,000 to 100,000 IU vitamin D to limit respiratory complications.
It has also recommended that those under 60 years old should take 800 to 1,000 IU daily if they receive a SARS-CoV-2 positive test [@url:https://www.academie-medecine.fr/communique-de-lacademie-nationale-de-medecine-vitamine-d-et-covid-19/].
In Slovenia, doctors have been advised to provide nursing home patients with vitamin D [@doi:10.1136/bmj.m1820].
Both Public Health England and Public Health Scotland have advised members of the Black, Asian, and minority ethnic communities to supplement for vitamin D in light of evidence that they may be at higher risk for vitamin D deficiency along with other COVID-19 risk factors, a trend that has also been observed in the United States [@doi:10.1136/bmj.m2475; @doi:10.1136/bmjnph-2020-000096].
However, other UK scientific bodies including the NICE recommend that individuals supplement for vitamin D as per usual UK government advice but warn that people should not supplement for vitamin D solely to prevent COVID-19.
All the same, the NICE has provided guidelines for research to investigate the supplementation of vitamin D in the context of COVID-19 [@url:https://www.nice.org.uk/guidance/ng187/resources/covid19-rapid-guideline-vitamin-d-pdf-66142026720709].
Despite vitamin D deficiency being a widespread issue in the United States [@doi:10.7759/cureus.2741], the National Institutes of Health have stated that there is "insufficient data to recommend either for or against the use of vitamin D for the prevention or treatment of COVID-19" [@url:https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/vitamin-d/].
These are just some examples of how public health guidance has responded to the emerging evidence regarding vitamin D and COVID-19.
Outside of official recommendations, there is also evidence that individuals may be paying increased attention to their vitamin D levels, as a survey of Polish consumers showed that 56% of respondents used vitamin D during the pandemic [@doi:10.3390/nu13010054].
However, some companies have used the emerging evidence surrounding vitamin D to sell products that claim to prevent and treat COVID-19, which in one incident required a federal court to intervene and issue an injunction barring the sale of vitamin-D-related products due to the lack of clinical data supporting these claims [@url:https://www.justice.gov/opa/pr/court-orders-georgia-defendants-stop-selling-vitamin-d-products-treatments-covid-19-and-other].
It it clear that further studies and clinical trials are required to conclusively determine the prophylactic and therapeutic potential of vitamin D supplementation against COVID-19.
Until such time that sufficient evidence emerges, individuals should follow their national guidelines surrounding vitamin D intake to achieve vitamin D sufficiency.

### Probiotics

Probiotics are “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” [@doi:10.1038/nrgastro.2014.66].
Some studies suggest that probiotics are beneficial against common viral infections, and there is modest evidence to suggest that they can modulate the immune response [@doi:10.4082/kjfm.2013.34.1.2; @doi:10.2174/1381612824666180116163411].
As a result, it has been hypothesized that probiotics may have therapeutic value worthy of investigation against SARS-CoV-2 [@doi:10.3389/fpubh.2020.00186].
Probiotics and next-generation probiotics, which are more akin to pharmacological-grade supplements, have been associated with multiple potential beneficial effects for allergies, digestive tract disorders, and even metabolic diseases through their anti-inflammatory and immunomodulatory effects [@doi:10.1038/nmicrobiol.2017.57; @doi:10.1093/advances/nmy063].
However, the mechanisms by which probiotics affect these various conditions would likely differ among strains, with the ultimate effect of the probiotic depending on the heterogeneous set of bacteria present [@doi:10.1093/advances/nmy063].
Some of the beneficial effects of probiotics include reducing inflammation by promoting the expression of anti-inflammatory mediators, inhibiting Toll-like receptors 2 and 4, competing directly with pathogens, synthesizing antimicrobial substances or other metabolites, improving intestinal barrier function, and/or favorably altering the gut microbiota and the brain-gut axis [@doi:10.1016/j.earlhumdev.2019.05.010; @doi:10.1093/advances/nmy063; @doi:10.1159/000342079].
It is also thought that lactobacilli such as _Lactobacillus paracasei, Lactobacillus plantarum_ and _Lactobacillus rhamnosus_ have the capacity to bind to and inactivate some viruses via adsorptive and/or trapping mechanisms [@doi:10.1016/j.ijfoodmicro.2006.10.044].
Other probiotic lactobacilli and even non-viable bacterium-like particles have been shown to reduce both viral attachment to host cells and viral titers, along with reducing cytokine synthesis, enhancing the antiviral IFN-α response, and inducing various other antiviral mechanisms [@doi:10.1111/lam.12160; @doi:10.1016/j.anaerobe.2011.04.022; @doi:10.4049/jimmunol.1800927; @doi:10.1016/j.ijfoodmicro.2006.10.044; @doi:10.3390/medicina55090519; @doi:10.1038/s41598-019-39602-7; @doi:10.3920/bm2016.0160; @doi:10.1016/j.intimp.2013.12.020; @doi:10.1016/j.intimp.2019.106115].
These antiviral and immunobiotic mechanisms and others have been reviewed in detail elsewhere [@doi:10.3390/nu12061718; @doi:10.1038/s41538-020-00078-9; @doi:10.3389/fpubh.2020.00186].
However, there is also a bi-directional relationship between the lungs and gut microbiota known as the gut-lung axis [@doi:10.1038/mi.2011.55], whereby gut microbial metabolites and endotoxins may affect the lungs via the circulatory system and the lung microbiota in return may affect the gut [@doi:10.1111/cmi.12966].
Therefore, the gut-lung axis may play role in our future understanding of COVID-19 pathogenesis and become a target for probiotic treatments [@doi:10.1016/j.virusres.2020.198018].
Moreover, as microbial dysbiosis of the respiratory tract and gut may play a role in some viral infections, it has been suggested that SARS-CoV-2 may interact with our commensal microbiota [@doi:10.3390/nu12061718; @doi:10.3389/fmicb.2020.01840; 10.3389/fmicb.2020.01840] and that the lung microbiome could play a role in developing immunity to viral infections [@doi:10.1016/j.humic.2020.100073].
These postulations, if correct, could lead to the development of novel probiotic and prebiotic treatments.
However, significant research is required to confirm these associations and their relevance to patient care, if any.

Probiotic therapies and prophylactics may also confer some advantages for managing symptoms of COVID-19 or risks associated with its treatment.
Probiotics have tentatively been associated with the reduction of risk and duration of viral upper respiratory tract infections [@doi:10.1007/s10096-014-2086-y; @doi:10.1002/14651858.CD006895.pub3; @doi:10.1016/j.ijantimicag.2008.11.005].
Some meta-analyses that have assessed the efficacy of probiotics in viral respiratory infections have reported moderate reductions in the incidence and duration of infection [@doi:10.1002/14651858.CD006895.pub3; @doi:10.1017/S0007114514000075].
Indeed, randomized controlled trials have shown that administering _Bacillus subtilis_ and _Enterococcus faecalis_ [@doi:10.1007/s00134-016-4303-x], _Lactobacillus rhamnosus GG_ [@doi:10.1164/rccm.200912-1853OC], or _Lactobacillus casei_ and _Bifidobacterium breve_ with galactooligosaccharides [@doi:10.1186/s13054-018-2167-x] via the nasogastric tube to ventilated patients reduced the occurrence of ventilator-associated pneumonia in comparison to the respective control groups in studies of viral infections and sepsis.
These findings were also supported by a recent meta-analysis [@doi:10.4187/respcare.07097].
Additionally, COVID-19 patients carry a significant risk of ventilator-associated bacterial pneumonia [@doi:10.6084/m9.figshare.12340496], but it can be challenging for clinicians to diagnose this infection due to the fact that severe COVID-19 infection presents with the symptoms of pneumonia [@doi:10.1186/s13054-020-03013-2].
Therefore, an effective prophylactic therapy for ventilator-associated pneumonia in severe COVID-19 patients would carry significant therapeutic value.
Additionally, in recent years, probiotics have become almost synonymous with the treatment of gastrointestinal issues due to their supposed anti-inflammatory and immunomodulatory effects [@doi:10/d2qp].
Notably, gastrointestinal symptoms commonly occur in COVID-19 patients [@doi:10.1053/j.gastro.2020.03.020], and angiotensin-converting enzyme 2, the portal by which SARS-CoV-2 enters human cells, is highly expressed in enterocytes of the ileum and colon, suggesting that these organs may be a potential route of infection [@doi:10.1101/2020.01.30.927806; @doi:10.1038/cr.2016.152].
Indeed, SARS-CoV-2 viral RNA has been detected in human feces [@doi:10/ggq8zp; @doi:10.1053/j.gastro.2020.02.055], and fecal-oral transmission of the virus has not yet been ruled out [@doi:10/ggpx7s].
Rectal swabs of some SARS-CoV-2 positive pediatric patients persistently tested positive for several days despite negative nasopharyngeal tests, indicating the potential for fecal viral shedding [@doi:10.1038/s41591-020-0817-4].
However, there is conflicting evidence for the therapeutic value of various probiotics against the incidence or severity of gastrointestinal symptoms in viral or bacterial infections such as gastroenteritis [@doi:10.1007/s00203-017-1400-3; @doi:10.1056/NEJMoa1802597].
Nevertheless, it has been proposed that the administration of probiotics to COVID-19 patients and healthcare workers may prevent or ameliorate the gastrointestinal symptoms of COVID-19, a hypothesis that several clinical trials are now preparing to investigate [@clinicaltrials:NCT04420676; @clinicaltrials:NCT04366180].
Other studies are investigating whether probiotics may affect patient outcomes following SARS-CoV-2 infection [@clinicaltrials:NCT04390477].

Generally, the efficacy of probiotic use is a controversial topic among scientists.
In Europe, EFSA has banned the term probiotics on products labels, which has elicited either criticism for EFSA or support for probiotics from researchers in the field [@doi:10.1016/j.bpg.2015.12.001; @doi:10.1017/S000711451100287X; @doi:10.1038/nrgastro.2014.66].
This regulation is due to the hyperbolic claims placed on the labels of various probiotic products, which lack rigorous scientific data to support their efficacy.
Overall, the data supporting probiotics in the treatment or prevention of many different disorders and diseases is not conclusive, as the quality of the evidence is generally considered low [@doi:10.1007/s10096-014-2086-y].
However, in the case of probiotics and respiratory infections, the evidence seems to be supportive of their potential therapeutic value.
Consequently, several investigations are underway to investigate the prophylactic and therapeutic potential of probiotics for COVID-19.
The blind use of conventional probiotics for COVID-19 is currently cautioned against until the pathogenesis of SARS-CoV-2 can be further established [@doi:10/d2qq].
Until clinical trials investigating the prophylactic and therapeutic potential of probiotics for COVID-19 are complete, it is not possible to provide an evidence-based recommendation for their use.
Despite these concerns, complementary use of probiotics as an adjuvant therapeutic has been proposed by the Chinese National Health Commission and National Administration of Traditional Chinese Medicine [@doi:10.1111/1751-2980.12851].
While supply issues prevented the probiotics market from showing the same rapid response to the COVID-19 as some other supplements, many suppliers are reporting growth during the pandemic [@url:https://www.bloomberg.com/press-releases/2020-08-03/probiotics-market-worth-76-7-billion-by-2027-exclusive-report-covering-pre-and-post-covid-19-market-analysis-by-meticulous].
Therefore, the public response once again seems to have adopted supplements promoted as bolstering the immune response despite a lack of evidence suggesting they are beneficial for preventing or mitigating COVID-19.

### Discussion

In this review, we report the findings to date of analyses of several dietary supplements and nutraceuticals.
While existing evidence suggests potential benefits of n-3 PUFA and probiotic supplementation for COVID-19 treatment and prophylaxis, clinical data is still lacking, although trials are underway.
Both zinc and vitamin C supplementation in hospitalized patients seem to be associated with positive outcomes; however, further clinical trials are required.
In any case, both vitamin C and zinc intake are part of a healthy diet and both likely presents minimal risk when supplemented for, though their potential prophylactic or therapeutic effects against COVID-19 are yet to be determined.
On the other hand, mounting evidence from observational studies indicates that there is an association between vitamin D deficiency and COVID-19 incidence has also been supported by meta-analysis [@doi:10.1080/10408398.2020.1841090].
Indeed, scientists are working to confirm these findings and to determine whether a patient's serum 25-hydroxyvitamin D levels are also associated with COVID-19 severity.
Clinical trials are required to determine whether preemptive vitamin D supplementation may mitigate against severe COVID-19.
In terms of the therapeutic potential of vitamin D, initial evidence from clinical trials are conflicting, but seem to indicate that vitamin D supplementation may reduce COVID-19 severity [@doi:10.1016/j.jsbmb.2020.105751].
The various clinical trials currently underway will be imperative to provide information on the efficacious use of vitamin D supplementation for COVID-19 prevention and/or treatment.

The purported prophylactic and therapeutic benefits of dietary supplements and nutraceuticals for multiple disorders, diseases, and infections has been the subject of significant research and debate for the last few decades.
Inevitably, scientists are also investigating the potential for these various products to treat or prevent COVID-19.
This interest also extends to consumers, which led to a remarkable increase of sales of dietary supplements and nutraceuticals throughout the pandemic due to a desire to obtain additional protections from infection and disease.
The nutraceuticals discussed in this review, namely vitamin C, vitamin D, n-3 PUFA, zinc, and probiotics, were selected because of potential biological mechanisms that could beneficially affect viral and respiratory infections and because they are currently under clinical investigation.
Specifically, these compounds have all been found to influence cellular processes related to inflammation.
Inflammation is particularly relevant to COVID-19 because of the negative outcomes (often death) observed in a large number of patients whose immune response becomes hyperactive in response to SARS-CoV-2, leading to severe outcomes such as ARDS and sepsis [@doi:10.1056/NEJMra2026131].
Additionally, there is a well-established link between diet and inflammation [@doi:10.1177/0884533610385703], potentially mediated in part by the microbiome [@doi:10.1096/fj.201802477R].
Thus, the idea that dietary modifications or supplementation could be used to modify the inflammatory response is tied to a broader view of how diet and the immune system are interconnected.
The supplements and nutraceuticals discussed here therefore lie in sharp contrast to other alleged nutraceutical or dietary supplements that have attracted during the pandemic, such as colloidal silver [@url:https://www.nccih.nih.gov/health/colloidal-silver], which have no known nutritional function and can be harmful.
Importantly, while little clinical evidence is available about the effects of any supplements against COVID-19, the risks associated with those discussed above are likely to be low, and in some cases, they can be obtained from dietary sources alone.

There are various other products and molecules that have garnered scientific interest and could merit further investigation.
These include polyphenols, lipid extracts, and tomato-based nutraceuticals, all of which have been suggested for the potential prevention of cardiovascular complications of COVID-19 such as thrombosis [@doi:10.3389/fnut.2020.583080; @doi:10.3390/nu12061718].
Melatonin is another supplement that has been identified as a potential antiviral agent against SARS-CoV-2 using computational methods [@doi:10.1038/s41421-020-0153-3], and it has also been highlighted as a potential therapeutic agent for COVID-19 due to its documented antioxidant, anti-apoptotic, immunomodulatory, and anti-inflammatory effects [@doi:10.3389/fnut.2020.583080; @doi:10.3390/antiox10010047; @doi:10.3390/nu13010047].
Notably, melatonin, vitamin D and zinc have attracted public attention because they were included in the treatment plan of the former President of the United States upon his hospitalization due to COVID-19 [@doi:10.1126/science.abf0974].
These are just some of the many substances and supplements that are currently under investigation but as of yet lack evidence to support their use for the prevention or treatment of COVID-19.
While there is plenty of skepticism put forward by physicians and scientists surrounding the use of supplements, these statements have not stopped consumers from purchasing these products, with one study reporting that online searches for dietary supplements in Poland began trending with the start of the pandemic [@doi:10.3390/nu13010054].
Additionally, supplement usage increased between the first and second wave of the pandemic.
Participants reported various reasons for their use of supplements, including to improve immunity (60%), to improve overall health (57%), and to fill nutrient gaps in their diet (53%).
Other efforts to collect large datasets regarding such behavior have also sought to explore a possible association between vitamin or supplement consumption and COVID-19.
An observational analysis of survey responses from 327,720 users of the COVID Symptom Study App found that the consumption of n-3 PUFA supplements, probiotics, multivitamins, and vitamin D was associated with a lower risk of SARS-CoV-2 infection in women but not men after adjusting for potential confounders [@doi:10.1101/2020.11.27.20239087].
According to the authors, the sexual dimorphism observed may in part be because supplements may better support females due to known differences between the male and female immune systems, or it could be due to behavioral and health consciousness differences between the sexes [@doi:10.1101/2020.11.27.20239087].
Certainly, randomized controlled trials are required to investigate these findings further.

Finally, it is known that a patient's nutritional status affects health outcomes in various infectious diseases [@doi:10.3390/nu12041181], and COVID-19 is no different [@doi:10.1016/j.clnu.2020.03.022; @doi:10.1093/advances/nmaa125; @doi:10.1016/j.clnesp.2020.09.214].
Some of the main risk factors for severe COVID-19, which also happen to be linked to poor nutritional status, include obesity, hypertension, cardiovascular diseases, type II diabetes mellitus, and indeed age-related malnutrition [@doi:10.1093/advances/nmaa125; @doi:10.3390/nu12051466; @doi:10.1002/jpen.1954].
Although not the main focus of this review, it is important to consider the nutritional challenges associated with severe COVID-19 patients.
Hospitalized COVID-19 patients tend to report an unusually high loss of appetite preceding admission, some suffer diarrhea and gastrointestinal symptoms that result in significantly lower food intake, and patients with poorer nutritional status were more likely to have worse outcomes and require nutrition therapy [@doi:10.1002/jpen.1953].
Dysphagia also seems to be a significant problem in pediatric patients that suffered multisystem inflammatory syndrome [@doi:10.1016/j.eclinm.2020.100527] and rehabilitating COVID-19 patients, potentially contributing to poor nutritional status [@doi:10.1038/s41430-020-0664-x].
Almost two-thirds of discharged COVID-19 ICU patients exhibit significant weight loss, of which 26% had weight loss greater than 10% [@doi:10.1016/j.clnesp.2020.09.214].
As investigated in this review, hospitalized patients also tend to exhibit vitamin D deficiency or insufficiency, which may be associated with greater disease severity [@doi:10.1080/10408398.2020.1841090].
Therefore, further research is required to determine how dietary supplements and nutraceuticals may contribute to the treatment of severely ill and rehabilitating patients, who often rely on enteral nutrition.

### Conclusions

Despite all the potential benefits of nutraceutical and dietary supplement interventions presented, currently there is a paucity of clinical evidence to support their use for the prevention or mitigation of COVID-19 infection.
Nevertheless, optimal nutritional status can prime an individual’s immune system to protect against the effects of acute respiratory viral infections by supporting normal maintenance of the immune system [@doi:10.3390/nu12041181; @doi:10.3390/nu12051466].
Nutritional strategies can also play a role in the treatment of hospitalized patients, as malnutrition is a risk to COVID-19 patients [@doi:10.1038/s41430-020-0664-x].
Overall, supplementation of vitamin C, vitamin D, and zinc may be an effective method of ensuring their adequate intake to maintain optimal immune function, which may also convey beneficial effects against viral infections due to their immunomodulatory effects.
Individuals should pay attention to their nutritional status, particularly their intake of vitamin D, considering that vitamin D deficiency is widespread.
The prevailing evidence seems to indicate an association between vitamin D deficiency with COVID-19 incidence and, potentially, severity [@doi:10.1111/joim.13149].
As a result, some international authorities have advised the general public, particularly those at high risk of infection, to consider vitamin D supplementation.
However, further well-controlled clinical trials are required to confirm these observations.

Many supplements and nutraceuticals designed for various ailments that are available in the United States and beyond are not strictly regulated [@doi:10.1080/10408398.2019.1592107].
Consequently, there can be safety and efficacy concerns associated with many of these products.
Often, the vulnerable members of society can be exploited in this regard and, unfortunately, the COVID-19 pandemic has proven no different.
As mentioned above, the FDA has issued warnings to several companies for advertising falsified claims in relation to the preventative and therapeutic capabilities of their products against COVID-19 [@url:https://www.fda.gov/news-events/press-announcements/coronavirus-update-fda-and-ftc-warn-seven-companies-selling-fraudulent-products-claim-treat-or].
Further intensive investigation is required to establish the effects of these nutraceuticals, if any, against COVID-19.
Until more effective therapeutics are established, the most effective mitigation strategies consist of encouraging standard public health practices such as regular hand washing with soap, wearing a face mask, and covering a cough with your elbow [@url:https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html], along with following social distancing measures, "stay at home" guidelines, expansive testing, and contact tracing [@doi:10.1101/2020.03.27.20045815; @doi:10.3201/eid2608.201093].
Indeed, in light of this review, it would also be pertinent to adopt a healthy diet and lifestyle following national guidelines in order to maintain optimal immune health.
Because of the broad public appeal of dietary supplements and nutraceuticals, it is important to evaluate the evidence regarding the use of such products.
We will continue to update this review as more findings become available.


## Vaccine Development Strategies for SARS-CoV-2

### Abstract

### Importance

### Introduction

For a highly infectious virus like SARS-CoV-2, a vaccine would hold particular value because it could bolster the immune response to the virus of the population broadly, thereby driving a lower rate of infection and likely significantly reducing fatalities.
However, the vaccine development process has historically been slow, and vaccines fail to provide immediate prophylactic protection or treat ongoing infections [@doi:10.3390/v10120680].

Flu-like illnesses caused by viruses are a common target of vaccine development programs, and influenza vaccine technology in particular has made many strides.
During the H1N1 influenza outbreak, vaccine development was accelerated because of the existing infrastructure, along with the fact that regulatory agencies had already decided that vaccines produced using egg- and cell-based platforms could be licensed under the regulations used for a strain change.
Critiques of the production and distribution of the H1N1 vaccine have stressed the need for alternative development-and-manufacturing platforms that can be readily adapted to new pathogens.
Although a monovalent H1N1 vaccine was not available before the pandemic peaked in the United States and Europe, it was available soon afterward as a stand-alone vaccine that was eventually incorporated into commercially available seasonal influenza vaccines [@doi:10.1056/NEJMp2005630].
If H1N1 vaccine development provides any indication, considering developing and manufacturing platforms for promising COVID-19 vaccine trials early could hasten the emergence of an effective prophylactic vaccine against SARS-CoV-2.

The first critical step towards developing a vaccine against SARS-CoV-2 was characterizing the target, which fortunately happened early in the COVID-19 outbreak with the sequencing and dissemination of the viral genome [@url:https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/].
The Coalition for Epidemic Preparedness Innovations (CEPI) is coordinating global health agencies and pharmaceutical companies to develop vaccines against SARS-CoV-2.
As of September 2020, there were over 180 vaccine candidates against SARS-CoV-2 in development [@doi:10.1038/s41586-020-2798-3].
Unlike many global vaccine development programs previously, such as with H1N1, the vaccine development landscape for COVID-19 includes vaccines produced by a wide array of technologies.
Experience in the field of oncology is encouraging COVID-19 vaccine developers to use next-generation approaches to vaccine development, which have led to the great diversity of vaccine development programs [@url:https://www.the-scientist.com/news-opinion/newer-vaccine-technologies-deployed-to-develop-covid-19-shot-67152].
These diverse technology platforms include DNA, RNA, virus-like particle, recombinant protein, both replicating and non-replicating viral vectors, live attenuated virus, and inactivated virus approaches (Figure @fig:vaccines).
Given the wide range of vaccines under development, it is possible that some vaccine products may eventually be shown to be more effective in certain subpopulations, such as children, pregnant women, immunocompromised patients, the elderly, etc.
The requirements for a successful vaccine trial and deployment are complex and may require coordination between government, industry, academia, and philanthropic entities [@doi:10.1126/science.abc5312].
While little is currently known about immunity to SARS-CoV-2, vaccine development typically tests for serum neutralizing activity, as this has been established as a biomarker for adaptive immunity in other respiratory illnesses [@doi:10.1056/NEJMoa2022483].

![
**Vaccine Development Strategies.**
Several different strategies can and are being employed for the development of vaccines.
Each approach capitalizes on different features of the SARS-CoV-2 virus and delivery through a different platform.
](images/N002-Vaccines.png){#fig:vaccines secno=1}

### DNA Vaccines

This vaccination method involves the direct introduction of a plasmid containing a DNA sequence encoding the antigen(s) against which an immune response is sought into appropriate tissues [@url:https://www.who.int/biologicals/areas/vaccines/dna/en/].
This approach may offer several advantages over traditional vaccination approaches, such as the stimulation of both B- as well as T-cell responses and the absence of any infectious agent.
Currently, a Phase I safety and immunogenicity clinical trial of INO-4800, a prophylactic vaccine against SARS-CoV-2, is underway [@clinicaltrials:NCT04336410].
The vaccine developer Inovio Pharmaceuticals Technology is overseeing administration of INO-4800 by intradermal injection followed by electroporation with the CELLECTRA® device to healthy volunteers.
Electroporation is the application of brief electric pulses to tissues in order to permeabilize cell membranes in a transient and reversible manner.
It has been shown that electroporation can enhance vaccine efficacy by up to 100-fold, as measured by increases in antigen-specific antibody titers [@doi:10.1016/j.coi.2011.03.008].
The safety of the CELLECTRA® device has been studied for over seven years, and these studies support the further development of electroporation as a safe vaccine delivery method [@doi:10.4161/hv.24702].
The temporary formation of pores through electroporation facilitates the successful transportation of macromolecules into cells, allowing cells to robustly take up INO-4800 for the production of an antibody response.
Approved by the U.S. FDA on April 6, 2020, the Phase I study is enrolling up to 40 healthy adult volunteers in Philadelphia, PA at the Perelman School of Medicine and at the Center for Pharmaceutical Research in Kansas City, MO.
The trial has two experimental arms corresponding to the two locations.
Participants in Experimental Group 1 will receive one intradermal injection of 1.0 milligram (mg) of INO-4800 followed by electroporation using the CELLECTRA® 2000 device twice, administered at Day 0 and Week 4.
Participants in Experimental Group 2 will receive two intradermal injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by electroporation using the CELLECTRA® 2000 device, administered at Day 0 and Week 4.
Safety data and the initial immune responses of participants from the trial are expected by the end of the summer of 2021.
The development of a DNA vaccine against SARS-CoV-2 by Inovio could be an important step forward in the world's search for a COVID-19 vaccine.
Although exciting, the cost of vaccine manufacturing and electroporation may make scaling the use of this technology for prophylactic use for the general public difficult.

### RNA Vaccines

RNA vaccines are nucleic-acid based modalities that code for viral antigens against which the human body elicits a humoral and cellular immune response.
The mRNA technology is transcribed _in vitro_ and delivered to cells via lipid nanoparticles (LNP) [@doi:10.1002/eji.1830230749].
They are recognized by ribosomes _in vivo_ and then translated and modified into functional proteins [@doi:10.3389/fimmu.2019.00594].
The resulting intracellular viral proteins are displayed on surface MHC proteins, provoking a strong CD8+ T cell response as well as a CD4+ T cell and B cell-associated antibody responses [@doi:10.3389/fimmu.2019.00594].
Naturally, mRNA is not very stable and can degrade quickly in the extracellular environment or the cytoplasm.
The LNP covering protects the mRNA from enzymatic degradation outside of the cell [@doi:10.4155/tde-2016-0006].
Codon optimization to prevent secondary structure formation and modifications of the poly-A tail as well as the 5’ untranslated region to promote ribosomal complex binding can increase mRNA expression in cells.
Furthermore, purifying out double-stranded RNA and immature RNA with FPLC (fast performance liquid chromatography) and HPLC (high performance liquid chromatography) technology will improve translation of the mRNA in the cell [@doi:10.3389/fimmu.2019.00594; @doi:10.1080/14760584.2017.1355245].
Vaccines based on mRNA delivery confer many advantages over traditional viral vectored vaccines and DNA vaccines.
In comparison to live attenuated viruses, mRNA vaccines are non-infectious and can be synthetically produced in an egg-free, cell-free environment, thereby reducing the risk of a detrimental immune response in the host [@doi:10.1016/j.immuni.2020.03.007].
Unlike DNA vaccines, mRNA technologies are naturally degradable and non-integrating, and they do not need to cross the nuclear membrane in addition to the plasma membrane for their effects to be seen [@doi:10.3389/fimmu.2019.00594].
Furthermore, mRNA vaccines are easily, affordably, and rapidly scalable.

Although mRNA vaccines have been developed for therapeutic and prophylactic purposes, none have previously been licensed or commercialized.
Nevertheless, they have shown promise in animal models and preliminary clinical trials for several indications, including rabies, coronavirus, influenza, and cytomegalovirus [@clinicaltrials:NCT01669096].
Preclinical data previously identified effective antibody generation against full-length FPLC-purified influenza hemagglutinin stalk-encoding mRNA in mice, rabbits, and ferrets [@doi:10.1038/s41467-018-05482-0].
Similar immunological responses for mRNA vaccines were observed in humans in Phase I and II clinical trials operated by the pharmaceutical-development companies Curevac and Moderna for rabies, flu, and zika [@doi:10.1080/14760584.2017.1355245].
Positively charged bilayer LNPs carrying the mRNA attract negatively charged cell membranes, endocytose into the cytoplasm [@doi:10.4155/tde-2016-0006], and facilitate endosomal escape.
LNPs can be coated with modalities recognized and engulfed by specific cell types, and LNPs that are 150 nm or less effectively enter into lymphatic vessels [@doi:10.4155/tde-2016-0006; @doi:10.1038/s41467-018-06936-1].
Therefore, this technology holds great potential for targeted delivery of modified mRNA.

There are three types of RNA vaccines: non-replicating, _in vivo_ self-replicating, and _in vitro_ dendritic cell non-replicating [@url:https://www.phgfoundation.org/briefing/rna-vaccines].
Non-replicating mRNA vaccines consist of a simple open reading frame (ORF) for the viral antigen flanked by the 5’ UTR and 3’ poly-A tail.
_In vivo_ self-replicating vaccines encode a modified viral genome derived from single-stranded, positive sense RNA alphaviruses [@doi:10.3389/fimmu.2019.00594; @doi:10.1080/14760584.2017.1355245].
The RNA genome encodes the viral antigen along with proteins of the genome replication machinery, including an RNA polymerase.
Structural proteins required for viral assembly are not included in the engineered genome [@doi:10.3389/fimmu.2019.00594].
Self-replicating vaccines produce more viral antigens over a longer period of time, thereby evoking a more robust immune response [@url:https://www.phgfoundation.org/briefing/rna-vaccines].
Finally, _in vitro_ dendritic cell non-replicating RNA vaccines limit transfection to dendritic cells.
Dendritic cells are potent antigen-presenting immune cells that easily take up mRNA and present fragments of the translated peptide on their MHC proteins, which can then interact with T cell receptors.
Ultimately, primed T follicular helper cells can stimulate germinal center B cells that also present the viral antigen to produce antibodies against the virus [@doi:10.1016/j.immuni.2014.10.004].
These cells are isolated from the patient, grown and transfected _ex vivo_, and reintroduced to the patient [@doi:10.1038/nrd.2017.243].

Given the potential for this technology to be quickly adapted for a new pathogen, it has held significant interest for the treatment of COVID-19.
In the vaccines developed under this approach, the spike protein, which is immunogenic [@doi:10.1016/j.immuni.2020.05.002], can be furnished to the immune system in order to train its response.
The vaccine candidates developed against SARS-CoV-2 using mRNA vectors utilize similar principles and technologies, although there are slight differences in implementation among candidates such as the formulation of the platform and the specific components of the spike protein encapsulated (e.g., the full Spike protein vs. the RBD alone) [@doi:10.3389/fphar.2020.00937].
The results of the interim analyses of two mRNA vaccine candidates became available at the end of 2020 and provided strong support for this emerging approach to vaccination.
Below we describe the results available as of February 2021 for two such candidates, mRNA-1273 produced by ModernaTX and BNT162b2 produced by Pfizer, Inc. and BioNTech.

#### ModernaTX mRNA Vaccine

ModernaTX's mRNA-1273 vaccine, which is an  was the first COVID-19 vaccine to enter a phase I clinical trial in the United States.
In this trial, Moderna spearheaded an investigation on the immunogenicity and reactogenicity of mRNA-1273, a conventional lipid nanoparticle encapsulated RNA encoding a full-length prefusion stabilized S protein for SARS-CoV-2 [@clinicaltrials:NCT04283461].
An initial report described the results of enrolling forty-five participants who were administered intramuscular injections of mRNA-1273 in their deltoid muscle on day 1 and day 29, and then followed for the next twelve months [@doi:10.1056/NEJMoa2022483].
Healthy males and non-pregnant females aged 18-55 years were recruited for this study and divided into three groups receiving 25, 100, or 250 micrograms (&mu;g) of mRNA-1273.
IgG ELISA assays on patient serology samples were used to examine the immunogenicity of the vaccine [@clinicaltrials:NCT04283461].
Binding antibodies were observed at two weeks after the first dose at all concentrations.
At the time point one week after the second dose was administered on day 29, the pseudotyped lentivirus reporter single-round-of-infection neutralization assay (PsVNA), which was used to assess neutralizing activity, reached a median level similar to the median observed in convalescent plasma samples.
Participants reported mild and moderate systemic adverse events after the day 1 injection, and one severe local event was observed in each of the two highest dose levels.
The second injection led to severe systemic adverse events for three of the participants at the highest dose levels, with one participant in the group being evaluated at an urgent care center on the day after the second dose.
The reported localized adverse events from the second dose were similar to those from the first.

Several months later, a press release from ModernaTX described the results of the first interim analysis of the vaccine [@url:https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy].
On November 16, 2020, a report was released describing the initial results from Phase III testing, corresponding to the first 95 cases of COVID-19 in the 30,000 enrolled participants [@url:https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy], with additional data released to the FDA on December 17, 2020 [@url:https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-17-2020-meeting-announcement#event-materials].
These results were subsequently published in a peer-reviewed journal (_The New England Journal of Medicine_) on December 30, 2020 [@doi:10.1056/NEJMoa2035389].
The first group of 30,420 study participants were randomized to receive the vaccine or a placebo at a ratio of 1:1 [@doi:10.1056/NEJMoa2035389].
Administration occurred at 99 sites within the United States in two sessions, spaced 28 days apart [@url:https://www.fda.gov/media/144434/download; @doi:10.1056/NEJMoa2035389].
Patients reporting COVID-19 symptoms upon follow-up were tested for SARS-CoV-2 using a nasopharyngeal swab that was evaluated with RT-PCR [@url:https://www.fda.gov/media/144434/download].
The initial preliminary analysis reported the results of the cases observed up until a cut-off date of November 11, 2020.
Of these first 95 cases reported, 90 occurred in participants receiving the placebo compared to 5 cases in the group receiving the vaccine [@url:https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy].
These results suggested the vaccine is 94.5% effective in preventing COVID-19.
Additionally, eleven severe cases of COVID-19 were observed, and all eleven occurred in participants receiving the placebo.
The publication reported the results through an extended cut-off date of November 21, 2020, corresponding to 196 cases [@doi:10.1056/NEJMoa2035389].
Of these, 11 occurred in the vaccine group and 185 in the placebo group, corresponding to an efficacy of 94.1%.
Once again, all of the severe cases of COVID-19 observed (n=30) occurred in the placebo group, including one death.
Thus, as more cases are reported, the efficacy of the vaccine has remained above 90%, and no cases of severe COVID-19 have yet been reported in participants receiving the vaccine.

These findings suggest the possibility that the vaccine might bolster immune defenses even for subjects who do still develop a SARS-CoV-2 infection.
The study was designed with an explicit goal of including individuals at high risk for COVID-19, including older adults, people with underlying health conditions, and people of color [@url:https://investors.modernatx.com/news-releases/news-release-details/moderna-has-completed-case-accrual-first-planned-interim].
The Phase III trial population was comprised by approximately 25.3% adults over age 65 in the initial report and 24.8% in the publication [@url:https://www.fda.gov/media/144434/download].
Among the cases reported by both interim analyses, 16-17% occurred in older adults [@url:https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy; @doi:10.1056/NEJMoa2035389]..
Additionally, approximately 10% of participants identified a Black or African-American background and 20% identified Hispanic or Latino ethnicity [@url:https://www.fda.gov/media/144434/download; @doi:10.1056/NEJMoa2035389].
Among the first 95 cases, 12.6% occurred in participants identifying a Hispanic or Latino background and 4% in participants reporting a Black or African-American background [@url:https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy]; in the publication, they indicated only that 41 of the cases reported in the placebo group and 1 case in the treatment group occurred in "communities of color", corresponding to 21.4% of all cases [@doi:10.1056/NEJMoa2035389].
While the sample size in both analyses is small relative to the study population of over 30,000, these results suggest that the vaccine is likely to be effective in people from a variety of backgrounds.
By all indications, this vaccine is likely to be highly useful in mitigating the damage of SARS-CoV-2.

In-depth safety data was released by ModernaTX as part of their application for an EUA from the FDA and summarized in the associated publication [@doi:10.1056/NEJMoa2035389; @url:https://www.fda.gov/media/144434/download].
Because the detail provided in the report is greater than that provided in the publication, here we emphasize the results observed at the time of the first analysis.
Overall, a large percentage of participants reported adverse effects when solicited, and these reports were higher in the vaccine group than in the placebo group (94.5% versus 59.5%, respectively, at the time of the initial analysis) [@url:https://www.fda.gov/media/144434/download].
Some of these events met the criteria for grade 3 (local or systemic) or grade 4 (systemic only) toxicity [@url:https://www.fda.gov/media/144434/download], but most were grade 1 or grade 2 and lasted 2-3 days [@doi:10.1056/NEJMoa2035389].
The most common local adverse reaction was pain at the injection site, reported by 83.7% of participants receiving the first dose of the vaccine and 88.4% upon receiving the second dose, compared to 19.8% and 19.8% and 17.0%, respectively, of patients in the placebo condition [@url:https://www.fda.gov/media/144434/download].
Fewer than 5% of vaccine recipients reported grade 3 pain at either administration.
Other frequent local reactions included erythema, swelling, and lymphadenopathy [@url:https://www.fda.gov/media/144434/download].
For systemic adverse reactions, fatigue was the most common [@url:https://www.fda.gov/media/144434/download].
Among participants receiving either dose of the vaccine, 68.5% reported fatigue compared to 36.1% participants receiving the placebo [@url:https://www.fda.gov/media/144434/download].
The level of fatigue experienced was usually fairly mild, with only 9.6% and 1.3% of participants in the vaccine and placebo conditions, respectively, reporting grade 3 fatigue [@url:https://www.fda.gov/media/144434/download], which corresponds to significant interference with daily activity [@url:https://www.fda.gov/media/73679/download].
Based on the results of the report, an EUA was issued on December 18, 2020 to allow distribution of this vaccine in the United States [@url:https://www.cdc.gov/mmwr/volumes/69/wr/mm695152e1.htm], and it was shortly followed by an Interim Order authorizing distribution of the vaccine in Canada [@url:https://investors.modernatx.com/news-releases/news-release-details/health-canada-authorizes-moderna-covid-19-vaccine-canada] and a conditional marketing authorization by the European Medicines Agency to facilitate distribution in the European Union [@url:https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu].

#### Pfizer/BioNTech BNT162b2

ModernaTX was, in fact, the second company to release news of a successful interim analysis of an mRNA vaccine and receive an EUA.
The first report came from Pfizer and BioNTech's mRNA vaccine BNT162b2 on November 9, 2020 [@url:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against], and a preliminary report was published in the _New England Journal of Medicine_ one month later [@doi:10.1056/NEJMoa2034577].
The vaccine candidate is contains the full prefusion stabilized, membrane-anchored SARS-CoV-2 spike protein in a vaccine formulation based on modified mRNA (modRNA) technology [@doi:10.1101/cshperspect.a014035; @url:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0].
This vaccine candidate should not be confused with a similar candidate from Pfizer/BioNTech, BNT162b1, that delivered only the RBD of the spike protein [@doi:10.1038/s41586-020-2639-4; @doi:10.1038/s41586-020-2814-7], which was not advanced to a stage III trial because of the improved reactogenicity/immunogenicity profile of BNT162b2 [@doi:10.1056/NEJMoa2027906].

During the Phase III trial of BNT162b2, 43,538 participants were enrolled 1:1 in the placebo and the vaccine candidate and received two 30-μg doses 21 days apart [@doi:10.1056/NEJMoa2034577].
Of these enrolled participants, 21,720 received BNT162b2 and 21,728 received a placebo [@doi:10.1056/NEJMoa2034577].
Recruitment occurred at 135 sites across six countries: Argentina, Brazil, Germany, South Africa, Turkey, and the United States.
An initial press release described the first 94 cases, which were consistent with 90% efficacy of the vaccine at 7 days following the second dose [@url:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against].
The release of the full trial information covered a longer period and analyzed the first 170 cases occurring at least 7 days after the second dose, 8 of which occurred in patients who had received BNT162b2.
The press release characterized the study population as diverse, reporting that 42% of the participants worldwide came from non-white backgrounds, including 10% Black and 26% Hispanic or Latino [@url:https://www.pfizer.com/science/coronavirus/vaccine].
Within the United States, 10% and 13% of participants, respectively, identified themselves as having Black or Hispanic/Latino backgrounds [@url:https://www.pfizer.com/science/coronavirus/vaccine].
Additionally, 41% of participants worldwide were 56 years of age or older [@url:https://www.pfizer.com/science/coronavirus/vaccine], and they reported that the efficacy of the vaccine in adults over 65 was 94% [@url:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine].
The primary efficacy analysis of the Phase III study was concluded on November 18, 2020 [@url:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine], and the final results indicted 94.6% efficacy of the vaccine [@doi:10.1056/NEJMoa2034577]v.

The safety profile of the vaccine was also assessed [@doi:10.1056/NEJMoa2034577].
A subset of patients were followed for reactogenicity using electronic diaries, with the data collected from these 8,183 participants comprising the solicited safety events analyzed.
Much like those who received the ModernaTX vaccine candidate, a large proportion of participants reported experiencing site injection pain within 7 days of vaccination.
While percentages are broken down by age group in the publication, these proportions correspond to approximately 78% and 73% of all participants after the first and second doses, respectively, overall.
Only a small percentage of these events (less than 1%) were rated as serious, with the rest being mild or moderate, and none reached grade 4.
Some participants also reported redness or swelling, and the publication indicates that in most cases, such events resolved within 1 to 2 days.
Participants also experienced systemic effects, including fever (in most cases lower than 38.9°C and more common after dose 2), fatigue (25-50% of participants depending on age group and dose), headache (25-50% of participants depending on age group and dose), chills, and muscle or joint pain; more rarely, patients could experience gastrointestinal effects such as vomiting or diarrhea.
As with the local events, these events were almost always grade I or II.
While some events were reported by the placebo groups, these events were much rarer than in the treatment group even though compliance was similar.
Based on the efficacy and safety information released, the vaccine was approved in early December by the United Kingdom's Medicines and Healthcare Products Regulatory Agency with administration outside of a clinical trial beginning on December 8, 2020 [@doi:10.1136/bmj.m4714; @url:https://www.bbc.com/news/uk-55227325].
As of December 11, 2020, the United States FDA approved this vaccine under an emergency use authorization [@url:https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19].

### Viral Vector Vaccines

#### COVID-19 Vaccine AstraZeneca

#### Sputnik-V

#### Janssen’s Ad26.COV2-S

### Inactivated Whole Virus Vaccines

<!--Rephrase to match figure? Or rephrase figure?-->

#### SinoVac's CoronaVac

<!--https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext-->

#### Sinopharm (2 candidates)

### Protein Subunit Vaccines

<!--Do we need to add this to the figure? Or does it fall in one of the other categories?-->

#### Novavax NVX-CoV2373

### Vaccine Development Summary

### Complementary Approaches to Vaccine Development

#### Adjuvants for Vaccines

Adjuvants include a variety of molecules or larger microbial-related products that have an effect on the immune system or an immune response of interest.
They can either be comprised of or contain immunostimulants or immunomodulators.
Adjuvants are sometimes included within vaccines, especially vaccines other than live-attenuated and inactivated viruses, in order to enhance the immune response.
A review on the development of SARS-CoV-2 vaccines [@doi:10.3390/vaccines8020153] also included a brief summary of the potential of adjuvants for these vaccines, including a brief description of some already commonly used adjuvants.
Different adjuvants can regulate different types of immune responses, so the type or combination of adjuvants used in a vaccine will depend on both the type of vaccine and concern related to efficacy and safety.
A variety of possible mechanisms for adjuvants have been researched [@doi:10.1038/nri2510; @doi:10.3389/fimmu.2018.02619; @doi:10.3390/vaccines8010128], including the following: induction of DAMPs that can be recognized by certain PRRs of the innate immune system; functioning as PAMP that can also be recognized by certain PRRs; and more generally enhancing the humoral or cellular immune responses.
Selection of one or more adjuvants requires considering how to promote the advantageous effects of the components and/or immune response and, likewise, to inhibit possible deleterious effects.
There are also considerations related to the method of delivering (or co-delivering) the adjuvant and antigen components of a vaccine.

#### Trained Immunity

Another approach that is being investigated explores the potential for vaccines that are not made from the SARS-CoV-2 virus to confer what has been termed trained immunity. 
In a recent review [@doi:10.1038/s41577-020-0285-6], trained immunity was defined as forms of memory that are temporary (e.g., months or years) and reversible. 
It is induced by exposure to whole-microorganism vaccines or other microbial stimuli that generates heterologous protective effects.
Trained immunity can be displayed by innate immune cells or innate immune features of other cells, and it is characterized by alterations to immune responsiveness to future immune challenges due to epigenetic and metabolic mechanisms.
These alterations can take the form of either an increased or decreased response to immune challenge by a pathogen.
Trained immunity elicited by non-SARS-CoV-2 whole-microorganism vaccines could potentially improve SARS-CoV-2 susceptibility or severity [@doi:10.1016/j.cell.2020.04.042].

One type of stimulus which research indicates can induce trained immunity is bacillus Calmette-Guerin (BCG) vaccination.
BCG is an attenuated form of bacteria _Mycobacterium bovis_.
The vaccine is most commonly administered for the prevention of tuberculosis in humans.
Clinical trials in non-SARS-CoV-2-infected adults have been designed to assess whether BCG vaccination could have prophylactic effects against SARS-CoV-2 by reducing susceptibility, preventing infection, or reducing disease severity.
A number of trials are now evaluating the effects of the BCG vaccine or the related vaccine VPM1002 [@doi:10.1016/j.cell.2020.04.042; @clinicaltrials:NCT04327206; @clinicaltrials:NCT04328441; @clinicaltrials:NCT04348370; @clinicaltrials:NCT04350931; @clinicaltrials:NCT04362124; @clinicaltrials:NCT04369794; @clinicaltrials:NCT04373291; @clinicaltrials:NCT04379336; @clinicaltrials:NCT04384549; @clinicaltrials:NCT04387409; @clinicaltrials:NCT04414267; @clinicaltrials:NCT04417335; @clinicaltrials:NCT04435379; @clinicaltrials:NCT04439045].

The ongoing trials are using a number of different approaches.
Some trials enroll healthcare workers, other trials hospitalized elderly adults without immunosuppression who get vaccinated with placebo or BCG at hospital discharge, and yet another set of trials older adults (>50 years) under chronic care for conditions like hypertension and diabetes.
One set of trials, for example, uses time until first infection as the primary study endpoint; more generally, outcomes measured in some of these trials are related to incidence of disease and disease severity or symptoms.
Some analyses have suggested a possible correlation at the country level between the frequency of BCG vaccination (or BCG vaccination policies) and the severity of COVID-19 [@doi:10.1016/j.cell.2020.04.042].
Currently it is unclear whether this correlation has any connection to trained immunity.
Many possible confounding factors are also likely to vary among countries, such as age distribution, detection efficiency, stochastic epidemic dynamic effects, differences in healthcare capacity over time in relation to epidemic dynamics, and these have not been adequately accounted for in current analyses. <!-- TO DO: add in study that debunks this-->
It is unclear whether there is an effect of the timing of BCG vaccination, both during an individual's life cycle and relative to the COVID-19 pandemic.
Additionally, given that severe SARS-CoV-2 may be associated with a dysregulated immune response, it is unclear what alterations to the immune response would be most likely to be protective versus pathogenic (e.g., [@doi:10.1016/j.chom.2020.04.009; @doi:10.1016/j.chom.2020.05.009; @doi:10.1016/j.cell.2020.04.042; @doi:10.1016/j.chom.2020.05.008]).
The article [@doi:10.1016/j.cell.2020.04.042] proposes that trained immunity might lead to an earlier and stronger response, which could in turn reduce viremia and the risk of later, detrimental immunopathology.
While trained immunity is an interesting possible avenue to complement vaccine development efforts through the use of an existing vaccine, additional research is required to assess whether the BCG vaccine is likely to confer trained immunity in the case of SARS-CoV-2.

### Discussion

Additionally, major advances in vaccines using mRNA and adenoviruses that have led to three vaccines becoming available or close to becoming available in late 2020 (Figure @fig:therapeutics). <!-- Update depending on where this goes and specify countries etc.-->

Though some concerns remain about the duration of sustained immunity for convalescents, vaccine development efforts are ongoing and show initial promising results.
<!-- TO DO: Needs to be updated with vaccine info about duration, this is changing rapidly so leaving for now-->
The Moderna trial, for example, reported that the neutralizing activity in participants who received two doses of the vaccine was similar to that observed in convalescent plasma.

One of the two mRNA vaccines, Pfizer and BioNTech's BNT162b2, has been issued an EUA for patients as young as 16 [@url:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization], while ModernaTX has begun a clinical trial to assess its mRNA vaccine in adolescents ages 12 to 18 [@url:https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-covid].



## Social Factors Influencing COVID-19 Exposure and Outcomes

### Social Factors Influencing COVID-19 Outcomes

In addition to understanding the fundamental biology of the SARS-CoV-2 virus and COVID-19, it is critical to consider how the broader environment can influence both COVID-19 outcomes and efforts to develop and implement treatments for the disease.
The evidence clearly indicates that social environmental factors are critical determinants of individuals' and communities' risks related to COVID-19.
There are distinct components to COVID-19 susceptibility, and an individual's risk can be elevated at one or all stages from exposure to recovery/mortality: an individual may be more likely to be exposed to the virus, more likely to get infected once exposed, more likely to have serious complications once infected, and be less likely to receive adequate care once they are seriously ill.
The fact that differences in survival between Black and white patients were no longer significant after controlling for comorbidities and socioeconomic status (type of insurance, neighborhood deprivation score, and hospital where treatment was received) in addition to sex and age [@doi:10.1001/jamanetworkopen.2020.18039] underscores the relevance of social factors to understanding mortality differences between racial and ethnic groups.
Moreover, the Black patients were younger and more likely to be female than white patients, yet still had a higher mortality rate without correction for the other variables [@doi:10.1001/jamanetworkopen.2020.18039].
Here, we outline a few systemic reasons that may exacerbate the COVID-19 pandemic in communities of color.

### Factors Observed to be Associated with Susceptibility

As COVID-19 has spread into communities around the globe, it has become clear that the risks associated with this disease are not equally shared by all individuals or all communities.
Significant disparities in outcomes have led to interest in the demographic, biomedical, and social factors that influence COVID-19 severity.
Untangling the factors influencing COVID-19 susceptibility is a complex undertaking.
Among patients who are admitted to the hospital, outcomes have generally been poor, with rates of admission to the intensive care unit (ICU) upwards of 15% in both Wuhan, China and Italy [@doi:10.1056/nejmoa2002032; @doi:10.1001/jama.2020.2648; @doi:10.1001/jama.2020.4031].
However, hospitalization rates vary by location [@doi:10.15585/mmwr.mm6915e3].
This variation may be influenced by demographic (e.g., average age in the area), medical (e.g., the prevalence of comorbid conditions such as diabetes), and social (e.g., income or healthcare availability) factors that vary geographically.
Additionally, some of the same factors may influence an individual's probability of exposure to SARS-CoV-2, their risk of developing a more serious case of COVID-19 that would require hospitalization, and their access to medical support.
As a result, quantifying or comparing susceptibility among individuals, communities, or other groups requires consideration of a number of complex phenomena that intersect across many disciplines of research.
In this section, the term "risk factor" is used to refer to variables that are statistically associated with more severe COVID-19 outcomes.
Some are intrinsic characteristics that have been observed to carry an association with variation in outcomes, whereas others may be more functionally linked to the pathophysiology of COVID-19.

#### Patient Traits Associated with Increased Risk

Two traits that have been consistently associated with more severe COVID-19 outcomes are male sex and advanced age (typically defined as 60 or older, with the greatest risk among those 85 and older [@url:https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html]).
In the United States, males and older individuals diagnosed with COVID-19 were found to be more likely to require hospitalization [@doi:10.1377/hlthaff.2020.00598; @doi:10.15585/mmwr.mm6925e1].
A retrospective study of hospitalized Chinese patients [@doi:10/ggnxb3] found that a higher probability of mortality was associated with older age, and world-wide, population age structure has been found to be an important variable for explaining differences in outbreak severity [@doi:10.1073/pnas.2004911117].
The CFR for adults over 80 has been estimated upwards of 14% or even 20% [@doi:10.1111/jgs.16472].
Male sex has also been identified as a risk factor for severe COVID-19 outcomes, including death [@doi:10.1136/bmj.m1985; @doi:10.1186/s13293-020-00304-9; @url:https://globalhealth5050.org/the-sex-gender-and-covid-19-project/].
Early reports from China and Europe indicated that even though the case rates were similar across males and females, males were at elevated risk for hospital admission, ICU admission, and death [@doi:10.1186/s13293-020-00304-9], although data from some US states indicates more cases among females, potentially due to gender representation in care-taking professions [@doi:10.1371/journal.ppat.1008570].
In older age groups (e.g., age 60 and older), comparable absolute numbers of male and female cases actually suggests a higher rate of occurrence in males, due to increased skew in the sex ratio [@doi:10.1186/s13293-020-00304-9].
Current estimates based on worldwide data suggest that, compared to females, males may be 30% more likely to be hospitalized, 80% more likely to be admitted to the ICU, and 40% more likely to die as a result of COVID-19 [@url:https://globalhealth5050.org/the-sex-gender-and-covid-19-project/].
There also may be a compounding effect of advanced age and male sex, with differences time to recovery worst for males over 60 years old relative to female members of their age cohort [@doi:10.1371/journal.ppat.1008520].

Both of these risk factors can be approached through the lens of biology.
The biological basis for greater susceptibility with age is likely linked to the prevalence of extenuating health conditions such as heart failure or diabetes [@doi:10.1111/jgs.16472].
Several hypotheses have been proposed to account for differences in severity between males and females.
For example, some evidence suggests that female sex hormones may be protective [@doi:10.1186/s13293-020-00304-9; @doi:10.1371/journal.ppat.1008570].
ACE2 expression in the kidneys of male mice was observed to be twice as high as that of females, and a regulatory effect of estradiol on ACE2 expression was demonstrated by removing the gonads and then supplementing with estradiol [@doi:10.1186/2042-6410-1-6; @doi:10.1371/journal.ppat.1008570].
Other work in mice has shown an inverse association between mortality due to SARS-CoV-1 and estradiol, suggesting a protective role for the sex hormone [@doi:10.1371/journal.ppat.1008570].
Similarly, evidence suggests that similar patterns might be found in other tissues.
A preliminary analysis identified higher levels of ACE2 expression in the myocardium of male patients with aortic valve stenosis showed  than female patients, although this pattern was not found in controls [@doi:10.1186/s13293-020-00304-9].
Additionally, research has indicated that females respond to lower doses than males of heart medications that act on the Renin angiotensin aldosterone system (RAAS) pathway, which is shared with ACE2 [@doi:10.1186/s13293-020-00304-9].
Additionally, several components of the immune response, including the inflammatory response, may differ in intensity and timing between males and females [@doi:10.1371/journal.ppat.1008570; @doi:10.1186/2042-6410-1-6].
This hypothesis is supported by some preliminary evidence showing that female patients who recovered from severe COVID-19 had higher antibody titers than males [@doi:10.1371/journal.ppat.1008570].
Sex steroids can also bind to immune cell receptors to influence cytokine production [@doi:10.1186/s13293-020-00304-9].
Additionally, social factors may influence risks related to both age and sex: for example, older adults are more likely to live in care facilities, which have been a source for a large number of outbreaks [@doi:10.1093/qjmed/hcaa136], and gender roles may also influence exposure and/or susceptibility due to differences in care-taking and/or risky behaviors (e.g., caring for elder relatives and smoking, respectively) [@doi:10.1186/s13293-020-00304-9] among men and women (however, it should be noted that both transgender men and women are suspected to be at heightened risk [@url:https://escholarship.org/uc/item/55t297mc].)

#### Comorbid Health Conditions

A number of pre-existing or comorbid conditions have repeatedly been identified as risk factors for more severe COVID-19 outcomes.
Several underlying health conditions were identified at high prevalence among hospitalized patients, including obesity, diabetes, hypertension, lung disease, and cardiovascular disease [@doi:10.15585/mmwr.mm6915e3].
Higher Sequential Organ Failure Assessment (SOFA) scores have been associated with a higher probability of mortality [@doi:10/ggnxb3], and comorbid conditions such as cardiovascular and lung disease as well as obesity were also associated with an increased risk of hospitalization and death, even when correcting for age and sex [@doi:10.1136/bmj.m1985].
Diabetes may increase the risk of lengthy hospitalization [@doi:10.1016/j.cmet.2020.04.021] or of death [@doi:10.1016/j.cmet.2020.04.021;@doi:10.1007/s00592-020-01546-0].
[@doi:10.1111/dom.14057] and [@doi:10.1152/ajpendo.00124.2020] discuss possible ways in which COVID-19 and diabetes may interact.
Obesity also appears to be associated with higher risk of severe outcomes from SARS-CoV-2 [@doi:10.1016/j.metabol.2020.154262; @doi:10.1101/2020.04.23.20076042].
Obesity is considered an underlying risk factor for other health problems, and the mechanism for its contributions to COVID-19 hospitalization or mortality is not yet clear [@doi:10.1016/j.medj.2020.06.005].
Dementia and cancer were also associated with the risk of death in an analysis of a large number (more than 20,000) COVID-19 patients in the United Kingdom [@doi:10.1136/bmj.m1985].
It should be noted that comorbid conditions are inextricably tied to age, as conditions tend to be accumulated over time, but that the prevalence of individual comorbidities or of population health overall can vary regionally [@doi:10.1073/pnas.2008760117].
Several comorbidities that are highly prevalent in older adults, such as COPD, hypertension, cardiovascular disease, and diabetes, have been associated with CFRs upwards of 8% compared to an estimate of 1.4% in people without comorbidities [@doi:10.1111/jgs.16472; @url:https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)]. <!-- will this url work for Manubot?-->
Therefore, both age and health are important considerations when predicting the impact of COVID-19 on a population [@doi:10.1073/pnas.2008760117].
However, other associations may exist, such as patients with sepsis having higher SOFA scores -- in fact, SOFA was developed for the assessment of organ failure in the context of sepsis, and the acronym originally stood for Sepsis-Related Organ Failure Assessment [@doi:10.1007/BF01709751; @doi:10.1001/jama.2016.0287].
Additionally, certain conditions are likely to be more prevalent under or exacerbated by social conditions, especially poverty, as is discussed further below.

#### Ancestry

A number of studies have suggested associations between individuals' racial and ethnic backgrounds and their COVID-19 risk.
In particular, Black Americans are consistently identified as carrying a higher burden of COVID-19 than white Americans [@doi:10.1377/hlthaff.2020.00598; @doi:10.15585/mmwr.mm6925e1], with differences in the rates of kidney complications from COVID-19 particularly pronounced [@doi:10.1016/j.kint.2020.05.006].
Statistics from a number of cities indicate significant discrepancies between the proportion of COVID-19 cases and deaths in Black Americans relative to their representation in the general population [@doi:10/ggv494].
In addition to Black Americans, disproportionate harm and mortality from COVID-19 has also been noted in Latino/Hispanic Americans and in Native American and Alaskan Native communities, including the Navajo nation [@doi:10.1001/jama.2020.8598; @doi:10.1136/bmj.m1483; @doi:10.1111/jrh.12451; https://www.nytimes.com/2020/04/09/us/coronavirus-navajo-nation.html?searchResultPosition=10; @url:https://www.nytimes.com/interactive/2020/07/05/us/coronavirus-latinos-african-americans-cdc-data.html; @doi:10.1093/tbm/ibaa055; @url:https://journalhosting.ucalgary.ca/index.php/jisd/article/view/70753/54416].
In Brazil, indigenous communities likewise carry an increased burden of COVID-19 [@doi:10.1126/science.abc0073].
In the United Kingdom, nonwhite ethnicity (principally Black or South Asian) was one of several factors found to be associated with a higher risk of death from COVID-19 [@doi:10.1038/s41586-020-2521-4].

From a genetic standpoint, it is highly unlikely that ancestry itself predisposes individuals to contracting COVID-19 or to experiencing severe COVID-19 outcomes.
Examining human genetic diversity indicates variation over a geographic continuum, and that most human genetic variation is associated with the African continent [@doi:10.1038/ng1438].
African-Americans are also a more genetically diverse group relative to European-Americans, with a large number of rare alleles and a much smaller fraction of common alleles identified in African-Americans [@doi:10.1146/annurev.genom.9.081307.164258].
Therefore, the idea that African ancestry (at the continent level) might convey some sort of genetic risk for severe COVID-19 contrasts with what is known about worldwide human genetic diversity [@doi:10.1126/science.abd4842].
The possibility for genetic variants that confer some risk or some protection remains possible, but has not been widely explored, especially at a global level.
Research in Beijing of a small number (n=80) hospitalized COVID-19 patients revealed an association between severe COVID-19 outcomes and homozygosity for an allele in the interferon-induced transmembrane protein 3 (IFITM3) gene, which was selected as a candidate because it was previously found to be associated with influenza outcomes in Chinese patients [@doi:10.1093/infdis/jiaa224].
Genetic factors may also play a role in the risk of respiratory failure for COVID-19 [@doi:10.1056/NEJMoa2020283; @doi:10.1093/gerona/glaa131; @doi:10.1101/2020.06.16.155101].
However, genetic variants associated with outcomes within ancestral groups are far less surprising than genetic variants explaining outcomes between groups.
Alleles in _ACE2_ and _TMPRSS2_ have been identified that vary in frequency among ancestral groups [@doi:10.1186/s12916-020-01673-z], but whether these variants are associated with COVID-19 susceptibility has not been explored.

Instead, examining patterns of COVID-19 susceptibility on a global scale that suggest that social factors are of primary importance in predicting mortality.
Reports from several sub-Saharan African countries have indicated that the effects of the COVID-19 pandemic have been less severe than expected based on the outbreaks in China and Italy.
In Kenya, for example, estimates of national prevalence based on testing blood donors for SARS-CoV-2 antibodies were consistent with 5% of Kenyan adults having recovered from COVID-19 [@doi:10.1101/2020.07.27.20162693].
This high seroprevalence of antibodies lies in sharp contrast to the low number of COVID-19 fatalities in Kenya, which at the time was 71 out of 2093 known cases [@doi:10.1101/2020.07.27.20162693].
Likewise, a serosurvey of health care workers in Blantyre City, Malawi reported an adjusted antibody prevalence of 12.3%, suggesting that the virus had been circulating more widely than thought and that the death rate was up eight times lower than models had predicted [@doi:10.1101/2020.07.30.20164970].
While several possible hypotheses for the apparent reduced impact of COVID-19 on the African continent are being explored, such as young demographics in many places [@doi:10.1126/science.369.6505.756], these reports present a stark contrast to the severity of COVID-19 in Americans and Europeans of African descent.
Additionally, ethnic minorities in the United Kingdom also tend to be younger than white British living in the same areas, yet the burden of COVID-19 is still more serious for minorities, especially people of Black Caribbean ancestry, both in absolute numbers and when controlling for age and location [@url:https://www.ifs.org.uk/inequality/chapter/are-some-ethnic-groups-more-vulnerable-to-covid-19-than-others/].
Furthermore, the groups in the United States and United Kingdom that have been identified as carrying elevated COVID-19 burden, namely Black American, indigenous American, and Black and South Asian British, are quite distinct in their position on the human ancestral tree.
What is shared across these groups is instead a history of disenfranchisement under colonialism and ongoing systematic racism.
A large analysis of over 11,000 COVID-19 patients hospitalized in 92 hospitals across U.S. states revealed that Black patients were younger, more often female, more likely to be on Medicaid, more likely to have comorbidities, and came from neighborhoods identified as more economically deprived than white patients [@doi:10.1001/jamanetworkopen.2020.18039].
This study reported that when these factors were accounted for, the differences in mortality between Black and white patients were no longer significant.
Thus, the current evidence suggests that the apparent correlations between ancestry and health outcomes must be examined in the appropriate social context.

### Environmental Influences on Susceptibility

#### Exposure to COVID-19

Social distancing has emerged as one of the main social policies used to manage the COVID-19 epidemic in many countries.
Many governments issued stay-at-home orders, especially in the initial months of the crisis.
However, data clearly indicates that these orders impacted different socioeconomic groups differently.
In U.S. counties with and without stay-at-home orders, smartphone tracking indicated a significant decrease in the general population's mobility in April relative to February through March of 2020 (-52.3% and -60.8%, respectively) [@doi:10.1101/2020.05.03.20084624].
A linear relationship was observed between counties' reduction in mobility and their wealth and health, as measured by access to health care, food security, income, space, and other factors [@doi:10.1101/2020.05.03.20084624].
Counties with greater reductions in mobility were also found to have much lower child poverty and household crowding and to be more racially segregated, and to have fewer youth and more elderly residents [@doi:10.1101/2020.05.03.20084624].
Similar associations between wealth and decreased mobility were observed in cellphone GPS data from Colombia, Indonesia, and Mexico collected between January and May 2020 [@arXiv:2006.15195], as well as in a very large data set from several US cities [@doi:10.1038/s41586-020-2923-3].
These disparities in mobility are likely to be related to the role that essential workers have played during the pandemic.
Essential workers are disproportionately likely to be female, people of color, immigrants, and to have an income below 200% of the poverty line [@url:https://mronline.org/wp-content/uploads/2020/06/2020-04-Frontline-Workers.pdf].
Black Americans in particular are over-represented among front-line workers and in professions where social distancing is infeasible [@doi:10.1002/ajim.23145].
Health care work in particular presents an increased risk of exposure to SARS-CoV-2 [@doi:10.1002/ajim.23145; @doi:10.1371/journal.pone.0232452; @url:https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregistereduptoandincluding20april2020; @url:https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/articles/whichoccupationshavethehighestpotentialexposuretothecoronaviruscovid19/2020-05-11; @url:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/892085/disparities_review.pdf].
In the United Kingdom, (South) Asians are more likely than their white counterparts to be medical professionals [@url:https://www.ifs.org.uk/inequality/chapter/are-some-ethnic-groups-more-vulnerable-to-covid-19-than-others/], although BAME medical professionals are still disproportionately represented in the proportion of National Health Service staff deaths [@url:https://www.hsj.co.uk/exclusive-deaths-of-nhs-staff-from-covid-19-analysed/7027471.article].
Similar trends have been reported for nurses, especially nurses of color, in the United States [@url:https://act.nationalnursesunited.org/page/-/files/graphics/0920_Covid19_SinsOfOmission_Data_Report.pdf].
Furthermore, beyond the risks associated with work itself, use of public transportation may also impact COVID-19 risk [@url:http://www.nber.org/papers/w27407].
The socioeconomic and racial/ethnic gaps in who is working on the front lines of the pandemic make it clear that socioeconomic privilege is likely to decrease the probability of exposure to SARS-CoV-2.

Increased risk of exposure can also arise outside the workplace.
Nursing homes and skilled nursing facilities received attention early on as high-risk locations for COVID-19 outbreaks [@doi:10.1001/jama.2020.11642].
Prisons and detention centers also confer a high risk of exposure or infection [@doi:10.1001/jamainternmed.2020.1856; @doi:10.1001/jama.2020.12528].
Populations in care facilities are largely older adults, and in the United States, incarcerated people are more likely to be male and persons of color, especially Black [@url:https://www.issuelab.org/resources/695/695.pdf].
Additionally, multi-generational households are less common among non-Hispanic white Americans than people of other racial and ethnic backgrounds [@doi:10.1111/j.1751-9020.2010.00306.x], increasing the risk of exposure for more susceptible family members.
Analysis suggests that household crowding may also be associated with increased risk of COVID-19 exposure [@doi:10.1101/2020.05.03.20084624], and household crowding is associated with poverty [@doi:10.1037/12057-014].
Forms of economic insecurity like housing insecurity, which is associated with poverty and more pronounced in communities subjected to racism [@doi:10.7916/D8WH2W9T; @doi:10.1093/socpro/spv025], would be likely to increase household crowding and other possible sources of exposure.
As a result, facets of systemic inequality such as mass incarceration of Black Americans and poverty are likely to increase the risk of exposure outside of the workplace.

#### Severity of COVID-19 Following Exposure

Following exposure to SARS-CoV-2, the likelihood that an individual develops COVID-19 and the severity of the disease presentation can be influenced by a number of social factors.
As discussed above, a number of patient characteristics are associated with the likelihood of severe COVID-19 symptoms.
In some cases, these trends run counter to those expected given rates of exposure: for example, although women are more likely to be exposed, men are more likely to be diagnosed with, hospitalized from, or die from COVID-19 [@doi:10.1371/journal.ppat.1008570].
In the case of comorbid conditions and racial/ethnic demographics, however, social factors are highly likely to modulate or at least influence the apparent association between these traits and the increased risk from COVID-19.
In particular, the comorbidities and racial/ethnic correlates of severe COVID-19 outcomes suggest that poverty confers additional risk for COVID-19.

In order to explore the relationship between poverty and COVID-19 outcomes, it is necessary to consider how poverty impacts biology.
In particular, we focus on the United States and the United Kingdom.
Comorbidities that increase risk for COVID-19, including obesity, type II diabetes, hypertension, and cardiovascular disease, are known to be intercorrelated [@doi:10/bpp37d].
Metabolic conditions related to heightened inflammation, like obesity, type II diabetes, and hypertension, are more strongly associated with negative COVID-19 outcomes than other comorbid conditions, such as chronic heart disease [@doi:10.2337/dbi19-0023].
As discussed above, dysregulated inflammation characteristic of cytokine release syndrome is one of the greatest concerns for COVID-19-related death.
Therefore, it is possible that chronic inflammation characteristic of these metabolic conditions predisposes patients to COVID-19-related death [@doi:10.2337/dbi19-0023].
The association between these diseases and severe COVID-19 outcomes is a concern from a health equity perspective because poverty exposes people to "obesogenic" conditions [@doi:10/gddg84] and is therefore unsurprisingly associated with higher incidence of obesity and associated disorders [@doi:10.5604/12321966.1120608].
Furthermore, cell phone GPS data suggests that lower socioeconomic status may also be associated with decreased access to healthy food choices during the COVID-19 pandemic [@doi:10.1002/oby.22940; @doi:10.1002/oby.22993], suggesting that health-related risk factors for COVID-19 may be exacerbated as the pandemic continues [@doi:10.1016/j.pcad.2020.07.002].
Chronic inflammation is a known outcome of chronic stress (e.g., [@doi:10.1067/mai.2000.110163; @doi:10.1037/0278-6133.21.6.531; @doi:10.1037/a0025536; @doi:10.1111/j.1467-8721.2006.00450.x]).
Therefore, the chronic stress of poverty is likely to influence health broadly (as summarized in [@doi:10.1038/scientificamerican1205-92]) and especially during the stress of the ongoing pandemic.

A preprint [@doi:10.1101/2020.04.05.20054502] provided observational evidence that geographical areas in the United States that suffer from worse air pollution by fine particulate matter have also suffered more COVID-19 deaths per capita, after adjusting for demographic covariates.
Although lack of individual-level exposure data and the impossibility of randomization make it difficult to elucidate the exact causal mechanism, this finding would be consistent with similar findings for all-cause mortality (e.g., [@doi:10.1073/pnas.1803222115]).
Exposure to air pollution is associated with both poverty (e.g., [@doi:10.3390/ijerph15061114]) and chronic inflammation [@doi:10.1016/j.neubiorev.2018.06.002].
Other outcomes of environmental racism, such as the proximity of abandoned uranium mines to Navajo land, can also cause respiratory illnesses and other health issues [@url:https://journalhosting.ucalgary.ca/index.php/jisd/article/view/70753/54416].
Similarly, preliminary findings indicate that nutritional status (e.g., vitamin D deficiency [@doi:10.1210/clinem/dgaa733]) may be associated with COVID-19 outcomes, and reduced access to grocery stores and fresh food often co-occurs with environmental racism [@url:https://journalhosting.ucalgary.ca/index.php/jisd/article/view/70753/54416; @doi:10.1056/NEJMp2021264].
Taken together, the evidence suggests that low-income workers who face greater exposure to SARS-CoV-2 due to their home or work conditions are also more likely to face environmental and social stressors associated with increased inflammation, and therefore with increased risk from COVID-19.
In particular, structural racism can play an important role on disease severity after SARS-CoV-2 exposure, due to consequences of racism which include an increased likelihood of poverty and its associated food and housing instability.
COVID-19 can thus be considered a "syndemic", or a synergistic interaction between several epidemics [@doi:10.1002/ajhb.23482].
As a result, it is not surprising that people from minoritized backgrounds and/or with certain pre-existing conditions are more likely to suffer severe effects of COVID-19, but these "risk factors" are likely to be causally linked to poverty.

#### Access to Treatment

Finally, COVID-19 outcomes can be influenced by access to healthcare.
Receiving care for COVID-19 can, but does not always, include receiving a positive test for the SARS-CoV-2 virus.
For example, it is common to see treatment guidelines for suspected cases regardless of whether the presence of SARS-CoV-2 has been confirmed (e.g., [@doi:10.1016/j.ajem.2020.03.036]).
Whether and where a patient is diagnosed can depend on their access to testing, which can vary both between and within countries.
In the United States, it is not always clear whether an individual will have access to free testing [@url:https://www.npr.org/sections/health-shots/2020/06/19/880543755/insurers-may-only-pay-for-coronavirus-tests-when-theyre-medically-necessary; @url:https://www.commonwealthfund.org/blog/2020/private-health-insurance-coverage-covid-19-public-health-emergency].
The concern has been raised that more economic privilege is likely to correspond to increased access to testing, at least within the United States [@doi:10.1016/j.jaad.2020.04.046].
This is supported by the fact that African Americans seem to be more likely to be diagnosed in the hospital, while individuals from other groups were more likely to have been diagnosed in ambulatory settings in the community [@doi:10.1377/hlthaff.2020.00598].
Any delays in treatment are a cause for concern [@doi:10.1016/j.jaad.2020.04.046], which could potentially be increased by an inability to acquire testing because in the United States, insurance coverage for care received can depend on a positive test [@url:https://www.hrsa.gov/coviduninsuredclaim/frequently-asked-questions].

Another important question is whether patients with moderate to severe cases are able to access hospital facilities and treatments, to the extent that they have been identified.
Early findings from China as of February 2020 suggested the COVID-19 mortality rate to be much lower in the most developed regions of the country [@doi:10/ggqscd], although reported mortality is generally an estimate of CFR, which is dependent on rates of testing.
Efforts to make treatment accessible for all confirmed and suspected cases of COVID-19 in China are credited with expanding care to people with fewer economic resources [@doi:10.1038/s41591-020-0823-6].
In the United States, access to healthcare varies widely, with certain sectors of the workforce less likely to have health insurance; many essential workers in transportation, food service, and other frontline fields are among those likely to be uninsured or underinsured [@doi:10.1016/j.jaad.2020.04.046].
As of 2018, Hispanic Americans of all races were much less likely to have health insurance than people from non-Hispanic backgrounds [@url:https://www.census.gov/content/dam/Census/library/publications/2019/demo/p60-267.pdf].
Therefore, access to diagnostics and care prior to the development of severe COVID-19 is likely to vary depending on socioeconomic and social factors, many of which overlap with the risks of exposure and of developing more severe COVID-19 symptoms.
This discrepancy ties into concerns about broad infrastructural challenges imposed by COVID-19.
A major concern in many countries has been the saturation of healthcare systems due to the volume of COVID-19 hospitalizations (e.g., [@doi:10.1073/pnas.2004064117]).
Similarly, there have been shortages of supplies such as ventilators that are critical to the survival of many COVID-19 patients, leading to extensive ethical discussions about how to allocate limited resources among patients [@doi:10.19044/esj.2020.v16n21p24; @doi:10.7249/PEA228-1; @arxiv:2008.00374; @doi:10.1016/j.surg.2020.04.044].
Although it is generally considered unethical to consider demographic factors such as age, sex, race, or ethnicity while making such decisions, and ideally this information would not be shared with triage teams tasked with allocating limited resources among patients [@doi:10.1080/15265161.2020.1764137], there are substantial concerns about implicit and explicit biases against older adults [@doi:10.1111/jgs.16539], premature infants [@doi:10.1111/apa.15334], and people with disabilities or comorbidities [@doi:10.1080/15265161.2020.1764138; @doi:10.2105/AJPH.2020.305837; @doi:10.1080/15265161.2020.1764137].
Because of the greater burden of chronic disease in populations subjected to systemic racism, algorithms intended to be blind to race and ethnicity could, in fact, reinforce systemic inequalities caused by structural racism [@doi:10.1080/15265161.2020.1777347; @doi:10.1016/j.jnma.2020.05.010; @doi:10.1056/NEJMp2023616].
Because of this inequality, it has been argued that groups facing health disparities should be prioritized by these algorithms [@doi:10.1080/15265161.2020.1795538].
This approach would carry its own ethical concerns, including the fact that many resources that need to be distributed do not have well-established risks and benefits [@doi:10.1080/15265161.2020.1795538].

As the pandemic has progressed, it has become clear that ICU beds and ventilators are not the only limited resources that needs to be allocated, and, in fact, the survival rate for patients who receive mechanical ventilation is lower than these discussions would suggest [@doi:10.1136/medethics-2020-106460].
Allocation of interventions that may reduce suffering, including palliative care, has become critically important [@doi:10.1136/medethics-2020-106460; @doi:10.1080/15265161.2020.1788663].
The ambiguities surrounding the risks and benefits associated with therapeutics that have been approved under emergency use authorizations also present ethical concerns related to the distribution of resources [@doi:10.1080/15265161.2020.1795538].
For example, remdesivir, discussed above, is currently available for the treatment of COVID-19 under compassionate use guidelines and through expanded access programs, and in many cases has been donated to hospitals by Gilead [@doi:10.1016/j.mayocp.2020.06.016; @doi:10.1080/15265161.2020.1795529].
Regulations guiding the distribution of drugs in situations like these typically do not address how to determine which patients receive them [@doi:10.1080/15265161.2020.1795529].
Prioritizing marginalized groups for treatment with a drug like remdesivir would also be unethical because it would entail disproportionately exposing these groups to a therapeutic that may or not be beneficial [@doi:10.1080/15265161.2020.1795538].
On the other hand, given that the drug is one of the most promising treatments available for many patients, using a framework that tacitly feeds into structural biases would also be unethical.
At present, the report prepared for the Director of the CDC by Ethics Subcommittee of the CDC fails to address the complexity of this ethical question given the state of structural racism in the United States, instead stating that "prioritizing individuals according to their chances for short-term survival also avoids ethically irrelevant considerations, such as race or socioeconomic status" [@url:https://www.cdc.gov/about/advisory/pdf/VentDocument_Release.pdf].
In many cases, experimental therapeutics are made available only through participation in clinical trials [@doi:10.1080/15265161.2020.1795541].
However, given the history of medical trials abusing minority communities, especially Black Americans, there is a history of unequal representation in clinical trial enrollment [@doi:10.1080/15265161.2020.1795541].
As a result, the standard practice of requiring enrollment in a clinical trial in order to receive experimental treatment may also reinforce patterns established by systemic racism.
<!--Risk of comorbid health conditions associated with more severe outcomes may be influenced by long-term damage caused by chronic stress related to traumatic social experiences [@doi:10.1007/s12170-013-0338-5], perhaps mediated by cardiovascular risk factors [@doi:10.1101/2020.05.10.20097253], although the effects of chronic stress have not yet been researched in the specific case of COVID-19 disparities.-->

#### Access to and Representation in Clinical Trials

Experimental treatments are often made available to patients primarily or even exclusively through clinical trials.
The advantage of this approach is that clinical trials are designed to collect rigorous data about the effects of a treatment on patients.
The disadvantage is that access to clinical trials is not equal among all people who suffer from a disease.
Two important considerations that can impact an individual's access to clinical trials are geography and social perceptions of clinical trials.
For the first, the geographic distribution of trial recruitment efforts are typically bounded and can vary widely among difference locations, and for the second, the social context of medical interactions can impact strategies for and the success of outreach to different communities.
Differential access to clinical trials raises concerns because it introduces biases that can influence scientific and medical research on therapeutics and prophylactics broadly.
Concerns about bias in clinical trials need to address both trial recruitment and operation.
In the present crisis, such biases are particularly salient because COVID-19 is a disease of global concern.
Treatment is needed by people all over the world, and clinical research that characterizes treatment outcomes in a variety of populations is critically important.

Global representation in clinical trials is important to ensuring that experimental treatments are available equally to COVID-19 patients who may need them.
The advantage to a patient of participation in a clinical trial is that they may receive an experimental treatment they would not have been able to access otherwise.
The potential downsides of participation include that the efficacy and side effects of such treatments are often poorly characterized and that patients who enroll in clinical trials will in some cases run the risk of being assigned to a placebo condition where they do not receive the treatment but miss out on opportunities to receive other treatments.
The benefits and burdens of clinical trials therefore need to be weighed carefully to ensure that they don't reinforce existing health disparities.
The WHO Director‐General Tedros Adhanom Ghebreyesus stated his condemnation of utilizing low and middle income countries as test subjects for clinical trials, yet having highly developed countries as the majority of clinical trial representation is also not the answer [@doi:10.1002/eahr.500055].
Figure @fig:ebm-map showcases two choropleths detailing COVID-19 clinical trial recruitment by country.
China, the United States, and France are among the countries with the most clinical trial recruiting for trials with single-country enrollment.
Many countries have little to no clinical trial recruiting, with the continents of Africa and South America much less represented than Asia, Europe, and North America.
Trials that recruit across multiple countries do appear to broaden geographic representation, but these trials seem to be heavily dominated by the United States and European Union.

![
**Geographic distribution of COVID-19 clinical trials.**
The density of clinical trials is reported at the country level.
As of November 9, 2020, there are 6,417 trials in the University of Oxford Evidence-Based Medicine Data Lab's COVID-19 TrialsTracker [@doi:10.5281/zenodo.3732709].
The top figure demonstrates the density of trials recruiting only from a singular country, while the bottom shows the distribution of recruitment for trials that involve more than one country.
](https://github.com/greenelab/covid19-review/raw/f91dbd581fcd3ac53f8247db97e52c9c10bcebec/ebmdatalab/ebmdatalab-map.svg "COVID-19 clinical trials"){#fig:ebm-map secno=1}

A few different concerns arise from this skewed geographic representation in clinical trial recruitment.
First, treatments such as remdesivir that are promising but primarily available to clinical trial participants are unlikely to be accessible by people in many countries.
Second, it raises the concern that the findings of clinical trials will be based on participants from many of the wealthiest countries, which may lead to ambiguity in whether the findings can be extrapolated to COVID-19 patients elsewhere.
Especially with the global nature of COVID-19, equitable access to therapeutics and vaccines has been a concern at the forefront of many discussions about policy (e.g., [@doi:10/ggq7mf], yet data like that shown in Figure @fig:ebm-map demonstrates that accessibility is likely to be a significant issue.
Another concern with the heterogeneous international distribution of clinical trials is that the governments of countries leading these clinical trials might prioritize their own populations once vaccines are developed, causing unequal health outcomes [@doi:10.1001/jama.2020.6641].
Additionally, even within a single state in the United States (Maryland), geography was found to influence the likelihood of being recruited into or enrolled in a clinical trial, with patients in under-served rural areas less likely to enroll [@doi:10.1016/j.cdp.2005.12.001].
Thus, geography both on the global and local levels may influence when treatments and vaccines are available and who is able to access them.
Efforts such as the African Union's efforts to coordinate and promote vaccine development [@doi:10/fgzk] are therefore critical to promoting equity in the COVID-19 response.


Even when patients are located within the geographic recruitment area of clinical trials, however, there can still be demographic inequalities in enrollment.
When efforts are made to ensure equal opportunity to participate in clinical trials, there is no significant difference in participation among racial/ethnic groups [@doi:10.1002/cncr.28483].
However, within the United States, real clinical trial recruitment numbers have indicated for many years that racial minorities, especially African-Americans, tend to be under-represented (e.g., [@doi:10.1001/jama.291.22.2720; @doi:10.1245/s10434-007-9500-y; @doi:10.1089/jwh.2010.2469; @doi:10.1007/s11926-018-0728-2]).
This trend is especially concerning given the disproportionate impact of COVID-19 on African-Americans.
Early evidence suggests that the proportion of Black, Latinx, and Native American participants in clinical trials for drugs such as remdesivir is much lower than the representation of these groups among COVID-19 patients [@doi:10.1056/NEJMp2021971].

One proposed explanation for differences among racial and ethnic groups in clinical trial enrollment refers to different experiences in healthcare settings.
While some plausible reasons for the disparity in communication between physicians and patients could be a lack of awareness and education, mistrust in healthcare professionals, and a lack of health insurance [@doi:10.1002/cncr.28483], a major concern is that patients from certain racial and ethnic groups are marginalized even while seeking healthcare.
In the United States, many patients experience "othering" from physicians and other medical professionals due to their race or other external characteristics such as gender (e.g., [@doi:10.1207/S15327027HC1602_7]).
Many studies have sought to characterize implicit biases in healthcare providers and whether they affect their perceptions or treatment of patients.
A systematic review that examined 37 such studies reported that most (31) identified racial and/or ethnic biases in healthcare providers in many different roles, although the evidence about whether these biases translated to different attitudes towards patients was mixed [@doi:10.1016/j.socscimed.2017.05.009], with similar findings reported by a second systematic review [@doi:10.1111/acem.13214].
However, data about real-world patient outcomes are very limited, with most studies relying on clinical vignette-based exercises [@doi:10.1016/j.socscimed.2017.05.009], and other analyses suggest that physician implicit bias could impact the patient's perception of the negativity/positivity of the interaction regardless of the physician's explicit behavior towards the patient [@doi:10.1016/j.jesp.2009.11.004].
Because racism is a common factor in both, negative patient experiences with medical professionals are likely to compound other issues of systemic inequality, such as a lack of access to adequate care, a lack of insurance, or increased exposure to SARS-CoV-2 [@doi:10.1542/peds.2020-003657].
Furthermore, the experience of being othered is not only expected to impact patients' trust in and comfort with their provider, but also may directly impact whether or not the patient is offered the opportunity to participate in a clinical trial at all.
Some studies suggest communication between physicians and patients impacts whether or not a physician offers a patient participation in a clinical trial.
For example, researchers utilized a linguistic analysis to assess mean word count of phrases related to clinical trial enrollment, such as voluntary participation, clinical trial, etc. [@doi:10.1002/cncr.28483].
The data indicated that the mean word count of the entire visit was 1.5 times more for white patients in comparison to Black patients.
In addition, the greatest disparity between white and Black patients' experience was the discussion of risks, with over 2 times as many risk-related words spoken with white patients than Black patients [@doi:10.1002/cncr.28483].
The trends observed for other clinical trials raise the concern that COVID-19 clinical trial information may not be discussed as thoroughly or as often with Black patients compared to white patients.

 These discrepancies are especially concerning given that many COVID-19 treatments are being or are considered being made available to patients prior to FDA approval through Emergency Use Authorizations.
In the past, African-Americans have been over-represented relative to national demographics in use of the FDA's Exception From Informed Consent (EFIC) pathway [@doi:10.1377/hlthaff.2018.0501].
Through this pathway, people who are incapacitated can receive an experimental treatment even if they are not able to consent and there is not sufficient time to seek approval from an authorized representative.
This pathway presents concerns, however, when it is considered in the context of a long history of systematic abuses in medical experimentation where informed consent was not obtained from people of color, such as the Tuskegee syphilis experiments [@doi:10.1067/mem.2003.17].
While the goal of EFIC approval is to provide treatment to patients who urgently need it, the combination of the ongoing legacy of racism in medicine renders this trend concerning.
With COVID-19, efforts to prioritize people who suffer from systemic racism are often designed with the goal of righting some of these inequalities (e.g., [@url:https://www.businessinsider.com/cdc-official-considering-giving-covid-19-vaccine-most-vulnerable-first-2020-10]), but particular attention to informed consent will be imperative in ensuring these trials are ethical given that the benefits and risks of emerging treatments are still poorly characterized.
Making a substantial effort to run inclusive clinical trials is also important because of the possibility that racism could impact how a patient responds to a treatment.
For example, as discussed above, dexamethasone has been identified as a promising treatment for patients experiencing cytokine release syndrome, but the mechanism of action is tied to the stress response.
A study from 2005 reported that Black asthma patients showed reduced responsiveness to dexamethasone in comparison to white patients and suggested Black patients might therefore require higher doses of the drug [@doi:10.1378/chest.127.2.571].
In the context of chronic stress caused by systemic racism, this result is not surprising: chronic stress is associated with dysregulated production of glucocorticoids [@doi:10.1146/annurev.physiol.67.040403.120816] and glucocorticoid receptor resistance [@doi:10.1073/pnas.1118355109].
However, it underscores the critical need for treatment guidelines to take into account differences in life experience, which would be facilitated by the recruitment of patients from a wide range of backgrounds.
Attention to the social aspects of clinical trial enrollment must therefore be an essential component of the medical research community's response to COVID-19.

<!--Table for future version: ### Indirect Effects of the Pandemic
Besides the direct harms caused by infection, many populations are in indirect risk of serious harm due to the social and economic effects of the pandemic and of the efforts needed to fight it.
These might include individuals with substance use disorder [@doi:10.7326/M20-1141], victims of natural disasters [@doi:10.1038/s41558-020-0804-2], and victims of human trafficking [@doi:10.1016/j.eclinm.2020.100409].
The pandemic could also delay the fight against other major infectious diseases, such as HIV, malaria and tuberculosis, potentially leading to a further increase of mortality [@doi:10.25561/78670].
Although they are beyond the scope of this paper, further research is needed in order to prevent these harms.
[There are already some policy recommendations in literature that we cite - we should probably direct folks there. I think we probably want a stronger synthesis and closing than this] -->

### Conclusions and Future Directions

As the COVID-19 pandemic evolves, the scientific community's response will be critical for identifying potential pharmacological and biotechnological developments that may aid in combating the virus and the disease it causes.
However, this global crisis highlights the importance of mounting a response based on collaboration among a wide variety of disciplines.
Understanding the basic science of the virus and its pathogenesis is imperative for identifying and envisioning possible diagnostic and therapeutic approaches; understanding how social factors can influence outcomes and shape implementation of a response is critical to disseminating any scientific advancements.
Summarizing such a complex and ever-changing topic presents a number of challenges.
This review represents the effort of over 50 contributors <!-- TO DO: check with final number -->to distill and interpret the available information.
However, this text represents a dynamic and evolving document, and we welcome continued contributions from all researchers who have insights into how these topics intersect.
A multidisciplinary perspective is critical to understanding this evolving crisis, and in this review we seek to use open science tools to coordinate a response among a variety of researchers.
We intend to publish additional updates as the situation evolves.


## Discussion

As of October 2020 the SARS-CoV-2 virus remains a serious worldwide threat.
The scientific community has responded by rapidly collecting and disseminating information about the SARS-CoV-2 virus and the associated illness, COVID-19.
The rapid identification of the genomic sequence of the virus allowed for early contextualization of SARS-CoV-2 among other known respiratory viruses.
The pathogen is a coronavirus that is closely related to SARS-CoV-1, which caused the SARS pandemics of the early 2000s.
Knowing the phylogenetic context and genomic sequence of the virus then allowed for rapid insights into its structure and pathogenesis.
As with other HCoV, the immune response to SARS-CoV-2 is likely driven by detection of its spike protein, which allows it to enter cells through the ACE2 receptor.
Epithelial cells have also emerged as the major cellular target of the virus, contextualizing the respiratory and gastrointestinal symptoms that are frequently observed in COVID-19.
However, as COVID-19 cases have been more widely characterized, it has become clear that the disease presentation is highly heterogeneous.
Many cases, especially in younger adults, present with mild symptoms or even asymptomatically, while others, especially in older adults, can be severe or fatal.
In children, the SARS-CoV-2 virus can present as two distinct diseases, COVID-19 or MIS-C.
While the overall infection fatality rate remains unknown, estimates suggest that it is not more than 1%; however, the severity of many non-lethal cases makes COVID-19 an ongoing, significant concern.

Characterizing the rate of infection and fatality rates hinges on the availability of rapid and accurate diagnostic testing.
Major advancements have been made in identifying diagnostic approaches.
The development of diagnostic technologies have been rapid, beginning with the release of the SARS-CoV-2 viral genome sequence in January.
As of October 2020, a range of diagnostic tests have become available.
One class of tests uses PCR (RT-PCR or qRT-PCR) to assess the presence of SARS-CoV-2 RNA, while another typically uses ELISA to test for the presence of antibodies to SARS-CoV-2.
The former approach is useful for identifying active infections, while the latter measures hallmarks of the immune response and therefore can detect either active infections or immunity gained from prior infection.
Combining these tests leads to extremely accurate detection of SARS-CoV-2 infection (98.6%), but when used alone, PCR-based tests are recommended before 5.5 days after the onset of the illness and antibody tests after 5.5 days [@doi:10.1001/jama.2020.8259].
Other strategies for testing can also influence the tests' accuracy, such as the use of nasopharyngeal swabs versus BALF [@doi:10.1001/jama.2020.8259], which allow for trade-offs between patient's comfort and test sensitivity.
Additionally, technologies such as digital PCR may allow for scale-up in the throughput of diagnostic testing, facilitating widespread testing.
One major question that remains is whether people who recover from SARS-CoV-2 develop sustained immunity, and over what period this immunity is expected to last.
Some reports have suggested that some patients may develop COVID-19 reinfections (e.g., [@doi:10/ghfgkt]), but the rates of reinfection are currently unknown.
Serologic testing combined with PCR testing will be critical to confirming purported cases of reinfection and to identifying the duration over which immunity is retained and to understanding reinfection risks.

One of the goals of characterizing the immune response is to identify strategies for the prophylactic enhancements of immunity.
Though some concerns remain about the duration of sustained immunity for convalescents, vaccine development efforts are ongoing and show initial promising results.
The Moderna trial, for example, reported that the neutralizing activity in participants who received two doses of the vaccine was similar to that observed in convalescent plasma.
Vaccine development for COVID-19 is progressing rapidly compared to typical timelines, but vaccine development is still a lengthy process.
In the meantime, some advances have also been made in the treatment of patients with COVID-19.
As cases have become better characterized, it has become evident that many patients experience an initial immune response to the virus that is typically characterized by fever, cough, dyspnea, and related symptoms.
However, the most serious concern is cytokine release syndrome, when the body's immune response becomes dysregulated, resulting in an extreme inflammatory response.
The RECOVERY trial, a large-scale, multi-arm trial enrolling about 15% of all COVID-19 patients in the United Kingdom, was the first to identify that the widely available steroid dexamethasone seems to be beneficial for patients suffering from this immune dysregulation [@doi:10.1101/2020.06.22.20137273].
Efforts to identify therapeutic treatments to treat patients early in the course of infection have been more ambiguous.
Early interest in the drugs hydroxychloroquine and chloroquine yielded no promising results from studies with robust experimental designs.
The experimental drug remdesivir, which was developed for Ebola, has received enough support from early analyses to receive FDA approval, but results have been mixed.
The potential for other drugs, such as tocilizumab, to reduce recovery time remains unclear, but some early results were promising.

### Additional Therapeutics of Interest

Given what is currently known about these therapeutics for COVID-19, a number of related therapies beyond those explored above may also prove to be of interest.
For example, the demonstrated benefit of dexamethasone and the ongoing potential of tocilizumab for treatment of COVID-19 suggests that other anti-inflammatory agents might also hold value for the treatment of COVID-19.
Given that current evidence about treating COVID-19 with dexamethasone suggests that the need to curtail the cytokine storm inflammatory response to the virus can transcend the risks of immunosuppression, exploration of more anti-inflammatory agents may be warranted.
While dexamethasone is considered widely available and generally affordable, the high costs of biologics such as tocilizumab therapy may present obstacles to wide-scale distribution of this drug if it proves of value.
At the doses used for rheumatoid arthritis patients, the cost for tocilizumab ranges from $179.20 to $896 per dose for the IV form and $355 for the pre-filled syringe [@url:https://www.ncbi.nlm.nih.gov/books/NBK349513/table/T43/].
There are several anti-inflammatory agents used for the treatment of autoimmune diseases that may also be able to counter the effects of the cytokine storm induced by the virus, some of which, such as cyclosporine, are likely to be more cost-effective and readily available than biologics [@url:https://escholarship.umassmed.edu/meyers_pp/385].
While tocilizumab targets IL-6, several other inflammatory markers could be potential targets, including TNF-alpha.
Inhibition of TNF-alpha by an inhibitor such as Etanercept has been previously suggested for treatment of SARS-CoV-1 [@doi:10.1185/030079903125002757] and may be relevant for SARS-CoV-2 as well.
Another anti-IL-6 antibody, sarilumab, is also being investigated [@url:http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19; @clinicaltrials:NCT04327388].
Baricitinib and other small molecule inhibitors of the Janus-activated kinase pathway also curtail the inflammatory response and have been suggested as potential options for SARS-CoV-2 infections [@doi:10/dph5].
Baricitinib in particular may be able to reduce the ability of SARS-CoV-2 to infect lung cells [@doi:10/ggnrsx].
Clinical trials studying baricitinib in COVID-19 have already begun in the US and in Italy [@url:https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testing-therapies-covid-19; @clinicaltrials:NCT04320277].
Identification and targeting of further inflammatory markers that are relevant in SARS-CoV-2 infection may be of value for curtailing the inflammatory response and lung damage.

In addition to immunosuppressive treatments that are most beneficial late in disease progression, much research is focused on identifying treatments would be likely to benefit early-stage patients.
For example, although studies of hydroxychloroquine have not supported the early theory-driven interest in this antiviral treatment, alternative compounds with related mechanisms may still have potential.
Hydroxyferroquine derivatives of HCQ have been described as a class of bioorganometallic compounds that exert antiviral effects with some selectivity for SARS-CoV-1 _in vitro_ [@doi:10.1021/jm0601856].
Future work could explore whether such compounds exert antiviral effects against SARS-CoV-2 and whether they would be safer for use in COVID-19.
Another potential approach is the development of antivirals, which could be broad-spectrum, specific to coronaviruses, or targeted to SARS-CoV-2.
Development of new antivirals is complicated by the fact that none have yet been approved for human coronaviruses.
Intriguing new options are emerging, however.
Beta-D-N4-hydroxycytidine (NHC) is an orally bioavailable ribonucleotide analog showing broad-spectrum activity against RNA viruses, which may inhibit SARS-CoV-2 replication _in vitro_ and _in vivo_ in mouse models of HCoVs [@doi:10.1126/scitranslmed.abb5883].
A range of other antivirals are also in development.
Development of antivirals will be further facilitated as research reveals more information about the interaction of SARS-CoV-2 with the host cell and host cell genome, mechanisms of viral replication, mechanisms of viral assembly, and mechanisms of viral release to other cells; this can allow researchers to target specific stages and structures of the viral life cycle.
Many researchers have also focused their attention to the potential use of dietary supplements and nutraceuticals.
Indeed, there has been recent interest for the potential use of vitamin D as a prophylactic and therapeutic agent against COVID-19 as several observational studies have linked low vitamin D status to its incidence [@doi:10.1111/joim.13149; @doi:10.1001/jamanetworkopen.2020.19722]. 
These associations have yet to be confirmed and rigorous trials are required before considering supplementation recommendations.
However, the nutritional status and general health of a patient can affect their outcomes in various diseases, thus it would be pertinent to advise people to follow a healthy diet and life style to the best of their ability to prevent nutrient deficiencies and insufficiencies and to maintain a healthy immune system [@doi:10.1093/advances/nmaa125].
Finally, antibodies against viruses, also known as antiviral monoclonal antibodies, could be an alternative as well and are described in detail in an above section.
The goal of antiviral antibodies is to neutralize viruses through either cell-killing activity or blocking of viral replication [@doi:10.1016/j.tim.2015.07.005].
They may also engage the host immune response, encouraging the immune system to hone in on the virus.
Given the cytokine storm that results from immune system activation in response to the virus, which has been implicated in worsening of the disease, a neutralizing antibody (nAb) may be preferable.
Upcoming work may explore the specificity of nAbs for their target, mechanisms by which the nAbs impede the virus, and improvements to antibody structure that may enhance the ability of the antibody to block viral activity.

Some research is also investigating potential therapeutics and prophylactics that would interact with components of the innate immune response.
For example, there are a variety of TLRs, PRRs that recognize PAMPs and DAMPs.
TLRs form a part of innate immune recognition and can more generally contribute to promoting both innate and adaptive responses [@ISBN:9780815332183].
In mouse models, poly(I:C) and CpG, which are agonists of toll-like receptors TLR3 and TLR9, respectively, showed protective effects when administered prior to SARS-CoV-1 infection [@doi:10.1128/JVI.01410-12].
Therefore, TLR agonists hold some potential for broad-spectrum prophylaxis.

Given that a large number of clinical trials are currently in progress, more information about the potential of these and other therapeutics should become available over time.
This information, combined with advances in understanding the molecular structure and viral pathogenesis of SARS-CoV-2, may lead to a more complete understanding of how the virus affects the human host and what strategies can improve outcomes.
To date, investigations of potential therapeutics for COVID-19 have focused primarily on repurposing existing drugs.
This approach is necessary given the urgency of the situation as well as the extensive time required for developing and testing new therapies.
However, in the long-term, new drugs specific for treatment of COVID-19 may also enter development.
Development of novel drugs is likely to be guided by what is known about the pathogenesis and molecular structure of SARS-CoV-2.
For example, understanding the various structural components of SARS-CoV-2 may allow for the development of small molecule inhibitors of those components.
Currently, crystal structures of the SARS-CoV-2 main protease have recently been resolved [@doi:10.1038/s41586-020-2223-y; @url:https://www.diamond.ac.uk/covid-19/for-scientists/Main-protease-structure-and-XChem.html], and efforts are already in place to perform screens for small molecule inhibitors of the main protease, which have yielded potential hits [@doi:10.1038/s41586-020-2223-y].
Much work remains to be done to determine further crystal structures of other viral components, understand the relative utility of targeting different viral components, perform additional small molecule inhibitor screens, and determine the safety and efficacy of the potential inhibitors.
While still nascent, work in this area is promising.
Over the longer term, this approach and others may lead to the development of novel therapeutics specifically for COVID-19 and SARS-CoV-2.



## Application of an Open Publishing Framework to an Emerging Public health Crisis

### Abstract

### Introduction

As international attention remains focused on the ongoing public health crisis, the scientific community has responded by mobilizing resources and turning much of its attention to the virus and disease.
This rapid influx of information is disseminated by traditional publishing mechanisms, preprint servers, and press releases, which provide a venue for scientists to release findings without undergoing the formal publication process.
While having information available is valuable to efforts to understand and combat COVID-19, many contributions come from researchers across a wide range of fields who have varying degrees of experience working on coronaviruses and related topics.
The volume of information available, much of which has not gone through rigorous peer review, presents a significant challenge to individual efforts to keep abreast of the state of COVID-19 research [@doi:10.1038/s42254-020-0175-7].
However, research on these topics is proceeding so rapidly that any static review is likely to quickly become dated.
Our goal as a community is to consolidate information about the virus in the context of related viruses and to synthesize rapidly emerging literature centered on the diagnosis and treatment of COVID-19.
We used an open publishing framework, Manubot [@doi:10.1371/journal.pcbi.1007128], to manage hundreds of contributions from the community to create a living, scholarly document.
We designed software to generate figures that automatically update using external data sources. <!-- TODO: replace figure reference with manuscript reference or reference figure conditionally based on template variable [, such as Figure @fig:csse-deaths,] -->
Our primary goal is to sort and distill informative content out of the overwhelming flood of information [@doi:10.1038/s42254-020-0175-7] and help the broader scientific community become more conversant on this critical subject.
Thus, our approach has been to develop a real-time, collaborative effort that welcomes submissions from scientists worldwide into this ongoing effort.
This document represents the first snapshot, which aims to reflect the state of the field as of October, 2020.
We plan to refine and expand this document until technologies to mitigate the pandemic are widely available.

In an effort to keep pace as new information about COVID-19 and SARS-CoV-2 becomes available, this project is an open, collaborative effort that invited contributions from the scientific community broadly, similar to previous efforts to develop collaborative reviews [@doi:10.1098/rsif.2017.0387; @url:https://greenelab.github.io/deep-review].
Contributors were recruited by word of mouth and on Twitter.
Existing efforts to train early-career scientists were also integrated: Appendix A contains summaries written by the students, post-docs, and faculty of the Immunology Institute at the Mount Sinai School of Medicine [@url:https://github.com/ismms-himc/covid-19_sinai_reviews; @doi:10.1038/s41577-020-0319-0], and two of the authors were recruited through the American Physician Scientist Association's Virtual Summer Research Program [@url:https://www.physicianscientists.org/page/summer-research-pilot-program].
The project was managed through GitHub [@url:https://github.com/greenelab/covid19-review] using Manubot [@doi:10.1371/journal.pcbi.1007128] to continuously generate a version of the manuscript online [@url:https://greenelab.github.io/covid19-review].
Contributors developed text that was proposed through GitHub's pull request system and then reviewed and approved by at least one other author.
While this document reflects the current version of record, the online version will continue to be developed as information about the pandemic emerges.
Below, we will describe the processes used to synthesize the literature.

### Technical Infrastructure

#### Collaborative Writing and Manuscript Generation

Manubot [@doi:10.1371/journal.pcbi.1007128] is a collaborative framework developed to adapt open-source software development techniques and version control for manuscript writing.
Here, Manubot was used to generate a manuscript from text maintained using GitHub, a popular, online version control interface.
The GitHub implementation allowed users to contribute either using git on the command line or using the GitHub user interface, and we developed documentation for users with less experience with this platform.
Manubot also provides a functionality to create a bibliography using digital object identifiers (DOIs), website URLs, or other identifiers such as PubMed identifiers and arXiv IDs.
Due to the needs of this project, project contributors also implemented new features in Manubot and [Zotero](https://www.zotero.org/), which Manubot uses to extract metadata for some types of citations.
These features support directly citing clinical trial identifiers such as `clinicaltrials:NCT04292899` [@clinicaltrials:NCT04292899] and generating the complete review manuscript along with the individual manuscripts reviewing specific topics. <!-- TODO: reference individual manuscripts -->
Finally, Manubot and GitHub Actions continuous integration allowed for scripted updates to be run each time the manuscript was generated.
These scripts were used to check that the manuscript was built correctly, run spellchecking, and cross-reference the manuscripts cited in this review, summarized in Appendix A, and discussed in the project's issues and pull requests.

#### Data Analysis and Visualization

The combination of Manubot and GitHub Actions also made it possible to dynamically update information such as statistics and visualizations in the manuscript.
Data about worldwide cases and deaths from the COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University [@https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series] were read using a Python script. <!-- TODO: replace figure reference with manuscript reference or reference figure conditionally based on template variable [to generate Figure @fig:csse-deaths.] -->
Similarly, the clinical trials statistics and figure were generated based on data from the University of Oxford Evidence-Based Medicine Data Lab's COVID-19 TrialsTracker [@doi:10.5281/zenodo.3732709]. <!-- TODO: replace figure reference with manuscript reference or reference figure conditionally based on template variable [Figure @fig:ebm-trials] -->
In both cases, frequency data were plotted using Matplotlib [@doi:10.1109/MCSE.2007.55] in Python.
The figure showing the geographic distribution of COVID-19 clinical trials was generated using the countries associated with the trials listed in the COVID-19 TrialsTracker, converting the country names to 3-letter ISO codes using pycountry or manual adjustment when necessary, and visualizing the geographic distribution of trial recruitment using geopandas. <!-- TODO: replace figure reference with manuscript reference or reference figure conditionally based on template variable [Figure @fig:ebm-map] -->

GitHub Actions runs a nightly workflow to update these external data and regenerate the statistics and figures for the manuscript.
The workflow uses the GitHub API to detect and save the latest commit of the external data sources, which are both GitHub repositories.
It then downloads versioned data from that snapshot of the external repositories and runs bash and Python scripts to calculate the desired statistics and produce the summary figures.
The statistics are stored in JSON files that are accessed by Manubot to populate the values of placeholder template variables dynamically every time the manuscript is built.
For instance, the template variable `{{ebm_trials_results}}` in the manuscript is replaced by the actual number of clinical trials with results, 168.
The template variables also include versioned URLs to the dynamically updated figures.
The JSON files and figures are stored in the `external-resources` branch of the manuscript's GitHub repository, which acts as versioned storage.
The GitHub Actions workflow automatically adds and commits the new JSON files and figures to the `external-resources` branch every time it runs, and Manubot uses the latest version of these resources when it builds the manuscript.

The workflow file is available from <https://github.com/greenelab/covid19-review/blob/master/.github/workflows/update-external-resources.yaml> and the scripts are available from <https://github.com/greenelab/covid19-review/tree/external-resources>.
The Python package versions are available in <https://github.com/greenelab/covid19-review/blob/external-resources/environment.yml>.
<!-- These files are archived with [Software Heritage](...). -->

### Article Selection and Evaluation

Relevant articles were identified and submitted as issues on [GitHub](https://github.com/greenelab/covid19-review) for review.
Articles were classified as _diagnostic_, _therapeutic_, or _other_, and a template was developed to guide the review of papers and preprints in each category.
Following a framework often used for assessing medical literature, the review consisted of examining methods used in each relevant article, assignment (whether the study was observational or randomized), assessment, results, interpretation, and how well the study extrapolates [@doi:10.5014/ajot.60.4.367].
For examples of each template, please see Appendices B-D.

#### Diagnostic Papers

##### Methods

Reviewers began by describing the study question(s) being investigated by the article.
They then described the study population, the sample size, the prevalence of the disease in the study population, countries / regions considered in case of human subjects, demographics of participants, the setting, and any remaining inclusion / exclusion criteria considered.
They then described the reference test or "gold standard," if one was utilized.

##### Assignment

Reviewers described how new and reference tests were assigned, including additional relevant details about the study design.
For example, reviewers were asked whether the diagnostic test resulted in rigorous assignments of case status or was biased towards sicker or healthier individuals.

##### Assessment

Reviewers described how the test was performed.
For example, for both standard and reference tests, reviewers described technical details of assays used, when measurements were taken and by whom.
Subsequently, they described how individuals were classified as positive or negative cases and whether results were precise and reproducible with repeated tests.
Reviewers described whether there were any missing data, whether some participants underwent only one test, or whether there were individuals with inconclusive results.

##### Results

Reviewers reported the estimated sensitivity, specificity, positive predictive value (PPV), and negative predicted value (NPV), as well as confidence bounds around these measures, if provided.

##### Interpretation

Reviewers reported how well the test ruled in or ruled out disease based on the population, if there were identified side effects, and patient adherence.

##### Extrapolation

Reviewers described how well this test will extrapolate outside the measured population.

#### Therapeutic Papers

##### Methods

Reviewers began by describing the study question(s) being investigated by the article.
They then described the study population, the sample size, the prevalence of the disease in the study population, countries / regions considered in case of human subjects, demographics of participants, the setting, and any remaining inclusion / exclusion criteria considered.

##### Assignment

Reviewers described how the treatment is assigned, whether it was an interventional or observational study, whether randomization took place, etc.

##### Assessment

###### Outcome Assessment

Reviewers described the outcome that was assessed and evaluated whether it was appropriate given the underlying study question.
They described whether there were any missing data such as whether there were individuals lost to follow up.
They then describe whether there were any potential sources of bias such as lack of blinding in a randomized controlled trial.

###### Statistical Methods Assessment

Reviewers described which statistical methods were used for inference and whether applied methods were appropriate for the study.
They then described whether adjustments were made for possible confounders.

##### Results

Reviewers described the estimated association between the treatment and outcome.
They described measures of confidence or statistical significance, if provided.

##### Interpretation

Reviewers described whether a causal claim could be made.
They described whether any side effects or interactions with other drugs were identified, as well as any subgroup findings.

##### Extrapolation

Reviewers describe how the study may extrapolate to a different species or population.

### Conclusions

![**Summary of the relationships among topics covered in this review.**](images/N000-overview.png){#fig:overview secno=1}

Several review articles on aspects of COVID-19 have already been published.
These have included reviews on the disease epidemiology [@doi:10.1016/j.molmed.2020.02.008], immunological response [@doi:10.1016/j.immuni.2020.05.002], diagnostics [@doi:10.1126/scitranslmed.abc1931], and pharmacological treatments [@doi:10.1016/j.immuni.2020.05.002; @doi:10.1001/jama.2020.6019].
Others [@doi:10.1038/d41591-020-00026-w; @doi:10.1001/jama.2020.12839] provide narrative reviews of progress on some important ongoing COVID-19 research questions.
With the worldwide scientific community uniting during 2020 to investigate SARS-CoV-2 and COVID-19 from a wide range of perspectives, findings from many disciplines are relevant on a rapid timescale to a broad scientific audience.
Additionally, many findings are published as preprints, which are available prior to going through the peer review process.
As a result, centralizing, summarizing, and critiquing new literature broadly relevant to COVID-19 can help to expedite the interdisciplinary scientific process that is currently happening at an advanced pace.
We are particularly interested in providing background to the development of diagnostic, prophylactic, and therapeutic approaches to COVID-19.
Two major concerns within diagnosis include the detection of current infections in individuals with and without symptoms, and the detection of past exposure without an active infection.
In the latter category, identifying whether individuals can develop or have developed sustained immunity is also a major consideration.
The development of high-throughput, affordable methods for detecting active infections and sustained immunity will be critical to understanding and controlling the disease.
The identification of interventions that can mitigate the effect of the virus on exposed and infected individuals is a significant research priority.
Some possible approaches include the identification of existing pharmaceuticals that reduce the severity of infection, either by reducing the virus' virulence (e.g., antivirals) or managing the most severe symptoms of infection.
Due to the long timeline for the development of novel pharmaceuticals, in most cases, research surrounding possible pharmaceutical interventions focuses on the identification and investigation of existing compounds whose mechanisms may be relevant to COVID-19.
Other foci of current research include the identification of antibodies produced by survivors of COVID-19 and the development of vaccines.
Understanding the mechanisms describing host-virus interactions between humans and SARS-CoV-2 is thus critical to identifying candidate therapeutics.
An overview of the topics covered is visualized in Figure @fig:overview.
Thus, in this review, we seek to consolidate information about efforts to develop strategies for diagnosis and therapeutics as new information is released by the scientific community.
We include information from both traditional peer-reviewed scientific literature and from preprints, which typically have not undergone peer review but have been critically evaluated by the scientists involved in this effort.
The goal of this manuscript is to present preliminary findings within the broader context of COVID-19 research and to identify the broad interpretations of new research, as well as limitations to interpretability.


## Additional Items {.page_break_before} 

### Competing Interests

|Author|Competing Interests|Last Reviewed|
|---|---|---|
|Halie M. Rando|None|2021-01-20|
|Casey S. Greene|None|2021-01-20|
|Michael P. Robson|None|2020-11-12|
|Simina M. Boca|None|2020-11-07|
|Nils Wellhausen|None|2020-11-03|
|Ronan Lordan|None|2020-11-03|
|Christian Brueffer|Employee and shareholder of SAGA Diagnostics AB.|2020-11-11|
|Sandipan Ray|None|2020-11-11|
|Lucy D\'Agostino McGowan|Received consulting fees from Acelity and Sanofi in the past five years|2020-11-10|
|Anthony Gitter|Filed a patent application with the Wisconsin Alumni Research Foundation related to classifying activated T cells|2020-11-10|
|Anna Ada Dattoli|None|2020-03-26|
|Ryan Velazquez|None|2020-11-10|
|John P. Barton|None|2020-11-11|
|Jeffrey M. Field|None|2020-11-12|
|Bharath Ramsundar|None|2020-11-11|
|Adam L. MacLean|None|2020-11-11|
|Alexandra J. Lee|None|2020-11-09|
|Immunology Institute of the Icahn School of Medicine|None|2020-04-07|
|Fengling Hu|None|2020-04-08|
|Nafisa M. Jadavji|None|2020-11-11|
|Elizabeth Sell|None|2020-11-11|
|Jinhui Wang|None|2021-01-21|
|Diane N. Rafizadeh|None|2020-11-11|
|Ashwin N. Skelly|None|2020-11-11|
|Marouen Ben Guebila|None|2020-11-11|
|Likhitha Kolla|None|2020-11-16|
|David Manheim|None|2020-11-11|
|Soumita Ghosh|None|2020-11-09|
|James Brian Byrd|Funded by FastGrants to conduct a COVID-19-related clinical trial|2020-11-12|
|YoSon Park|Now employed by Pfizer (subsequent to contributions to this project)|2020-01-22|
|Vikas Bansal|None|2021-01-25|
|Stephen Capone|None|2020-11-11|
|John J. Dziak|None|2020-11-11|
|Yuchen Sun|None|2020-11-11|
|Yanjun Qi|None|2020-07-09|
|Lamonica Shinholster|None|2020-11-11|
|Temitayo Lukan|None|2020-11-10|
|Sergey Knyazev|None|2020-11-11|
|Dimitri Perrin|None|2020-11-11|
|Serghei Mangul|None|2020-11-11|
|Shikta Das|None|2020-08-13|
|Gregory L Szeto|None|2020-11-16|
|Tiago Lubiana|None|2020-11-11|
|David Mai|None|2021-01-08|
|COVID-19 Review Consortium|None|2021-01-16|
|Rishi Raj Goel|None|2021-01-20|

### Author Contributions

|Author|Contributions|
|---|---|
|Halie M. Rando|A, D, E, Project Administration, Writing - Original Draft, Writing - Review & Editing|
|Casey S. Greene|Conceptualization, Project Administration, Software, Supervision, Writing - Review & Editing|
|Michael P. Robson|Software|
|Simina M. Boca|Writing - Review & Editing|
|Nils Wellhausen|Visualization, Writing - Original Draft, Writing - Review & Editing|
|Ronan Lordan|Conceptualization, Project Administration, Writing - Original Draft, Writing - Review & Editing|
|Christian Brueffer|Writing - Original Draft, Writing - Review & Editing|
|Sandipan Ray|Writing - Original Draft, Writing - Review & Editing|
|Lucy D\'Agostino McGowan|Writing - Original Draft, Writing - Review & Editing|
|Anthony Gitter|Methodology, Project Administration, Software, Writing - Review & Editing|
|Anna Ada Dattoli|Writing - Original Draft|
|Ryan Velazquez|Writing - Review & Editing|
|John P. Barton|Writing - Original Draft, Writing - Review & Editing|
|Jeffrey M. Field|Writing - Original Draft|
|Bharath Ramsundar|Investigation, Writing - Review & Editing|
|Adam L. MacLean|Writing - Original Draft, Writing - Review & Editing|
|Alexandra J. Lee|Writing - Original Draft, Writing - Review & Editing|
|Immunology Institute of the Icahn School of Medicine|Data Curation|
|Fengling Hu|Writing - Original Draft, Writing - Review & Editing|
|Nafisa M. Jadavji|Writing - Original Draft, Writing - Review & Editing|
|Elizabeth Sell|Writing - Original Draft, Writing - Review & Editing|
|Jinhui Wang|Writing - Review & Editing|
|Diane N. Rafizadeh|Writing - Original Draft, Writing - Review & Editing|
|Ashwin N. Skelly|Writing - Original Draft, Writing - Review & Editing|
|Marouen Ben Guebila|Writing - Original Draft, Writing - Review & Editing|
|Likhitha Kolla|Writing - Original Draft|
|David Manheim|Investigation, Writing - Original Draft|
|Soumita Ghosh|Writing - Original Draft|
|James Brian Byrd|Writing - Original Draft, Writing - Review & Editing|
|YoSon Park|Writing - Original Draft, Writing - Review & Editing|
|Vikas Bansal|Writing - Original Draft, Writing - Review & Editing|
|Stephen Capone|Writing - Original Draft, Writing - Review & Editing|
|John J. Dziak|Writing - Original Draft, Writing - Review & Editing|
|Yuchen Sun|Visualization|
|Yanjun Qi|Visualization|
|Lamonica Shinholster|Writing - Original Draft|
|Temitayo Lukan|Investigation, Writing - Original Draft|
|Sergey Knyazev|Writing - Original Draft, Writing - Review & Editing|
|Dimitri Perrin|Writing - Original Draft, Writing - Review & Editing|
|Serghei Mangul|Writing - Review & Editing|
|Shikta Das|Writing - Review & Editing|
|Gregory L Szeto|Writing - Review & Editing|
|Tiago Lubiana|Writing - Review & Editing|
|David Mai|Writing - Original Draft, Writing - Review & Editing|
|COVID-19 Review Consortium|Project Administration|
|Rishi Raj Goel|Writing - Original Draft, Writing - Review & Editing|

### Acknowledgements

We thank Nick DeVito for assistance with the Evidence-Based Medicine Data Lab COVID-19 TrialsTracker data and Vincent Rubinetti and Daniel Himmelstein for feedback on and support with Manubot.
We thank Yael Evelyn Marshall who contributed writing (original draft) as well as reviewing and editing of pieces of the text but who did not formally approve the manuscript, as well as Ronnie Russell, who contributed text to and helped develop the structure of the manuscript early in the writing process and Matthias Fax who helped with writing and editing text related to diagnostics.
We are grateful to the following contributors for reviewing pieces of the text: Nadia Danilova, James Eberwine and Ipsita Krishnan.


## References {.page_break_before}

<!-- Explicitly insert bibliography here -->
<div id="refs"></div>

<!-- Define citation tags below -->
[@tag:Park2020_distancing]: url:https://github.com/parksw3/Korea-analysis/blob/master/v1/korea.pdf
[@synairgen-SNG001]: https://www.synairgen.com/wp-content/uploads/2020/03/200318-Synairgen-to-start-trial-of-SNG001-in-COVID-19-imminently-.pdf


## Appendix A {.page_break_before}

This appendix contains reviews produced by the Immunology Institute of the Icahn School of Medicine


<!-- Appendix source: https://github.com/ismms-himc/covid-19_sinai_reviews/tree/05d387bf10b829dad6bedb4bf313686750b78cc9 -->

### Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Tian et al. *Emerg Microbes Infect 2020* [@doi:10.1101/2020.01.28.923011]

#### Keywords

- Monoclonal antibody
- Cross-reactivity
- receptor binding domain

#### Summary

Considering the relatively high identity of the receptor binding domain
(RBD) of the spike proteins from 2019-nCoV and SARS-CoV (73%), this
study aims to assess the cross-reactivity of several anti-SARS-CoV
monoclonal antibodies with 2019-nCoV. The results showed that the
SARS-CoV-specific antibody CR3022 can potently bind 2019-nCoV RBD.

#### Main Findings

The structure of the 2019-nCoV spike RBD and its conformation in complex
with the receptor angiotensin-converting enzyme (ACE2) was modeled *in
silico* and compared with the SARS-CoV RBD structure. The models
predicted very similar RBD-ACE2 interactions for both viruses. The
binding capacity of representative SARS-CoV-RBD specific monoclonal
antibodies (m396, CR3014, and CR3022) to recombinant 2019-nCoV RBD was
then investigated by ELISA and their binding kinetics studied using
biolayer interferometry. The analysis showed that only CR3022 was able
to bind 2019-nCoV RBD with high affinity (KD of 6.3 nM), however it did
not interfere with ACE2 binding. Antibodies m396 and CR3014, which
target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike
protein.

#### Limitations

The 2019-nCoV RBD largely differ from the SARS-CoV at the C-terminus
residues, which drastically impact the cross-reactivity of antibodies
described for other B beta-coronaviruses, including SARS-CoV. This study
claims that CR3022 antibody could be a potential candidate for therapy.
However, none of the antibodies assayed in this work showed
cross-reactivity with the ACE2 binding site of 2019-nCoV, essential for
the replication of this virus. Furthermore, neutralization assays with
2019-nCoV virus or pseudovirus were not performed. Although the use of
neutralizing antibodies is an interesting approach, these results
suggest that it is critical the development of novel monoclonal
antibodies able to specifically bind 2019-nCoV spike protein.

#### Credit

*Review by D.L.O as part of a project by students, postdocs and faculty
at the Immunology Institute of the Icahn School of Medicine, Mount
Sinai.*


### Integrative Bioinformatics Analysis Provides Insight into the Molecular Mechanisms of 2019-nCoV

He et al. *medRxiv* [@doi:10.1101/2020.02.03.20020206]

#### Keywords

- ACE2
- lungs
- smoking
- COPD
- asthma
- SARS-Cov
- IL-1
- IL-10
- IL-6
- IL-8

#### Main Findings

The authors used bioinformatics tools to identify features
of ACE2 expression in the lungs of different patent groups: healthy,
smokers, patients with chronic airway disease (i.e., COPD) or asthma.
They used gene expression data publicly available from GEO that included
lung tissues, bronchoalveolar lavage, bronchial epithelial cells, small
airway epithelial cells, or SARS-Cov infected cells.

The authors describe no significant differences in ACE2 expression in
lung tissues of Healthy, COPD, and Asthma groups (p=0.85); or in BAL of
Healthy and COPD (p=0.48); or in epithelial brushings of Healthy and
Mild/Moderate/Severe Asthma (p=0.99). ACE2 was higher in the small
airway epithelium of long-term smokers vs non-smokers (p&lt;0.001).
Consistently, there was a trend of higher ACE2 expression in the
bronchial airway epithelial cells 24h post-acute smoking exposure
(p=0.073). Increasing ACE2 expression at 24h and 48h compared to 12h
post SARS-Cov infection (p=0.026; n=3 at each time point) was also
detected.

15 lung samples’ data from healthy participants were separated into high
and low ACE2 expression groups. “High” ACE2 expression was associated
with the following GO pathways: innate and adaptive immune responses, B
cell mediated immunity, cytokine secretion, and IL-1, IL-10, IL-6, IL-8
cytokines. The authors speculate that a high basal ACE2 expression will
increase susceptibility to SARS-CoV infection.

In 3 samples SARS-Cov infection was associated with IL-1, IL-10 and IL-6
cytokine production (GO pathways) at 24h. And later, at 48h, with T-cell
activation and T-cell cytokine production. It is unclear whether those
changes were statistically significant.

The authors describe a time course quantification of immune infiltrates
in epithelial cells infected with SARS-Cov infection. They state that in
healthy donors ACE2 expression did not correlate with the immune cell
infiltration. However, in SARS-Cov samples, at 48h they found that ACE2
correlated with neutrophils, NK-, Th17-, Th2-, Th1- cells, and DCs.
Again, while authors claim significance, the corresponding correlation
coefficients and p-values are not presented in the text or figures. In
addition, the source of the data for this analysis is not clear.

Using network analysis, proteins SRC, FN1, MAPK3, LYN, MBP, NLRC4, NLRP1
and PRKCD were found to be central (Hub proteins) in the regulating
network of cytokine secretion after coronavirus infection. Authors
conclude this indicates that these molecules were critically important
in ACE2-induced inflammatory response. Additionally, authors speculate
that the increased expression of ACE2 affected RPS3 and SRC, which were
the two hub genes involved in viral replication and inflammatory
response.

#### Limitations

The methods section is very limited and does not
describe any of the statistical analyses; and description of the
construction of the regulatory protein networks is also limited. For the
findings in Figures 2 authors claim significance, which is not supported
by p-values or coefficients. For the sample selection, would be useful
if sample sizes and some of the patients’ demographics (e.g. age) were
described.

For the analysis of high vs low ACE2 expression in healthy subjects, it
is not clear what was the cut off for ‘high’ expression and how it was
determined. Additionally, further laboratory studies are warranted to
confirm that high ACE2 gene expression would have high correlation with
the amount of ACE2 protein on cell surface. For the GO pathway analysis
significance was set at p&lt;0.05, but not adjusted for multiple
comparisons.

There were no samples with SARS-CoV-2 infection. While SARS-Cov and
SARS-CoV-2 both use ACE2 to enter the host cells, the analysis only
included data on SARS-Cov and any conclusions about SARS-CoV2 are
limited.

Upon checking GSE accession numbers of the datasets references, two
might not be cited correctly: GSE37758 ("A spergillus niger: Control
(fructose) vs. steam-exploded sugarcane induction (SEB)"" was used in
this paper as “lung tissue” data) and GSE14700 ("Steroid Pretreatment
of Organ Donors to Prevent Postischemic Renal Allograft Failure: A
Randomized, Controlled Trial" – was used as SARS-Cov infection data).

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Diarrhea may be underestimated: a missing link in 2019 novel coronavirus

Liang et al. *medRxiv* [@doi:10.1101/2020.02.03.20020289]

#### Keywords

- SARS-CoV-2
- diarrhea
- ACE2
- scRNA-seq

#### Main Findings

This study examined the incidence of diarrhea in
patients infected with SARS-CoV-2 across three recently published
cohorts and found that there are statistically significant differences
by Fisher’s exact test. They report that this could be due to subjective
diagnosis criterion for diarrhea or from patients first seeking medical
care from gastroenterologist. In order to minimize nosocomial infections
arising from unsuspected patients with diarrhea and gain comprehensive
understanding of transmission routes for this viral pathogen, they
compared the transcriptional levels of ACE2 of various human tissues
from NCBI public database as well as in small intestine tissue from
CD57BL/6 mice using single cell sequencing. They show that ACE2
expression is not only increased in the human small intestine, but
demonstrate a particular increase in mice enterocytes positioned on the
surface of the intestinal lining exposed to viral pathogens. Given that
ACE2 is the viral receptor for SARS-CoV-2 and also reported to regulate
diarrhea, their data suggests the small intestine as a potential
transmission route and diarrhea as a potentially underestimated symptom
in COVID19 patients that must be carefully monitored. Interestingly,
however, they show that ACE2 expression level is not elevated in human
lung tissue.

#### Limitations

Although this study demonstrates a
statistical difference in the incidence of diarrhea across three
separate COVID19 patient cohorts, their conclusions are limited by a
small sample size. Specifically, the p-value computed by Fisher’s exact
test is based on a single patient cohort of only six cases of which 33%
are reported to have diarrhea, while the remaining two larger cohorts
with 41 and 99 cases report 3% and 2% diarrhea incidence, respectively.
Despite showing significance, they would need to acquire larger sample
sizes and cohorts to minimize random variability and draw meaningful
conclusions. Furthermore, they do not address why ACE2 expression level
is not elevated in human lung tissue despite it being a major
established route of transmission for SARS-CoV-2. It could be helpful to
validate this result by looking at ACE2 expression in mouse lung tissue.
Finally, although this study is descriptive and shows elevated ACE2
expression in small intestinal epithelial cells, it does not establish a
mechanistic link to SARS-CoV-2 infection of the host. Overall, their
claim that infected patients exhibiting diarrhea pose an increased risk
to hospital staff needs to be further substantiated.

#### Significance

This study provides a possible transmission route and a
potentially underappreciated clinical symptom for SARS-CoV-2 for better
clinical management and control of COVID19.

#### Credit

*Summary generated as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection

Chai et al. *bioRxiv* [@doi:10.1101/2020.02.03.931766]

#### Keywords

- ACE2
- Cholangiocytes
- COVID-associated Liver Damage

#### Summary

Using both publicly available scRNA-seq dataset of liver
samples from colorectal patients and scRNA-sequencing of four liver
samples from healthy volunteers, the authors show that ACE2 is
significantly enriched in the majority of cholangiocytes (59.7 %) but
not in hepatocytes (2.6%).

#### Main Findings

Using bioinformatics approaches of
RNASeq analysis, this study reveals that ACE2 dominates in
cholangiocytes and is present at very low levels in hepatocytes.

#### Limitations

The
study does not provide mechanistic insights into how SARS-CoV-2 can
infect and replicate in cholangiocytes and the types of intrinsic
anti-viral responses induced by cholangiocytes when infected. In
addition, because the study relies on the assumption that SARS-CoV-2
infects cells only through ACE2, it cannot discount the possibility that
the virus can infect hepatocytes through mechanisms other than
ACE2-mediated entry. Furthermore, because the scRNA-seq analysis were
performed on healthy liver samples, one cannot draw any definitive
conclusions about gene expression states (including ACE2 expression in
liver cell types) in system-wide inflammatory contexts.

#### Significance

This article with other studies on liver
damage in COVID patients suggests that liver damage observed in COVID
patients is more due to inflammatory cytokines than direct infection of
the liver. Even if cholangiocytes are infectable by SARS-CoV-2 (which
was demonstrated by human liver ductal organoid study
([@doi:10.1101/2020.03.16.990317]),
published clinical data show no significant increase in bile duct injury
related indexes (i.e. alkaline phosphatase, gamma-glutamyl
transpeptidase and total bilirubin). In sum, it underscores the
importance of future studies characterizing cellular responses of
extra-pulmonary organs in the context of COVID or at least in viral lung
infections..

#### Credit

*Summary generated by Chang Moon as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism

Wang et al. *medRxiv*. [@doi:10.1101/2020.02.05.20020545]

#### Keywords

- single cell RNA seq
- ACE2 expression
- human colonic biopsy

#### Main Findings

Colonic enterocytes primarily express ACE2. Cellular pathways associated with ACE2 expression include innate immune signaling, HLA up regulation, energy metabolism and apoptotic signaling.  

#### Limitations

This is a study of colonic biopsies taken from 17 children with and without IBD and analyzed using scRNAseq to look at ACE2 expression and identify gene families correlated with ACE2 expression. The authors find ACE2 expression to be primarily in colonocytes.  It is not clear why both healthy and IBD patients were combined for the analysis. Biopsies were all of children so extrapolation to adults is limited. The majority of genes found to be negatively correlated with ACE2 expression include immunoglobulin genes (IGs). IG expression will almost certainly be low in colonocytes irrespective of ACE2 expression.  

#### Significance

This study performs a retrospective analysis of ACE2 expression using an RNAseq dataset from intestinal biopsies of children with and without IBD. The implications for the CoV-19 epidemic are modest, but do provide support that ACE2 expression is specific to colonocytes in the intestines.  The ontological pathway analysis provides some limited insights into gene expression associated with ACE2.

#### Credit

*Summary generated as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic Mice

Bao et al. *bioRxiv* [@doi:10.1101/2020.02.07.939389]

#### Keywords

- Covid-19 mouse model
- hACE2 mice
- 2019-nCoV model
- ACE2
- 2019-nCoV 

#### Main Findings

Using a transgenic human Angiotensin-converting enzyme 2
(hACE2) mouse that has previously been shown susceptible to infection by
SARS-CoV, Bao et al. create a model of pandemic 2019-nCoV strain
coronavirus. The model includes interstitial hyperplasia in lung tissue,
moderate inflammation in bronchioles and blood vessels, and histology
consistent with viral pneumonia at 3 days post infection. Wildtype did
not experience these symptoms. In addition, viral antigen and hACE2
receptor were found to co-localize the lung by immunofluorescence 3-10
days post infection only in the hACE2 infected mice.

#### Limitations

The characterization of the infection remains incomplete,
as well as lacking characterization of the immune response other than
the presence of a single antiviral antibody. Though they claim to
fulfill Koch’s postulates, they only isolate the virus and re-infect
Vero cells, rather than naive mice.

#### Significance

This paper establishes a murine model for 2019-nCoV
infection with symptoms consistent with viral pneumonia. Though not
fully characterized, this model allows in vivo analysis of viral entry
and pathology that is important for the development of vaccines and
antiviral therapeutics.

#### Credit

*Review by Dan Fu Ruan, Evan Cody and Venu Pothula as part of a project by students, postdocs and faculty
at the Immunology Institute of the Icahn School of Medicine, Mount
Sinai.*


### Caution on Kidney Dysfunctions of 2019-nCoV Patients

Li et al. *medRxiv*. [@doi:10.1101/2020.02.08.20021212]

#### Keywords

CoVID-19, 2019-nCoV, SARS-CoV-2, kidney, clinical, creatinine,
proteinuria, albuminuria, CT

#### Main Findings

-   Retrospective study of 59 patients assayed key function indicators
    of the kidney–including urine protein, blood urea nitrogen (BUN),
    plasma creatinine (Cre), and renal CT scan data.

-   Found that 34% of patients developed massive albuminuria on the
    first day of admission, and 63% developed proteinuria during their
    stay in hospital; and 19% of patients had high plasma creatinine,
    especially the terminal cases.

-   CT analyses of 27 patients showed all patients to have abnormal
    kidney damage; indicate that inflammation and edema of the renal
    parenchyma very common.

#### Limitations

-   No analysis of immunity-dependent damage and cytokines in
    blood/plasma/urine. Will be worth correlating disease progression
    with cytokine production, immune activity and kidney function.

-   Extrapolating to earlier SARS-CoV studies provides the only
    rationale for viral-damage in kidney and resultant pathologic immune
    response *(understandable for this clinical study)*.

#### Significance

-   Multiple lines of evidence along this study’s finding point to the
    idea that renal impairment/injury is a key risk factor in 2019-nCoV
    patients similar to what has been reported for SARS-CoV[@doi:10.1111/j.1523-1755.2005.67130.x]; this
    may be one of the major causes of virally-induced damage and
    contribute to multiorgan failure.

-   ACE2 expression in kidney proximal tubule epithelia and bladder
    epithelia [@doi:10.1101/2020.02.08.939892] support
    these clinical findings.

-   Study argues for closely monitoring kidney function, and applying
    potential interventions including continuous renal replacement
    therapies (CRRT) for protecting kidney functions as early as
    possible, particularly for those with rising plasma creatinine.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Profiling the immune vulnerability landscape of the 2019 Novel Coronavirus

Zhu et al. *bioRxiv* [@doi:10.1101/2020.02.08.939553]

#### Keywords

- epitope prediction
- vaccine development.

#### Main Findings

This study harnesses bioinformatic profiling to predict the potential of
COV2 viral proteins to be presented on MHC I and II and to form linear
B-cell epitopes. These estimates suggest a T-cell antigenic profile
distinct from SARS-CoV or MERS-CoV, identify focused regions of the
virus with a high density of predicted epitopes, and provide preliminary
evidence for adaptive immune pressure in the genetic evolution of the
virus.

#### Limitations

While the study performs a comprehensive analysis of potential epitopes
within the virus genome, the analysis relies solely on bioinformatic
prediction to examine MHC binding affinity and B-cell epitope potential
and does not capture the immunogenicity or recognition of
these epitopes. Future experimental validation in data from patients
infected with SARS-CoV-2 will be important to validate and refine these
findings. Thus some of the potential conclusions stated, including viral
evolution toward lower immunogenicity or a dominant role for CD4+
T-cells rather than CD8+ T-cells in viral clearance, require further
valiadtion.

#### Significance

These findings may help direct peptide vaccine design toward relevant
epitopes and provide intriguing evidence of viral evolution in response
to immune pressure.

#### Credit

*Summary generated as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Single-cell Analysis of ACE2 Expression in Human Kidneys and Bladders Reveals a Potential Route of 2019-nCoV Infection

Lin et al. *bioRxiv* [@doi:10.1101/2020.02.08.939892]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- ACE2
- scRNAseq
- kidney
- bladder
- public dataset

#### Main Findings

-   To investigate the possible cause of kidney damage in 2019-nCoV
    patients, authors used published kidney and bladder cell atlas data
    (GSE131685, GSE108097; 3 healthy donors each) as well as an
    unpublished kidney single-cell RNA-Seq data (in-house from 2
    transplant donors) to evaluate ACE2 gene expressions in all cell
    types of healthy kidneys and bladders.

-   They find enriched expression of ACE2 transcript in all subtypes of
    proximal tubule cells of kidney, with 5%-15% of both straight and
    convoluted proximal tubule cells expressing ACE2.

-   They also find detectable levels of ACE2 in bladder epithelial
    cells, noting expression from around 1.5% of cells in the outer
    layer umbrella cells of the bladder epithelium and decreasing in the
    basal cells.

-   Importantly endothelial or immune cells in kidney/bladder do not
    express ACE2.

#### Limitations

-   This study primarily characterizes ACE2 expression (amongst other
    genes) from a small healthy-donor dataset, and will benefit from
    supporting data in (expired) patient samples to show functional
    viral damage. ACE2 transcript does not necessarily translate to
    viral permissiveness in kidney/bladder epithelia or cytokine
    release.

-   This study focuses on only healthy tissue; it will be useful to
    analyze kidney/bladder epithelial ACE2 expression under inflammatory
    conditions or in patients with underlying kidney conditions.

-   Given what is known about protease TMPRSS2 expression during
    SARS-CoV-2 infection, ACE2+TMPRSS2+ double-positive cell
    identification would be useful in these datasets.

#### Significance

-   ACE2 protein is spatially restricted to brush border of proximal
    tubules and in bladder umbrella cells [@doi:10.1002/path.1570], such cells in direct
    contact with viral particles are likely to be highly sensitive to
    viral-induced damage.

-   SARS-CoV and MERS-CoV have been shown to be detected in urine of
    patients and associate with higher mortality [@doi:10.1111/j.1523-1755.2005.67130.x; @doi:10.7326/m13-2486], thus worth
    understanding kidney damage and resultant immune response in
    SARS-CoV-2 as well.

-   This study argues for a potential mode of viral infectivity and
    resultant inflammatory responses in these tissue in addition to
    reported infectivity in the lung and digestive system, which is
    supported by clinical data showing acute and early kidney
    complications in 2019-nCoV patients [@doi:10.1101/2020.02.08.20021212].

-   Clinically, thus very important to track urinary CoVID-19 shedding
    as well as study acute kidney injury-related co-morbidities.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage

Liu et al. *medRxiv* [@doi:10.1101/2020.02.10.20021584]

#### Keywords

- severe disease
- pneumonia
- lymphocytes
- neutrophils

#### Main Findings

This study aimed to find prognostic biomarkers of COVID-19
pneumonia severity. Sixty-one (61) patients with COVID-19 treated in
January at a hospital in Beijing, China were included. On average,
patients were seen within 5 days from illness onset. Samples were
collected on admission; and then patients were monitored for the
development of severe illness with a median follow-up of 10 days\].

Patients were grouped as “mild” (N=44) or “moderate/severe” (N=17)
according to symptoms on admission and compared for different
clinical/laboratory features. “Moderate/severe” patients were
significantly older (median of 56 years old, compared to 41 years old).
Whereas comorbidies rates were largely similar between the groups,
except for hypertension, which was more frequent in the severe group (p=
0.056). ‘Severe’ patients had higher counts of neutrophils, and serum
glucose levels; but lower lymphocyte counts, sodium and serum chlorine
levels. The ratio of neutrophils to lymphocytes (NLR) was also higher
for the ‘severe’ group. ‘Severe’ patients had a higher rate of bacterial
infections (and antibiotic treatment) and received more intensive
respiratory support and treatment.

26 clinical/laboratory variables were used to select NLR and age as the
best predictors of the severe disease. Predictive cutoffs for a severe
illness as NLR ≥ 3.13 or age ≥ 50 years.

#### Limitations

Identification of early biomarkers is important for
making clinical decisions, but large sample size and validation cohorts
are necessary to confirm findings. It is worth noting that patients
classified as “mild” showed pneumonia by imaging and fever, and in
accordance with current classifications this would be consistent with
“moderate” cases. Hence it would be more appropriate to refer to the
groups as “moderate” vs “severe/critical”. Furthermore, there are
several limitations that could impact the interpretation of the results:
e.g. classification of patients was based on symptoms presented on
admission and not based on disease progression, small sample size,
especially the number of ‘severe’ cases (with no deaths among these
patients). Given the small sample size, the proposed NLR and age cut
offs might not hold for a slightly different set of patients. For
example, in a study of &gt;400 patients, ‘non-severe’ and ‘severe’ NLR
were 3.2 and 5.5, respectively [@doi:10.1093/cid/ciaa248].

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Wan et. al. *medRxiv* [@doi:10.1101/2020.02.10.20021832]

#### Keywords

- Cytokines
- lymphocyte subsets
- CD8 + T
- B cells
- NK cells,
- PBMCs
- IL-6
- IL-10

#### Main Findings

The authors analyzed lymphocyte subsets and cytokines of 102 patients
with mild disease and 21 with severe disease. CD8+T cells and CD4+T
cells were significantly reduced in both cohort. particularly in severe
patients. The cytokines IL6 and IL10 were significantly elevated in
severe patients as compared to mild. No significant differences were
observed in frequency of B cells and NK cells.

The authors argue that the measurement of T cell frequencies and
cytokine levels of IL6 and IL10 can be used to predict progression of
disease from Mild to severe Cov-2 infection.

#### Limitations

The study demonstrates in a limited cohort
similar associations to several other reported studies. The authors
didn’t compare the changes in lymphocyte and cytokine with healthy
individual (Covid-19 Negative) rather used an internal standard value.
The recently preprint in LANCET shows The degree of lymphopenia and a
pro-inflammatory cytokine storm is higher in severe COVID-19 patients
than in mild cases, and is associated with the disease severity [@doi:10.2139/ssrn.3539682].

#### Significance

This translational data identifies key cytokines and lymphopenia
associated with disease severity although mechanism and key cellular
players are still unknown. Higher level IL-6 production in severe
patient suggests potential role of Tocilizumab (anti-IL6R) biologic
although clinical trial will be necessary.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China

Li et al. *medRxiv* [@doi:10.1101/2020.02.11.20022053]

#### Keywords

- epidemiology
- clinical characteristics

#### Major Findings

These authors looked at 17 hospitalized patients with COVID-19
confirmed by RT-PCR in Dazhou, Sichuan. Patients were admitted between
January 22 and February 10 and the final data were collected on February
11. Of the 17 patients, 12 remained hospitalized while 5 were discharged
after meeting national standards. The authors observed no differences
based on the sex of the patients but found that the discharged patients
were younger in age (p = 0.026) and had higher lymphocyte counts (p =
0.005) and monocyte counts (p = 0.019) upon admission.

#### Limitations

This study is limited in the sample size of the study and the last
data collection point was only one day after some of the patients were
admitted.

#### Significance

These findings have been somewhat supported by subsequent studies
that show that older age and an immunocompromised state are more likely
to result in a more severe clinical course with COVID-19. However, other
studies have been published that report on larger numbers of cases.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection

[@doi:10.1101/2020.02.12.20022418]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- kidney
- testis
- ACE2
- scRNAseq

#### Main Findings

-   Study used online datasets (scRNAseq GSE131685, scRNAseq GSE107585,
    Human Protein Atlas, GTEx portal, CCLE) to analyze ACE2 expression
    in different human organs.

-   Study re-analyzed three clinical datasets (n=6, n=99, and n=41) to
    show 3\~10% of 2019-nCoV patients present with abnormal renal
    function.

-   results indicate ACE2 highly expressed in renal tubular cells,
    Leydig cells and seminiferous ductal cells of testis.

#### Limitations

-   Very preliminary transcript/protein dataset analysis in healthy
    cohorts; does not necessarily translate to actual viral tropism and
    permissiveness.

-   Clinically, would be important to determine with larger longitudinal
    dataset if SARS-CoV-2 infection changes sperm quality or testicular
    inflammation.

-   Similarly, would be important to determine if simultaneous HBV or
    syphilis infection and orchitis impacts SARS-CoV-2 severity.

-   Examination and follow-up of renal function and viral orchitis/sperm
    quality of CoVID-19 patients not done in this preliminary study.

#### Significance

-   Kidney ACE2 result supports other concurrent sequencing studies
    [@doi:10.1101/2020.02.08.939892] and clinical reports
    of abnormal renal function or even kidney damage in patients
    infected with 2019-nCoV
    [@doi:10.1101/2020.02.08.20021212].

-   High ACE2 expression in testis suggests potential tropism of the
    virus to testicular tissues and indicates potential risks for male
    fertility. Viral orchitis reported for SARS-CoV previously \[1\],
    but no clear evidence so far of infertility in SARS, MERS or
    CoVID-19 patients.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus

[@doi:10.1101/2020.02.12.945576]

#### Keywords
- immunopathology
- Th1
- inflammatory monocytes
- GM-CSF
- IFN-γ
- IL-6

#### Main Findings

The authors of this study sought to characterize the immune
mechanism causing severe pulmonary disease and mortality in 2019-nCoV
(COVID-19) patients. Peripheral blood was collected from hospitalized
ICU (n=12) and non-ICU (n=21) patients with confirmed 2019-nCoV and from
healthy controls (n=10) in The First Affiliated Hospital of University
of Science and Technology China (Hefei, Anhui). Immune analysis was
conducted by flow cytometry. 2019-nCoV patients had decreased
lymphocyte, monocyte, and CD4 T cell counts compared to healthy
controls. ICU patients had fewer lymphocytes than non-ICU patients. CD4
T cells of 2019-nCoV patients expressed higher levels of activation
markers (OX40, CD69, CD38, CD44) and exhaustion markers (PD-1 and Tim3)
than those of healthy controls. CD4 cells of ICU patients expressed
significantly higher levels of OX40, PD-1, and Tim3 than those of
non-ICU patients. 2019-nCoV patients had higher percentages of CD4 T
cells co-expressing GM-CSF and IL-6 compared to healthy controls, while
ICU patients had a markedly higher percentage of GM-CSF+ IFN-γ+ CD4 T
cells than non-ICU patients. The CD4 T cells of nCoV patients and
healthy controls showed no differences in TNF-α secretion.

The CD8 T cells of 2019-nCoV patients also showed higher expression of
activation markers CD69, CD38, and CD44, as well as exhaustion markers
PD-1 and Tim3, compared to healthy controls. CD8 T cells of ICU patients
expressed higher levels of GM-CSF than those of non-ICU patients and
healthy controls. No IL-6 or TNF-α was found in the CD8 T cells of any
group. There were no differences in numbers of NK cells or B cells in
2019-nCoV patients and healthy controls, nor was there any GM-CSF or
IL-6 secretion from these cells in either group.

Percentages of CD14+ CD16+ GM-CSF+ and CD14+ CD16+ IL-6+ inflammatory
monocytes were significantly increased in nCoV patients compared to
healthy controls; in particular, patients in the ICU had greater
percentages of CD14+ CD16+ IL-6+ monocytes than non-ICU patients. The
authors suggest that in 2019-nCoV patients, pathogenic Th1 cells produce
GM-CSF, recruiting CD14+ CD16+ inflammatory monocytes that secrete high
levels of IL-6. These may enter pulmonary circulation and damage lung
tissue while initiating the cytokine storm that causes mortality in
severe cases. This is consistent with the cytokine storm seen in similar
coronaviruses, as IL-6, IFN-γ, and GM-CSF are key inflammatory mediators
seen in patients with SARS-CoV-1 and MERS-CoV.

#### Limitations

Though the results of this study open
questions for further investigation, this is an early study on a small
cohort of patients, and as such there are a number of limitations. The
study included only 12 ICU patients and 21 non-ICU patients, and ideally
would be repeated with a much larger patient cohort. Though the authors
make claims about differences in lymphocyte and monocyte counts between
patients and healthy controls, they did not report baseline laboratory
findings for the control group. Additionally, severity of disease was
classified based on whether or not patients were in the ICU. It would be
interesting to contextualize the authors’ immunological findings with
more specific metrics of disease severity or time course. Noting
mortality, time from disease onset, pre-existing conditions, or severity
of lung pathology in post-mortem tissue samples would paint a fuller
picture of how to assess risk level and the relationship between
severity of disease and immunopathology. Another limitation is the
selection of cytokines and immune markers for analysis, as the selection
criteria were based on the cell subsets and cytokine storm typically
seen in SARS-CoV-1 and MERS-CoV patients. Unbiased cytokine screens and
immune profiling may reveal novel therapeutic targets that were not
included in this study.

#### Significance

This study identifies potential therapeutic targets
that could prevent acute respiratory disease syndrome (ARDS) and
mortality in patients most severely affected by COVID-19. The authors
propose testing monoclonal antibodies against IL6-R or GM-CSF to block
recruitment of inflammatory monocytes and the subsequent cytokine storm
in these patients.

#### Credit

*Review by Gabrielle Lubitz as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical Characteristics of 2019 Novel Infected Coronavirus Pneumonia：A Systemic Review and Meta-analysis

Qian et al. *medRxiv*.
[@doi:10.1101/2020.02.14.20021535]

#### Keywords
- White Blood Cells
- Lymphocytes
- Neutrophils

#### Main Findings

The authors performed a meta analysis of literature on clinical,
laboratory and radiologic characteristics of patients presenting with
pneumonia related to SARSCoV2 infection, published up to Feb 6 2020.
They found that symptoms that were mostly consistent among studies were
sore throat, headache, diarrhea and rhinorrhea. Fever, cough, malaise
and muscle pain were highly variable across studies. Leukopenia (mostly
lymphocytopenia) and increased white blood cells were highly variable
across studies. They identified three most common patterns seen on CT
scan, but there was high variability across studies. Consistently across
the studies examined, the authors found that about 75% of patients need
supplemental oxygen therapy, about 23% mechanical ventilation and about
5% extracorporeal membrane oxygenation (ECMO). The authors calculated a
staggering pooled mortality incidence of 78% for these patients.

#### Limitations

The authors mention that the total number of studies included in this
meta analysis is nine, however they also mentioned that only three
studies reported individual patient data. It is overall unclear how many
patients in total were included in their analysis. This is mostly
relevant as they reported an incredibly high mortality (78%) and mention
an absolute number of deaths of 26 cases overall. It is not clear from
their report how the mortality rate was calculated.

The data is based on reports from China and mostly from the Wuhan area,
which somewhat limits the overall generalizability and applicability of
these results.

#### Significance

This meta analysis offers some important data for clinicians to refer to
when dealing with patients with COVID-19 and specifically with
pneumonia. It is very helpful to set expectations about the course of
the disease.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Liu et al. *medRxiv* [@doi:10.1101/2020.02.16.20023671]

#### Keywords

- Lymphopenia
- Neutrophil to CD8 T cell ratio (N8R)
- inflammatory cytokines

#### Main Findings

Liu et al. enrolled a cohort of 40 patients from Wuhan
including 27 mild cases and 13 severe cases of COVID-19. They performed
a 16-day kinetic analysis of peripheral blood from time of disease
onset. Patients in the severe group were older (medium age of 59.7,
compared to 48.7 in mild group) and more likely to have hypertension as
a co-morbidity. Lymphopenia was observed in 44.4% of the mild patients
and 84.6% of the severe patients. Lymphopenia was due to low T cell
count, specially CD8 T cells. Severe patients showed higher neutrophil
counts and an increase of cytokines in the serum (IL2, IL6, IL10 and
IFNγ). The authors measured several other clinical laboratory parameters
were also higher in severe cases compared to mild, but concluded that
neutrophil to CD8 T cell ratio (N8R) as the best prognostic factor to
identify the severe cases compared to other receiver operating
characteristic (ROC).

#### Limitations

This was a small cohort (N=40), and two of the patients
initially included in the severe group (N=13) passed away and were
excluded from the analysis due to lack of longitudinal data. However, it
would be most important to be able to identify patients with severe
disease with higher odds of dying. It seems that the different time
points analyzed relate to hospital admission, which the authors describe
as disease onset. The time between first symptoms and first data points
is not described. It would have been important to analyze how the
different measured parameters change according to health condition, and
not just time (but that would require a larger cohort). The predictive
value of N8R compared to the more commonly used NLR needs to be assessed
in other independent and larger cohorts. Lastly, it is important to note
that pneumonia was detected in patients included in the “mild” group,
but according to the Chinese Clinical Guidance for COVID-19 Pneumonia
Diagnosis and Treatment (7th edition) this group should be considered
“moderate”.

#### Significance

Lymphopenia and cytokine storm have been described to be
detrimental in many other infections including SARS-CoV1 and MERS-CoV.
However, it was necessary to confirm that this dramatic immune response
was also observed in the SARS-CoV2 infected patients. These results and
further validation of the N8R ratio as a predictor of disease severity
will contribute for the management of COVID19 patients and potential
development of therapies.

#### Credit

*Review by Pauline Hamon as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019

Chen et al. *medRxiv* [@doi:10.1101/2020.02.16.20023903]

#### Keywords

- severe disease
- lymphocytes
- cytokines
- IFNy
- CD4 Tcells
- HLA-DR CD8
- Tcells

#### Main Findings

This study retrospectively evaluated clinical, laboratory,
hematological, biochemical and immunologic data from 21 subjects
admitted to the hospital in Wuhan, China (late December/January) with
confirmed SARS-CoV-2 infection. The aim of the study was to compare
‘severe’ (n=11, \~64 years old) and ‘moderate’ (n=10, \~51 years old)
COVID-19 cases. Disease severity was defined by patients’ blood oxygen
level and respiratory output. They were classified as ‘severe’ if SpO2
93% or respiratory rates 30 per min.

In terms of the clinical laboratory measures, ‘severe’ patients had
higher CRP and ferritin, alanine and aspartate aminotransferases, and
lactate dehydrogenase but lower albumin concentrations.

The authors then compared plasma cytokine levels (ELISA) and immune cell
populations (PBMCs, Flow Cytometry). ‘Severe’ cases had higher levels of
IL-2R, IL-10, TNFa, and IL-6 (marginally significant). For the immune
cell counts, ‘severe’ group had higher neutrophils, HLA-DR+ CD8 T cells
and total B cells; and lower total lymphocytes, CD4 and CD8 T cells
(except for HLA-DR+), CD45RA Tregs, and IFNy-expressing CD4 T cells. No
significant differences were observed for IL-8, counts of NK cells,
CD45+RO Tregs, IFNy-expressing CD8 T and NK cells.

#### Limitations

Several potential limitations should be noted: 1) Blood samples were
collected 2 days post hospital admission and no data on viral loads were
available; 2) Most patients were administered medications (e.g.
corticosteroids), which could have affected lymphocyte counts.
Medications are briefly mentioned in the text of the manuscript; authors
should include medications as part of Table 1. 3) ‘Severe’ cases were
significantly older and 4/11 ‘severe’ patients died within 20 days.
Authors should consider a sensitivity analysis of biomarkers with the
adjustment for patients’ age.

#### Significance

Although the sample size was small, this paper presented a broad range
of clinical, biochemical, and immunologic data on patients with
COVID-19. One of the main findings is that SARS-CoV-2 may affect T
lymphocytes, primarily CD4+ T cells, resulting in decreased IFNy
production. Potentially, diminished T lymphocytes and elevated cytokines
can serve as biomarkers of severity of COVID-19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development

Sun et al. *bioRxiv* [@doi:10.1101/2020.02.16.951723]

#### Keywords

- SARS-CoV
- SARS-CoV-2
- ACE2
- Spike (S) protein
- receptor binding domain (RBD)
- receptor binding motif (RBM)
- neutralizing antibody

#### Main Findings

This study compared the structure of SARS-CoV and SARS-CoV-2 Spike (S)
protein receptor binding domain (RBD) and interactions with ACE2 using
computational modeling, and interrogated cross-reactivity and
cross-neutralization of SARS-CoV-2 by antibodies against SARS-CoV. While
SARS-CoV and SARS-CoV-2 have over 70 % sequence homology and share the
same human receptor ACE2, the receptor binding motif (RBM) is only 50%
homologous.

Computational prediction of the SARS-CoV-2 and ACE2 interactions based
on the previous crystal structure data of SARS-CoV, and measurement of
binding affinities against human ACE2 using recombinant SARS-CoV and
SARS-CoV-2 S1 peptides, demonstrated similar binding of the two S1
peptides to ACE2, explaining the similar transmissibility of SARS-CoV
and SARS-CoV-2 and consistent with previous data (Wall et al Cell
2020).

The neutralization activity of SARS-CoV-specific rabbit polyclonal
antibodies were about two-order of magnitude less efficient to
neutralize SARS-CoV-2 than SARS-CoV, and four potently neutralizing
monoclonal antibodies against SARS-CoV had poor binding and neutralizing
activity against SARS-CoV-2. In contrast, 3 poor SARS-CoV-binding
monoclonal antibodies show some efficiency to bind and neutralize
SARS-CoV-2. The results suggest that that antibodies to more conserved
regions outside the RBM motif might possess better cross-protective
neutralizing activities between two strains.

#### Limitations

It would have been helpful to show the epitopes recognized by the
monoclonal antibodies tested on both SARS-CoV, SARS-CoV-2 to be able to
make predictions for induction of broadly neutralizing antibodies. The
data on monoclonal antibody competition with ACE2 for binding to
SARS-CoV RBD should have also included binding on SARS-CoV2, especially
for the three monoclonal antibodies that showed neutralization activity
for SARS-CoV2. Because of the less homology in RBM sequences between
viruses, it still may be possible that these antibodies would recognize
the ACE2 RBD in SARS-CoV-2.

#### Significance

It is noteworthy that immunization to mice and rabbit with SARS-CoV S1
or RBD protein could induce monoclonal antibodies to cross-bind and
cross-neutralize SARS-CoV-2 even if they are not ACE2-blocking. If these
types of antibodies could be found in human survivors or in the
asymptomatic populations as well, it might suggest that exposure to
previous Coronavirus strains could have induced cross-neutralizing
antibodies and resulted in the protection from severe symptoms in some
cases of SARS-CoV2.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Protection of Rhesus Macaque from SARS-Coronavirus challenge by recombinant adenovirus vaccine

Chen et al. *bioRxiv* [@doi:10.1101/2020.02.17.951939]

#### Keywords

- SARS-CoV-1
- rhesus macaque
- recombinant adenovirus vaccine

#### Main Findings

Rhesus macaques were immunized intramuscularly twice (week 0 and
week 4) with SV8000 carrying the information to express a S1-orf8
fusion protein and the N protein from the BJ01 strain of SARS-CoV-1.
By week 8, immunized animals had signs of immunological protection
(IgG and neutralization titers) against SARS-CoV-1 and were
protected against challenge with the PUMC-1 strain, with fewer
detectable symptoms of respiratory distress, lower viral load,
shorter periods of viral persistence, and less pathology in the
lungs compared to non-immunized animals.

#### Limitations

The authors should write clearer descriptions of the methods used in
this article. They do not describe how the IgG titers or
neutralization titers were determined. There are some issues with
the presentation of data, for example, in Figure 1a, y-axis should
not be Vmax; forming cells and 1d would benefit from showing error
bars. Furthermore, although I inferred that the animals were
challenged at week 8, the authors did not explicitly detail when the
animals were challenged. The authors should explain the design of
their vaccine, including the choice of antigens and vector. The
authors also do not include a description of the ethical use of
animals in their study.

#### Significance

The authors describe a vaccine for SARS-CoV-1 with no discussion of
possible implications for the current SARS-CoV-2 pandemic. Could a
similar vaccine be designed to protect against SARS-CoV-2 and would
the concerns regarding emerging viral mutations that the authors
describe as a limitation for SARS-CoV-1 also be true in the context
of SARS-CoV-2?

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Reduction and Functional Exhaustion of T cells in Patients with Coronavirus Disease 2019 (COVID-19)

[@doi:10.1101/2020.02.18.20024364]

#### Keywords

- T cell exhaustion
- T cell lymphopenia
- IL-6
- IL-10
- TNF-α

#### Main Findings

Based on a retrospective study of 522 COVID patients and 40
healthy controls from two hospitals in Wuhan, China, authors show both
age-dependent and clinical severity-dependent decrease in T cell numbers
with elderly patients and patients who are in ICU-care showing the most
dramatic decrease in T cell counts. Cytokine profiling of COVID patients
reveal that TNF-α, IL-6 and IL-10 are increased in infected patients
with patients in the ICU showing the highest levels. Interestingly,
these three cytokine levels were inversely correlated with T cell counts
and such inverse relationship was preserved throughout the disease
progression. Surface staining of exhaustion markers (PD-1 and Tim-3) and
flow cytometry of stained peripheral blood of 14 patients and 3 healthy
volunteers demonstrate that T cells of COVID patients have increased
expression of PD-1 with patients in ICU having the highest number of
CD8^+^PD-1^+^ cells than their counterparts in non-ICU groups.

#### Limitations

Compared to the number of patients, number of control (n=
40) is small and is not controlled for age. Additional data linking
inflammatory cytokines and the quality of the adaptive response
including humoral and antigen specific T cell response is much needed. T
cell exhaustion study relies on marker-dependent labeling of T cell
functionality of a very limited sample size (n=17)—a
functional/mechanistic study of these T cells from PBMCs would have
bolstered their claims.

#### Significance

Limited but contains interesting
implications. It is already known in literature that in the context of
acute respiratory viral infections CD8 T cells exhibit exhaustion-like
phenotypes which further underscores the importance of mechanistic
studies that can elucidate how COVID infection leads to lymphopenia and
T cell exhaustion-like phenotype.

However, as authors have noted, the data does point to an interesting
question: How these inflammatory cytokines (TNF-α, IL-6 and IL-10)
correlate with or affect effective viral immunity and what types of
cells produce these cytokines? Answering that question will help us
refine our targets for immune-modulatory therapies especially in
patients suffering from cytokine storms.

#### Credit

*This review by Chang Moon was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical Characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China

[@doi:10.1101/2020.02.19.20025239]

#### Keywords

- COVID-19
- pneumonia
- hypertension
- diabetes
- biomarker
- neutrophilia
- lymphopenia

#### Main Findings

Most common chronic conditions among 25 patients that died from
COVID-19 related respiratory failure were hypertension (64%) and
diabetes (40%). Disease progression was marked by progressive organ
failure, starting first with lung dysfunction, then heart (e.g.
increased cTnI and pro-BNP), followed by kidney (e.g. increased BUN,
Cr), and liver (e.g. ALT, AST). 72% of patients had neutrophilia and 88%
also had lymphopenia. General markers of inflammation were also
increased (e.g. PCT, D-Dimer, CRP, LDH, and SAA).

#### Limitations

The limitations of this study include small sample size and
lack of measurements for some tests for several patients. This study
would also have been stronger with comparison of the same measurements
to patients suffering from less severe disease to further validate and
correlate proposed biomarkers with disease severity.

#### Significance

This study identifies chronic conditions (i.e. hypertension
and diabetes) that strongly correlates with disease severity. In
addition to general markers of inflammation, the authors also identify
concomitant neutrophilia and lymphopenia among their cohort of patients.
This is a potentially interesting immunological finding because we would
typically expect increased lymphocytes during a viral infection.
Neutrophilia may also be contributing to cytokine storm. In addition,
PCT was elevated in 90.5% of patients, suggesting a role for sepsis or
secondary bacterial infection in COVID-19 related respiratory failure.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 infection does not significantly cause acute renal injury: an analysis of 116 hospitalized patients with COVID-19 in a single hospital, Wuhan, China

[@doi:10.1101/2020.02.19.20025288]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- kidney
- clinical
- longitudinal

#### Main Findings

-   Clinical data from 116 hospitalized CoVID-19 patients analyzed over
    4 weeks for correlation with renal injury. Comorbidities included
    chronic renal failure (CRF) in 5 patients (4.3%).

-   10.8% of patients with no prior kidney disease showed elevations in
    blood urea or creatinine, and 7.2% of patients with no prior kidney
    disease showed albuminuria.

-   Patients with pre-existing CRF underwent continuous renal
    replacement therapy (CRRT) alongside CoVID-19 treatment. Renal
    functions remained stable in these patients.

-   All 5 patients with CRF survived CoVID-19 therapy without
    progression to ARDS or worsening of CRF.

#### Limitations

-   Renal injury biomarkers in patients with incipient kidney
    abnormalities not tabulated separately, making overall data hard to
    interpret. It will be critical to separately examine kidney function
    (BUN, urine creatinine and eGFR) in patients that developed any
    kidney abnormalities (7.2\~10.8% of cohort).

-   No information on type of CoVID-19 therapy used across cohort; will
    be useful to correlate how treatment modality influences kidney
    function (and other parameters).

-   Invokes previous clinical-correlation studies that indicate low
    instances of kidney damage[@doi:10.1001/jama.2020.1585; @doi:10.1101/2020.02.06.20020974], but those studies did not track
    longitudinal urine samples for acute renal injury markers and viral
    shedding.

-   CRRT in patients with CRF is standard therapy irrespective of
    CoVID-19 status; it will be important to compare clinical parameters
    of these patients (n=5) with virus-naïve CRF patients (none in this
    study) to make any meaningful conclusions.

#### Significance

-   This study argues that renal impairment is uncommon in CoVID-19 and
    not associated with high mortaility, in stark contrast with a
    concurrent study [@doi:10.1101/2020.02.08.20021212].
    If supported by further studies, this argues kidney impairment is
    secondary to cytokine storm/inflammation-induced organ failure, and
    not due to direct viral replication.

-   Will be important to comprehensively characterize large-datasets of
    CoVID-19 patients to conclude if kidney function actively disrupted
    due to viral infection.


#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Potential T-cell and B-Cell Epitopes of 2019-nCoV

[@doi:10.1101/2020.02.19.955484]

#### Keywords

- COVID-19
- vaccine
- epitopes
- spike protein
- MHC-I
- MHC-II
- neutralizing antibodies
- ACE2

#### Main Findings

The authors use 2 neural network algorithms, NetMHCpan4 and
MARIA, to identify regions within the COVID-19 genome that are
presentable by HLA. They identify 405 viral epitopes that are
presentable on MHC-I and MHC-II and validate using known epitopes from
SARS-CoV. To determine whether immune surveillance drives viral
mutations to evade MHC presentation, the authors analyzed 68 viral
genomes from 4 continents. They identified 93 point mutations that
occurred preferentially in regions predicted to be presented by MHC-I
(p=0.02) suggesting viral evolution to evade CD8 T-cell mediated
killing. 2 nonsense mutations were also identified that resulted in loss
of presentation of an associated antigen (FGDSVEEVL) predicted to be
good antigen for presentation across multiple HLA alleles.

To identify potential sites of neutralizing antibody binding, the
authors used homology modeling to the SARS-CoV’s spike protein (S
protein) to determine the putative structure of the CoV2 spike protein.
They used Discotope2 to identify antibody binding sites on the protein
surface in both the down and up conformations of the S protein. The
authors validate this approach by first identifying antibody binding
site in SARS-CoV S protein. In both the down and up conformation of the
CoV2 S protein, the authors identified a potential antibody binding site
on the S protein receptor binding domain (RBD) of the ACE2 receptor
(residues 440-460, 494-506). While RBDs in both SARS-CoV and CoV2 spike
proteins may be important for antibody binding, the authors note that
SARS-CoV has larger attack surfaces than CoV2. These results were later
validated on published crystal structures of the CoV2 S protein RBD and
human ACE2. Furthermore, analysis of 68 viral genomes did not identify
any mutations in this potential antibody binding site in CoV2.

Finally, the authors compile a list of potential peptide vaccine
candidates across the viral genome that can be presented by multiple HLA
alleles. Several of the peptides showed homology to SARS-CoV T-cell and
B-cell epitopes.

#### Limitations

While the authors used computational methods of validation,
primarily through multiple comparisons to published SARS-CoV structures
and epitopes, future work should include experimental validation of
putative T-cell and B-cell epitopes.

#### Significance

The authors identified potential T-cell and B-cell epitopes
that may be good candidates for peptide based vaccines against CoV2.
They also made interesting observations in comparing SARS-CoV and CoV2
potential antibody binding sites, noting that SARS-CoV had larger attack
surfaces for potential neutralizing antibody binding. One of the
highlights of this paper was the authors’ mutation analysis of 68 viral
genomes from 4 continents. This analysis not only validated their
computational method for identifying T-cell epitopes, but showed that
immune surveillance likely drives viral mutation in MHC-I binding
peptides. The smaller attack surface may point to potential mechanisms
of immune evasion by CoV2. However, absence of mutations in the RBD of
CoV2 and the small number of mutations in peptides presentable to T
cells suggests that vaccines against multiple epitopes could still
elicit robust immunity against CoV2.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Structure, Function, and Antigenicity of the SARSCoV-2 Spike Glycoprotein

Walls et al. *bioRxiv*. [@doi:10.1101/2020.02.19.956581] now [@doi:10.1016/j.cell.2020.02.058]

#### Keywords
- binding affinity
- antigenicity
- neutralizing antibody

#### Main Findings

The authors highlight a human angiotensin-converting enzyme 2
(hACE2), as a potential receptor used by the current Severe Acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) as a host factor that
allows the virus target human cells. This virus-host interaction
facilitates the infection of human cells with a high affinity comparable
with SARS-CoV. The authors propose this mechanism as a probable
explanation of the efficient transmission of SARS-CoV-2 between humans.
Besides, Walls and colleagues described SARS-CoV-2 S glycoprotein S by
Cryo-EM along with neutralizing polyclonal response against SAR-CoV-2 S
from mice immunized with SAR-CoV and blocking SAR-CoV-2 S-mediated entry
into VeroE6 infected cells.**

#### Limitations

The SARS-CoV-2 depends on the cell factors ACE2 and TMPRSS2, this
last, according to a recent manuscript by Markus Hoffman et al., *Cell*,
2020. The authors used green monkey (VeroE6) and hamster (BHK) cell
lines in the experiments to drive its conclusions to humans; however, it
is well known the caucasian colon adenocarcinoma human cell line
(CaCo-2), highly express the hACE2 receptor as the TMPRSS2 protease as
well. In humans, ACE2 protein is highly expressed in the
gastrointestinal tract, which again, makes the CaCo-2 cell line suitable
for the following SARS-CoV-2 studies.


#### Significance

The results propose a functional receptor used by SARS-CoV-2 to
infect humans worldwide and defining two distinct conformations of spike
(S) glycoprotein by cryogenic electron microscopy (Cryo-EM). This study
might help establish a precedent for initial drug design and treatment
of the current global human coronavirus epidemic.

#### Credit
*Review by postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19

Thevarajan et al. *medRxiv* [@doi:10.1101/2020.02.20.20025841]

#### Keywords

- IgG
- IgM
- TfH cells
- NK cells
- SNP

#### Main Findings

The authors characterized the immune response in peripheral blood of a
47-year old COVID-19 patient.

SARS-CoV2 was detected in nasopharyngeal swab, sputum and faeces
samples, but not in urine, rectal swab, whole blood or throat swab. 7
days after symptom onset, the nasopharyngeal swab test turned negative,
at day 10 the radiography infiltrates were cleared and at day 13 the
patient became asymptomatic.

Immunofluorescence staining shows from day 7 the presence of
**COVID-19-binding IgG and IgM** antibodies in plasma, that increase
until day 20.

Flow cytometry on whole blood reveals a plasmablast peak at day 8, a
gradual increase in T follicular helper cells, stable HLA-DR^+^ NK
frequencies and decreased monocyte frequencies compared to healthy
counterparts. The expression of CD38 and HLA-DR peaked on T cells at D9
and was associated with higher production of cytotoxic mediators by
CD8^+^ T cells.

IL-6 and IL-8 were undetectable in plasma.

The authors further highlight the presence of the **IFITM3
SNP-rs12252-C/C variant** in this patient, which is associated with
higher susceptibility to influenza virus.

#### Limitations

These results need to be confirmed in additional patients.

COVID-19 patients have increased infiltration of macrophages in their
lungs [@doi:10.1101/2020.02.23.20026690]. Monitoring monocyte proportions in blood earlier in the
disease might help to evaluate their eventual migration to the lungs.

The stable concentration of HLA-DR^+^ NK cells in blood from day 7 is
not sufficient to rule out NK cell activation upon SARS-CoV2 infection.
In response to influenza A virus, NK cells express higher levels of
activation markers CD69 and CD38, proliferate better and display higher
cytotoxicity [@doi:10.3389/fimmu.2019.01116]. Assessing these parameters in COVID-19 patients is
required to better understand NK cell role in clearing this infection.

Neutralization potential of the COVID-19-binding IgG and IgM antibodies
should be assessed in future studies.

This patient was able to clear the virus, while presenting a SNP
associated with severe outcome following influenza infection. The
association between this SNP and outcome upon SARS-CoV2 infection should
be further investigated.

#### Significance

This study is among the first to describe the appearance of
COVID-19-binding IgG and IgM antibodies upon infection. The emergence of
new serological assays might contribute to monitor more precisely the
seroconversion kinetics of COVID-19 patients [@doi:10.1101/2020.03.17.20037713]. Further association
studies between IFITM3 SNP-rs12252-C/C variant and clinical data might
help to refine the COVID-19 outcome prediction tools.

#### Credit

*Review by Bérengère Salomé as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

Liao et al. *medRxiv* [@doi:10.1101/2020.02.23.20026690]

#### Keywords

- COVID-19
- SARS-CoV-2
- Broncho-alveolar lavage
- macrophages
- NK cells
- T cells
- cytokine storm
- scRNAseq

#### Main Findings

The authors performed single-cell RNA sequencing (scRNAseq) on
bronchoalveolar lavage fluid (BAL) from 6 COVID-19 patients (n=3 mild
cases, n=3 severe cases). Data was compared to previously generated
scRNAseq data from healthy donor lung tissue (n=8).

Clustering analysis of the 6 patients revealed distinct immune cell
organization between mild and severe disease. Specifically, they found
that transcriptional clusters annotated as tissue resident alveolar
macrophages were strongly reduced while monocytes-derived FCN1^+^SPP1^+^
inflammatory macrophages dominated the BAL of patients with severe
COVID19 diseases. They show that inflammatory macrophages upregulated
interferon-signaling genes, monocytes recruiting chemokines including
CCL2, CCL3, CCL4 as well as IL-6, TNF, IL-8 and profibrotic cytokine
TGF-β, while alveolar macrophages expressed lipid metabolism genes, such
as PPARG.

The lymphoid compartment was overall enriched in lungs from patients.
Clonally expanded CD8 T cells were enriched in mild cases suggesting
that CD8 T cells contribute to viral clearance as in Flu infection,
whereas proliferating T cells were enriched in severe cases.

SARS-CoV-2 viral transcripts were detected in severe patients, but
considered here as ambient contaminations.

#### Limitations

These results are based on samples from 6 patients and should therefore
be confirmed in the future in additional patients. Longitudinal
monitoring of BAL during disease progression or resolution would have
been most useful.

The mechanisms underlying the skewing of the macrophage compartment in
patients towards inflammatory macrophages should be investigated in
future studies.

Deeper characterization of the lymphoid subsets is required. The
composition of the “proliferating” cluster and how these cells differ
from conventional T cell clusters should be assessed. NK and CD8 T cell
transcriptomic profile, in particular the expression of cytotoxic
mediator and immune checkpoint transcripts, should be compared between
healthy and diseased lesions.

#### Significance

COVID-19 induces a robust inflammatory cytokine storm in patients that
contributes to severe lung tissue damage and ARDS [@doi:10/ggjfnn]. Accumulation of
monocyte-derived inflammatory macrophages at the expense of Alveolar
macrophages known to play an anti-inflammatory role following
respiratory viral infection, in part through the PPARγ pathway [@doi:10.3389/fimmu.2018.01777; @doi:10.1128/JVI.00030-19] are
likely contributing to lung tissue injuries. These data suggest that
reduction of monocyte accumulation in the lung tissues could help
modulate COVID-19-induced inflammation. Further analysis of lymphoid
subsets is required to understand the contribution of adaptive immunity
to disease outcome.

#### Credit

*Review by Bérengère Salomé and Assaf Magen as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Can routine laboratory tests discriminate 2019 novel coronavirus infected pneumonia from other community-acquired pneumonia?

Pan et al. *medRxiv* [@doi:10.1101/2020.02.25.20024711]

#### Keywords

- Routine laboratory testing

#### Main Findings

In an attempt to use standard laboratory testing for the discrimination
between “Novel Coronavirus Infected Pneumonia” (NCIP) and a usual
community acquired pneumonia (CAP), the authors compared laboratory
testing results of 84 NCIP patients with those of a historical group of
316 CAP patients from 2018 naturally COVID-19 negative. The authors
describe significantly lower white blood- as well as red blood- and
platelet counts in NCIP patients. When analyzing differential blood
counts, lower absolute counts were measured in all subsets of NCIP
patients. With regard to clinical chemistry parameters, they found
increased AST and bilirubin in NCIP patients as compared to CAP
patients.

#### Limitations

The authors claim to describe a simple method to rapidly assess a
pre-test probability for NCIP. However, the study has substantial
weakpoints. The deviation in clinical laboratory values in NCIP patients
described here can usually be observed in severely ill patients. The
authors do not comment on how severely ill the patients tested here were
in comparison to the historical control. Thus, the conclusion that the
tests discriminate between CAP and NCIP lacks justification.

#### Significance

The article strives to compare initial laboratory testing results in
patients with COVID-19 pneumonia as compared to patients with a usual
community acquired pneumonia. The implications of this study for the
current clinical situation seem restricted due to a lack in clinical
information and the use of a control group that might not be
appropriate.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia

[@doi:10.1101/2020.02.25.20025643]

#### Keywords
- cytokine
- COVID-19 pneumonia
- severity
- disease progression

#### Main Findings

This study is a cross-sectional analysis of 100 patients with
COVID-19 pneumonia, divided into mild (n = 34), severe (n = 34), and
critical (n = 32) disease status based on clinical definitions.

The criteria used to define disease severity are as follows:

1.  *Severe* – any of the following: respiratory distress or respiratory
    rate ≥ 30 respirations/minute; oxygen saturation ≤ 93% at rest;
    oxygen partial pressure (PaO2)/oxygen concentration (FiO2) in
    arterial blood ≤ 300mmHg, progression of disease on imaging
    to &gt;50% lung involvement in the short term.

2.  *Critical* – any of the following: respiratory failure that requires
    mechanical ventilation; shock; other organ failure that requires
    treatment in the ICU.

3.  Patients with pneumonia who test positive for COVID-19 who do not
    have the symptoms delineated above are considered *mild*.

Peripheral blood inflammatory markers were correlated to disease status.
Disease severity was significantly associated with levels of IL-2R,
IL-6, IL-8, IL-10, TNF-α, CRP, ferroprotein, and procalcitonin. Total
WBC count, lymphocyte count, neutrophil count, and eosinophil count were
also significantly correlated with disease status. Since this is a
retrospective, cross-sectional study of clinical laboratory values,
these data may be extrapolated for clinical decision making, but without
studies of underlying cellular causes of these changes this study does
not contribute to a deeper understanding of SARS-CoV-2 interactions with
the immune system.

It is also notable that the mean age of patients in the mild group was
significantly different from the mean ages of patients designated as
severe or critical (p &lt; 0.001). The mean patient age was not
significantly different between the severe and critical groups. However,
IL-6, IL-8, procalcitonin (Table 2), CRP, ferroprotein (Figure 3A, 3B),
WBC count, and neutrophil count (Figure 4A, 4B) were all significantly
elevated in the critical group compared to severe. These data suggest
underlying differences in COVID-19 progression that is unrelated to age.

#### Significance

Given the inflammatory profile outlined in this study,
patients who have mild or severe COVID-19 pneumonia, who *also* have any
elevations in the inflammatory biomarkers listed above, should be
closely monitored for potential progression to critical status.

#### Credit

*This review by JJF was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors' CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

Herst et al. *bioRxiv* [@doi:10.1101/2020.02.25.963546]

#### Keywords

- Peptide vaccine
- Ebolavirus
- nucleocapsid
- epitope
- vaccine design
- microsphere

#### Main Findings

Vaccination of mice with a single dose of a 9-amino-acid peptide NP44-52
located in a conserved region of ebolavirus (EBOV) nucleocapsid protein
(NP) confers CD8+ T-cell-mediated immunity against mouse adapted EBOV
(maEBOV). Bioinformatic analyses predict multiple conserved CD8+ T cell
epitopes in the SARS-CoV-2 NP, suggesting that a similar approach may be
feasible for vaccine design against SARS-CoV-2.

The authors focus on a site within a 20-peptide region of EBOV NP which
was commonly targeted by CD8+ T cells in a group of EBOV survivors
carrying the HLA-A\*30:01:01 allele. To justify the testing of specific
vaccine epitopes in a mouse challenge setting, the authors cite known
examples of human pathogen-derived peptide antigens that are also
recognized by C57BL/6 mice, as well as existing data surrounding known
mouse immunogenicity of peptides related to this EBOV NP region. Testing
3 distinct 9mer peptides over an 11 amino-acid window and comparing to
vaccination with the 11mer with a T-cell reactivity readout demonstrated
that optimizing peptide length and position for immunogenicity may be
crucial, likely due to suboptimal peptide processing and MHC-class-I
loading.

Vaccines for maEBOV challenge studies were constructed by packaging
NP44-52 in d,l poly(lactic-co-glycolic) acid microspheres. CpG was also
packaged within the microspheres, while Monophosphoryl Lipid A (a TLR4
ligand) was added to the injectate solution. A second peptide consisting
of a predicted MHC-II epitope from the EBOV VG19 protein was added using
a separate population of microspheres, and the formulation was injected
by intraperitoneal administration. The vaccine was protective against a
range of maEBOV doses up to at least 10,000 PFU. Survival was
anticorrelated with levels of IL6, MCP-1 (CCL2), IL9, and GM-CSF, which
recapitulated trends seen in human EBOV infection.

While HLA-A\*30:01:01 is only present in a minority of humans, the
authors state that MHC binding algorithms predict NP44-52 to be a strong
binder of a set of more common HLA-A\*02 alleles. The authors predict
that a peptide vaccine based on the proposed formulation could elicit
responses in up to 50% of people in Sudan or 30% of people in North
America.

SARS-CoV-2 NP, meanwhile, has conserved regions which may provide
peptide-vaccine candidates. Scanning the SARS-CoV-2 NP sequence for
HLA-binding 9mers identified 53 peptides with predicted binding affinity
&lt; 500nM, including peptides that are predicted to bind to HLA-class-I
alleles of 97% of humans, 7 of which have previously been tested
*in-vitro*.

The results support previously appreciated correlations between certain
cytokines and disease severity, specifically IL6 which relates to
multiple trial therapies. Prediction of HLA-class-I binding of
SARS-CoV-2 NP peptides suggests the plausibility of a peptide vaccine
targeting conserved regions of SARS-CoV-2 NP although further validation
in previously infected patient samples will be essential.

#### Credit

*Review by Andrew M. Leader as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2

Li et al. *bioRxiv*. [@doi:10.1101/2020.02.25.965434]

#### Keywords
- SARS-CoV-2
- immune-informatics
- vaccine design
- T cell epitope
- B cell epitope

#### Main Findings

This study employs a series of bioinformatic
pipelines to identify T and B cell epitopes on spike (S) protein of
SARS-CoV-2 and assess their properties for vaccine potential. To
identify B cell epitopes, they assessed structural accessibility,
hydrophilicity, and beta-turn and flexibility which are all factors that
promote their targeting by antibodies. To identify T cell epitopes, they
filtered for peptides with high antigenicity score and capacity to bind
3 or more MHC alleles. Using the protein digest server, they also
demonstrated that their identified T and B cell epitopes are stable,
having multiple non-digesting enzymes per epitope. Epitopes were also
determined to be non-allergenic and non-toxin as assessed by Allergen FP
1.0 and ToxinPred, respectively. For T cell epitopes, they assessed the
strength of epitope-HLA interaction via PepSite. Overall, they predict
four B cell and eleven T cell epitopes (two MHC I and nine MHC II
binding) to pass stringent computational thresholds as candidates for
vaccine development. Furthermore, they performed sequence alignment
between all identified SARS-CoV-2 S protein mutations and predicted
epitopes, and showed that the epitopes are conserved across 134 isolates
from 38 locations worldwide. However, they report that these conserved
epitopes may soon become obsolete given the known mutation rate of
related SARS-CoV is estimated to be 4x10-4/site/year, underscoring the
urgency of anti-viral vaccine development.

#### Limitations

While spike (S) protein may have a
critical role in viral entry into host cells and their epitope
prediction criterion were comprehensive, this study did not examine
other candidate SARS-CoV-2 proteins. This point is particularly
important given that a single epitope may not be sufficient to induce
robust immune memory, and recent approaches involve multi-epitope
vaccine design. Furthermore, their study only included a direct
implementation of various published methods, but did not validate
individual bioinformatic tools with controls to demonstrate robustness.
Finally, it is critical that these predicted epitopes are experimentally
validated before any conclusions can be drawn about their potential as
vaccine candidates or their clinical efficacy.

#### Significance

This study provides a computational framework to
rapidly identify epitopes that may serve as potential vaccine candidates
for treating SARS-CoV-2.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis

Wang Jr. et al. *medRxiv*.
[@doi:10.1101/2020.02.26.20026989]

#### Keywords
- Cytokine release syndrome (CRS)
- biomarkers
- ARDS
- IL-6
- lymphopenia

#### Main Findings

This study describes the occurrence of a cytokine release syndrome-like
(CRSL) toxicity in ICU patients with COVID-19 pneumonia. The median time
from first symptom to acute respiratory distress syndrome (ARDS) was 10
days. All patients had decreased CD3, CD4 and CD8 cells, and a
significant increase of serum IL-6. Furthermore, 91% had decreased NK
cells. The changes in IL-6 levels preceded those in CD4 and CD8 cell
counts. All of these parameters correlated with the area of pulmonary
inflammation in CT scan images. Mechanical ventilation increased the
numbers of CD4 and CD8 cells, while decreasing the levels of IL-6, and
improving the immunological parameters.

#### Limitations

The number of patients included in this retrospective single center
study is small (n=11), and the follow-up period very short (25 days).
Eight of the eleven patients were described as having CRSL, and were
treated by intubation (7) or ECMO (2). Nine patients were still in the
intensive care unit at the time of publication of this article, so their
disease outcome is unknown.

#### Significance

The authors define a cytokine release syndrome-like toxicity in patients
with COVID-19 with clinical radiological and immunological criteria: 1)
decrease of circulating CD4, CD8 and NK cells; 2) substantial increase
of IL-6 in peripheral blood; 3) continuous fever; 4) organ and tissue
damage. This event seems to occur very often in critically ill patients
with COVID-19 pneumonia. Interestingly, the increase of IL-6 in the
peripheral blood preceded other laboratory alterations, thus, IL-6 might
be an early biomarker for the severity of COVID-19 pneumonia. The
manuscript will require considerable editing for organization and
clarity.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China

Huang et al. *medRxiv*. [@doi:10.1101/2020.02.27.20029009]

#### Keywords

- Clinical Characteristics
- Non Survivors
- retrospective study

#### Main Findings

This is a simple study reporting clinical
characteristics of patients who did not survive COVID-19. All patients
(mean age=69.22 years) had acute respiratory distress syndrome (ARDS)
and their median time from onset to ARDS was 11 days. The median time
from onset to death was 17 days. Most patients were older male (70%
male) with co-morbidities and only 11 % were smokers. 75% patients
showed bilateral pneumonia. Many patients had chronic diseases,
including hypertension (58.33%). cardiovascular disease (22.22%) and
diabetes (19.44%). Typical clinical feature measured in these patients
includes lymphopenia and elevated markers of inflammation.

#### Limitations

As noted by the authors, the conclusions of this study are
very limited because this is single-centered study focusing on a small
cohort of patients who did not survive. Many clinical parameters
observed by the authors (such* as increase levels of serum CRP, PCT,
IL-6) have also been described in other COVID19 patients who survived
the infection

#### Significance

This study is essentially descriptive and may be useful for
clinical teams monitoring COVID19 patients.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Risk Factors Related to Hepatic Injury in Patients with Corona Virus Disease 2019

[@doi:10.1101/2020.02.28.20028514]

#### Keywords

- COVID-related Hepatic Injury

#### Main Findings

Based on a retrospective study of 85 hospitalized COVID
patients in a Beijing hospital, authors showed that patients with
elevated ALT levels (n = 33) were characterized by significantly higher
levels of lactic acid and CRP as well as lymphopenia and hypoalbuminemia
compared to their counterparts with normal ALT levels. Proportion of
severe and critical patients in the ALT elevation group was
significantly higher than that of normal ALT group. Multivariate
logistic regression performed on clinical factors related to ALT
elevation showed that CRP $\geq$ 20mg/L and low lymphocyte count
(&lt;1.1\*10\^9 cells/L) were independently related to ALT elevation—a
finding that led the authors to suggest cytokine storm as a major
mechanism of liver damage.

#### Limitations

The article’s most attractive claim that liver damage seen in COVID
patients is caused by cytokine storm (rather than direct infection of
the liver) hinges solely on their multivariate regression analysis.
Without further mechanistic studies a) demonstrating how high levels of
inflammatory cytokines can induce liver damage and b) contrasting types
of liver damage incurred by direct infection of the liver vs.
system-wide elevation of inflammatory cytokines, their claim remains
thin. It is also worth noting that six of their elevated ALT group
(n=33) had a history of liver disease (i.e. HBV infection, alcoholic
liver disease, fatty liver) which can confound their effort to pin down
the cause of hepatic injury to COVID.

#### Significance

Limited. This article confirms a rich body
of literature describing liver damage and lymphopenia in COVID patients.

#### Credit

*Review by Chang Moon as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

[@doi:10.1101/2020.02.29.20029520]

#### Keywords

- ARDS
- interleukin-6 (IL-6)
- procalcitonin (PCT)
- pro-inflammatory cytokines
- SARS-CoV-2 RNAaemia

#### Main Findings

48 adult patients diagnosed with Covid19 according to Chinese guidelines
for Covid19 diagnosis and treatment version 6 were included in this
study. Patients were further sub-divided into three groups based on
clinical symptoms and disease severity: (1) mild, positive Covid19 qPCR
with no or mild clinical symptoms (fever; respiratory; radiological
abnormalities); (2) severe, at least one of the following: shortness of
breath/respiratory rate &gt;30/min, oxygen saturation SaO~2~&lt;93%,
Horowitz index paO2/FiO~2~ &lt; 300 mmHg (indicating moderate pulmonary
damage); and (3) critically ill, at least one additional complicating
factor: respiratory failure with need for mechanical ventilation;
systemic shock; multi-organ failure and transfer to ICU. Serum samples
and throat-swaps were collected from all 48 patients enrolled.
SARS-CoV-2 RNA was assessed by qPCR with positive results being defined
as Ct values &lt; 40, and serum interleukin-6 (IL-6) was quantified
using a commercially available detection kit. Briefly, patient
characteristics in this study confirm previous reports suggesting that
higher age and comorbidities are significant risk factors of clinical
severity. Of note, 5 out of 48 of patients (10.41%), all in the
critically ill category, were found to have detectable serum SARS-CoV-2
RNA levels, so-called RNAaemia. Moreover, serum IL-6 levels in these
patients were found to be substantially higher and this correlated with
the presence of detectable SARS-CoV-2 RNA levels. The authors
hypothesize that viral RNA might be released from acutely damages
tissues in moribund patients during the course of Covid19 and that
RNaemia along with IL-6 could potentially be used as a prognostic
marker.

#### Limitations

While this group’s report generally confirms some of the major findings
of a more extensive study, published in early February 2020, [@doi:10/ggjfnn],
there are limitations that should be taken into account. First, the
number of patients enrolled is relatively small; second, interpretation
of these data would benefit from inclusion of information about study
specifics as well as providing relevant data on the clinical course of
these patients other than the fact that some were admitted to ICU (i.e.
demographics on how many patients needed respiratory support, dialysis,
APACHE Ii/III or other standard ICU scores as robust prognostic markers
for mortality etc). It also remains unclear at which time point the
serum samples were taken, i.e. whether at admission, when the diagnosis
was made or during the course of the hospital stay (and potentially
after onset of therapy, which could have affected both IL-6 and RNA
levels). The methods section lacks important information on the qPCR
protocol employed, including primers and cycling conditions used. From a
technical point of view, Ct values &gt;35 seem somewhat non-specific
(although Ct &lt;40 was defined as the CDC cutoff as well) indicating
that serum RNA levels are probably very low, therefore stressing the
need for highly specific primers and high qPCR efficiency. In addition,
the statistical tests used (t-tests, according to the methods section)
do not seem appropriate as the organ-specific data such as BUN and
troponin T values seem to be not normally distributed across groups (n=
5 RNAaemia+ vs. n= 43 RNAaemia-). Given the range of standard deviations
and the differences in patient sample size, it is difficult to believe
that these data are statistically significantly different.

#### Significance

This study is very rudimentary and lacks a lot of relevant clinical
details. However, it corroborates some previously published observations
regarding RNAemia and IL-6 by another group. Generally, regarding future
studies, it would be important to address the question of IL-6 and other
inflammatory cytokine dynamics in relation to Covid19 disease kinetics
(high levels of IL-6, IL-8 and plasma leukotriene were shown to have
prognostic value at the onset of ARDS ; serum IL-2 and IL-15 have been
associated with mortality; reviewed by Chen W & Ware L, Clin Transl Med.
2015 [@doi:10.1186/s40169-015-0065-2]).

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

[@doi:10.1101/2020.03.01.20029074]

#### Keywords

- Lymphopenia

#### Main Findings
Based on a retrospective study of 162 COVID patients from a
local hospital in Wuhan, China, the authors show an inverse correlation
between lymphocyte % (LYM%) of patients and their disease severity. The
authors have also tracked LYM% of 70 cases (15 deaths; 15 severe; 40
moderate) throughout the disease progression with fatal cases showing no
recovery of lymphocytes ( &lt;5%) even after 17-19 days post-onset. The
temporal data of LYM % in COVID patients was used to construct a
Time-Lymphocyte% model which is used to categorize and predict patients’
disease severity and progression. The model was validated using 92
hospitalized cases and kappa statistic test was used to assess agreement
between predicted disease severity and the assigned clinical severity (k
= 0.49).

#### Limitations

Time-Lymphocyte % Model (TLM) that authors have proposed as
a predictive model for clinical severity is very simple in its
construction and derives from correlative data of 162 patients. In order
for the model to be of use, it needs validation using a far more robust
data set and possibly a mechanistic study on how COVID leads to
lymphopenia in the first place. In addition, it should be noted that no
statistical test assessing significance of LYM % values between disease
severities was performed.

#### Significance

This article is of limited significance as
it simply reports similar descriptions of COVID patients made in
previous literature that severe cases are characterized by lymphopenia.

#### Credit

*Review by Chang Moon as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The potential role of IL-6 in monitoring severe case of coronavirus disease 2019

Liu et al. *medRxiv*. [@doi:10.1101/2020.03.01.20029769]

#### Keywords
- Cytokine Release Syndrome
- lymphocytopenia
- IL-6
- CRP
- COVID19
- pneumonia

#### Main Findings

Study on blood biomarkers on 80 COVID19 patients (69 severe
and 11 non-severe). Patients with severe symptoms at admission
(baseline) showed obvious lymphocytopenia and significantly increased
interleukin-6 (IL-6) and CRP, which was positively correlated with
symptoms severity. IL-6 at baseline positively correlates with CRP, LDH,
ferritin and D-Dimer abundance in blood.

Longitudinal analysis of 30 patients (before and after treatment) showed
significant reduction of IL-6 in remission cases.

#### Limitations

Limited sample size at baseline, especially for the
non-severe leads to question on representativeness. The longitudinal
study method is not described in detail and suffers from
non-standardized treatment. Limited panel of pro-inflammatory cytokine
was analyzed. Patients with severe disease show a wide range of altered
blood composition and biomarkers of inflammation, as well as differences
in disease course (53.6% were cured, about 10% developed acute
respiratory distress syndrome). The authors comment on associations
between IL-6 levels and outcomes, but these were not statistically
significant (maybe due to the number of patients, non-standardized
treatments, etc.) and data is not shown. Prognostic biomarkers could
have been better explored. Study lacks multivariate analysis.

#### Significance

IL-6 could be used as a pharmacodynamic
marker of disease severity. Cytokine Release Syndrome (CRS) is a
well-known side effect for CAR-T cancer therapy and there are several
effective drugs to manage CRS. Drugs used to manage CRS could be tested
to treat the most severe cases of COVID19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel Coronavirus Disease 2019 in Hefei, China

Zhao et al. *medRxiv*. [@doi:10.1101/2020.03.01.20029785]

#### Keywords

- Routine laboratory testing

#### Main Findings

The authors of this study provide a comprehensive analysis of clinical
laboratory assessments in 75 patients (median age 47 year old)
hospitalized for Corona virus infection in China measuring differential
blood counts including T-cell subsets (CD4, CD8), coagulation function,
basic blood chemistry, of infection-related biomarkers including CRP,
Procalcitonin (PCT) (Precursor of calcitonin that increases during
bacterial infection or tissue injury), IL-6 and erythrocyte
sedimentation rate as well as clinical parameters. Among the most common
hematological changes they found increased neutrophils, reduced CD4 and
CD8 lymphocytes, increased LDH, CRP and PCT

When looking at patients with elevated IL-6, the authors describe
significantly reduced CD4 and CD8 lymphocyte counts and elevated CRP and
PCT levels were significantly increased in infected patients suggesting
that increased IL-6 may correlate well with disease severity in COVID-19
infections

#### Limitations

The authors performed an early assessment of clinical standard
parameters in patients infected with COVID-19. Overall, the number of
cases (75) is rather low and the snapshot approach does not inform about
dynamics and thus potential relevance in the assessment of treatment
options in this group of patients.

#### Significance

The article summarizes provides a good summary of some of the common
changes in immune cells inflammatory cytokines in patients with a
COVID-19 infection and. Understanding how these changes can help predict
severity of disease and guide therapy including IL-6 cytokine receptor
blockade using Tocilizumab or Sarilumab will be important to explore.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome

Yang et al. *medRxiv* [@doi:10.1101/2020.03.02.20029975]

#### Keywords

- cytokine
- IP-10
- MCP-3
- IL-1Ra
- lymphocyte
- neutrophil
- stratification
- disease severity
- viral load
- lung function
- complications
- clinical data

#### Summary

Plasma cytokine analysis (48 cytokines) was
performed on COVID-19 patient plasma samples, who were sub-stratified as
severe (N=34), moderate (N=19), and compared to healthy controls (N=8).
Patients were monitored for up to 24 days after illness onset: viral
load (qRT-PCR), cytokine (multiplex on subset of patients), lab tests,
and epidemiological/clinical characteristics of patients were reported.



#### Main Findings

-   Many elevated cytokines with COVID-19 onset compared to healthy
    controls (IFNy, IL-1Ra, IL-2Ra, IL-6, IL-10, IL-18, HGF, MCP-3, MIG,
    M-CSF, G-CSF, MIG-1a, and IP-10).

-   IP-10, IL-1Ra, and MCP-3 (esp. together) were associated with
    disease severity and fatal outcome.

-   IP-10 was correlated to patient viral load (r=0.3006, p=0.0075).

-   IP-10, IL-1Ra, and MCP-3 were correlated to loss of lung function
    (PaO~2~/FaO~2~ (arterial/atmospheric O2) and Murray Score (lung
    injury) with MCP-3 being the most correlated (r=0.4104 p&lt;0.0001
    and r=0.5107 p&lt;0.0001 respectively).

-   Viral load (Lower Ct Value from qRT-PCR) was associated with
    upregulated IP-10 only (not IL-1Ra or MCP-3) and was mildly
    correlated with decreased lung function: PaO~2~/FaO~2~
    (arterial/atmospheric O2) and Murray Score (lung injury).

-   Lymphopenia (decreased CD4 and CD8 T cells) and increased neutrophil
    correlated w/ severe patients.

-   Complications were associated with COVID severity (ARDS, hepatic
    insufficiency, renal insufficiency).

#### Limitations

Collection time of clinical data and lab results
not reported directly (likely 4 days (2,6) after illness onset), making
it very difficult to determine if cytokines were predictive of patient
outcome or reflective of patient compensatory immune response (likely
the latter). Small N for cytokine analysis (N=2 fatal and N=5
severe/critical, and N=7 moderate or discharged). Viral treatment
strategy not clearly outlined.

#### Expanded Results

*NOTE*: Moderate COVID-19 was classified by fever, respiratory
manifestations, and radiological findings consistent with pneumonia
while severe patients had one or more of the following: 1) respiratory
distraction, resting O2 saturation, or 3) arterial PaO2/FiO2 *&lt;* 300
mmHg.

Cytokine Results (Human Cytokine Screening Panel, Bio-Rad):

-   **Significant elevation of cytokines observed in COVID patients
    compared to healthy controls: IFNy, IL-1Ra, IL-2Ra, IL-6, IL-10,
    IL-18, HGF, MCP-3, MIG, M-CSF, G-CSF, MIG-1a, and IP-10.**

-   Severity was correlated **with increase in measured IP-10, MCP-3,
    and IL-Ra** as measure by area under the curve analysis during
    sample timecourse (2-24 days after illness onset).

-   IL-1Ra incr. significant 0-7 days after onset, MCP-3 signif.
    upregulated throughout observation timecourse, and IP-10 increased
    and upregulated throughout (trending downwards over time).

-   **The three cytokines together (IP-10, IL-1Ra, and MCP-3 AUC) served
    as the best predictors of disease deterioration and fatal outcome.**

-   No significant differences between moderate/severe observed between
    groups in IL-2Ra, IL-6, IL-10, IL-18, CTACK, G-CSF, HGF, M-CSF,
    MIP-1a, MIG, and IFNy at any timepoints.

-   **Viral load (Lower Ct Value from qRT-PCR) was associated with
    upregulated IP-10 only (not IL-1Ra or MCP-3) and was highly
    correlated with decreased lung function: PaO~2~/FaO~2~
    (arterial/atmospheric O2) and Murray Score (lung injury).**

-   **Antibodies against these cytokines (esp. anti-IP-10) may serve as
    a potential treatment for amelioration of COVID-19 (and associated
    ARDS).**

Lab results:

-   **Decreased lymphocytes (%) in all patients – lymphopenia corr. w/
    severe patients**

    -   **Decreased CD4 and CD8 T cells** – no monocyte or
        eosino/basophil % measured

-   **Increased neutrophils (%)**

-   Increased BUN (mmol/L) – other kidney markers, liver markers, and
    LDH were not significantly different between groups and were not
    compared to healthy controls.

Clinical features (between moderate vs. severe patient groups):

-   **Complications were associated with severity (ARDS, hepatic
    insufficiency, renal insufficiency).**

-   Coexisting conditions between groups were not significantly
    different (chronic heart/lung/renal/liver disease, diabetes, or
    cancer) and patient time courses (onset to admission and onset to
    viral tx) also not significantly different – 4 days (2, 6) on
    average for admission and 4 (3,7) for antiviral.

-   Increased corticosteroids and mechanical/ invasive mechanical
    ventilation in severe patients.

-   Increased median age in severe group (Median (Range = 63.5 (42-74)
    vs. 51 (22-78)) and patients *&gt;* 60 yrs had higher ratio of
    severe patients as compared patients 16-59 yrs.

-   Higher incidence of fever is severe patients (91.2 vs. 68.4%),
    myalgia (57.7 vs. 48.1%), and chill (17.6% vs. 0%).

-   No differences in cough, headache, nausea/vomiting, or diarrhea.

#### Significance

Outline of pathological time course (implicating innate
immunity esp.) and identification key cytokines associated with disease
severity and prognosis (+ comorbidities). Anti-IP-10 as a possible
therapeutic intervention (ex: Eldelumab).

#### Credit

*Review by Natalie Vaninov as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Zhao Jr. et al. *medRxiv*. [@doi:10.1101/2020.03.02.20030189]

#### Keywords
- SARS-CoV-2 IgG
- seroconversion rate
- total Ab
- Ig
- IgM

#### Main Findings

This study examined antibody responses in
the blood of COVID-19 patients during the early SARS CoV2 outbreak in
China. Total 535 plasma samples were collected from 173 patients (51.4%
female) and were tested for seroconversion rate using ELISA. Authors
also compared the sensitivity of RNA and antibody tests over the course
of the disease . The key findings are:

-   Among 173 patients, the seroconversion rates for total antibody
    (Ab), IgM and IgG were 93.1% (161/173), 82.7% (143/173) and 64.7%
    (112/173), respectively.

-   The seroconversion sequentially appeared for Ab, IgM and then IgG,
    with a median time of 11, 12 and 14 days, respectively. Overall, the
    seroconversion of Ab was significantly quicker than that of IgM (p =
    0.012) and IgG (p &lt; 0.001). Comparisons of seroconversion rates
    between critical and non-critical patients did not reveal any
    significant differences.

-   RNA tests had higher sensitivity in early phase and within 7 days of
    disease onset than antibody assays (66.7% Vs 38.3% respectively).

-   The sensitivity of the Ab assays was higher 8 days after disease
    onset, reached 90% at day 13 and 100% at later time points (15-39
    days). In contrast, RNA was only detectable in 45.5% of samples at
    days 15-39.

-   In patients with undetectable RNA in nasal samples collected during
    day 1-3, day 4-7, day 8-14 and day 15-39 since disease onset, 28.6%
    (2/7), 53.6% (15/28), 98.2% (56/57) and 100% (30/30) had detectable
    total Ab titers respectively Combining RNA and antibody tests
    significantly raised the sensitivity for detecting COVID-19 patients
    in different stages of the disease (p &lt; 0.001).

-   There was a strong positive correlation between clinical severity
    and antibody titer 2-weeks after illness onset.

-   Dynamic profiling of viral RNA and antibodies in representative
    COVID-19 patients (n=9) since onset of disease revealed that
    antibodies may not be sufficient to clear the virus. It should be
    noted that increases in of antibody titers were not always
    accompanied by RNA clearance.

#### Limitations

Because different types of ELISA assays were used for
determining antibody concentrations at different time points after
disease onset, sequential seroconversion of total Ab, IgM and IgG may
not represent actual temporal differences but rather differences in the
affinities of the assays used. Also, due to the lack of blood samples
collected from patients in the later stage of illness, how long the
antibodies could last remain unknown. For investigative dynamics of
antibodies, more samples were required.

#### Significance

Total and IgG antibody titers could be used to understand
the epidemiology of SARS CoV-2 infection and to assist in determining
the level of humoral immune response in patients.

The findings provide strong clinical evidence for routine serological
and RNA testing in the diagnosis and clinical management of COVID-19
patients. The understanding of antibody responses and their half-life
during and after SARS CoV2 infection is important and warrants further
investigations.

#### Credit

*This review was undertaken by Zafar Mahmood and edited by K Alexandropoulos as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients

Chen et al. *medRxiv* [@doi:10.1101/2020.03.03.20030437]

#### Keywords

- COVID-19
- T cell
- B cell
- NK cell
- IL-6
- pro-calcitonin
- cytokine storm

#### Main Findings

The authors collected data on 25 COVID-19 patients (n=11 men, n=14
women) using standard laboratory tests and flow cytometry. All patients
were treated with antibiotics. Twenty-four of the 25 patients were also
treated with anti-viral Umefinovir and 14 of the patients were treated
with corticosteroids. 14 patients became negative for the virus after
8-14 days of treatment. The same treatment course was extended to 15-23
days for patients who were still positive for the virus at day 14.

The authors found a negative association between age and resolution of
infection. Patients with hypertension, diabetes, malignancy or chronic
liver disease were all unable to clear the virus at day 14, though not
statistically significant.

Elevated procalcitonin and a trend for increased IL-6 were also found in
peripheral blood prior to the treatment.

A trend for lower NK cell, T cell and B cell counts in patients was also
reported. B cell, CD4 and CD8 T cell counts were only increased upon
treatment in patients who cleared the virus. NK cell frequencies
remained unchanged after treatment in all the patients.

#### Limitations

73% of the patients who remained positive for SARS-CoV2 after the 1^st^
treatment, and 43% of all patients who cleared the virus were treated
with corticosteroids. Corticosteroids have strong effects on the immune
compartment in blood [@doi:10.1038/srep23002]. The authors should have accounted for
corticosteroid treatment when considering changes in T, NK and B cell
frequencies.

Assessing if IL-6 concentrations were back to baseline levels following
treatment would have provided insights into the COVID-19 cytokine storm
biology. Patients with higher baseline levels of IL-6 have been reported
to have lower CD8 and CD4 T cell frequencies [@doi:10.1101/2020.03.01.20029785]. Correlating IL-6 with
cell counts before and after treatment would thus have also been of
interest. The report of the laboratory measures in table 2 is incomplete
and should include the frequencies of patients with increased/decreased
levels for each parameter.

Correction is needed for the 1^st^ paragraph of the discussion as data
does not support NK cell restoration upon treatment in patients who
cleared the virus. NK cells remain unchanged after the 1^st^ treatment
course and only seem to increase in 2 out of 6 donors after the 2^nd^
treatment course in those patients.

#### Significance

Previous reports suggest an association between disease severity and
elevated IL-6 or pro-calcitonin concentrations in COVID-19
patients [@doi:10.1101/2020.02.29.20029520; @doi:10.1016/j.cca.2020.03.004]. IL-6 receptor blockade is also being administered to
patients enrolled in clinical trials (NCT04317092). This report thus
contributes to highlight elevated concentrations of these analytes in
COVID-19 patients. Mechanisms underlying the association between viral
clearance and restoration of the T cell and B cell frequencies suggests
viral-driven immune dysregulation, which needs to be investigated in
further studies.

#### Credit

*Review by Bérengère Salomé as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical findings in critically ill patients infected with SARS-CoV-2 in Guangdong Province, China: a multi-center, retrospective, observational study


Xu et al. *medRxiv*. [@doi:10.1101/2020.03.03.20030668]

#### Keywords

- clinical outcomes
- prognosis
- critically ill patients
- ICU
- lymphopenia
- LDH

#### Main Findings:

This work analyses laboratory and clinical data from 45 patients treated
in the in ICU in a single province in China. Overall, 44% of the
patients were intubated within 3 days of ICU admission with only 1
death.

Lymphopenia was noted in 91% of patient with an inverse correlation with
LDH.

Lymphocyte levels are negatively correlated with Sequential Organ
Failure Assessment (SOFA) score (clinical score, the higher the more
critical state), LDH levels are positively correlated to SOFA score.
Overall, older patients (&gt;60yo), with high SOFA score, high LDH
levels and low lymphocytes levels at ICU admission are at higher risk of
intubation.

Of note, convalescent plasma was administered to 6 patients but due to
limited sample size no conclusion can be made.

#### Limitations

While the study offers important insights into disease course and
clinical lab correlates of outcome, the cohort is relatively small and
is likely skewed towards a less-severe population compared to other ICU
reports given the outcomes observed. Analysis of laboratory values and
predictors of outcomes in larger cohorts will be important to make
triage and treatment decisions. As with many retrospective analyses,
pre-infection data is limited and thus it is not possible to understand
whether lymphopenia was secondary to underlying comorbidities or
infection.

Well-designed studies are necessary to evaluate the effect of
convalescent plasma administration.

#### Significance

This clinical data enables the identification of at-risk
patients and gives guidance for research for treatment options. Indeed,
further work is needed to better understand the causes of the
lymphopenia and its correlation with outcome.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Immune Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2)

[@doi:10.1101/2020.03.03.962332]

#### Keywords

- Vaccine
- in silico
- B cell epitopes
- T cell epitopes

#### Main Findings

Using in silico bioinformatic tools, this study identified putative
antigenic B-cell epitopes and HLA restricted T-cell epitopes from the
spike, envelope and membrane proteins of SARS-CoV-2, based on the genome
sequence available on the NCBI database. T cell epitopes were selected
based on predicted affinity for the more common HLA-I alleles in the
Chinese population. Subsequently, the authors designed vaccine peptides
by bridging selected B-cell epitopes and adjacent T-cell epitopes.
Vaccine peptides containing only T-cell epitopes were also generated.

From 61 predicted B-cell epitopes, only 19 were exposed on the surface
of the virion and had a high antigenicity score. A total of 499 T-cell
epitopes were predicted. Based on the 19 B-cell epitopes and their 121
adjacent T-cell epitopes, 17 candidate vaccine peptides were designed.
Additionally, another 102 vaccine peptides containing T-cell epitopes
only were generated. Based on the epitope counts and HLA score, 13 of
those were selected. Thus, a total of 30 peptide vaccine candidates were
designed.

#### Limitations

While this study provides candidates for the development of vaccines
against SARS-CoV-2, in vitro and in vivo trials are required to validate
the immunogenicity of the selected B and T cell epitopes. This could be
done using serum and cells from CoV-2-exposed individuals, and in
preclinical studies. The implication of this study for the current
epidemic are thus limited. Nevertheless, further research on this field
is greatly needed.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China

Cao et al. *medRxiv* [@doi:10.1101/2020.03.04.20030395]

#### Keywords

- Disease severity
- clinical features
- laboratory abnormalities

#### Main Findings

This single-center cohort study analyzes the clinical and
laboratory features of 198 patients with confirmed COVID-19 infection in
Shanghai, China and correlated these parameters with clinical disease
severity, including subsequent intensive care unit (ICU) admission. 19
cases (9.5%) required ICU admission after developing respiratory failure
or organ dysfunction. Age, male sex, underlying cardiovascular disease,
and high symptom severity (high fever, dyspnea) were all significantly
correlated with ICU admission. Additionally, ICU admission was more
common in patients who presented with lymphopenia and elevated
neutrophil counts, among other laboratory abnormalities. Flow cytometric
analysis revealed that patients admitted to the ICU had significantly
reduced circulating CD3+ T cell, CD4+ T cell, CD8+ T cell, and CD45+
leukocyte populations compared to the cohort of patients not requiring
ICU admission.

#### Limitations

The limitations of this study include the relatively
small sample size and lack of longitudinal testing. The authors also did
not assess whether respiratory comorbidity – such as asthma or chronic
obstructive lung disease – in addition to immunosuppression affected ICU
admission likelihood.

#### Significance

COVID-19 has already sickened thousands across the globe,
though the severity of these infections is markedly diverse, ranging
from mild symptoms to respiratory failure requiring maximal
intervention. Understanding what clinical, laboratory, and immunologic
factors predict the clinical course of COVID-19 infection permits
frontline providers to distribute limited medical resources more
effectively.

#### Credit

*Review by Andrew Charap as part of a project by students, postdocs and
faculty at the Immunology Institute of the Icahn School of Medicine at
Mount Sinai.*


### Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing

Zhang et al. *medRxiv*. [@doi:10.1101/2020.03.04.20030916]

#### Keywords

- Immunoassay
- serum IgM and IgG
- specific antibodies

#### Main Finding

This study showed that both anti-2019-nCov IgM and IgG were detected by
automated chemiluminescent immunoassay in the patients who had been
already confirmed as positive by nucleic acid detection, while single
positivity of IgM or IgG were detected in a very few cases in the other
population including 225 non-COVID-19 cases. In addition to the increase
of anti-2019-nCov IgM 7-12 days after morbidity, the increase of IgG was
detected in three patients with COVID-19 within a very short of time
(0-1 day).

#### Limitations

The limitation of this study is only
3 confirmed COVID-19 cases were included, so that the relationship
between anti-2019-nCov antibodies and disease progression might not be
clearly defined. Another limitation is that they did not show the course
of 2019-nCov specific antibodies in the cases with positive for COVID-19
but without clinical symptoms.

#### Significance

The detection of anti-2019-nCov antibodies can be an alternative method
to diagnose and treat COVID-19 more comprehensively by distinguish non
COVID-19 patients. It may be helpful to understand the course of
individual cases with COVID-19 to predict the prognosis if more cases
will be evaluated.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

[@doi:10.1101/2020.03.04.20031120]

#### Keywords

- Kidney/Renal Failure
- Macrophage Infiltration
- Complement Activation

#### Main Finding

Analyzing the eGFR (effective glomerular flow rate) of 85 Covid-19
patients and characterizing tissue damage and viral presence in
post-mortem kidney samples from 6 Covid-19 patients, the authors
conclude that significant damage occurs to the kidney, following
Covid-19 infection. This is in contrast to the SARS infection from the
2003 outbreak. They determine this damage to be more prevalent in
patients older than 60 years old, as determined by analysis of eGFR. H&E
and IHC analysis in 6 Covid-19 patients revealed that damage was in the
tubules, not the glomeruli of the kidneys and suggested that macrophage
accumulation and C5b-9 deposition are key to this process. 

#### Limitations

Severe limitations include that the H&E and IHC samples were performed
on post-mortem samples of unknown age, thus we cannot assess how/if age
correlates with kidney damage, upon Covid-19 infection. Additionally,
eGFR was the only *in-vivo* measurement. Blood urea nitrogen and
proteinuria are amongst other measurements that could have been obtained
from patient records. An immune panel of the blood was not performed to
assess immune system activation. Additionally, patients are only from
one hospital. 

#### Significance

This report makes clear that kidney damage is prevalent
in Covid-19 patients and should be accounted for. 

#### Credit

*Review by Dan Fu Ruan, Evan Cody and Venu Pothula as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine at Mount Sinai.*


### COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients

Song et al. *medRxiv*. [@doi:10.1101/2020.03.05.20031906]

#### Keywords

- retrospective
- electronic health records
- blood counts
- diagnostic
- prognostic
- modeling

#### Main Findings

The aim of this study was to identify diagnostic or prognostic criteria
which could identify patients with COVID-19 and predict patients who
would go on to develop severe respiratory disease. The authors use EMR
data from individuals taking a COVID-19 test at Zhejiang hospital, China
in late January/Early February. A large number of clinical parameters
were different between individuals with COVID-19 and also between
‘severe’ and ‘non-severe’ infections and the authors combine these into
a multivariate linear model to derive a weighted score, presumably
intended for clinical use.

#### Limitations

Unfortunately, the paper is lacking a lot of crucial information, making
it impossible to determine the importance or relevance of the findings.
Most importantly, the timings of the clinical measurements are not
described relative to the disease course, so it is unclear if the
differences between ‘severe’ and ‘non-severe’ infections are occurring
before progression to severe disease (which would make them useful
prognostic markers), or after (which would not).

#### Significance

This paper is one of many retrospective studies coming from hospitals in
China studying individuals with COVID-19. Because of the sparse
description of the study design, this paper offers little new
information. However, studies like this could be very valuable and we
would strongly encourage the authors to revise this manuscript to
include more information about the timeline of clinical measurements in
relation to disease onset and more details of patient outcomes.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### LY6E impairs coronavirus fusion and confers immune control of viral disease

Pfaender et al. *bioRxiv*. [@doi:10.1101/2020.03.05.979260]

#### Keywords

- interferon-stimulated genes
- antiviral interferons
- human coronaviruses (CoV)
- murine hepatitis virus (MHV)

#### Main Findings

Screening a cDNA library of &gt;350 human interferon-stimulated genes
for antiviral activity against endemic human coronavirus HCoV-229E
(associated with the common cold), Pfaender S & Mar K *et al.* identify
lymphocyte antigen 6 complex, locus E (Ly6E) as an inhibitor of cellular
infection of Huh7 cells, a human hepatoma cell line susceptible to
HCoV-229E and other coronaviruses. In a series of consecutive *in vitro*
experiments including both stable Ly6E overexpression and
CRISPR-Cas9-mediated knockout the authors further demonstrate that Ly6E
reduces cellular infection by various other coronaviruses including
human SARS-CoV and SARS-CoV-2 as well as murine CoV mouse hepatitis
virus (MHV). Their experiments suggest that this effect is dependent on
Ly6E inhibition of CoV strain-specific spike protein-mediated membrane
fusion required for viral cell entry.

To address the function of Ly6E *in vivo*, hematopoietic stem
cell-specific Ly6E knock-out mice were generated by breeding Ly6E^fl/fl^
mice (referred to as functional wild-type mice) with transgenic
*Vav-iCre* mice (offspring referred to as Ly6E HSC ko mice); wild-type
and Ly6E HSC ko mice of both sexes were infected intraperitoneally with
varying doses of the natural murine coronavirus MHV, generally causing a
wide range of diseases in mice including hepatitis, enteritis and
encephalomyelitis. Briefly, compared to wild-type controls, mice lacking
hematopoietic cell-expressed Ly6E were found to present with a more
severe disease phenotype as based on serum ALT levels (prognostic of
liver damage), liver histopathology, and viral titers in the spleen.
Moreover, bulk RNAseq analysis of infected liver and spleen tissues
indicated changes in gene expression pathways related to tissue damage
and antiviral immune responses as well as a reduction of genes
associated with type I IFN response and inflammation. Finally, the
authors report substantial differences in the numbers of hepatic and
splenic APC subsets between wild-type and knockout mice following MHV
infection and show that Ly6E-deficient B cells and to a lesser extent
also DCs are particularly susceptible to MHV infection *in vitro*.

#### Limitations

Experiments and data in this study are presented in an overall logical
and coherent fashion; however, some observations and the conclusions
drawn are problematic and should be further addressed & discussed by the
authors. Methodological & formal limitations include relatively low
replicate numbers as well as missing technical replicates for some *in
vitro* experiments (*cf*. Fig. legend 1; Fig. legend 2e); the omission
of “outliers” in Fig. legend 2 without an apparent rationale as to why
this approach was chosen; the lack of detection of actual Ly6E protein
levels in Ly6E HSC ko or wild-type mice; and most importantly, missing
information on RNAseq data collection & analysis in the method section
and throughout the paper. A more relevant concern though is that the
interpretation of the experimental data presented and the language used
tend to overrate and at times overgeneralize findings: for example,
while the authors demonstrate statistically significant, Ly6E-mediated
reduction of coronavirus titers in stable cells lines *in vitro*, it
remains unclear whether a viral titer reduction by one log decade would
be of actual biological relevance in face of high viral titers *in
vivo*. After high-dose intraperitoneal MHV infection *in vivo*, early
viral titers in Ly6E HSC knockout vs. wt mice only showed an elevation
in the spleen (\~1.5 log decades) but not liver of the ko mice (other
tissue not evaluated), and while ko mice presented with only modestly
increased liver pathology, both male and female ko mice exhibited
significantly higher mortality. Thus, the manuscript tile statement that
“Ly6E … confers immune control of viral disease” is supported by only
limited *in vivo* data, and gain-of-function experiments (eg. Ly6E
overexpression) were not performed. Of additional note here, tissue
tropism and virulence differ greatly among various MHV strains and
isolates whereas dose, route of infection, age, genetic background and
sex of the mice used may additionally affect disease outcome and
phenotype (*cf*. Taguchi F & Hirai-Yuki A,
<https://doi.org/10.3389/fmicb.2012.00068>; Kanolkhar A et al,
[https://jvi.asm.org/content/
83/18/9258](https://jvi.asm.org/content/%2083/18/9258)). Observations
attributed to hematopoietic stem cell-specific Ly6E deletion could
therefore be influenced by the different genetic backgrounds of floxed
and cre mice used, and although it appears that littermates wt and ko
littermates were used in the experiments, the potentially decisive
impact of strain differences should at least have been discussed. Along
these lines, it should also be taken into account that the majority of
human coronaviruses cause respiratory symptoms, which follow a different
clinical course engaging other primary cellular mediators than the
hepatotropic murine MHV disease studied here. It therefore remains
highly speculative how the findings reported in this study will
translate to human disease and it would therefore be important to test
other routes of MHV infection and doses that have been described to
produce a more comparable phenotype to human coronavirus disease (*cf.*
Kanolkhar A et al, [https://jvi.asm.org/content/
83/18/9258](https://jvi.asm.org/content/%2083/18/9258)). Another
important shortcoming of this study is the lack of any information on
functional deficits or changes in Ly6E-deficient immune cells and how
this might relate to the phenotype observed. Overall, the *in vitro*
experiments are more convincing than the *in vivo* studies which appear
somewhat limited.

#### Significance

Despite some shortcomings, the experiments performed in this study
suggest a novel and somewhat unexpected role of Ly6E in the protection
against coronaviruses across species. These findings are of relevance
and should be further explored in ongoing research on potential
coronavirus therapies. Yet an important caveat pertains to the authors’
suggestion that “therapeutic mimicking of Ly6E action” may constitute a
first line of defense against novel coronaviruses since their own prior
work demonstrated that Ly6E can enhance rather than curtail infection
with influenza A and other viruses.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Liu et al. *medRxiv*. [@doi:10.1101/2020.03.06.20031856]

#### Keywords
- diagnosis
- serological assay
- ELISA
- RT-PCR

#### Main Findings

While RT-PCR is being used currently to routinely diagnose infection
with SARS-CoV-2, there are significant limitations to the use of a
nucleic acid test that lead to a high false-negative rate. This
article describes ELISAs that can measure IgM and IgG antibodies
against the N protein of SARS-CoV-2 to test samples from 238
patients (153 positive by RT-PCR and 85 negative by RT-PCR) at
different times after symptom onset. The positivity rate of the IgM
and/or IgG ELISAs was greater than that of the RT-PCR (81.5%
compared to 64.3%) with similar positive rates in the confirmed and
suspected cases (83% and 78.8%, respectively), suggesting that many
of the suspected but RT-PCR-negative cases were also infected. The
authors also found that the ELISAs have higher positive rates later
after symptom onset while RT-PCR is more effective as a diagnostic
test early during the infection.

#### Limitations

I cannot identify any limitations to this study.

#### Significance

The authors make a strong case for using a combination of ELISA and
RT-PCR for diagnosis of infection with SARS-CoV-2, especially
considering the dynamics of positivity rates of RT-PCR and ELISA.
Fewer false-negative diagnoses would improve infection control and
patient management.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2

[@doi:10.1101/2020.03.06.980037]

#### Keywords

- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- Spike protein
- Cross- reactive antibodies

#### Main Findings

Whole genome sequencing-based comparisons of the 2003
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the 2019
SARS-CoV-2 revealed conserved receptor binding domain (RBD) and host
cell receptor, angiotensin-converting enzyme 2 (ACE2). In line with
this, the authors tested cross-reactivity of murine monoclonal
antibodies (mAbs) previously generated against the SARS-CoV spike (S)
glycoprotein involved in viral entry. One of the screened mAb, 1A9, was
able to bind and cross-neutralize multiple strains of SARS-CoV, as well
as, detect the S protein in SARS-CoV-2-infected cells. mAb 1A9 was
generated using an immunogenic fragment in the S2 subunit of SARS-CoV
and binds through a novel epitope within the S2 subunit at amino acids
1111-1130. It is important to note that CD8+ T lymphocyte epitopes
overlap with these residues, suggesting that S2 subunit could be
involved in inducing both, humoral and cell-mediated immunity.

#### Limitations

The authors used previously generated mouse mAbs
against the S protein in SARS-CoV expressed in mammalian cell line.
Future experimental validation using COVID-19 patient samples is needed
to validate these findings. In addition, the results of these studies
are predominantly based on in vitro experiments and so, evaluating the
effects of the mAb 1A9 in an animal model infected with this virus will
help us better understand the host immune responses in COVID-19 and
potential therapeutic vaccines.

#### Significance

This study identified mAbs that recognize the new
coronavirus, SARS-Cov-2. These cross-reactive mAbs will help in
developing diagnostic assays for COVID-19.

#### Credit

*This review was undertaken by Tamar Plitt and Katherine Lindblad as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Mortality of COVID-19 is Associated with Cellular Immune Function Compared to Immune Function in Chinese Han Population

Zeng et al. *medRxiv*. [@doi:10.1101/2020.03.08.20031229]

#### Keywords
- WBC
- peripheral blood
- CD4
- CD8 T cells

#### Main Findings

Retrospective study of the clinical characteristics of 752
patients infected with COVID-19 at Chinese PLA General Hospital, Peking
Union Medical College Hospital, and affiliated hospitals at Shanghai
University of medicine & Health Sciences. This study is the first one
that compares PB from healthy controls from the same regions in Shanghai
and Beijing, and infected COVID-19 patients to standardize a reference
range of WBCs of people at high risk.

#### Limitations

Lower levels of leukocyte counts -B cells, CD4 and CD8 T
cells- correlated with mortality (WBCs are significantly lower in severe
or critical UCI patients vs mild ones). Based on 14,117 normal controls
in Chinese Han population (ranging in age from 18-86) it is recommended
that reference ranges of people at high risk of COVID-19 infection are
CD3+ lymphocytes below 900 cells/mm3, CD4+ lymphocytes below 500
cells/mm3, and CD8+ lymphocytes below 300 cells/mm3. Importantly, this
study also reported that the levels of D-dimer, C-reactive protein and
IL-6 were elevated in COVID-19 pts., indicating clot formation, severe
inflammation and cytokine storm.

#### Significance

This study sets a threshold to identify patients at risk
by analyzing their levels of leukocytes, which is an easy and fast
approach to stratify individuals that require hospitalization. Although
the study is limited (only counts of WBC are analyzed and not its
profile) the data is solid and statistically robust to correlate levels
of lymphopenia with mortality.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Retrospective Analysis of Clinical Features in 101 Death Cases with COVID-19

Chen et al. *medRxiv*. [@doi:10.1101/2020.03.09.20033068]

#### Keywords

- death biomarkers
- cardiac damage
- Troponin
- Blood type
- respiratory failure
- hypertension

#### Main Findings

This is a retrospective study involving 101 death cases with COVID-19 in
Wuhan Jinyintan Hospital. The aim was to describe clinical,
epidemiological and laboratory features of fatal cases in order to
identify the possible primary mortality causes related to COVID-19.

Among 101 death cases, 56.44% were confirmed by RT-PCR and 43.6% by
clinical diagnostics. Males dominated the number of deaths and the
average age was 65.46 years. All patients died of respiratory failure
and multiple organs failure, except one (acute coronary syndrome). The
predominant comorbidities were hypertension (42.57%) and diabetes
(22.77%). 25.74% of the patients presented more than two underlying
diseases. 82% of patients presented myocardial enzymes abnormalities at
admission and further increase in myocardial damage indicators with
disease progression: patients with elevated Troponin I progressed faster
to death. Alterations in coagulation were also detected. Indicators of
liver and kidney damage increased 48 hours before death. The authors
studied the deceased patients’ blood type and presented the following
results: type A (44.44%), type B (29.29%), type AB (8.08%) and type O
(18.19%), which is inconsistent with the distribution in Han population
in Wuhan.

Clinical analysis showed that the most common symptom was fever (91.9%),
followed by cough and dyspnea. The medium time from onset of symptoms to
acute respiratory distress syndrome (ARDS) development was 12 days.
Unlike SARS, only 2 patients with COVID-19 had diarrhea. 98% presented
abnormal lung imaging at admission and most had double-lung
abnormalities. Related to the laboratorial findings some inflammatory
indicators gradually increased during the disease progression, such as
IL-6 secretion in the circulation, procalcitonin (PCT) and C-reactive
protein (CRP), while platelets numbers decreased. The authors also
reported an initial lymphopenia that was followed by an increase in the
lymphocytes numbers. Neutrophil count increased with disease
progression.

The patients received different treatments such as antiviral drugs
(60.40%), glucocorticoids, thymosin and immunoglobulins. All patients
received antibiotic treatment and some received antifungal drugs. All
patients received oxygen therapy (invasive or non-invasive ones).

#### Limitations

This study involves just fatal patients, lacking comparisons with other
groups of patients e.g. patients that recovered from COVID-19. The
authors didn’t discuss the different approaches used for treatments and
how these may affect the several parameters measured. The possible
relationship between the increase of inflammatory indicators and
morbidities of COVID-19 are not discussed.

#### Significance

This study has the largest cohort of fatal cases reported so far. The
authors show that COVID-19 causes fatal respiratory distress syndrome
and multiple organ failure. This study highlights prevalent myocardial
damage and indicates that cardiac function of COVID-19 patients should
be carefully monitored. The data suggest that Troponin I should be
further investigated as an early indicator of patients with high risk of
accelerated health deterioration. Secondary bacterial and fungal
infections were frequent in critically ill patients and these need to be
carefully monitored in severe COVID-19 patients. Differences in blood
type distribution were observed, suggesting that type A is detrimental
while type O is protective – but further studies are needed to confirm
these findings and elucidate if blood type influences infection or
disease severity. Several inflammatory indicators (neutrophils, PCT, CRP
and IL-6, D-dimer) increased according to disease severity and should be
assessed as biomarkers and to better understand the biology of
progression to severe disease.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Relationship between the ABO Blood Group and the COVID-19 Susceptibility

Zhao et al. *medRxiv*. [@doi:10.1101/2020.03.11.20031096]

#### Keywords

- ABO blood group
- COVID-19 susceptibility

#### Main Findings

These authors compared the ABO blood group of 2,173 patients with
RT-PCR-confirmed COVID-19 from hospitals in Wuhan and Shenzhen with the
ABO blood group distribution in unaffected people in the same cities
from previous studies (2015 and 2010 for Wuhan and Shenzhen,
respectively). They found that people with blood group A are
statistically over-represented in the number of those infected and who
succumb to death while those with blood group O are statistically
underrepresented with no influence of age or sex.

#### Limitations

This study compares patients with COVID-19 to the general population
but relies on data published 5 and 10 years ago for the control. The
mechanisms that the authors propose may underlie the differences they
observed require further study.

#### Significance

Risk stratification based on blood group may be beneficial for
patients and also healthcare workers in infection control. Additionally,
investigating the mechanism behind these findings could lead to better
developing prophylactic and therapeutic targets for COVID-19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Matsuyama et al. *bioRxiv* [@doi:10.1101/2020.03.11.987016]

#### Keywords

- Corticosteroids
- ciclesonide
- mometasone
- NSP15
- MERS-CoV

#### Main Findings

This study reconsiders the use of inhaled corticosteroids in the
treatment of pneumonia by coronavirus. Corticosteroids were associated
with increased mortality for SARS in 2003 and for MERS in 2013, probably
due to that fact that systemic corticosteroids suppress the innate
immune system, resulting in increased viral replication. However, some
steroid compounds might block coronavirus replication. The authors
screened steroids from a chemical library and assessed the viral growth
suppression and drug cytotoxicity. Ciclesonide demonstrated low
cytotoxicity and potent suppression of MERS-CoV viral growth. The
commonly used systemic steroids cortisone, prednisolone and
dexamethasone did not suppress viral growth, nor did the commonly used
inhaled steroid fluticasone. To identify the drug target of virus
replication, the authors conducted 11 consecutive MERS-CoV passages in
the presence of ciclesonide or mometasone, and they could generate a
mutant virus that developed resistance to ciclesonide, but not to
mometasone. Afterwards, they performed next-generation sequencing and
identified an amino acid substitution in nonstructural protein 15
(NSP15) as the predicted mechanism for viral resistance to ciclesonide.
The authors were able to successfully generate a recombinant virus
carrying that amino acid substitution, which overcome the antiviral
effect of ciclesonide, suggesting that ciclosenide interacts with NSP15.
The mutant virus was inhibited by mometasone, suggesting that the
antiviral target of mometasone is different from that of ciclesonide.
Lastly, the effects of ciclesonide and mometason on suppressing the
replication of SARS-CoV-2 were evaluated. Both compounds were found to
suppress viral replication with a similar efficacy to lopinavir.

#### Limitations

Most of the experiments, including the identification of the mutation in
NSP15 were conducted with MERS-CoV. This is not the closest related
virus to SARS-CoV-2, as that would be SARS-CoV. Thus, to repeat the
initial experiments with SARS-CoV, or preferably SARS-CoV-2, is
essential. The manuscript should address this and, therefore, it will
require considerable editing for organization and clarity. Also, in
terms of cell immunogenic epitopes, while SARS-CoV-2 spike protein
contains several predicted B and T cell immunogenic epitopes that are
shared with other coronaviruses, some studies have shown critical
differences between MERS-CoV, SARS-CoV and SARS-CoV-2. A main criticism
is that the authors only used VeroE6/TMPRSS2 cells to gauge the direct
cytotoxic effects of viral replication. To evaluate this in other cell
lines, including human airway epithelial cells, is crucial, as the
infectivity of coronavirus strains greatly varies in different cell
lines,

#### Significance

Nevertheless, these findings encourage evaluating ciclesonide and
mometasone as better options for patients with COVID-19 in need of
inhaled steroids, especially as an alternative to other corticosteroids
that have been shown to increase viral replication in vitro. This should
be evaluated in future clinical studies.

#### Credit

*This review was undertaken by Alvaro Moreira, MD as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A human monoclonal antibody blocking SARS-CoV-2 infection **

Wang et al. *bioRxiv*. [@doi:10.1101/2020.03.11.987958]

#### Keywords

- Monoclonal antibodies
- SARS-CoV2
- cross-neutralization
- potential treatment
- spike receptor

#### Main Findings

The authors reported a human monoclonal
antibody that neutralizes SARS-CoV-2 and SARS-Cov which belong to same
family of corona viruses. For identifying mAbs, supernatants of a
collection of 51 hybridomas raised against the spike protein of SARS-CoV
(SARS-S) were screened by ELISA for cross-reactivity against the spike
protein of SARS-CoN2 (SARS2-S). Hybridomas were derived from immunized
transgenic H2L2 mice (chimeric for fully human VH-VL and rat constant
region). Four SARS-S hybridomas displayed cross-reactivity with SARS2-S,
one of which (47D11) exhibited cross-neutralizing activity for SARS-S
and SARS2-S pseudotyped VSV infection. A recombinant, fully human IgG1
isotype antibody was generated and used for further characterization.

The humanized 47D11 antibody inhibited infection of VeroE6 cells with
SARS-CoV and SARS-CoV-2 with IC50 values of 0.19 and 0.57 μg/ml
respectively. 47D11 mAb bound a conserved epitope on the spike receptor
binding domain (RBD) explaining its ability to cross-neutralize SARS-CoV
and SARS-CoV-2. 47D11 was shown to target the S1B RBD of SARS-S and
SARS2-S with similar affinities. Interestingly, binding of 47D11 to
SARS-S1B and SARS2-S1B did not interfere with S1B binding to ACE2
receptor-expressing cells assayed by flow cytometry.

#### Limitations

These results show that the human 47D11 antibody
neutralizes SARS-CoV and SARS-Cov2 infectivity via an as yet unknown
mechanism that is different from receptor binding interference.
Alternative mechanisms were proposed but these as yet remain to be
tested in the context of SARS-CoV2. From a therapeutic standpoint and in
the absence of in vivo data, it is unclear whether the 47D11 ab can
alter the course of infection in an infected host through virus
clearance or protect an uninfected host that is exposed to the virus.
There is a precedent for the latter possibility as it relates to
SARS-CoV that was cited by the authors and could turn out to be true for
SARS-CoV2.

#### Significance

This study enabled the identification of novel neutralizing
antibody against COV-that could potentially be used as first line of
treatment in the near future to reduce the viral load and adverse
effects in infected patients. In addition, neutralizing antibodies such
as 47D11 represent promising reagents for developing
antigen-antibody-based detection test kits and assays.

#### Credit

*This review was edited by K. Alexandropoulos as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


**Heat inactivation of serum interferes with the immunoanalysis of
antibodies to SARS-CoV-2**

Heat inactivation, immunochromatography, diagnosis, serum antibodies,
IgM, IgG

*Summary*

The use of heat inactivation to neutralize pathogens in serum samples
collected from suspected COVID-19 patients reduces the sensitivity of a
fluorescent immunochromatographic assay to detect anti-SARS-CoV-2 IgM
and IgG.

*Major findings*

Coronaviruses can be killed by heat inactivation, and this is an
important safety precaution in laboratory manipulation of clinical
samples. However, the effect of this step on downstream
SARS-CoV-2-specific serum antibody assays has not been examined. The
authors tested the effect of heat inactivation (56 deg C for 30 minutes)
versus no heat inactivation on a fluorescence immunochromatography
assay. Heat inactivation reduced all IgM measurements by an average of
54% and most IgG measurements (22/36 samples, average reduction of 50%),
consistent with the lower thermal stability of IgM than that of IgG.
Heat inactivation caused a subset of IgM but not IgG readings to fall
below a specified positivity threshold.

*Limitations*

Limitations included the use of only one type of assay for testing heat
inactivated vs non-inactivated sera, and the use of the same baseline
for heat inactivated and non-inactivated sera. The results indicate that
heat inactivation affects the quantification of SARS-CoV-2-antibody
response, specially IgM, but still allows to distinguish positive
specific IgG. Therefore, the effect of heat inactivation should be
studied when designing assays that quantitatively associate
immunoglobulin levels (especially IgM) to immune state.

*Review by Andrew M. Leader as part of a project by students, postdocs
and faculty at the Immunology Institute of the Icahn school of medicine,
Mount Sinai.*


### Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19

Zhang et al. *medRxiv* [@doi:10.1101/2020.03.12.20035048]

#### Keywords

- Biomarkers
- cytokines
- IgG
- immune cells

#### Main Findings

In a cohort of 222 patients, anti-SARS-CoV-2 IgM and IgG levels were
analyzed during acute and convalescent phases (up to day 35) and
correlated to the diseases’ severity. The same was done with
neutrophil-to-lymphocyte ratio. High IgG levels and high
neutrophil-to-lymphocyte ratio in convalescence were both independently
associated to the severity of the disease. The simultaneous occurrence
of both of these laboratory findings correlated even stronger to the
diseases’ severity.

Severe cases with high neutrophil-to-lymphocyte ratios had clearly
higher levels of IL-6. The authors propose that a robust IgG response
leads to immune-mediated tissue damage, thus explaining the worse
outcome in patients with overexuberant antibody response.

#### Limitations

A main criticism is that the criteria for stratifying patients in severe
vs. non-severe are not described. The only reference related to this is
the difference between the percentage of patients who needed mechanical
ventilation, which was greater in patients with both high IgG levels and
high neutrophil-to-lymphocyte ratio. No patient with both low IgG levels
and low neutrophil-to-lymphocyte ratio was treated with mechanical
ventilation.

The proposed correlation of severity with IL-2 and IL-10 levels is not
very strong.

Furthermore, although mostly ignored in the paper’s discussion, one of
the most interesting findings is that an early increase in
anti-SARS-CoV-2 IgM levels also seems to correlate with severe disease.
However, as only median values are shown for antibody kinetics curves,
the extent of variation in acute phase cannot be assessed.

#### Significance

Anti-SARS-CoV-2 IgG levels and with neutrophil-to-lymphocyte ratio
predict severity of COVID-19 independently of each other. An additive
predictive value of both variables is noticeable. Importantly, an
early-on increase in anti-SARS-CoV-2 IgM levels also seem to predict
outcome.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Reinfection could not occur in SARS-2 CoV-2 infected rhesus macaques

Bao et al. *bioRxiv* [@doi:10.1101/2020.03.13.990226]

#### Keywords

- SARS-CoV-2
- viral load
- reinfection
- relapse
- non-human primate model

#### Main Findings

This study addresses the issue or acquired immunity after a primary
COVID-19 infection in rhesus monkeys. Four Chinese rhesus macaques were
intratracheally infected with SARS-CoV-2 and two out of the four were
re-infected at 28 days post initial infection (dpi) with the same viral
dose after confirming the recovery by the absence of clinical symptoms,
radiological abnormalities and viral detection (2 negative RT-PCR
tests). While the initial infection led the viral loads in nasal and
pharyngeal swabs that reach approximately 6.5 log~10~ RNA copies/ml at 3
dpi in all four monkeys, viral loads in the swabs tested negative after
reinfection in the two reinfected monkeys. In addition, the necropsies
from a monkey (M1) at 7 days after primary infection, and another monkey
(M3) at 5 days post reinfection, revealed the histopathological damages
and viral replication in the examined tissues from M1, while no viral
replication as well as no histological damages were detected in the
tissues from M3. Furthermore, sera from three monkeys at 21 and 28 dpi
exhibited neutralizing activity against SARS-CoV-2 in vitro, suggesting
the production of protective neutralizing antibodies in these monkeys.
Overall, this study indicates that primary infection with SARS-CoV-2 may
protect from subsequent exposure to the same virus.

#### Limitations

In human, virus has been detected by nasopharyngeal swabs until 9 to 15
days after the onset of symptoms. In the infected monkeys in this study,
virus were detected from day 1 after the infection, declining to
undetectable level by day 15 post infection. It may suggest that there
is a faster viral clearance mechanism in monkeys, therefore the
conclusions of reinfection protection for humans need to be carefully
considered. In addition, only two monkeys were re-infected in this study
and the clinical signs of these monkeys were not similar: M3 did not
show weight loss and M4 showed relatively higher fever on the day of
infection and the day of re-challenge.

#### Significance

This study showed clear viral clearance and no indications of relapse or
viremia after a secondary infection with SARS-CoV-2 in a Chinese rhesus
macaque model. These results support the idea that patients with full
recovery (two negative RT-PCR results) may also be protected from
secondary SARS-CoV-2 infection. Recovered patients may be able to
reintegrate to normal public life and provide protective serum perhaps
even if having had a mild infection. The results are also encouraging
for successful vaccine development against SARS-CoV-2.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV

[@doi:10.1101/2020.03.13.991570]

#### Keywords

- neutralizing antibody
- cross-reactivity

#### Main Findings

Given the sequence similarity of the surface spike glycoprotein (S) of
SARS-CoV-2 and SAR-CoV, Yuan et al. (2020) propose that neutralizing
antibodies isolated from convalescent SARS-CoV patients may offer
insight into cross-reactive antibodies targeting SARS-CoV-2. In
particular, they find that the receptor-binding domain (RBD) of
SARS-CoV-2 S protein shares 86% sequence similarity with the RBD of
SARS-CoV S protein that binds to the CR3022 neutralizing antibody.
CR3022 also displays increased affinity for the “up” conformation of the
SARS-CoV-2 S protein compared to the “down” conformation as it does for
the SARS-CoV S protein. Therefore, the authors propose that this
cross-reactive antibody may confer some degree of protection *in vivo*
even if it fails to neutralize *in vitro*.

#### Limitations
Although the authors offer a logical rationale for
identifying cross-reactive neutralizing antibodies derived from
SARS-CoV, their study using only CR3022 failed to demonstrate whether
this approach will be successful. After all, CR3022 failed to neutralize
*in vitro* despite the binding affinity to a similar epitope on
SARS-CoV-2. They would benefit from testing more candidates and using an
*in vivo* model to demonstrate their claim that protection may be
possible in the absence neutralization if combinations are used *in
vivo.*

#### Significance

The ability to make use of previously characterized
neutralizing antibodies for conserved epitopes can expedite drug design
and treatment options.

#### Credit

*This review was undertaken by Dan Fu Ruan, Evan Cody and Venu Pothula as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Highly accurate and sensitive diagnostic detection of SARS-CoV-2 by digital PCR

Dong et al. *medRxiv* [@doi:10.1101/2020.03.14.20036129]

#### Keywords

- Diagnosis
- digital PCR

#### Main Findings

The authors present a digital PCR (dPCR) diagnostic test for
SARS-CoV-2 infection. In 103 individuals that were confirmed in a
follow-up to be infected, the standard qPCR test had a positivity
rate of 28.2% while the dPCR test detected 87.4% of the infections
by detecting an additional 61 positive cases. The authors also
tested samples from close contacts (early in infection stage) and
convalescing individuals (late in infection stage) and were able to
detect SARS-CoV-2 nucleic acid in many more samples using dPCR
compared to qPCR.

#### Limitations

I did not detect limitations.

#### Significance

The authors make a strong case for the need for a highly sensitive
and accurate confirmatory method for diagnosing COVID-19 during this
outbreak and present a potential addition to the diagnostic arsenal.
They propose a dPCR test that they present has a dramatically lower
false negative rate than the standard RT-qPCR tests and can be
especially beneficial in people with low viral load, whether they
are in the earlier or later stages of infection.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 invades host cells via a novel route: CD147-spike protein

Wang et al. *bioRxiv* [@doi:10.1101/2020.03.14.988345]

#### Keywords

- spike protein
- viral entry
- CD147
- SARS-CoV-2

#### Main Findings

The authors propose a novel mechanism of SARS-CoV-2 viral entry through
the interaction of the viral spike protein (SP) and the immunoglobulin
superfamily protein CD147 (also known as Basigin). Using an in-house
developed humanized antibody against CD147 (maplazumab), they show that
blocking CD147 decreases viral replication in Vero E6 cells. Using
surface plasmon resonance (SPR), ELISA, and Co-IP assays, they show that
the spike protein of SARS-CoV-2 directly interacts with CD147. Lastly,
they utilize immune-election microscopy to show spike protein and CD147
localize to viral inclusion bodies of Vero E6 cells.

#### Limitations

The authors claim that an anti-CD147 antibody (Meplazumab) inhibits
SARS-CoV-2 replication by testing cell growth and viral load in cells
infected with SARS-CoV-2, however there are key pieces of this
experiment that are missing. First, the authors fail to use a
non-specific antibody control. Second, the authors claim that viral
replication is inhibited, and that they test this by qPCR, however this
data is **not shown.** To further prove specificity, the authors should
introduce CD147 to non-susceptible cells and show that they become
permissive.

The authors claim that there is a direct interaction between CD147 and
SP through SPR, ELISA, and Co-IP, and this data seems generally
convincing. The electron microscopy provides further correlative
evidence that SARS-CoV-2 may interact with CD147 as they are both found
in the same viral inclusion body. A quantification of this data would
make the findings more robust.

Finally, the data in this paper lacks replicates, error bars, and
statistics to show that the data are reproducible and statistically
significant.

#### Significance

It has been shown in various studies that SARS-CoV-2 binds to the cell
surface protein ACE2 for cell entry, yet ACE2 is highly expressed in
heart, kidney, and intestinal cells, raising the concern that blocking
ACE2 would result in harmful side effects [@doi:10.1093/ndt/gfu302] CD147 on the other hand
is highly expressed in various tumor types, inflamed tissues, and
pathogen infected cells, suggesting that the inhibition of CD147 would
not result in major side effects [@doi:10.1016/j.yexmp.2018.05.001; @pmid:20551248] The research in this paper has
resulted in an ongoing clinical trail in China to test the safety and
efficacy of anti-CD147 Meplazumab to treat COVID-19. (ClinicalTrails.gov
identifier NCT04275245).

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Blood single cell immune profiling reveals that interferon-MAPK pathway mediated adaptive immune response for COVID-19

Huang et al. *medRxiv* [@doi:10.1101/2020.03.15.20033472]

#### Keywords

- COVID-19
- SARS-CoV-2
- PBMC
- single cell
- MAPK

#### Main Findings

The authors performed single-cell RNA sequencing (scRNAseq) of
peripheral blood mononuclear cells isolated from whole blood samples of
COVID-19 patients (n=10). Data was compared to scRNAseq of samples
collected from patients with influenza A (n=1), acute pharyngitis (n=1),
and cerebral infarction (n=1), as well as, three healthy controls.
COVID-19 patients were categorized into those with moderate (n=6),
severe (n=1), critical (n=1), and cured (n=2) disease. Analysis across
all COVID-19 disease levels revealed 56 different cellular subtypes,
among 17 immune cell types; comparisons between each category to the
normal controls revealed **increased proportions of CD1c^+^ dendritic
cells, CD8^+^ CTLs, and plasmacytoid dendritic cells and a decrease in
proportions of B cells and CD4^+^ T cells**.

**TCR sequencing revealed that greater clonality is associated with
milder COVID-19 disease**; BCR sequencing revealed that COVID-19
patients have circulating antibodies against known viral antigens,
including EBV, HIV, influenza A, and other RNA viruses. This may suggest
that the immune response to SARS-CoV-2 infection elicits production of
antibodies against known RNA viruses.

Excluding enriched pathways shared by COVID-19 patients and patients
with other conditions (influenza A, acute pharyngitis, and cerebral
infarction), the authors identified the **interferon-MAPK signaling
pathway as a major response to SARS-CoV-2 infection**. The authors
performed quantitative real-time reverse transcriptase polymerase chain
reaction (RT-PCR) for interferon-MAPK signaling genes: *IRF27, BST2,*
and *FOS*. These samples were collected from a separate cohort of
COVID-19 patients (critical, n=3; severe, n=3; moderate, n=19; mild,
n=3; and cured, n=10; and healthy controls, n=5). Notably, consistent
with the original scRNAseq data, *FOS* showed up-regulation in COVID-19
patients and down-regulation in cured patients. **The authors propose
that *FOS* may be a candidate marker gene for curative COVID-19
disease**.

#### Limitations

The sample size of this study is limited. To further delineate
differences in the immune profile of peripheral blood of COVID-19
patients, a greater sample size is needed, and longitudinal samples are
needed, as well. A better understanding of the immunological
interactions in cured patients, for example, would require a profile
before and after improvement.

Moreover, the conclusions drawn from this scRNAseq study point to
potential autoimmunity and immune deficiency to distinguish different
severities of COVID-19 disease. However, this requires an expanded
number of samples and a more robust organization of specific immune cell
subtypes that can be compared across different patients. Importantly,
this criterion is likely needed to ensure greater specificity in
identifying markers for COVID-19 infection and subsequent immune
response.

#### Significance

At the single-cell level, COVID-19 disease has been characterized in the
lung, but a greater understanding of systemic immunological responses is
furthered in this study. Type I interferon is an important signaling
molecule for the anti-viral response. The identification of the
interferon-MAPK signaling pathway and the differential expression of
MAPK regulators between patients of differing COVID-19 severity and
compared to cured patients may underscore the importance of either
immune deficiency or autoimmunity in COVID-19 disease.

#### Credit

*This review was undertaken by Matthew D. Park as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infection.

Lv et al. *bioRxiv* [@doi:10.1101/2020.03.15.993097]

#### Keywords

SARS-CoV-2, SARS-CoV, spike protein, RBD, cross-reactivity,
cross-neutralization, antibody, human patients, mouse

#### Main Findings

The authors explore the antigenic differences between SARS-CoV-2 and
SARS-CoV by analyzing plasma samples from SARS-CoV-2 (n = 15) and
SARS-CoV (n = 7) patients. Cross-reactivity in antibody binding to the
spike protein between SARS-CoV-2 and SARS-CoV was found to be common,
mostly targeting non-RBD regions in plasma from SARS-CoV-2 patients.
Only one SARS-CoV-2 plasma sample was able to cross-neutralize SARS-CoV,
with low neutralization activity. No cross-neutralization response was
detected in plasma from SARS-CoV patients.

To further investigate the cross-reactivity of antibody responses to
SARS-CoV-2 and SARS-CoV, the authors analyzed the antibody response of
plasma collected from mice infected or immunized with SARS-CoV-2 or
SARS-CoV (n = 5 or 6 per group). Plasma from mice immunized with
SARS-CoV-2 displayed cross-reactive responses to SARS-CoV S ectodomain
and, to a lesser extent, SARS-CoV RBD. Similarly, plasma from mice
immunized with SARS-CoV displayed cross-reactive responses to SARS-CoV-2
S ectodomain. Cross-neutralization activity was not detected in any of
the mouse plasma samples.

#### Limitations

The size of each patient cohort is insufficient to accurately determine
the frequency of cross-reactivity and cross-neutralization in the
current SARS-CoV-2 pandemic. Recruitment of additional patients from a
larger range of geographical regions and time points would also enable
exploration into the effect of the genetic diversity and evolution of
the SARS-CoV-2 virus on cross-reactivity. This work would also benefit
from the mapping of specific epitopes for each sample. Future studies
may determine whether the non-neutralizing antibody responses can confer
*in vitro* protection or lead to antibody-dependent disease enhancement.

#### Significance

The cross-reactive antibody responses to S protein in the majority of
SARS-CoV-2 patients is an important consideration for development of
serological assays and vaccine development during the current outbreak.
The limited extent of cross-neutralization demonstrated in this study
indicates that vaccinating to cross-reactive conserved epitopes may have
limited efficacy, presenting a key concern for the development of a more
universal coronavirus vaccine to address the global health risk of novel
coronavirus outbreaks.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study

Duan et al. *medRxiv* [@doi:10.1101/2020.03.16.20036145]

#### Keywords

- COVID-19
- SARS-CoV-2
- convalescent plasma
- treatment outcome
- pilot
- therapy
- transfusion

#### Main Findings

This is the first report to date of convalescent plasma therapy as a
therapeutic against COVID-19 disease. This is a feasibility pilot study.
The authors report the administration and clinical benefit of 200 mL of
convalescent plasma (CP) (1:640 titer) derived from recently cured
donors (CP selected among 40 donors based on high neutralizing titer and
ABO compatibility) to 10 severe COVID-19 patients with confirmed
viremia. The primary endpoint was the safety of CP transfusion. The
secondary endpoint were clinical signs of improvement based on symptoms
and laboratory parameters.

The authors reported use of methylene blue photochemistry to inactivate
any potential residual virus in the plasma samples, without compromising
neutralizing antibodies, and no virus was detected before transfusion.

The authors report the following:

-   No adverse events were observed in all patients, except 1 patient
    who exhibited transient facial red spotting.

-   All patients showed significant improvement in or complete
    disappearance of clinical symptoms, including fever, cough,
    shortness of breath, and chest pain after 3 days of CP therapy.

-   Reduction of pulmonary lesions revealed by chest CT.

-   Elevation of lymphocyte counts in patients with lymphocytopenia.

-   Increase in SaO~2~ in all patients, indicative of recuperating lung
    function.

-   Resolution of SARS-CoV-2 viremia in 7 patients and increase in
    neutralizing antibody titers in 5 patients. Persistence of
    neutralizing antibody levels in 4 patients.

#### Limitations

It is important to note that most recipients had high neutralization
titers of antibodies before plasma transfusion and even without
transfusion it would be expected to see an increase in neutralizing
antibodies over time. In addition to the small sample set number (n=10),
there are additional limitations to this pilot study:

1.  All patients received concurrent therapy, in addition to the CP
    transfusion. Therefore, it is unclear whether a combinatorial or
    synergistic effect between these standards of care and CP
    transfusion contributed to the clearance of viremia and improvement
    of symptoms in these COVID-19 patients.

2.  The kinetics of viral clearance was not investigated, with respect
    to the administration of CP transfusion. So, the definitive impact
    of CP transfusion on immune dynamics and subsequent viral load is
    not well defined.

3.  Comparison with a small historical control group is not ideal.

#### Significance

For the first time, a pilot study provides promising results involving
the use of convalescent plasma from cured COVID-19 patients to treat
others with more severe disease. The authors report that the
administration of a single, high-dose of neutralizing antibodies is
safe. In addition, there were encouraging results with regards to the
reduction of viral load and improvement of clinical outcomes. It is,
therefore, necessary to expand this type of study with more
participants, in order to determine optimal dose and treatment kinetics.
It is important to note that CP has been studied to treat H1N1
influenza, SARS-CoV-1, and MERS-CoV, although it has not been proven to
be effective in treating these infections.

#### Credit

*Review by Matthew D. Park and revised by Alice O. Kamphorst and Maria A. Curotto de Lafaille as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial

[@doi:10.1101/2020.03.16.20037135]

#### Keywords

- hydroxychloroquine
- clearance
- viral load
- clinical trial

#### Main Findings

This study was a single-arm, open label clinical trial with
600 mg hydroxychloroquine (HCQ) in the treatment arm (n = 20). Patients
who refused participation or patients from another center not treated
with HCQ were included as negative controls (n = 16). Among the patients
in the treatment arm, 6 received concomitant azithromycin to prevent
superimposed bacterial infection. The primary endpoint was respiratory
viral loads on day 6 post enrollment, measured by nasopharyngeal swab
followed by real-time reverse transcription-PCR.

HCQ alone was able to significantly reduce viral loads by day 6 (n =
8/14, 57.1% complete clearance, p &lt; 0.001); azithromycin appears to
be synergistic with HCQ, as 6/6 patients receiving combined treatment
had complete viral clearance (p &lt; 0.001).

#### Limitations

Despite what is outlined above, this study has a number
of limitations that must be considered. First, there were originally n =
26 patients in the treatment arm, with 6 lost to follow up for the
following reasons: 3 transferred to ICU, 1 discharge, 1
self-discontinued treatment d/t side effects, and 1 patient expired.
Total length of clinical follow up was 14 days, but the data beyond day
6 post-inclusion are not shown.

Strikingly, in supplementary table 1, results of the real-time RT-PCR
are listed for the control and treatment arms from D0 – D6. However, the
data are not reported in a standard way, with a mix of broadly positive
or negative result delineation with Ct (cycle threshold) values, the
standard output of real time PCR. It is impossible to compare what is
defined as a positive value between the patients in the control and
treatment arms without a standardized threshold for a positive test.
Further, the starting viral loads reported at D0 in the groups receiving
HCQ or HCQ + azithromycin were significantly different (ct of 25.3 vs
26.8 respectively), which could explain in part the differences observed
in the response to treatment between 2 groups. Finally, patients in the
control arm from outside the primary medical center in this study
(Marseille) did not actually have samples tested by PCR daily. Instead,
positive test results from every other day were extrapolated to mean
positive results on the day before and after testing as well (Table 2,
footnote ^a^).

Taken together, the results of this study suggest that HCQ represents a
promising treatment avenue for COVID-19 patients. However, the limited
size of the trial, and the way in which the results were reported does
not allow for other medical centers to extrapolate a positive or
negative result in the treatment of their own patients with HCQ +/-
azithromycin. Further larger randomized clinical trials will be required
to ascertain the efficacy of HCQ +/- azithromycin in the treatment of
COVID-19.

#### Significance

Chloroquine is thought to inhibit viral infection,
including SARS-Cov-2, by increasing pH within endosomes and lysosomes,
altering the biochemical conditions required for viral fusion [@doi:10.1038/s41422-020-0282-0; @doi:10.1016/j.imlet.2013.07.004].
However, chloroquine also has immuno-modulatory effects that I think may
play a role. Chloroquine has been shown to increase CTLA-4 expression at
the cell surface by decreasing its degradation in the endo-lysosome
pathway; AP-1 traffics the cytoplasmic tail of CTLA-4 to lysosomes, but
in conditions of increased pH, the protein machinery required for
degradation is less functional [@doi:10.1126/science.aaa1663]. As such, more CTLA-4 remains in
endosomes and is trafficked back to the cell surface. It is possible
that this may also contribute to patient recovery via reduction of
cytokine storm, in addition to the direct anti-viral effects of HCQ.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Recapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids

[@doi:10.1101/2020.03.16.990317]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- liver
- organoids
- Cholangiocyte

#### Main Findings

-   Used human liver ductal organoids to determine ACE2+ cholangiocytes
    in healthy liver (2.92% of all cells) are infectable and support
    SARS-CoV-2 viral replication.

-   Plaque-purified SARS-CoV-2 viral infection disrupted organoid
    barrier and bile transporting functions of cholangiocytes through
    dysregulation of genes involved in tight junction formation (CLDN1)
    and bile acid transportation (ASBT and CFTR).

#### Limitations:

-   Unclear if liver damage observed in patients due to direct
    cholangiocyte infection or due to secondary immune/cytokine effects.
    This study argues for direct damage as it lacks immune contexture;
    but further studies needed with autopsy samples or organoid-immune
    cell co-culture to conclude strongly.

-   Would be important to measure cholangiocyte-intrinsic anti-viral
    response and alarmins secreted upon infection, and furthermore study
    tropism of various immune cells to conditioned media from organoids
    infected with SARS-CoV-2.

-   Does not address how cirrhotic liver or
    alcohol/smoking/obesity-associated liver organoids respond to
    SARS-CoV-2 infectivity and replication, worth pursuing to
    experimentally address clinical data indicating co-morbidities.

#### Significance


-   Useful model to rapidly study drug activity against SARS-CoV-2
    infection in liver, while monitoring baseline liver damage.

-   Liver abnormality observed in &gt;50% of CoVID-19 patients; the
    results from this study could explain the bile acid accumulation and
    consequent liver damage observed.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2

[@doi:10.1101/2020.03.16.994236]

#### Keywords

- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- Spike protein S
- ACE2

#### Main Findings

Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) infects cells through S spike glycoprotein binding
angiotensin-converting enzyme (ACE2) on host cells. S protein can bind
both membrane-bound ACE2 and soluble ACE2 (sACE2), which can serve as a
decoy that neutralizes infection. Recombinant sACE2 is now being tested
in clinical trials for COVID-19. To determine if a therapeutic sACE2
with higher affinity for S protein could be designed, authors generated
a library containing every amino acid substitution possible at the 117
sites spanning the binding interface with S protein. The ACE2 library
was expressed in human Expi293F cells and cells were incubated with
medium containing the receptor binding domain (RBD) of SARS-CoV-2 fused
to GFP. Cells with high or low affinity mutant ACE2 receptor compared to
affinity of wild type ACE2 for the RBD were FACS sorted and transcripts
from these sorted populations were deep sequenced. Deep mutagenesis
identified numerous mutations in ACE2 that enhance RBD binding. This
work serves to identify putative high affinity ACE2 therapeutics for the
treatment of CoV-2.

#### Limitations

The authors generated a large library of mutated
ACE2, expressed them in human Expi293F cells, and performed deep
mutagenesis to identify enhanced binders for the RBD of SARS-CoV-2 S
protein. While these data serve as a useful resource, the ability of the
high affinity ACE2 mutants identified to serve as therapeutics needs
further validation in terms of conformational stability when purified as
well as efficacy/safety both *in vitro* and *in vivo*. Additionally,
authors mentioned fusing the therapeutic ACE2 to Fc receptors to elicit
beneficial host immune responses, which would need further design and
validation.

#### Significance

This study identified structural ACE2 mutants that
have potential to serve as therapeutics in the treatment of SARS-CoV-2
upon further testing and validation.

#### Credit

*This review was undertaken by Katherine Lindblad and Tamar Plitt as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


***Title***:  A serological assay to detect SARS-Cov-2 seroconversion in
humans

***Immunology keywords***:  specific serological assay - ELISA -
seroconversion - antibody titers

*Note: the authors of this review work in the same institution as the
authors of the study*

***Main findings***:  

Production of recombinant whole Spike (S) protein and the smaller
Receptor Binding Domain (RBD) based on the sequence of Wuhan-Hu-1
SARS-CoV-2 isolate. The S protein was modified to allow trimerization
and increase stability. The authors compared the antibody reactivity of
59 banked human serum samples (non-exposed) and 3 serum samples from
confirmed SARS-CoV-2 infected patients. All Covid-19 patient sera
reacted to the S protein and RBD domain compared to the control sera.

The authors also characterized the antibody isotypes from the Covid-19
patients, and observed stronger IgG3 response than IgG1. IgM and IgA
responses were also prevalent.

***Limitations of the study***:  

The authors analyzed a total of 59 control human serum samples, and
samples from only three different patients to test for reactivity
against the RBD domain and full-length spike protein. It will be
important to follow up with a larger number of patient samples to
confirm the data obtained. Furthermore, it would be interesting to
assess people at different age groups and determine whether unexposed
control kids have a higher “background”.

Applications of the assay described in this study in diagnosis are
limited, since antibody response should start to be detectable only one
to two weeks after infection. Future studies will be required to assess
how long after infection this assay allow to detect anti-CoV2
antibodies. Finally, while likely, the association of seroconversion
with protective immunity against SARS-Cov-2 infection still needs to be
fully established.

***Relevance***:

This study has strong implications in the research against SARS-Cov-2.
First, it is now possible to perform serosurveys and determine who has
been infected, allowing a more accurate estimate of infection prevalence
and death rate. Second, if it is confirmed that re-infection does not
happen (or is rare), this assay can be used as a tool to screen
healthcare workers and prioritize immune ones to work with infected
patients. Third, potential convalescent plasma donors can now be
screened to help treating currently infected patients. Of note, this
assay does not involve live virus handling. experimentally, this is an
advantage as the assay does not require the precautions required by
manipulation of live virus. Finally, the recombinant proteins described
in this study represent new tools that can be used for further
applications, including vaccine development.


### COMPARATIVE PATHOGENESIS OF COVID-19, MERS AND SARS IN A NON-HUMAN PRIMATE MODEL

[@doi:10.1101/2020.03.17.995639]

#### Keywords

- SARS-CoV2
- cynomolgus macaque
- SARS-CoV

#### Main Findings

This work assesses SARS-CoV-2 infection in young adult and aged
cynomolgus macaques. 4 macaques per age group were infected with
low-passage clinical sample of SARS-CoV-2 by intranasal and
intratracheal administration. Viral presence was assessed in nose,
throat and rectum through RT-PCR and viral culture. SARS-CoV-2
replication was confirmed in the respiratory track (including nasal
samples), and it was also detected in ileum. Viral nucleocapsid
detection by IHC showed infection of type I and II pneumocytes and
epithelia. Virus was found to peak between 2 and 4 days after
administration and reached higher levels in aged vs. young animals. The
early peak is consistent with data in patients and contrasts to SARS-CoV
replication. SARS-CoV-2 reached levels below detection between 8 and 21
days after inoculation and macaques established antibody immunity
against the virus by day 14. There were histopathological alteration in
lung, but no overt clinical signs. At day 4 post inoculation of
SARS-CoV-2, two of four animals presented foci of pulmonary
consolidation, with limited areas of alveolar edema and pneumonia, as
well as immune cell infiltration. In sum, cynomolgus macaques are
permissive to SARS- CoV-2 and develop lung pathology (less severe than
SARC-CoV, but more severe than MERS-CoV).

#### Limitations

Even though cynomolgus macaques were permissive to SARS-CoV-2
replication, it is unclear if the viral load reaches levels comparable
to humans and there wasn’t overt clinical pathology.

#### Significance

The development of platforms in which to carry out relevant
experimentation on SARS-CoV-2 pathophysiology is of great urgency.
Cynomolgus macaques offer an environment in which viral replication can
happen, albeit in a limited way and without translating into clinically
relevant symptoms. Other groups are contributing to SARS-CoV2 literature
using this animal model [@doi:10.1101/2020.03.13.990226], potentially showing protection against
reinfection in cured macaques. Therefore, this platform could be used to
examine SARS-CoV2 pathophysiology while studies in other animal models
are also underway [@doi:10.1128/JVI.02012-06; @doi:10.1101/2020.02.07.939389].

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Investigating the Impact of Asymptomatic Carriers on COVID-19 Transmission

[@doi:10.1101/2020.03.18.20037994]

#### Keywords

- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- asymptomatic carriers
- mathematical model
- transmission

#### Main Findings

Multiple studies reported the same level of infectiousness
between symptomatic and asymptomatic carriers of SARS-CoV-2. Given that
asymptomatic and undocumented carriers escape public health surveillance
systems, a better mathematical model of transmission is needed to
determine a more accurate estimate of the basic reproductive number
(R~0~) of the virus to assess the contagiousness of virus. The authors
developed a SEYAR dynamical model for transmission of the new
coronavirus that takes into account asymptomatic and undocumented
carriers. The model was validated using data reported from thirteen
countries during the first three weeks of community transmission. While
current studies estimate R~0~ to be around 3, this model indicates that
the value could range between 5.5 to 25.4.

#### Limitations

The SEYAR model realistically depicts
transmission of the virus only during the initial stages of the disease.
More data is necessary to better fit the model with current trends. In
addition, multiple factors (e.g. behavioral patterns, surveillance
capabilities, environmental and socioeconomic factors) affect
transmission of the virus and so, these factors must be taken into
consideration when estimating the R~0~.

#### Significance

Public health authorities use the basic reproductive
number to determine the severity of disease. An accurate estimate of
R~0~ will inform intervention strategies. This model can be applied to
different locations to assess the potential impact of COVID-19.

#### Credit

*This review was undertaken by Tamar Plitt and Katherine Lindblad as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice

Long et al. *medRxiv* [@doi:10.1101/2020.03.18.20038018]

#### Keywords

- Serum antibodies
- IgM
- IgG
- immunoassay
- diagnosis
- seroconversion

#### Main Findings

This study investigated the profile of the acute antibody response
against SARS-CoV-2 and provided proposals for serologic tests in
clinical practice. Magnetic Chemiluminescence Enzyme Immunoassay was
used to evaluate IgM and IgG seroconversion in 285 hospital admitted
patients who tested positive for SARS-CoV-2 by RT-PCR and in 52 COVID-19
suspected patients that tested negative by RT-PCR. A follow up study
with 63 patients was performed to investigate longitudinal effects. In
addition, IgG and IgM titers were evaluated in a cohort of close
contacts (164 persons) of an infected couple.

The median day of seroconversion for both IgG and IgM was 13 days after
symptom onset. Patients varied in the order of IgM/ IgG seroconversion
and there was no apparent correlation of order with age, severity, or
hospitalization time. This led the authors to conclude that for
diagnosis IgM and IgG should be detected simultaneously at the early
phase of infection.

IgG titers, but not IgM titers were higher in severe patients compared
to non-severe patients after controlling for days post-symptom onset.
Importantly, 12% of COVID-19 patients (RT-PCR confirmed) did not meet
the WHO serological diagnosis criterion of either seroconversion or
*&gt;* 4-fold increase in IgG titer in sequential samples. This suggests
the current serological criteria may be too stringent for COVID-19
diagnosis.

Of note, 4 patients from a group of 52 suspects (negative RT-PCR test)
had anti-SARS-Cov-2 IgM and IgG. Similarly, 4.3% (7/162) of "close
contacts" who had negative RT-PCR tests were positive for IgG and/or
IgM. This highlights the usefulness of a serological assay to identify
asymptomatic infections and/or infections that are missed by RT-PCR.

#### Limitations

This group’s report generally confirms the findings of others that have
evaluated the acute antibody response to SARS-Cov-2. However, these data
would benefit from inclusion of data on whether the participants had a
documented history of viral infection. Moreover, serum samples that were
collected prior to SARS-Cov-2 outbreak from patients with other viral
infections would serve as a useful negative control for their assay.
Methodological limitations include that only one serum sample per case
was tested as well as the heat inactivation of serum samples prior to
testing. It has previously been reported that heat inactivation
interferes with the level of antibodies to SARS-Cov-2 and their protocol
may have resulted in diminished quantification of IgM, specifically [@doi:10.1101/2020.03.12.20034231].

#### Significance

Understanding the features of the antibody responses against SARS-CoV is
useful in the development of a serological test for the diagnosis of
COVID-19. This paper addresses the need for additional screening methods
that can detect the presence of infection despite lower viral titers.
Detecting the production of antibodies, especially IgM, which are
produced rapidly after infection can be combined with PCR to enhance
detection sensitivity and accuracy and map the full spread of infection
in communities, Moreover, serologic assays would be useful to screen
health care workers in order to identify those with immunity to care for
patients with COVID19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 specific antibody responses in COVID-19 patients

[@doi:10.1101/2020.03.18.20038059]

#### Keywords
- immunoassay
- antibody specificity
- serology
- cross-reactivity
  
#### Main findings

Antibodies specific to SARS-CoV-2 S protein, the S1 subunit and the RBD (receptor-binding domain) were detected in all SARS-CoV-2 patient sera by 13 to 21 days post onset of disease.  Antibodies specific to SARS-CoV N protein (90% similarity to SARS-CoV-2) were able to neutralize SARS-CoV-2 by PRNT (plaque reduction neutralizing test).  SARS-CoV-2 serum cross-reacted with SARS-CoV S and S1 proteins, and to a lower extent with MERS-CoV S protein, but not with the MERS-CoV S1 protein, consistent with an analysis of genetic similarity.  No reactivity to SARS-CoV-2 antigens was observed in serum from patients with ubiquitous human CoV infections (common cold) or to non-CoV viral respiratory infections.  
 
#### Limitations

Authors describe development of a serological ELISA based assay for the detection of neutralizing antibodies towards regions of the spike and nucleocapsid domains of the SARS-CoV-2 virus.  Serum samples were obtained from PCR-confirmed COVID-19 patients.  Negative control samples include a cohort of patients with confirmed recent exposure to non-CoV infections (i.e. adenovirus, bocavirus, enterovirus, influenza, RSV, CMV, EBV) as well as a cohort of patients with confirmed infections with ubiquitous human CoV infections known to cause the common cold. The study also included serum from patients with previous MERS-CoV and SARS-CoV zoonotic infections. This impressive patient cohort allowed the authors to determine the sensitivity and specificity of the development of their in-house ELISA assay. Of note, seroconversion was observed as early as 13 days following COVID-19 onset but the authors were not clear how disease onset was determined.  
 
#### Significance

Validated serological tests are urgently needed to map the full spread of SARS-CoV-2 in the population and to determine the kinetics of the antibody response to SARS-CoV-2.  Furthermore, clinical trials are ongoing using plasma from patients who have recovered from SARS-CoV-2 as a therapeutic option.  An assay such as the one described in this study could be used to screen for strong antibody responses in recovered patients.  Furthermore, the assay could be used to screen health care workers for antibody responses to SARS-CoV-2 as personal protective equipment continues to dwindle.  The challenge going forward will be to standardize and scale-up the various in-house ELISA’s being developed in independent laboratories across the world.  
 
 


### A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19

Belhadi et al. [@doi:10.1101/2020.03.18.20038190]

#### Keywords

- Clinical trials
- COVID-19
- SARS CoV-2
- 2019-nCoV
- SARS Cov-2
- Hcov-19
- novel coronal virus
- new corona virus
- antiviral drugs

#### Main Findings

Summary of clinical trials registered as
of March7, 2020 from U.S, Chinese, Korean, Iranian and European
registries. Out of the 353 studies identified, 115 were selected for
data extraction. 80% of the trials were randomized with parallel
assignment and the median number of planned inclusions was 63 (IRQ,
36-120). Most frequent therapies in the trials included; 1) antiviral
drugs \[lopinavir/ritonavir (n-15); umifenovir (n=9); favipiravir (n=7);
redmesivir (n=5)\]; 2) anti-malaria drugs \[chloroquine (n-11);
hydroxychloroquine (n=7)}; immunosuppressant drugs \[methylprednisolone
(n=5)\]; and stem cell therapies (n=23). Medians of the total number of
planned inclusions per trial for these therapies were also included.
Stem cells and lopunavir/ritonavir were the most frequently evaluated
candidate therapies (23 and 15 trials respectively), whereas remdesivir
was only tested in 5 trials but these trials had the highest median
number of planned inclusions per trial (400, IQR 394-453). Most of the
agents used in the different trials were chosen based on preclinical
assessments of antiviral activity against SARS CoV and MERS Cov corona
viruses.

The primary outcomes of the studies were clinical (66%); virological
(23%); radiological (8%); or immunological (3%). The trials were
classified as those that included patients with severe disease only;
trials that included patients with moderate disease; and trials that
included patients with severe or moderate disease.

#### Limitations

The trials evaluated provided incomplete information:
23% of these were phase IV trials but the bulk of the trials (54%) did
not describe the phase of the study. Only 52% of the trials (n=60)
reported treatment dose and only 34% (n=39) reported the duration. A lot
of the trials included a small number of patients and the trials are
still ongoing, therefore no insight was provided on the outcome of the
trials.

#### Significance

Nonetheless, this review serves as framework for
identifying COVID-19 related trials, which can be expanded upon as new
trials begin at an accelerated rate as the disease spreads around the
world.

#### Credit

*This review was undertaken by K Alexandropoulos as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19

Leung et al. *medRxiv*. [@doi:10.1101/2020.03.18.20038455]

#### Keywords

- chronic obstructive pulmonary disease
- COPD
- smokingE-2
- risk factors

#### Main Findings

In bronchial epithelial samples from 3 different cohorts of
individuals, ACE-2 gene expression was found to be significantly
increased in both COPD patients and smokers relative to healthy
controls. Across all test subjects, ACE-2 gene expression was also
highly correlated with decreased forced expiratory volume in 1 second
(FEV1), which may explain the increased COVID-19 disease severity in
COPD patients. Former smokers were also found to show decreased ACE2
expression relative to current smokers and had no significant difference
when compared to non-smokers.

#### Limitations

While the upregulation of ACE-2 is an interesting
hypothesis for COVID-19 disease severity in COPD patients, this study
leaves many more unanswered questions than it addresses. Further studies
are required to show whether the specific cell type isolated in these
studies is relevant to the pathophysiology of COVID-19. Furthermore,
there is no attempt to show whether that increased ACE-2 expression
contributes to greater disease severity. Does the increased ACE-2
expression lead to greater infectivity with SARS-CoV-2? There is no
mechanistic explanation for why ACE-2 levels are increased in COPD
patients. The authors could also have considered the impact of
co-morbidities and interventions such as corticosteroids or
bronchodilators on ACE-2 expression. Finally, given the extensive
sequencing performed, the authors could have conducted significantly
more in-depth analyses into gene signature differences.

#### Significance

This study attempts to address an
important clinical finding that both smokers and COPD patients show
increased mortality from COVID-19. The novel finding that ACE-2
expression is induced in smokers and COPD patients suggests not only a
mechanism for the clinical observation, but also highlights the
potential benefit of smoking cessation in reducing the risk of severe
COVID-19 disease.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Dynamic profile of severe or critical COVID-19 cases

[@doi:10.1101/2020.03.18.20038513]

#### Keywords
- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- progressive lymphopenia (PLD)
- T-lymphocytes
- clinical data
- co-infection
- influenza A

#### Main Findings

Authors evaluate clinical correlates of 10 patients (6 male
and 4 female) hospitalized for severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2). All patients required oxygen support and
received broad spectrum antibiotics and 6 patients received anti-viral
drugs. Additionally, 40% of patients were co-infected with influenza A.
All 10 patients developed lymphopenia, two of which developed
progressive lymphopenia (PLD) and died. Peripheral blood (PB)
lymphocytes were analyzed – low CD4 and CD8 counts were noted in most
patients, though CD4:CD8 ratio remained normal.

#### Limitations

The authors evaluated a small cohort of severe
SARS-CoV-2 cases and found an association between T cell lymphopenia and
adverse outcomes. However, this is an extremely small and diverse cohort
(40% of patients were co-infected with influenza A). These findings need
to be validated in a larger cohort. Additionally, the value of this data
would be greatly increased by adding individual data points for each
patient as well as by adding error bars to each of the figures.

#### Significance

This study provides a collection of clinical data and
tracks evolution of T lymphocyte in 10 patients hospitalized for
SARS-CoV-2, of which 4 patients were co-infected with influenza A.

#### Credit

*This review was undertaken by Katherine Lindblad and Tamar Plitt as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Association between Clinical, Laboratory and CT Characteristics and RT-PCR Results in the Follow-up of COVID-19 patients

Fu et al. *medRxiv*. [@doi:10.1101/2020.03.19.20038315]

#### Keywords

- COVID-19
- clinical
- lymphocyte
- CRP
- LDH
- HSST TNT
- PCR test
- readmission
- CT
- GGO
- disease progression

#### Study description

Data analyzed from 52 COVID-19 patients admitted
and then discharged with COVID-19. Clinical, laboratory, and
radiological data were longitudinally recorded with illness timecourse
(PCR + to PCR-) and 7 patients (13.5%) were readmitted with a follow up
positive test (PCR+) within two weeks of discharge.

#### Main Findings

-   At admission:

    -   The majority of patients had increased CRP at admission (63.5%).

    -   LDH, and HSST TNT were significantly increased at admission.

    -   Radiographic signs via chest CT showed increased involvement in
        lower lobes: right lower lobe (47 cases, 90.4%), left lower lobe
        (37 cases, 71.2%).

    -   GGO (90.4%), interlobular septal thickening (42.3%), vascular
        enlargement (42.3%), and reticulation (11.5%) were most commonly
        observed.

-   After negative PCR test (discharge):

    -   CRP levels decreased lymphocyte counts (\#/L) increased
        significantly (CD3+, CD3+/8+ and CD3+/4+) after negative PCR.

    -   Consolidation and mixed GGO observed in longitudinal CT imaging
        w different extents of inflammatory exudation in lungs, with
        overall tendency for improvement (except 2/7 patients that were
        readmitted after discharge with re-positive test) after negative
        PCR.

-   Seven patients repeated positive RT-PCR test and were readmitted to
    the hospital (9 to 17 day after initial discharge).

    -   Follow up CT necessary to monitor improvement during recovery
        and patients with lesion progression should be given more
        attention.

    -   Dynamic CT in addition to negative test essential in clinical
        diagnosis due to nasal swab PCR sampling bias (false-negatives).

    -   Increase in CRP occurred in 2 readmitted patients (and decr. in
        lymphocytes in one patient), but was not correlated with new
        lesions or disease progression vs. improvement (very low N).

    -   Patients readmitted attributed to false-negative PCR vs.
        re-exposure.

#### Limitations

Patients sampled in this study were generally
younger (65.4% &lt; 50 yrs) and less critically ill/all discharged.
Small number of recovered patients (N=18). Time of follow up was
relatively short.. Limited clinical information available about patients
with re-positive test (except CRP and lymph tracking).

#### Extended Results

*NOTE*: Patients sampled in this study were generally younger (65.4%
&lt; 50 yrs) and less critically ill/all discharged. After two
consecutive negative PCR tests, patients were discharged.

Clinical Results at Admission

-   Median interval disease onset to admission (5 days, IQR: 3-7)

-   Most common symptoms included fever, fatigue, dry cough, and
    expectoration.

-   Fifteen patients had reduced lymphocyte counts (28.8%).

-   No change in WBC or Neutrophil counts.

-   **The majority of patients had increased CRP at admission (63.5%).**

-   **LDH, and HSST TNT were significantly increased at admission.**

-   Fibrinogen was trending high though not significant.

-   No major changes in liver function observed.

-   **Radiographic signs via chest CT showed increased involvement in
    lower lobes: right lower lobe (47 cases, 90.4%), left lower lobe (37
    cases, 71.2%).**

-   **GGO (90.4%), interlobular septal thickening (42.3%), vascular
    enlargement (42.3%)**, and reticulation (11.5%) were most commonly
    observed.

Change in Clinical Results following Negative Test

-   **CRP levels decreased after negative PCR.**

-   **Lymphocyte counts (\#/L) increased significantly (CD3+, CD3+/8+
    and CD3+/4+).**

-   No significant change to CD4/8 ratio.

-   LDH, HSST TNT, and Fibronegin remained high throughout, though range
    observed decreased over time.

-   **Consolidation and mixed GGO observed in longitudinal CT imaging.**

-   **Patients showed different extents of inflammatory exudation in
    lungs, with overall tendency for improvement (except 2/7 patients
    that were readmitted after discharge with re-positive test).**

Patients Readmitted with PCR+ test

-   **Seven patients repeated positive RT-PCR test and were readmitted
    to the hospital (9 to 17 day after initial discharge).**

-   Improvement during readmission in 4 patients and observation of
    segmental progression CT in 2 patients (2/18 or 11.1% - re-positive
    9 and 10 days post-discharge).

-   Two patients showed new GGO, while others improved greatly.

-   **Follow up CT necessary to monitor improvement during recovery and
    patients with lesion progression should be given more attention.**

-   **Dynamic CT in addition to negative test essential in clinical
    diagnosis due to nasal swab PCR sampling bias (false-negatives).**

-   **Increase in CRP occurred in 2 readmitted patients (and decr. in
    lymphocytes in one patient), but was not correlated with new lesions
    or disease progression vs. improvement (very low N).**

#### Significance

Study tracked key clinical features associated with
disease progression, recovery, and determinants of clinical
diagnosis/management of COVID-19 patients.

#### Credit

*This review was undertaken by Natalie Vaninov as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple 2 endemic, epidemic and bat coronavirus

Sheahan et al. *bioRxiv*. [@doi:10.1101/2020.03.19.997890]

#### Keywords
- Treatment
- Antiviral
- Broad spectrum antiviral
- ribonucleoside analog β-D-N4 30 hydroxycytidine (NHC)
- Remdesivir

#### Main Findings

β-D-N4 30 –hydroxycytidine (NHC, EIDD-1931) is an
orally bioavailable ribonucleoside with antiviral activity against
various RNA viruses including Ebola, Influenza and CoV. NHC activity
introduce*d*~~s~~ mutations in the viral (but not cellular) RNA in a
dose dependent *manner* that directly correlated with a decrease in
viral titers. Authors show that NHC inhibited multiple genetically
distinct Bat-CoV viruses in human primary epithelial cells *without
affecting* *cell viability even at high concentrations (100* *µM)*.
Prophylactic oral administration of NHC in C57BL/6 mice reduce lung
titers of SARS-CoV and prevented weight loss and hemorrhage. Therapeutic
administration of NHC in C57BL/6 mice 12 hours post infected with
SARS-CoV reduced acute lung injury, viral titer, and lung hemorrhage.
The degree of clinical benefit was dependent on the time of treatment
initiation post infection. The authors also demonstrate that NHC reduces
MERS-CoV infection titers, pathogenesis, and viral RNA in prophylactic
and therapeutic settings.

#### Limitations

Most of the experiments were conducted using MERS-CoV, and
SARS-CoV and a few experiments were conducted using other strains of CoV
as opposed to SARS-CoV-2. The authors note the core residues that make
up the RNA interaction sites (which constitutes the NHC interaction
sites) are highly conserved among CoV and because of this conservation
their understanding is that NHC can inhibit a broad-spectrum of CoV
including SARS-CoV-2.

The increased viral mutation rates associated with NHC activity may have
adverse effects if mutations cause the virus to become drug resistant,
more infectious or speed-up immune evasion. *In addition, the temporal
diminishing effectiveness of NHC on clinical outcome when NHC was used
therapeutically is concerning. However, the longer window (7-10 days)
for clinical disease onset in human patients from the time of infection
compared to that of mice (24-48 hours), may associate with increased NHC
effectiveness in the clinic.*

#### Significance

Prophylactic or therapeutic oral administration of NHC
reduces lung titers and prevents acute lung failure in C57B\\6 mice
infected with CoV. Given its *broad-spectrum antiviral activity, NHC
could turn out to be a useful drug for treating current, emerging and
future corona virus outbreaks.*
 
#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

Sangeun Jeon et al. [@doi:10.1101/2020.03.20.999730]

#### Keywords

- COVID-19
- SARS CoV-2
- antiviral drugs
- niclosamide
- ciclesonide

#### Main Findings

A panel of \~3,000 FDA- and IND-approved
antiviral drugs were previously screened for inhibitory efficacy against
SARS CoV, a coronavirus related to the novel coronavirus SARS CoV-2
(79.5%) homology. 35 of these drugs along with another 15 (suggested by
infectious disease specialists) were tested in vitro for their ability
to inhibit SARS CoV-2 infectivity of Vero cells while preserving cell
viability. The infected cells were scored by immunofluorescence analysis
using an antibody against the N protein of SARS CoV-2. Chloroquine,
lopinavir and remdesivir were used as reference drugs.

Twenty four out of 50 drugs exhibited antiviral activity with IC50
values ranging from 0.1-10µM. Among these, two stood ou: 1) the-anti
helminthic drug niclosamide which exhibited potent antiviral activity
against SARS CoV-2 (IC50=0.28 µM). The broad-spectrum antiviral effect
of niclosamide against SARS and MERS-CoV have been previously documented
and recent evidence suggests that in may inhibit autophagy and reduce
MERS C0V replication. 2) Ciclesonide, a corticosteroid used to treat
asthma and allergic rhinitis, also exhibited antiviral efficacy but with
a lower IC50 (4.33µM) compared to niclosamide. The antiviral effects of
ciclesonide were directed against NSP15, a viral riboendonuclease which
is the molecular target of this drug.

#### Limitations

The drugs were tested against SARS CoV-2 infectivity in
vitro only, therefore preclinical studies in animals and clinical trials
in patients will be need for validation of these drugs as therapeutic
agents for COVID-19. In addition, niclosamide exhibits low adsorption
pharmatokinetically which could be alleviated with further development
of drug formulation to increase effective delivery of this drug to
target tissues. Nonetheless, niclosamide and ciclesonide represent
promising therapeutic agents against SARS CoV-2 given that other
compounds tested in the same study including favipiravir (currently used
in clinical trials) and atazanavir (predicted as the most potent
antiviral drug by AI-inference modeling) did not exhibit antiviral
activity in the current study.

#### Credit

*This review was undertaken by K Alexandropoulos as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2

Munster et al. *bioRxiv*. [@doi:10.1101/2020.03.21.001628]

#### Keywords

animal model, pulmonary infiltrates, dynamic
of antibody response, cytokine

#### Main Findings

Inoculation of 8 Resus macaques with SARS-Cov-2 , which
all showed clinical signs of infection (respiratory pattern, reduced
appetite, weight loss, elevated body temperature) resulting in moderate,
transient disease. Four animals were euthanized at 3dpi, the 4 others at
21 dpi. Study of viral loads in different organs showed that nose swab
and throat swabs were the most sensitive, with bronchio-alveolar lavage.
Interstitial pneumonia was visible in radiographies and at the
histological scale too. Clinically, the macaques had similar symptoms as
described in human patients with moderate disease.

Viral shedding was consistently detected in nose swabs and throat swabs
immediately after infection but less consistent thereafter which could
reflect virus administration route (intranasal, oral). Bronchoalveolar
lavages performed as a measure of virus replication in the lower
respiratory tract on animals maintained for 21 days, contained high
viral loads in 1 and 3dpi. The majority of the animals exhibited
pulmonary edema and mild to moderate interstitial pneumonia on terminal
bronchioles. In addition to the lung, viral RNA could also be detected
throughout the respiratory track where viral replication mainly
occurred.

Immunologic responses included leukocytosis, neutrophilia, monocytosis
and lymphopenia in the majority of the animals at 1dpi. Lymphocytes and
monocytes re-normalized at 2dpi. Neutrophils declined after 3dpi and
through 10dpi after which they started to recover. After infection,
serum analysis revealed significant increases in **IL1ra, IL6, IL10,
IL15, MCP-1, MIP-1b, but quick normalization** (3dpi). **Antibody
response started around 7dpi, and the antibody titers stayed elevated
until 21dpi** (day of animal euthanasia).

#### Limitations

The macaques were inoculated via a combination
of intratracheal, intranasal, ocular and oral routes, which might not
reproduce how humans get infected. Maybe this can lead to different
dynamics in the host immune response. Also, the authors noted that the
seroconversion was not directly followed by a decline in viral loads, as
observed in covid19 patients.

#### Significance

This work confirms that rhesus
macaques can be a good model to study Covid-19, as it has been shown by
other groups [@doi:10.1101/2020.03.13.990226; @doi:10.1101/2020.03.13.990036; @doi:10.1101/2020.03.17.995639]. While these experiments recapitulate
moderate COVID-19 in humans, the mode of inoculation via a combination
of intratracheal, intranasal, ocular and oral routes, might not
reproduce how humans get infected and may lead to different dynamics in
the host immune response. For example, the authors noted that the
seroconversion was not directly followed by a decline in viral loads, as
observed in COVID-19 patients. Therefore, it will be interesting to
follow their antibody titers longer and further assess the
possibility/effect of reinfection in these macaques. It is essential to
be able to understand the dynamic of the disease and associated immune
responses, and to work on vaccine development and antiviral drug
testing.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19

[@doi:10.1101/2020.03.21.20040261]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- lung
- comorbidities
- histone
- epigenetics

#### Main Findings

-   Transcriptomic analysis using systems-level meta-analysis and
    network analysis of existing literature to determine ACE2 regulation
    in patients who have frequent COVID-19 comorbidities \[eg-
    cardiovascular diseases, familial pulmonary hypertension, cancer\].

-   Enrichment analyses indicated pathways associated with inflammation,
    metabolism, macrophage autophagy, and ER stress.

-   ACE2 higher in adenocarcinoma compared to adjacent normal lung; ACE2
    higher in COPD patients compared to normal.

-   Co-expression analysis identified genes important to viral entry
    such as RAB1A, ADAM10, HMGBs, and TLR3 to be associated with ACE2 in
    diseased lungs.

-   ACE2 expression could be potentially regulated by enzymes that
    modify histones, including HAT1, HDAC2, and KDM5B.

#### Limitations:

-   Not actual CoVID-19 patients with co-morbidities, so interpretations
    in this study need to be confirmed by analyzing upcoming
    transcriptomics from CoVID-19 patients having co-morbidity metadata.

-   As mentioned by authors, study does not look at diabetes and
    autoimmunity as risk factors in CoVID-19 patients due to lack of
    data; would be useful to extend such analyses to those datasets when
    available.

-   Co-expression analysis is perfunctory and needs
    validation-experiments especially in CoVID-19 lung samples to mean
    anything.

-   Epigenomic analyses are intriguing but incomplete, as existence of
    histone marks does not necessarily mean occupancy. Would be
    pertinent to check cell-line data (CCLE) or actual CoVID-19 patient
    samples to confirm ACE2 epigenetic control.

#### Significance

-   Study implies vulnerable populations have ACE2 upregulation that
    could promote CoVID-19 severity. Shows important data-mining
    strategy to find gene-networks associated with ACE2 upregulation in
    co-morbid patients.

-   Several of the genes co-upregulated with ACE2 in diseased lung might
    play an important role in CoVID-19 and can be preliminary targets
    for therapeutics

-   If in silico findings hold true, epigenetic control of ACE2
    expression could be a new target for CoVID-19 therapy with
    strategies such as KDM5 demethylases.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial

Bian et al. *medRxiv*. [@doi:10.1101/2020.03.21.20040691]

#### Keywords

- Meplazumab
- CD147
- humanized antibody
- clinical trial

#### Main Findings

This work is based on previous work by the same group
that demonstrated that SARS-CoV-2can also enter host cells via CD147
(also called Basigin, part of the immunoglobulin superfamily, is
expressed by many cell types) consistent with their previous work with
SARS-CoV-1. ^1^ A prospective clinical trial was conducted with 17
patients receiving Meplazumab, a humanized anti-CD147 antibody, in
addition to all other treatments. 11 patients were included as a control
group (non-randomized).

They observed a faster overall improvement rate in the Meplazumab group
(e.g. at day 14 47% vs 17% improvement rate) compared to the control
patients. Also, virological clearance was more rapid with median of 3
days in the Meplazumab group vs 13 days in control group. In laboratory
values, a faster normalization of lymphocyte counts in the Meplazumab
group was observed, but no clear difference was observed for CRP levels.

#### Limitations

While the results from the study are encouraging, this
study was non-randomized, open-label and on a small number of patients,
all from the same hospital. It offers evidence to perform a larger scale
study. Selection bias as well as differences between treatment groups
(e.g. age 51yo vs 64yo) may have contributed to results. The authors
mention that there was no toxic effect to Meplazumab injection but more
patient and longer-term studies are necessary to assess this.

#### Significance

These results seem promising as for now there are
limited treatments for Covid-19 patients, but a larger cohort of patient
is needed. CD147 has already been described to facilitate HIV [@doi:10.1073/pnas.111583198],
measles virus [@doi:10.1128/JVI.02168-09], and malaria [@doi:10.1038/nature10606] entry into host cells. This group was
the first to describe the CD147-spike route of SARS-Cov-2 entry in host
cells [@doi:10.1101/2020.03.14.988345] p147. Indeed, they had previously shown in 2005 that SARS-Cov
could enter host cells via this transmembrane protein [@doi:10.1086/427811]. Further
biological understanding of how SARS-CoV-2 can enter host cells and how
this integrates with ACE2R route of entry is needed. Also, the specific
cellular targets of the anti-CD147 antibody need to be assessed, as this
protein can be expressed by many cell types and has been shown to
involved in leukocytes aggregation [@doi:10.1371/journal.pone.0215557]. Lastly, Meplazumab is not a
commercially-available drug and requires significant health resources to
generate and administer which might prevent rapid development and use.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Potent human neutralizing antibodies elicited 1 by SARS-CoV-2 infection

Ju et al. *bioRxiv*. [@doi:10.1101/2020.03.21.990770]

#### Keywords

- monoclonal antibodies
- neutralization
- antibody cross-reactivity
- Receptor Binding Domain

#### Main Findings

In this study the authors report the affinity, cross reactivity (with
SARS-CoV and MERS-CoV virus) and viral neutralization capacity of 206
monoclonal antibodies engineered from isolated IgG memory B cells of
patients suffering from SARS-CoV-2 infection in Wuhan, China. All
patients but one recovered from disease. Interestingly, the patient that
did not recover had less SARS-CoV-2 specific B cells circulating
compared to other patients.

Plasma from all patients reacted to trimeric Spike proteins from
SARS-CoV-2, SARS-CoV and MERS-CoV but no HIV BG505 trimer. Furthermore,
plasma from patients recognized the receptor binding domain (RBD) from
SARS-CoV-2 but had little to no cross-reactivity against the RBD of
related viruses SARS-CoV and MERS-CoV, suggesting significant
differences between the RBDs of the different viruses. Negligible levels
of cross-neutralization using pseudoviruses bearing Spike proteins of
SARS-CoV-2, SARS-CoV or MERS-CoV, were observed, corroborating the ELISA
cross-reactivity assays on the RBDs.

SARS-CoV-2 RBD specific B cells constituted 0.005-0.065% of the total B
cell population and 0.023-0.329% of the memory subpopulation. SARS-CoV
specific IgG memory B cells were single cell sorted to sequence the
antibody genes that were subsequently expressed as recombinant IgG1
antibodies. From this library, 206 antibodies with different binding
capacities were obtained. No discernible patterns of VH usage were found
in the 206 antibodies suggesting immunologically distinct responses to
the infection. Nevertheless, most high-binding antibodies were derived
by clonal expansion. Further analyses in one of the patient derived
clones, showed that the antibodies from three different timepoints did
not group together in phylogenetic analysis, suggesting selection during
early infection.

Using surface plasmon resonance (SPR) 13 antibodies were found to have
10^-8^ tp 10^-9^ dissociation constants (Kd). Of the 13 antibodies, two
showed 98-99% blocking of SARS-CoV-2 RBD-ACE2 receptor binding in
competition assays. Thus, low Kd values alone did not predict ACE2
competing capacities. Consistent with competition assays the two
antibodies that show high ACE2 blocking (P2C-2F6 and P2C-1F11) were the
most capable of neutralizing pseudoviruses bearing SARS-CoV-2 spike
protein (IC~50~ of 0.06 and 0.03 µg/mL, respectively). Finally, using
SPR the neutralizing antibodies were found to recognize both overlapping
and distinct epitopes of the RBD of SARS-CoV-2.

#### Limitations

1.  Relatively low number of patients

    a.  No significant conclusion can be drawn about the possible
        > correlation between humoral response and disease severity

2.  *In vitro* Cytopathic Effect Assay (CPE) for neutralization activity

    a.  Huh7 cells were used in neutralization assays with
        > pseudoviruses, and they may not entirely mimic what happens in
        > the upper respiratory tract

    b.  CPE assay is not quantitative

3.  Duplicated panel in Figure 4C reported (has been fixed in version 2)

#### Significance

This paper offers an explanation as to why
previously isolated antibodies against SARS-CoV do not effectively block
SARS-CoV-2. Also, it offers important insight into the development of
humoral responses at various time points during the first weeks of the
disease in small but clinically diverse group of patients. Furthermore,
it provides valuable information and well characterized antibody
candidates for the development of a recombinant antibody treatment for
SARS-CoV-2. Nevertheless, it also shows that plasmapheresis might have
variability in its effectiveness, depending on the donor’s antibody
repertoire at the time of donation.

#### Credit

*Review by Jovani Catalan-Dibene as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Characterisation of the transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry reveals evidence for a cell passage induced in-frame deletion in the spike glycoprotein that removes the furin-like cleavage site.

Davidson et al. [@doi:10.1101/2020.03.22.002204]

#### Keywords

- Transcription
- RNA-seq
- proteomics
- mass spec
- furin cleavage site
- mutation
- pathogenicity

#### Main Findings

The authors performed long read RNA sequencing using an Oxford Nanopore
MinION as well as tandem mass spec (MS) on Vero cells (a cell line
derived from kidney cells of the African green monkey that is deficient
in interferon) infected with SARS-CoV-2.

The authors found that passage of the virus in Vero cells gave rise to a
spontaneous 9 amino acid deletion (679-NSPRRARSV-687 to I) in the spike
(S) protein. The deleted sequence overlaps a predicted furin cleavage
site at the S1 / S2 domain boundary that is present in SARS-CoV-2 but
not SARS-CoV or the closely related bat coronavirus RaTG13, which are
cleaved at S1 / S2 by other proteases [@doi:10.1126/science.abb2507]. Furin cleavage sites at
similar positions in other viruses have been linked to increased
pathogenicity and greater cell tropism [@doi:10.1128/JVI.00797-10]. Loss of this site in
SARS-CoV-2 has also already been shown to increase viral entry into Vero
but not BHK cells (which are also interferon deficient) [@doi:10.1016/j.cell.2020.02.058]. The
authors therefore make an important contribution in demonstrating that
passage in Vero cells may lead to spontaneous loss of a key
pathogenicity-conferring element in SARS-CoV-2.

#### Limitations

As the authors note, a similar study posted earlier by Kim et al., which
also passaged SARS-CoV-2 in Vero cells, did not identify any loss in the
S protein furin cleavage site [@doi:10.1101/2020.03.12.988865]. It therefore remains to be
determined how likely it is that this mutation spontaneously arises. A
quantitative investigation using multiple experimental replicas to
understand the spontaneous viral mutation rate at this site and
elsewhere would be informative. Also, the mechanistic basis for the
higher viral fitness conferred by loss of the furin cleavage site in
Vero cells – but, evidently, not in vivo in humans, as this site is
maintained in all currently sequenced circulating isolates - remains to
be understood.

Due to the high base-call error rate of MinION sequencing, the authors’
bioinformatic pipeline required aligning transcripts to a reference to
correct sequencing artifacts. This presumably made it difficult or
impossible to identify other kinds of mutations, such as single
nucleotide substitutions, which may occur even more frequently than the
deletions identified in this work. Pairing long read sequencing with
higher-accuracy short-read sequencing may be one approach to overcome
this issue.

#### Significance

As the authors suggest, animal studies using live virus challenge may
need to periodically verify the genomic integrity of the virus, or
potentially risk unknowingly using a likely less-pathogenic variant of
the virus.

More broadly, the results emphasize the complexity and plasticity of the
SARS-CoV-2 viral transcriptome and proteome. For example, the authors
found multiple versions of transcripts encoding the nucleocapsid (N)
protein, each with different small internal deletions, some of which
were verified for translation by MS. A number of peptides arising from
translation of unexpected rearrangements of transcripts were also
detected. Additionally, the authors identified phosphorylation of a
number of viral proteins (N, M, ORF 3a, nsp3, nsp9, nsp12 and S). For
any cases where these have functional consequences, targeting the
kinases responsible could be an avenue for drug development.
Understanding the functional consequences of the mutations, transcript
variations, and post translational modifications identified in this
study will be important future work.

#### Credit

*This review was undertaken by Tim O’Donnell, Maria Kuksin as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug- Repurposing

Gordon et al. *bioRxiv* [@doi:10.1101/2020.03.22.002386]

#### Keywords

- protein-protein interactions
- mass spectrometry
- drug targets

#### Main Findings

Gordon et al cloned, tagged and expressed 26 of the 29
SARS-CoV-2 proteins individually in HEK293T cells and used mass
spectrometry to identify protein-protein interactions. They identified
332 viral-host protein-protein interactions. Furthermore, they used
these interactions to identify 66 existing drugs known to target host
proteins or host pathways (eg SARS-CoV-2 N and Orf8 proteins interact
with proteins regulated by the mTOR pathway, so mTOR inhibitors
Silmitasertib and Rapamycin are possible drug candidates).

#### Limitations

The main limitation of the study stems from
the reductionist model: overexpression of plasmids encoding individual
viral proteins in HEK293T cells. This precludes any interactions between
the viral proteins, or the combined effects of multiple proteins on the
host, as they are expressed individually. Moreover, HEK293T cells come
from primary embryonic kidney and therefore might not reflect how
SARS-CoV-2 interacts with its primary target, the lung. However, the
authors found that the proteins found to interact with viral proteins in
their experiments are enriched in lung tissue compared to HEK293Ts.

#### Significance

The authors provide a “SARS-CoV-2 interaction map,”
which may provide potential hypotheses as to how the virus interacts
with the host. Further, they identified existing drugs that could
disrupt these host-viral interactions and curb SARS-CoV-2 infection.
Although these interactions have not been validated, this paper acts as
a valuable resource.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients

Chen et al. *medRxiv*.
[@doi:10.1101/2020.03.22.20034041]

#### Keywords
- Clinical study
- HCV protease inhibitor
- Danoprevir
- Ritonavir
- Covid19 treatment

#### Main Findings

The authors treated 11 Covid-19 patients with Danoprevir, a
commercialized HCV protease inhibitor [@doi:10.1128/AAC.00699-08]^(p4)^, boosted by ritonavir [@doi:10.14218/JCTH.2019.00033], a
CYP3A4 inhibitor (which enhances the plasma concentration and
bioavailabilty of Danoprevir). Two patients had never received
anti-viral therapy before (=naïve), whereas nine patients were on
Lopinavir/Ritonavir treatment before switching to Danoprevir/Ritonavir
(=experienced). The age ranged from 18 to 66yo.

Naïve patients that received Danoprevir/Ritonavir treatment had a
decreased hospitalization time. Patients treated with
Lopinavir/Ritonavir did not have a negative PCR test, while after
switching to Danoprevir/Ritonavir treatment, the first negative PCR test
occurred at a median of two days.

#### Limitations

The results of the study are very hard to interpret as there is no
control group not receiving Danoprevir/Ritonavir treatment. This was
especially true in naïve patients who seemed to have more mild symptoms
before the start of the study and were younger (18 and 44yo) compared to
the experienced patients (18 to 66yo). The possibility that the patients
would have recovered without Danoprevir/Ritonavir treatment cannot be
excluded.

#### Significance

The authors of the study treated patients with Danoprevir, with the
rational to that this is an approved and well tolerated drug for HCV
patients [@doi:10.14218/JCTH.2019.00033], and that it could also target the protease from SARS-CoV-2
(essential for viral replication and transcription). Indeed, homology
modelling data indicated that HCV protease inhibitors have the highest
binding affinity to Sars-Cov2 protease among other approved drugs [@doi:10.1101/2020.02.05.936013].

While this study shows that the combination of Danoprevir and Ritonavir
might be beneficial for Covid-19 patients, additional clinical trials
with more patients and with better methodology (randomization and
control group) are needed to make further conclusions.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

[@doi:10.1101/2020.03.22.20040758]

#### Keywords

- hydroxychloroquine

#### Study Description

This is a randomized clinical trial of hydroxychloroquine (HCQ) efficacy
in the treatment of COVID-19. From February 4 – February 28, 2020 142
COVID-19 positive patients were admitted to Renmin Hospital of Wuhan
University. 62 patients met inclusion criteria and were enrolled in a
double blind, randomized control trial, with 31 patients in each arm.

Inclusion criteria:

1.  Age ≥ 18 years

2.  Positive diagnosis COVID-19 by detection of SARS-CoV-2 by RT-PCR

3.  Diagnosis of pneumonia on chest CT

4.  Mild respiratory illness, defined by SaO~2~/SPO~2~ ratio &gt; 93% or
    PaO~2~/FIO~2~ ratio &gt; 300 mmHg in hospital room conditions (Note:
    relevant clinical references described below.)

    a.  Hypoxia is defined as an SpO2 of 85-94%; severe hypoxia &lt;
        85%.

    b.  The PaO~2~/FIO~2~ (ratio of arterial oxygen tension to fraction
        of inspired oxygen) is used to classify the severity of acute
        respiratory distress syndrome (ARDS). Mild ARDS has a
        PaO~2~/FIO~2~ of 200-300 mmHg, moderate is 100-200, and severe
        &lt; 100.

5.  Willing to receive a random assignment to any designated treatment
    group; not participating in another study at the same time

Exclusion criteria:

1.  Severe or critical respiratory illness (not explicitly defined,
    presumed to be respiratory function worse than outlined in inclusion
    criteria); or participation in trial does not meet patient’s maximum
    benefit or safe follow up criteria

2.  Retinopathy or other retinal diseases

3.  Conduction block or other arrhythmias

4.  Severe liver disease, defined by Child-Pugh score ≥ C or AST &gt;
    twice the upper limit

5.  Pregnant or breastfeeding

6.  Severe renal failure, defined by eGFR ≤ 30 mL/min/1.73m^2^, or on
    dialysis

7.  Potential transfer to another hospital within 72h of enrollment

8.  Received any trial treatment for COVID-19 within 30 days before the
    current study

All patients received the standard of care: oxygen therapy, antiviral
agents, antibacterial agents, and immunoglobulin, with or without
corticosteroids. Patients in the HCQ treatment group received additional
oral HCQ 400 mg/day, given as 200 mg 2x/day. HCQ was administered from
days 1-5 of the trial. The primary endpoint was 5 days post enrollment
or a severe adverse reaction to HCQ. The primary outcome evaluated was
time to clinical recovery (TTCR), defined as return to normal body
temperature and cough cessation for &gt; 72h. Chest CT were imaged on
days 0 and 6 of the trial for both groups; body temperature and patient
reports of cough were collected 3x/day from day 0 – 6. The mean age and
sex distribution between the HCQ and control arms were comparable.

#### Main Findings

There were 2 patients showing mild secondary effects of HCQ treatment.
More importantly, while 4 patients in the control group progressed to
severe disease, none progressed in the treatment group.

TTCR was significantly decreased in the HCQ treatment arm; recovery from
fever was shortened by one day (3.2 days control vs. 2.2 days HCQ, p =
0.0008); time to cessation of cough was similarly reduced (3.1 days
control vs. 2.0 days HCQ, p = 0.0016).

Overall, it appears that HCQ treatment of patients with mild COVID-19
has a modest effect on clinical recovery (symptom relief on average 1
day earlier) but may be more potent in reducing the progression from
mild to severe disease.

#### Limitations

This study is limited in its inclusion of only patients with mild
disease, and exclusion of those on any treatment other than the standard
of care. It would also have been important to include the laboratory
values of positive RT-PCR detection of SARS-CoV-2 to compare the
baseline and evolution of the patients’ viral load.

#### Limitations

Despite its limitations, the study design has good rigor as a double
blind RCT and consistent symptom checks on each day of the trail. Now
that the FDA has approved HCQ for treatment of COVID-19 in the USA, this
study supports the efficacy of HCQ use early in treatment of patients
showing mild symptoms, to improve time to clinical recovery, and
possibly reduce disease progression. However, most of the current
applications of HCQ have been in patients with severe disease and for
compassionate use, which are out of the scope of the findings presented
in this trial. Several additional clinical trials to examine
[hydroxychloroquine](https://twitter.com/hashtag/hydroxychloroquine?src=hashtag_click)
are now undergoing; their results will be critical to further validate
these findings.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


**Structure-based modeling of SARS-CoV-2 peptide/HLA-A02 antigens**

<https://doi.org/10.1101/2020.03.23.004176>

*Immunology keywords*:

CoVID-19, 2019-nCoV, SARS-CoV-2, comparative, homology, peptide,
modeling, simulation, HLA-A, antigen

*Summary of Findings*:

-   The authors utilize homology modeling to identify peptides from the
    SARS-CoV-2 proteome that potentially bind HLA-A\*02:01.

-   They utilize high-resolution X-ray structures of peptide/MHC
    complexes on Protein Data Bank, substitute homologous peptides with
    SARS-CoV-2 peptides, and calculate MHC/SARS-CoV-2 peptide Rosetta
    binding energy.

-   They select MHC/SARS-CoV-2 complex models with highest binding
    energy for further study and publish models in an online database
    (https://rosettamhc.chemistry.ucsc.edu).

*Limitations*:

-   The authors only utilize computational methods and predicted
    SARS-CoV-2 peptides must be validated experimentally for
    immunogenicity and clinical response.

-   Due to computational burden and limited availability of high
    resolution X-ray structures on PDB, authors only simulate 9-mer and
    10-mer peptide binding to HLA-A\*02:01.

-   Since the authors compare select existing X-ray structures as a
    starting point, backbone conformations that deviate significantly
    between test and template peptides are not captured. Furthermore,
    Rosetta modeling protocols do not capture all possible structures
    and binding energy scoring does not fully recapitulate fundamental
    forces.^1,2^

*Importance/Relevance:*

-   The authors identify and publish high-scoring SARS-CoV-2 peptides
    that may direct a targeted, experimental validation approach toward
    a COVID-19 vaccine.

-   The authors utilize Rosetta simulation to further filter results
    from NetMHCpan 4.0, supporting machine learning prediction with
    structural analysis.

-   The authors develop RosettaMHC, a computationally efficient method
    of leveraging existing X-ray structures for identification of
    immunogenic peptides.

*References:*

1.  Bender, B. J., Cisneros, A., 3rd, Duran, A. M., Finn, J. A., Fu, D.,
    Lokits, A. D., . . . Moretti, R. (2016). Protocols for Molecular
    Modeling with Rosetta3 and RosettaScripts. Biochemistry, 55(34),
    4748-4763. doi:10.1021/acs.biochem.6b00444

2.  Alford, R. F., Leaver-Fay, A., Jeliazkov, J. R., O'Meara, M. J.,
    DiMaio, F. P., Park, H., . . . Gray, J. J. (2017). The Rosetta
    All-Atom Energy Function for Macromolecular Modeling and Design. J
    Chem Theory Comput, 13(6), 3031-3048. doi:10.1021/acs.jctc.7b00125

*Review by Jonathan Chung as part of a project by students, postdocs and
faculty at the Immunology Institute of the Icahn school of medicine,
Mount Sinai.*


### Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset

Lou et al. *medRxiv*. [@doi:10.1101/2020.03.23.20041707]

#### Keywords

- Seroconversion rate
- Total Antibody
- Ab
- IgG and IgM
- antibody

#### Main Findings

Currently, the diagnosis of SARS-CoV-2 infection
entirely depends on the detection of viral RNA using polymerase chain
reaction (PCR) assays. False negative results are common, particularly
when the samples are collected from upper respiratory. Serological
detection may be useful as an additional testing strategy. In this study
the authors reported that a typical acute antibody response was induced
during the SARS-CoV-2 infection, which was discuss earlier^1^. The
seroconversion rate for Ab, IgM and IgG in COVID-19 patients was 98.8%
(79/80), 93.8% (75/80) and 93.8% (75/80), respectively. The first
detectible serology marker was total antibody followed by IgM and IgG,
with a median seroconversion time of 15, 18 and 20 days-post exposure
(d.p.e) or 9, 10- and 12-days post-onset (d.p.o). Seroconversion was
first detected at day 7d.p.e in 98.9% of the patients. Interestingly
they found that viral load declined as antibody levels increased. This
was in contrast to a previous study [@doi:10.1101/2020.03.02.20030189], showing that increased antibody
titers did not always correlate with RNA clearance (low number of
patient sample).

#### Limitations

Current knowledge of the antibody response to SAR-CoV-2
infection and its mechanism is not yet well elucidated. Similar to the
RNA test, the absence of antibody titers in the early stage of illness
could not exclude the possibility of infection. A diagnostic test, which
is the aim of the authors, would not be useful at the early time points
of infection but it could be used to screen asymptomatic patients or
patients with mild disease at later times after exposure.

#### Significance

Understanding the antibody responses against SARS-CoV2 is
useful in the development of a serological test for the diagnosis of
COVID-19. This manuscript discussed acute antibody responses which can
be deducted in plasma for diagnostic as well as prognostic purposes.
Thus, patient-derived plasma with known antibody titers may be used
therapeutically for treating COVID-19 patients with severe illness.
[[]{#OLE_LINK4 .anchor}]{#OLE_LINK3 .anchor}

#### Credit

*This review was undertaken and edited by Konstantina A as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems

Blanco-Melo et al. *bioRxiv*. [@doi:10.1101/2020.03.24.004655]

#### Keywords

- host cellular response
- host-pathogen interaction
- type I interferon
- type III interferon
- inflammation
- RNA-seq
- comparative analysis

#### Main Findings

Given the high mortality rate of SARS-CoV-2 relative to
other respiratory viruses such seasonal IAV and RSV, there may be
underlying host-pathogen interactions specific to SARS-CoV-2 that
predispose to a worse clinical outcome. Using *in vivo*, *ex vivo*, and
*in vitro* systems, the authors profiled host cell transcriptional
responses to SARS-CoV-2 and to other common respiratory viruses
(seasonal IAV and RSV). SARS-CoV-2 infection *in vitro* led to an
induction of type I interferon response signaling and the upregulation
of cytokine/chemokines transcripts. In comparison with IAV and RSV
infection, SARS-CoV-2 *in vitro* appears to uniquely induce less type I
and type III interferon expression and higher levels of two cytokines
previously implicated in respiratory inflammation. Lastly, *in vivo*
data from ferrets showed a reduced induction of cytokines and chemokines
by SARS-CoV-2 infection relative to IAV infection.

#### Limitations

While these results are promising, there are several
key weaknesses of this paper. 1) As the authors point out, there is an
undetectable level of SARS-CoV-2 putative receptor (ACE2) and protease
(TMPRSS2) expression in the lung epithelial cell line used for the *in
vitro* studies. This raises the important question of whether viral
replication actually occurs in any of the models used, which may explain
the lack of interferon production observed *in vitro* in SARS-CoV-2
treated cells. Further studies characterizing viral titers across
timepoints are needed. 2) Furthermore, these studies only characterize
the host response at a single dose and timepoint per virus, and it is
unclear why these doses/timepoints were chosen. This leaves open the
possibility that the observed differences between viruses could be due
to differences in dose, timing, host response, or a combination of all
of these. 3) It is unclear whether ferrets are productively infected,
which cell types are infected, and the extent/timing of the clinical
course of infection. Moreover, the *in vitro* and *in vivo* data do not
strongly correlate and the reasons for this are unclear.

#### Significance

This paper describes potentially unique
transcriptional signatures of host cells exposed to SARS-CoV-2. If
validated, these findings may help explain clinical outcomes and could
be targeted in future therapeutic interventions.

#### Potential Conflicts of Interest Disclosure

The reviewers are also researchers at the Icahn School
of Medicine at Mount Sinai.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China

Zhou et al. *bioRxiv*. [@doi:10.1101/2020.03.24.20042119]

#### Keywords

- disease severity
- clinical data
- Neutrophils/lymphocytes ratio
- CRP
- D-dimer

#### Main Findings

377 hospitalized patients were divided into two groups: severe and
non-severe pneumonia. The laboratory results of their first day of
admission were retrospectively analyzed to identify predictors of
disease severity.

After adjusting for confounding factors from chronic comorbidities (such
as high blood pressure, type 2 diabetes, coronary heart disease, and
chronic obstructive pulmonary disease), the independent risk factors
identified for severe pneumonia were **age**, the **ratio of
neutrophil/lymphocytes counts**, **CRP** and **D-dimer** levels.

To further increase the specificity and sensibility of these markers,
they showed that their multiplication **\[(Neutrophil/lymphocyte count)
\* CRP \* D-dimer\]** was a better predictor of disease severity, with
higher sensitivity (95.7%) and specificity (63.3%), with a cutoff value
of 2.68.

#### Limitations

This study included 377 hospitalized patients. Among them, 45.6%
patients tested positive for SARS-Cov-2 nucleic acid test results, and
others were included in the study based on clinically diagnosis even if
the molecular diagnosis was negative. Thus, additional studies are
needed to verify this on a larger number of covid-19 certified patients
and the cutoff value might be adjusted. Also, all the patients that did
not have the clinical characteristics of severe pneumonia were included
in the non-severe pneumonia group, but usually patients are also divided
into moderate and mild disease.

Also, studying different subset of lymphocytes could lead to a more
specific predictor. Another study showed that the neutrophils to CD8+ T
cells ratio was a strong predictor of disease severity [@doi:10.1101/2020.02.16.20023671]. Another more
precise study showed that the percentage of helper T cells and
regulatory T cells decrease but the percentage of naïve helper T cells
increases in severe cases [@doi:10.1093/cid/ciaa248]. Taking these subpopulations into account
might make the predictor more powerful.

Other studies also noted an inverse correlation between disease severity
and LDH [@doi:10.1101/2020.03.03.20030668] or IL6 [@doi:10.1101/2020.03.08.20031229] levels, but the authors here do not discuss LDH nor
IL6 levels, although this could help to strengthen the predictor.

The study is based on the results obtained on the first day of
admission, studying the dynamic of the changes in patients might also be
interesting to better predict disease severity.

#### Significance

This study confirms that the neutrophil to lymphocyte ratio can be a
predictor of disease severity as shown by many others [@doi:10.1093/cid/ciaa248; @doi:10.1001/jama.2020.1585; @doi:10.1101/2020.02.10.20021584]. The
novelty here is that they show that a combination with other markers can
enhance the specificity and sensibility of the predictor, although the
study could be improved by taking into account sub-populations of
lymphocytes and more biological factors from patients such as LDH and
IL6.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study

Shuke Nie et al. *medRxiv*. [@doi:10.1101/2020.03.24.20042283]

#### Keywords

- metabolism
- fasting blood glucose
- serum total protein
- albumin
- blood lipid
- HDL-C
- APOA1
- lymphocytopenia
- IL-6
- CRP
- severity prediction of COVID19

#### Main Findings

Retrospective Study on 97 COVID-19 hospitalized patients
(25 severe and 72 non-severe) analyzing clinical and laboratory
parameter to predict transition from mild to severe disease based on
more accessible indicators (such as fasting blood glucose, serum protein
or blood lipid) than inflammatory indicators. In accordance with other
studies, age and hypertension were risk factors for disease severity,
and lymphopenia and increased IL-6 was observed in severe patients. The
authors show that fasting blood glucose (FBG) was altered and patients
with severe disease were often hyperglycemic. Data presented support
that hypoproteinaemia, hypoalbuminemia, and reduction in
high-densitylipoprotein (HDL-C) and ApoA1 were associated with disease
severity.

#### Limitations

In this study non-severe patients were divided in two groups based on
average course of the disease: mild group1 (14 days, n=28) and mild
group 2 (30 days, n=44). However mild patients with a longer disease
course did not show an intermediate phenotype (between mild patients
with shorter disease course and severe patients), hence it is unclear
whether this was a useful and how it impacted the analysis. Furthermore,
the non-exclusion of co-morbidity factors in the analysis may bias the
results (e.g. diabetic patients and glucose tests) It is not clear at
what point in time the laboratory parameters are sampled. In table 3, it
would have been interesting to explore a multivariate multiple
regression. The correlation lacks of positive control to assess the
specificity of the correlation to the disease vs. correlation in any
inflammatory case. The dynamic study assessing the predictability of the
laboratory parameter is limited to 2 patients. Hence there are several
associations with disease severity, but larger studies are necessary to
test the independent predictive value of these potential biomarkers.

#### Significance

As hospital are getting overwhelmed a set of
easily accessible laboratory indicators (such as serum total protein)
would potentially provide a triage methodology between potentially
severe cases and mild ones. This paper also opens the question regarding
metabolic deregulation and COVID-19 severity.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Viral Kinetics and Antibody Responses in Patients with COVID-19

[@doi:10.1101/2020.03.24.20042382]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- IgG
- IgM
- clinical
- kinetics
- antibodies

#### Main Findings

-   Prospective cohort of 67 patients, clinical specimens taken and
    follow-up conducted.

-   Viral shedding, serum IgM, IgG antibody against NP evaluated and
    correlated to disease severity and clinical outcome

-   Viral RNA levels peaked at 1 week from febrile/cough symptom onset
    in sputum, nasal swabs, and stool samples. Shedding ranged from
    12-19 days (median ranges) and was longer in severe patients.

-   IgM and IgG titers stratified patients into three archetypes as
    ‘strong vs weak vs non-responders’. Strong responders (with higher
    IgM/IgG titers) were significantly higher in severe patients.

#### Limitations

Specific for immune monitoring.

-   Not clear if stool RNA captured from live infection in
    intestine/liver or from swallowed sputum. Transmission electron
    microscopy (TEM) carried out on sputum samples as proof of concept,
    but not stools. TEM unreasonable for actual clinical diagnosis.

-   Several patients had co-morbidities (such as pulmonary and liver
    disease) that were not accounted for when tracking antibody
    responses. Viral kinetics and IgM/IgG titers in subsets of patients
    with underlying conditions/undergoing certain medication would be
    informative.

#### Significance

-   Three archetypes of antibody response to SARS-CoV-2 with different
    disease progression and kinetics is useful to stratify patients, and
    for future serological tests.

-   Strong spike-IgG levels often correlate with lymphopenia and
    CoVID-19 disease severity [@doi:10.1101/2020.03.20.20039495], similar to macaque
    studies in SARS [@doi:10.1172/jci.insight.123158]. It would be critical to see if anti-NP or
    anti-Spike IgG antibodies for SARS-CoV-2 also elicit similar
    detrimental effects before clinical use.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome

[@doi:10.1101/2020.03.24.20042655]

#### Keywords

- Monocytes
- FSC-high
- PBMC
- ACE2
- inflammatory cytokines

#### Main Findings

This study is based on flow cytometry immunophenotyping of
PBMCs from 28 patients diagnosed positive for SARS-Cov2 (COVID19). The
authors identify a population of abnormally large (FSC-hi) monocytes,
present in COVID19 patients, but absent in PBMCs of healthy volunteers
(n=16) or patients with different infections (AIDS, malaria, TB). This
FSC-hi monocytic population contains classical, intermediate and
non-classical (monocytes (based on CD14 and CD16 expression) that
produce inflammatory cytokines (IL-6, TNF and IL-10). The authors
suggest an association of FSC-hi monocytes with poor outcome and
correlate a high percentage of FSC-low monocytes, or higher ratio of
FSC-low/hi monocytes, with faster hospital discharge.

#### Limitations

While identification of the monocytic population based
on FSC is rather robust, the characterization of these cells remains
weak. A comprehensive comparison of FSC-hi monocytes with FSC-low
monocytes from patients and healthy controls would be of high value. It
is unclear if percentages in blood are among CD45+ cells. Furthermore,
it would have been important to include absolute numbers of different
monocytic populations (in table 1 there are not enough samples and it is
unclear what the authors show).

The authors show expression of the ACE2 receptor on the surface of the
monocytes, and highlight these cells as potential targets of SARS-Cov2.
However, appropriate controls are needed. CD16 has high affinity to
rabbit IgG and it is unclear whether the authors considered unspecific
binding of rabbit anti-ACE2 to Fc receptors. Gene expression of ACE-2 on
monocytes needs to be assessed. Furthermore, it would be important to
confirm infection of monocytes by presence of viral proteins or viral
particles by microscopy.

Considering the predictive role of FSC-hi monocytes on the development
of the disease and its severity, some data expected at this level are
neither present nor addressed. Although the cohort is small, it does
include 3 ICU patients. What about their ratio of FSC-low vs FSC-hi
monocytes in comparison to other patients? Was this apparent early in
the disease course? Does this population of FSC-hi monocytes differ
between ICU patients and others in terms of frequency, phenotype or
cytokine secretion?

In general, figures need to revised to make the data clear. For example,
in Fig. 5, according to the legend it seems that patients with FSC-high
monocytes are discharged faster from the hospital. However according to
description in the text, patients were grouped in high or low levels of
FSC-low monocytes.

#### Significance

Despite the limitations of this study, the discovery of
a FSC-high monocyte population in COVID-19 patients is of great
interest. With similar implication, a the recent study by Zhou et al. [@doi:10.1101/2020.02.12.945576]
identified a connection between an inflammatory CD14+CD16+ monocyte
population and pulmonary immunopathology leading to deleterious clinical
manifestations and even acute mortality after SARS-CoV-2 infections.
Although the presence of these monocytes in the lungs has yet to be
demonstrated, such results support the importance of monocytes in the
critical inflammation observed in some COVID19 patients.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study

Miller et al. *medRxiv*. [@doi:10.1101/2020.03.24.20042937]

#### Keywords

- BCG vaccine
- epidemiology
- vaccination policy

#### Main Findings

The authors compared middle and high income countries that never had a
universal BCG vaccination policy (Italy, Lebanon, Nederland, Belgium)
and countries with a current policy (low income countries were excluded
from the analysis as their number of cases and deaths might be
underreported for the moment). **Countries that never implement BCG
vaccination have a higher mortality rate than countries which have a BCG
vaccination policy** (16.38 deaths per million people vs 0.78). Next,
**the authors show that an earlier start of vaccination correlates with
a lower number of deaths per million inhabitants**. They interpret this
as the vaccine protecting a larger fraction of elderly people, which are
usually more affected by COVID-19. Moreover, higher number of COVID-19
**cases** were presented in countries that never implemented a universal
BCG vaccination policy.

#### Limitations

While this study aims to test an intriguing hypothesis unfortunately,
the data is not sufficient at this time to accurately make any
determinations. Several caveats must be noted including: not all
countries are in the same stage of the pandemic, the number of
cases/deaths is still changing very rapidly in a lot of countries and
thus the association may only reflect exposure to the virus. This
analysis would need to be re-evaluated when all the countries are passed
the pandemic and more accurate numbers are available. Additionally, very
few middle and high-income countries ever implemented universal BCG
vaccination, which can be a source of bias (5 countries, vs 55 that have
a BCG vaccine policy). Effective screening and social isolation policies
also varied considerable across the countries tested and may reflect
another important confounder. The authors could consider analyzing the
Case Fatality Rate (CFR, % of patients with COVID-19 that die), to more
correct for exposure although testing availability will still bias this
result. Variability in mortality within countries or cities with
variable vaccination and similar exposure could also be appropriate
although confounders will still be present.

#### Significance

BCG vaccine is a live attenuated strain derived from *Mycobacterium
bovis* and used for a vaccine for tuberculosis (TB). This vaccine has
been proven to be efficient in preventing childhood meningitis TB, but
doesn’t prevent adult TB as efficiently. For this reason, several
countries are now only recommending this vaccine for at-risk population
only.

**This study shows that there is a correlation between BCG vaccination
policy and reduced mortality for Covid-19**. Indeed, BCG vaccine has
been shown to protect against several viruses and enhance innate
immunity [@doi:10.1016/j.cmi.2019.04.020], which could explain why it could protect against SARS-CoV-2
infection, but the exact mechanism is still unknown. **Moreover, the
efficiency of adult/older people vaccination and protection against
Covid-19 still needs to be assessed.** Regarding this, Australian
researchers are starting a clinical trial of BCG vaccine for healthcare
workers [@url:https://www.mcri.edu.au/BRACE], to assess if it can protect them against Covid-19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium

[@doi:10.1101/2020.03.25.009084]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- anosmia
- olfaction
- scRNAseq


#### Main Findings

-   Study analyzed bulk and scRNAseq data of olfactory cell types from
    publicly-available mouse, nonhuman primate and human datasets.

-   show that *ACE2* and *TMPRSS2* (genes involved in SARS-CoV-2 entry)
    are expressed in olfactory epithelial (OE) cells, basal stem cells
    and respiratory epithelium (RE), but not sensory neurons.

-   Comparison of human RE and OE datasets (Deprez et al. 2019; Durante
    et al. 2020) revealed that *ACE2* and *TMPRSS2* expression in OE
    sustentacular cells was similar to expression in the remainder of
    the non-nasal respiratory tract.

#### Limitations

-   Transcript data alone from healthy respiratory/olfactory cells is
    not sufficient to confirm infectivity of nasal passage, or to
    indicate damage to epithelia.

-   No mechanism defined for anosmia; it is not clear if epithelial
    injury leads to reduced sensitivity or increased inflammation and
    altered immune contexture drives neural/epithelial dysfunction. Will
    be critical to test this in CoVID-19 patient samples or mouse
    models.

#### Significance

-   Study provides possible rationale for anosmia observed in several
    CoVID-19 patients.

-   Raises possibility that nasal respiratory goblet, ciliated cells,
    and olfactory epithelia may serve as a viral reservoir after initial
    SARS-CoV-2 infection.

-   Human olfactory sensory neurons express several other molecules
    important to CoV (not CoV-19) entry such as *FURIN, ST6GAL1,
    ST3GAL4*; this suggests wider mechanism of neuronal infectivity in
    other coronaviruses.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and
faculty at the Immunology Institute of the Icahn School of Medicine,
Mount Sinai.*


**Title: **

**SARS-CoV-2 proteome microarray for mapping COVID-19 antibody
interactions at amino acid resolution**

**Immunology keywords:** SARS-CoV-2, COVID-19, high throughput, peptide
microarray, antibody epitope screening

**The main finding of the article: **

This study screened the viral protein epitopes recognized by antibodies
in the serum of 10 COVID-19 patients using a new SARS-CoV-2 proteome
peptide microarray. The peptide library was constructed with 966 linear
peptides, each 15 amino acids long with a 5 amino acid overlap, based on
the protein sequences encoded by the genome of the Wuhan-Hu-1 strain.

To investigate crossreactivity between SARS-CoV-1 and SARS-CoV-2, they
tested rabbit monoclonal and polyclonal antibodies against SARS-CoV-1
nucleocapsid (N) in the microarray. Antibodies against SARS-CoV-1 N
displayed binding to the SARS-CoV-2 nucleocapsid (N) peptides.
Polyclonal antibodies showed some crossreactivity to other epitopes from
membrane (M), spike (S), ORF1ab and ORF8. This suggests that previous
exposure to SARS-CoV-1 may induced antibodies recognizing both viruses.

Screening of IgM and IgG antibodies from 10 COVID-19 patients showed
that many antibodies targeted peptides on M, N, S, Orf1ab, Orf3a, Orf7a,
and Orf8 from SARS-CoV-2, while immunodominant epitopes with antibodies
in more than 80 % COVID-19 patients were present in N, S and Orf3. It is
shown that the receptor binding domain (RBD) resides on S protein and
RBD is important for SARS-CoV-2 to enter the host cells via ACE2. Among
six epitopes on S protein, structural analysis predicted that three
epitopes were located at the surface and three epitopes were located
inside of the protein. Furthermore, some IgM antibodies from 1 patient
and IgG antibodies from 2 patients bound to the same epitope (residue
456-460, FRKSN) which resided within the RBD, and structural analysis
determined that this epitope was located in the region of the RBD loop
that engages with ACE2.

**Critical analysis of the study:**

In addition to the limitations mentioned in the manuscript, it would
have been informative to do the analysis over the course of the disease.
The pattern of antibody recognition, especially on S protein, and the
course of antibodies of different isotypes recognizing the same peptide
might correlate to the clinical course in these patients. It would alos
have been informative to analyze the presence of cross-reactive
antibodies from pateints previously exposed to SARS-CoV-1.

**The importance and implications for the current epidemics:**

This study identified linear immunodominant epitopes on SARS-CoV-2,
Wuhan-Hu-1 strain. This is a valuable information to design vaccines
that will elicit desirable immune responses.


**The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Directly Decimates Human Spleens and Lymph Nodes**

Review by Matthew D. Park

Revised by Miriam Merad

Keywords: COVID-19, SARS-CoV-2, spleen, lymph node, ACE2, macrophage

*Main findings*

It has been previously reported that COVID-19 patients exhibit severe
lymphocytopenia, but the mechanism through which this depletion occurs
has not been described. In order to characterize the cause and process
of lymphocyte depletion in COVID-19 patients, the authors performed
gross anatomical and *in situ* immune-histochemical analyses of spleens
and lymph nodes (hilar and subscapular) obtained from post-mortem
autopsies of 6 patients with confirmed positive viremia and 3 healthy
controls (deceased due to vehicle accidents).

Primary gross observations noted significant splenic and LN atrophy,
hemorrhaging, and necrosis with congestion of interstitial blood vessels
and large accumulation of mononuclear cells and massive lymphocyte
death. They found that CD68^+^ CD169^+^ cells in the spleens, hilar and
subscapular LN, and capillaries of these secondary lymphoid organs
expressed the ACE2 receptor and stain positive for the SARS-CoV-2
nucleoprotein (NP) antigen, while CD3^+^ T cells and B220^+^ B cells
lacked both the ACE2 receptor and SARS-CoV-2 NP antigen. ACE2^+^ NP^+^
CD169^+^ macrophages were positioned in the splenic marginal zone (MZ)
and in the marginal sinuses of LN, which suggests that these macrophages
were positioned to encounter invading pathogens first and may contribute
to virus dissemination.

Since SARS-CoV-2 does not directly infect lymphocytes, the authors
hypothesized that the NP^+^ CD169^+^ macrophages are responsible for
persistent activation of lymphocytes via Fas::FasL interactions that
would mediate activation-induced cell death (AICD). Indeed, the
expression of Fas was significantly higher in virus-infected tissue than
that of healthy controls, and TUNEL staining showed significant
lymphocytic apoptosis. Since pro-inflammatory cytokines like IL-6 and
TNF-α can also engage cellular apoptosis and necrosis, the authors
interrogated the cytokine expression of the secondary lymphoid organs
from COVID-19 patients; IL-6, not TNF-α, was elevated in virus-infected
splenic and lymph node tissues, compared to those of healthy controls,
and immunofluorescent staining showed that IL-6 is primarily produced by
the infected macrophages. *In vitro* infection of THP1 cells with
SARS-CoV-2 spike protein resulted in selectively increased *Il6*
expression, as opposed to *Il1b* and *Tnfa* transcription. Collectively,
the authors concluded that a combination of Fas up-regulation and IL-6
production by NP^+^ CD169^+^ macrophages induce AICD in lymphocytes in
secondary lymphoid organs, resulting in lymphocytopenia.

In summary, this study reports that CD169^+^ macrophages in the splenic
MZ, subscapular LN, and the lining capillaries of the secondary lymphoid
tissues express ACE2 and are susceptible to SARS-CoV-2 infection. The
findings point to the potential role of these macrophages in viral
dissemination, immunopathology of these secondary lymphoid organs,
hyperinflammation and lymphopenia.

*Limitations*

*Technical*

A notable technical limitation is the small number of samples (n=6);
moreover, the analysis of these samples using multiplexed
immunohistochemistry and immunofluorescence do not necessarily provide
the depth of unbiased interrogation needed to better identify the cell
types involved.

*Biological*

The available literature and ongoing unpublished studies, including
single-cell experiments of spleen and LN from organ donors, do not
indicate that ACE2 is expressed by macrophages; however, it remains
possible that ACE2 expression may be triggered by type I IFN in COVID-19
patients. Importantly, the SARS-CoV-2 NP staining of the macrophages
does not necessarily reflect direct infection of these macrophages;
instead, positive staining only indicates that these macrophages carry
SARS-CoV-2 NP as antigen cargo, which may have been phagocytosed. Direct
viral culture of macrophages isolated from the secondary lymphoid organs
with SARS-CoV-2 is required to confirm the potential for direct
infection of macrophages by SARS-CoV-2. Additionally, it is important to
note that the low to negligible viremia reported in COVID-19 patients
to-date does not favor a dissemination route via the blood, as suggested
by this study, which would be necessary to explain the presence of
virally infected cells in the spleen.

*Relevance*

Excess inflammation in response to SARS-CoV-2 infection is characterized
by cytokine storm in many COVID-19 patients. The contribution of this
pathology to the overall fatality rate due to COVID-19, not even
necessarily directly due to SARS-CoV-2 infection, is significant. A
better understanding of the full effect and source of some of these
major cytokines, like IL-6, as well as the deficient immune responses,
like lymphocytopenia, is urgently needed. In this study, the authors
report severe tissue damage in spleens and lymph nodes of COVID-19
patients and identify the role that CD169^+^ macrophages may play in the
hyperinflammation and lymphocytopenia that are both characteristic of
the disease. It may, therefore, be important to note the effects that
IL-6 inhibitors like Tocilizumab and Sarilumab may specifically have on
splenic and LN function. It is important to note that similar
observations of severe splenic and LN necrosis and inflammation in
patients infected with SARS-CoV-1 further support the potential
importance and relevance of this study.


### Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2

[@doi:10.1101/2020.03.28.013672]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- respiration
- cigarette
- ACE2
- lung

#### Main Findings

-   Study uses scRNAseq, bulk seq data and air-liquid interface culture
    experiments to show that cigarette smoke causes a dose-dependent
    upregulation of ACE2 in mouse and human lungs (transplantation,
    tumor resection, or IPF datasets).

-   ACE2 was not up-regulated in patients with asthma or
    lung-sarcoidosis or in mouse models of cystic fibrosis or carcinogen
    exposure.

-   Cathepsin B (alternate protease involved in viral entry) is
    increased in smoke-exposed mouse or human lungs.

-   Smoke triggers a protective expansion of mucus-secreting MUC5AC+
    goblet and SCGB1A1+ club cells; ACE2 presence in these cells is
    increased upon smoke exposure.

#### Limitations:

-   Long-term smokers usually have several co-morbidities including
    immune dysfunction, which can affect interpretation of CoV-2
    susceptibility in these datasets. Ideally, analyses can control for
    major co-morbidities across smokers and non-smokers (immune
    suppression, cardiovascular disease and atherosclerosis).

-   Hyperplasia of ACE2+ goblet cells upon smoking needs to be separated
    from ACE2 upregulation in existing goblet cells.

-   ACE2 expression increase alone does not confirm increased viral
    entry into goblet cells; future studies with air-liquid interface
    cultures testing CoV-2 infectivity in *ex vivo* epithelial cells
    from human epithelial lines, ex vivo samples or hACE2 mice will be
    very informative.

#### Significance

-   This study may partially explain why smokers are more likely to
    develop severe SARS-CoV-2 infections. Also, the reversibility of
    ACE2 expression upon smoking cessation suggests that quitting
    smoking could lessen CoV-2 susceptibility.

-   Absence of ACE2 upregulation in other lung inflammation pathologies
    implies CoV-2 susceptibility might be smoking-specific, and not
    fibrosis-specific.

-   Another preprint showed ACE2 expression increases in lung of
    patients with CoV-2 co-morbidities such as hypertension [@doi:10.1101/2020.03.21.20040261]; these studies
    collectively paint a better picture of CoV-2 susceptibility before
    actual experiments can be carried out.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis

Liu et al. *medRxiv*.
[@doi:10.1101/2020.03.28.20045765]

#### Keywords

- IgM/IgG antibody test
- nucleic acid test
- SARS-CoV-2 detection

#### Main Findings

The study compares IgM and IgG antibody testing to RT-PCR detection of
SARS-CoV-2 infection. 133 patients diagnosed with SARS-CoV-2 in Renmin
Hospital (Wuhan University, China) were analyzed. The positive ratio was
78.95% (105/133) in IgM antibody test (SARS-CoV-2 antibody detection kit
from YHLO Biotech) and 68.42% (91/133) in RT-PCR (SARS-CoV-2 ORF1ab/N
qPCR detection kit). There were no differences in the sensitivity of
SARS-CO-V2 diagnosis in patients grouped according to disease severity.
For example, IgG responses were detected in 93.18% of moderate cases,
100% of severe cases and 97.3% of critical cases. In sum, positive
ratios were higher in antibody testing compared to RT-PCR detection,
demonstrating a higher detection sensitivity of IgM-IgG testing for
patients hospitalized with COVID-19 symptoms.

#### Limitations

This analysis only included one-time point of 133 hospitalized patients,
and the time from symptom onset was not described. There was no
discussion about specificity of the tests and no healthy controls were
included. It would be important to perform similar studies with more
patients, including younger age groups and patients with mild symptoms
as well as asymptomatic individuals. It is critical to determine how
early after infection/symptom onset antibodies can be detected and the
duration of this immune response.

#### Significance

The IgM-IgG combined testing is important to improve clinical
sensitivity and diagnose COVID-19 patients. The combined antibody test
shows higher sensitivity than individual IgM and IgG tests or nucleic
acid-based methods, at least in patients hospitalized with symptoms.

#### Credit

*Review by Erica Dalla as part of a project by students, postdocs and
faculty at the Immunology Institute of the Icahn School of Medicine,
Mount Sinai.*


**Title:** Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike
binding to ACE2

**Immunology keywords:** defensins, spike protein, intestinal Paneth
cells, ACE2 binding

**Main Findings:**

Human ACE2 was previously identified as the host receptor for
SARS-CoV-2. Despite ACE2 being expressed in both lung alveolar
epithelial cells and small intestine enterocytes, respiratory problems
are the most common symptom after viral infection while intestinal
symptoms are much less frequent. Thus, the authors here investigate the
biology behind the observed protection of the intestinal epithelium from
SARS-CoV-2. Human defensin 5 (HD5), produced by Paneth cells in the
small intestine, was shown to interact with human ACE2, with a binding
affinity of 39.3 nM by biolayer interferometry (BLI). A blocking
experiment using different doses of HD5 coating ACE2 showed that HD5
lowered viral spike protein S1 binding to ACE2. Further, a molecular
dynamic simulation demonstrated a strong intermolecular interaction
between HD5 and the ACE2 ligand binding domain. To test HD5 inhibitory
effect on S1 binding to ACE2, human intestinal epithelium Caco-2 cells
were preincubated with HD5. Preincubation strongly reduced adherence of
S1 to surface of cells. HD5 was effective at a concentration as low as
10 µg/mL, comparable to the concentration found in the intestinal fluid.

**Limitations:**

The study focuses exclusively on intestinal cells. However, HD5 could
have been tested to block ACE2-S1 binding in human lung epithelial cells
as a potential treatment strategy. It would be useful to know whether
HD5 could also prevent viral entry in lung cells.

**Relevance:**

This work provides the first understanding of the different efficiency
of viral entry and infection among ACE2-expressing cells and tissues.
Specifically, the authors show that human defensin 5 produced in the
small intestine is able to block binding between S1 and ACE2 necessary
for viral entry into cells. The study provides a plausible explanation
on why few patients show intestinal symptoms and suggests that patients
with intestinal disease that decrease defensins’ production may be more
susceptible to SARS-CoV-2. It also indicates that HD5 could be used as a
molecule to be exogenously administered to patients to prevent viral
infection in lung epithelial cells.


**Title: **

**Susceptibility of ferrets, cats, dogs and different domestic animals
to SARS-coronavirus-2**

**Immunology keywords:** SARS-CoV-2, ferret, cat, laboratory animal,
domestic animals

**The main finding of the article: **

This study evaluated the susceptibility of different model laboratory
animals (ferrets), as well as companion (cats and dogs), and domestic
animals (pigs, chickens and ducks) to SARS-CoV-2. They tested infection
with two SARS-CoV2 isolates, one from an environmental sample collected
in the Huanan Seafood Market in Wuhan (F13-E) and the other from a human
patient in Wuhan (CTan-H).

*Ferrets* were inoculated with either of the two viruses by intranasal
route with 10^5^ pfu, and the viral replication was evaluated. Two
ferrets from each group were euthanized on day 4 post infection (p.i.).
AT day 4 p.i., viral RNA and infectious viruses were detected only in
upper respiratory tract (nasal turbinate, upper palate, tonisls, but not
in the trachea, lungs or other tissues. Viral RNA and virus titer in the
remaining ferrets were monitored in nasal washes and rectal swabs on
days 2, 4, 6, 8 and 10 p.i. Viral RNA and infectious viruses were
detected in nasal washes until day 8 p.i. One ferret in each group
developed fever and loss of appetite on days 10 and 12 p.i., however,
viral RNA was practically undetactable. These two ferrets showed severe
lymphoplasmacytic perivasculitis and vasculitis in the lungs and lower
antibody titers compare to other 4 ferrets.

*Cats*. Five *s*ubadult 8-month-old domestic cats were inoculated with
CTan-h virus and three uninfected cats were placed in a cage adjacent to
each of the infected cats to monitor respiratory droplet transmission.
Viral RNA was detected in the upper respiratory organs from all infected
cats and in one out of three exposed cats. All infected (inoculated and
exposed) cats developed elevated antibodies against SARS-CoV2. Viral
replication studies with juvenile cats (70-100 days) revealed massive
lesions in the nasal and tracheal mucosa epithelium and lungs of two
inoculated cats which died or were euthanized on day 3 p.i., and
infection in one out of three exposed cats. These results indicated
SARS-CoV2 could replicate in cats, that juvenile cats were more
susceptible that adults, and theat SARS-CoV2 could be transmit via
respiratory droplets between cats.

*Dogs and others.* Five 3-month-old beagle dogs were inoculated and
housed with two uninoculated beagles in a room. Two virus inoculated
dogs seroconverted, but others including two contact dogs were all
seronegative for SARS-CoV2 and infectious virus was not detected in any
swabs collected. Viral RNA was not detected in swabs from pigs,
chickens, and ducks inoculated or contacted. These results indicated
that dogs, pigs, chickens, and ducks might have low or no susceptibility
to SARS-CoV2.

**Critical analysis of the study:**

This manuscript describes the viral replication and clinical symptoms of
SARS-CoV2 infection in ferrets, and the SARS-CoV2 infection and
transmission in cats. Clinical and pathological analysis was not
performed in cats, therefore the correlation of virus titer with
symptoms severity in the adult and juvenile cats could not be
determined.

**The importance and implications for the current epidemics:**

SARS-CoV-2 transmission to tigers, cats and dogs has been previously
reported. It should be noted that this manuscript did not evaluate the
transmission from cats to human. Nevertheless, it clearly showed higher
susceptibility of ferrets and domestic cats to SARS-CoV-2. This data
strongly indicates the need for surveillance of possible infection and
transmission of SARS-CoV-2 by domestic cats.


### Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis

Li et al. *bioRxiv*.
[@doi:10.1101/2020.03.31.019216]

#### Keywords
- PBMC
- virulence factors
– interaction network
– nsp9
- nsp10
– NKRF

#### Main findings

The authors identified **intra-viral protein-protein interactions**
(PPI) with two different approaches: genome wide yeast-two hybrid (Y2H)
and co-immunoprecipitation (co-IP). A total of 58 distinct PPI were
characterized. A screen of **viral-host PPI** was also established by
overexpressing all the SARS-CoV-2 genes with a Flag epitope into HEK293
cells and purifying each protein complex. Interacting host proteins were
then identified by liquid chromatography and tandem mass spectrometry.
251 cellular proteins were identified, such as subunits of ATPase, 40S
ribosomal proteins, T complex proteins and proteasome related proteins,
for a total of 631 viral-host PPI. Several interactions suggesting
protein-mediated modulation of the immune response were identified,
highlighting the multiple ways SARS-CoV-2 might reprogram infected
cells.

Subsequently, the authors compared global proteome profiles of PBMCs
from healthy donors (n=6) with PBMC from COVID-19 patients with mild
(n=22) or severe (n=13) symptoms. 220 proteins were found to be
differentially expressed between *healthy donors and mild COVID-19
patients*, and a pathway analysis showed **a general activation of the
innate immune response.** 553 proteins were differentially expressed
between the PBMC of *mild and severe COVID-19 patients*, most of them
(95%) being downregulated in severe patients*.* Functional pathway
analysis indicated a defect of T cell activation and function in severe
COVID-19. There was also evidence suggesting reduced antibody secretion
by B cells. Together, these results suggest a **functional decline of
adaptive immunity**. A FACS analysis of PBMC from severe patients
indicated higher levels of IL6 and IL8 but not IL17 compared to mild
patients.

Finally, the authors focused on NKRF, an endogenous repressor of IL8/IL6
synthesis that was previously identified as interacting with SARS-Cov-2
nsp9,10,12,13 and 15. Individually expressed nsp9 and nsp10 (but not
nsp12, nsp13, nsp15) induced both IL6 and IL8 in lung epithelial A459
cells, indicating that nsp9 and nsp10 may be directly involved in the
induction of these pro-inflammatory cytokines. The authors finally argue
that nsp9 and nsp10 represent potential drug targets to prevent
over-production of IL6 and IL8 in infected cells, and reducing the
over-activation of neutrophils.

#### Limitations

First, the authors seem to have forgotten to include the extended data
in the manuscript, and their proteomic data does not seem to be publicly
available for the moment, which limits greatly our analysis of their
results.

While this work provides important data on host and viral PPI, only 19
interactions were identified by Y2H system but 52 with co-IP. The
authors do not comment about what could lead to such differences between
the two techniques and they don’t specify whether they detected the same
interactions using the two techniques.

Moreover, the PBMC protein quantification was performed comparing bulk
PBMC. Consequently, protein differences likely reflect differences in
cell populations rather than cell-intrinsic differences in protein
expression. While this analysis is still interesting, a similar
experiment performed on pre-sorted specific cell populations would allow
measuring proteome dynamics at a higher resolution.

Finally, the authors did not discussed their results in regards to
another SARS-CoV-2 interactome of host-viral PPI that had been published
previously^1^. This study reported 332 host-virus PPI, but no
interaction of viral proteins with NKRF was found. Some interactions
were found in both studies (eg. N and G3BP1, Orf6 and RAE1). However,
the time point used to lyse the cells were different (40h previously vs
72h here), which could explain some of the differences.

#### Relevance

The identification of many interactions between intra-viral and
host-virus PPI provides an overview of host protein and pathways that
are modulated by SARS-CoV-2, which can lead to the identification of
potential targets for drug development.

In the model proposed by the authors, nsp9 and nsp10 from SARS-Cov-2
induce an over-expression of IL6 and IL8 by lung epithelial cells, which
recruits neutrophils and could lead to an excess in lung infiltration.
Nsp9 has been shown to be essential for viral replication for
SARS-Cov-1^2^, and shares a 97% homology with nsp9 from SARS-Cov-2^3^.
Further, nsp9 crystal structure was recently solved^3^, which can help
to develop drug inhibitors if this protein is further confirmed as being
important for the virulence of SARS-Cov-2.

1\. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-Human
Protein-Protein Interaction Map Reveals Drug Targets and Potential
Drug-Repurposing. *bioRxiv*. March 2020:2020.03.22.002386.
doi:10.1101/2020.03.22.002386

2\. Miknis ZJ, Donaldson EF, Umland TC, Rimmer RA, Baric RS, Schultz LW.
Severe acute respiratory syndrome coronavirus nsp9 dimerization is
essential for efficient viral growth. *J Virol*. 2009;83(7):3007-3018.
doi:10.1128/JVI.01505-08

3\. Littler DR, Gully BS, Colson RN, Rossjohn J. *Crystal Structure of
the SARS-CoV-2 Non-Structural Protein 9, Nsp9*. Molecular Biology; 2020.
doi:10.1101/2020.03.28.013920


***Title:*** Prediction and Evolution of B Cell Epitopes of Surface
Protein in SARS-CoV-2

***Keywords:*** SARS-CoV-2; Epitopes; Bioinformatics; Evolution

***Summary/Main findings: ***

Lon et al. used a bioinformatic analysis of the published SARS-CoV-2
genomes in order to identify conserved linear and conformational B cell
epitopes found on the spike (S), envelope (E), and membrane (M)
proteins. The characterization of the surface proteins in this study
began with an assessment of the peptide sequences in order to identify
hydrophilicity indices and protein instability indices using the
Port-Param tool in ExPASy. All three surface proteins were calculated to
have an instability score under 40 indicating that they were stable.
Linear epitopes were identified on the basis of surface probability and
antigenicity, excluding regions of glycosylation. Using BepiPred 2.0
(with a cutoff value of 0.35) and ABCpred (with a cutoff value of 0.51),
4 linear B cell epitopes were predicted for the S protein, 1 epitope for
the E protein, and 1 epitope for the M protein. For structural analysis,
SARS-CoV assemblies published in the Protein Data Bank (PDB) acting as
scaffolds for the SARS-CoV-2 S and E amino acid sequences were used for
input into the SWISS-MODEL server in order to generate three-dimensional
structural models for the assessment of conformational epitopes. Using
Ellipro (cutoff value of 0.063) and SEPPA (cutoff value of 0.5), 1
conformational epitope was identified for the S protein and 1 epitope
was identified for the E protein, both of which are accessible on the
surface of the virus. Finally, the Consurf Server was used to assess the
conservation of these epitopes. All epitopes were conserved across the
published SARS-CoV-2 genomes and one epitope of the spike protein was
predicted to be the most stable across coronavirus phylogeny.

***Critical Analysis/Limitations:***

While this study provides a preliminary identification of potential
linear and conformational B cell epitopes, the translational value of
the epitopes described still needs extensive experimental validation to
ascertain whether these elicit a humoral immune response. The
conformational epitope analyses are also limited by the fact that they
are based off of predicted 3D structure from homology comparisons and
not direct crystal structures of the proteins themselves. Additionally,
since there was not a published M protein with a high homology to
SARS-CoV-2, no conformational epitopes were assessed for this protein.
Finally, while evolutionary conservation is an important consideration
in understanding the biology of the virus, conservation does not
necessarily imply that these sites neutralize the virus or aid in
non-neutralizing *in vivo* protection.

***Relevance/Implications:***

With further experimental validation that confirms that these epitopes
induce effective antibody responses to the virus, the epitopes described
can be used for the development of treatments and vaccines as well as
better characterize the viral structure to more deeply understand
pathogenesis.




## Appendix B {.page_break_before}
Contributors were asked to complete this template to summarize and evaluate new papers related to diagnostics.


<!--Hi there! Please use the template below as a guide for what information about this paper to include. It's ok to leave fields blank so that other contributors can fill them in later, or to add fields that you think are important.-->

Title: Please edit the title to add the name of the paper after the colon

Please paste a link to the paper or a citation here:

Link:

What is the paper's [Manubot-style citation](https://github.com/greenelab/covid19-review/blob/master/USAGE.md#citations)?
<!--Leave the citation blank if you are unsure.-->

Citation:

Please list some keywords (3-10) that help identify the relevance of this paper to COVID-19

* keyword 1 (replace me, copy and paste more than three if needed)
* keyword 2 (replace me, copy and paste more than three if needed)
* keyword 3 (replace me, copy and paste more than three if needed)

Please note the publication / review status
<!--Replace one of the empty brackets below with [x].-->

- [ ] Pre-print
- [ ] New Peer-Reviewed Paper
- [ ] Peer-Reviewed Paper Pre-2020

Which areas of expertise are particularly relevant to the paper?
<!--Replace the empty brackets below with [x].-->

- [ ] virology
- [ ] epidemiology
- [ ] biostatistics
- [ ] immunology
- [ ] pharmacology

<!-- The following questions are the things that we'll want to answer about each paper reporting a diagnostic. If you are ready to answer some of them now, please create the issue, then answer them in a comment. Otherwise, just create the issue so that a future reviewer can address them in the comments.-->

Questions to answer about each paper:

Please provide 1-2 sentences introducing the study and its main findings



Study question(s) being investigated:

What type of testing scenario is being considered?

Is it a screening test (used for individuals with no symptoms), diagnostic test (used for individuals with symptoms), or definitive test (used for individuals who have had previous positive test results on diagnostic or screening tests)?

Study population:

What is the model system (e.g., human study, animal model, cell line study)?

What is the sample size?

What is the "pre-test" probability of disease in the study population (i.e., what is the anticipated prevalence of the disease?)

For human studies, the following are related to the pre-test probability:

What countries/regions are considered?

What is the age range, gender, other relevant characteristics?

What is the setting of the study (e.g., random sample of school children, retirement communities, etc.)?

What other specific inclusion-exclusion criteria are considered?

Reference test:

What reference test is considered as a "gold standard" comparator for the test under investigation?

Test assignment:

How are the new and reference tests assigned?

Examples of assignment could include: Recruited individuals have initially undergone neither the new nor the reference test; individuals tested as positive or negative by the reference test undergo the new test; individuals who have undertaken the new test are assessed by the standard test.

Are there any other relevant details about the study design?

Depending on how individuals are chosen, the test may be biasing towards more sick or less sick individuals or very clear-cut positive/negative cases.
Any factors that would influence this bias should be included here.

Test conduct:

How were tests performed?

Describe technical details of assays used, when measurements were taken and by whom, etc. for both the new and standard tests.

Test Assessment

Describe how individuals are classified as positive or negative, e.g. if a threshold is used.

Is there evidence that the test is precise/reproducible when repeated more than once?

Are measurements complete?

For example: Do some participants undergo just one test (the new or the reference test)?
Are there individuals with inconclusive results?

Results summary:

What are the estimated sensitivity, specificity, positive predictive value (PPV), and negative predicted value (NPV)?

Note that the PPV and NPV represent "post-test" probabilities of disease and are generally more meaningful than sensitivity and specificity.
Sometimes the post-test odds will be given instead.

What are the confidence bounds around these intervals?

Interpretation of results for study population:

How good is the test at ruling in or ruling out a disease based on the post-test probabilities?

Are there identified side affects of the test?

Is patient adherence to the test likely to be an issue?

Extrapolation of conclusions to other groups of individuals

How well is the test likely to work in populations with different pretest odds?

For example, if the prevalence is lower, then the PPV will also be lower, but the NPV will be higher.

How costly is the test?

How difficult is it to perform the test in different settings?

Could the test be combined with other existing tests?

Summary of reliability

1-2 sentences on concluding remarks, including summary of strengths, weaknesses, limitations.

Progress

_Check off the components as they are completed. If the component is not applicable, check the box as well._

<!--Check off the components that you have completed. It is fine if you have not completed all of them, we hope others will add on in the comments. Switch to "Preview" mode to click the box(es), or else replace the empty brackets below with [x].-->

- [ ] 1-2 sentences introducing the study and its main findings
- [ ] Describe testing scenario 
- [ ] Describe model system 
- [ ] Sample size 
- [ ] Describe prevalnce of disease 
- [ ] Describe countries/regions are considered 
- [ ] Describe age range, gender, other relevant characteristics 
- [ ] Describe setting of the study 
- [ ] Describe other specific inclusion-exclusion criteria 
- [ ] Describe "gold standard" 
- [ ] Describe how  the new and reference tests assigned 
- [ ] Describe other relevant details about the study design 
- [ ] Describe how the tests were performed 
- [ ] Describe how individuals are classified as positive or negative 
- [ ] Describe if test is precise/reproducible 
- [ ] Describe whether measurements are complete 
- [ ] What are the estimated sensitivity, specificity, positive predictive value (PPV), and negative predicted value (NPV)? 
- [ ] What are the confidence bounds around these intervals? 
- [ ] Describe post-test probabilities 
- [ ] Describe side affects of the test 
- [ ] Describe patient adherence 
- [ ] Describe how it will extrapolate 
- [ ] How costly is the test? 
- [ ] How difficult is it to perform the test in different settings? 
- [ ] Could the test be combined with other existing tests?
- [ ] Summary of reliability

## Appendix C {.page_break_before}
Contributors were asked to complete this template to summarize and evaluate new papers related to therapeutics.


<!--Hi there! Please use the template below as a guide for what information about this paper to include. It's ok to leave fields blank so that other contributors can fill them in later, or to add fields that you think are important.-->

Title: Please edit the title to add the name of the paper after the colon

Please paste a link to the paper or a citation here:

Link:

What is the paper's [Manubot-style citation](https://github.com/greenelab/covid19-review/blob/master/USAGE.md#citations)?
<!--Leave the citation blank if you are unsure.-->

Citation:

Please list some keywords (3-10) that help identify the relevance of this paper to COVID-19

* keyword 1 (replace me, copy and paste more than three if needed)
* keyword 2 (replace me, copy and paste more than three if needed)
* keyword 3 (replace me, copy and paste more than three if needed)

Please note the publication / review status
<!--Replace one of the empty brackets below with [x].-->

- [ ] Pre-print
- [ ] New Peer-Reviewed Paper
- [ ] Peer-Reviewed Paper Pre-2020

Which areas of expertise are particularly relevant to the paper? 
<!--Replace the empty brackets below with [x].-->

- [ ] virology
- [ ] epidemiology
- [ ] biostatistics
- [ ] immunology
- [ ] pharmacology

<!-- The following questions are the things that we'll want to answer about each paper reporting a diagnostic. If you are ready to answer some of them now, please create the issue, then answer them in a comment. Otherwise, just create the issue so that a future reviewer can address them in the comments.-->

Questions to answer about each paper:

Please provide 1-2 sentences introducing the study and its main findings


Study question(s) being investigated:

How many/what drugs/combinations are being considered?


What are the main hypotheses being tested?


Study population:

What is the model system (e.g., human study, animal model, cell line study)?


What is the sample size? If multiple groups are considered, give sample size for each group (including controls).

* number treated with treatment A
* number treated with treatment B

For human studies:

What countries/regions are considered?

What is the age range, gender, other relevant characteristics?

What is the setting of the study (random sample of school children, inpatient, outpatient, etc)?

What other specific inclusion-exclusion criteria are considered?

For example, do the investigators exclude patients with diagnosed neoplasms or patients over/under a certain age?


Treatment assignment:

How are treatments assigned?

For example, is it an interventional or an observational study?

Is the study randomized?

A study can be interventional but not randomized (e.g., a phase I or II clinical trial is interventional but often not randomized).

Provide other relevant details about the design.

This includes possible treatment stratification (e.g., within litters for animal studies, within hospitals for human studies), possible confounding variables (e.g., having a large age range of individuals), possible risks of bias and how they are addressed (e.g., is there masking in a clinical trial? how are individuals chosen in an observational study?).


Outcome Assessment:

Describe the outcome that is assessed and whether it is appropriate.

For example: Is the outcome assessed by a clinician or is it self-reported?
Is the outcome based on viral load or a functional measurement (e.g., respiratory function, discharge from hospital)?
What method is used to measure the outcome?
How long after a treatment is the outcome measured?

Are outcome measurements complete?

For example, are there individuals lost to follow up?

Are outcome measurements subject to various kinds of bias?

For example, a lack of masking in randomized clinical trials.


Statistical Methods Assessment:

What methods are used for inference?

For example, logistic regression, nonparametric methods.

Are the methods appropriate for the study?

For example, are clustered data treated independently or are clusters adjusted for, such as different hospitals or litters?

Are adjustments made for possible confounders?

For example, adjustment for age, sex, or comorbidities.


Results Summary:

What is the estimated association?

For example, is it an estimated odds ratio, a median difference in detected cases, etc?

What measures of confidence or statistical significance are provided?

For example, confidence intervals, p-values, and/or Bayes factors.


Interpretation of results for study population:

Can we make a causal interpretation for the individuals in the study of drug -> outcome, such as "taking drug A improves likelihood of survival twofold over taking drug B."

For example, with a well-performed animal study or randomized trial it is often possible to infer causality.
If is an observational study, does it match up with some of the Bradford Hill criteria? https://www.edwardtufte.com/tufte/hill https://en.wikipedia.org/wiki/Bradford_Hill_criteria

Are there identified side effects or interactions with other drugs?

For example, is the treatment known to cause liver damage or to not be prescribed for individuals with certain comorbities?

Are there specific subgroups with different findings?

For example, do individuals with a specific baseline seem to do particularly well? Be particularly cautious with respect to multiple testing here.


Extrapolation of conclusions to other groups of individuals not specifically included in the study:

If the study is an animal study, which animal and how relevant is that model?

Is the model system appropriate? Is there evidence from past use that it's highly-relevant to therapeutic design in this context?

If it is a human study, what characteristics of the study population may support/limit extrapolation?

* Can results extrapolate easily to other similar groups? (e.g., same country, similar age groups)
* What would happen if conditions are extended in terms of dose or duration?
* Can results be extrapolated to other populations or in very different settings? (e.g., different age group, primary care setting vs emergency department etc)


Summary of reliability

1-2 sentences on concluding remarks, including summary of strengths, weaknesses, limitations.

Progress

_Check off the components as they are completed. If the component is not applicable, check the box as well._

<!--Check off the components that you have completed. It is fine if you have not completed all of them, we hope others will add on in the comments. Switch to "Preview" mode to click the box(es), or else replace the empty brackets below with [x].-->

- [ ] 1-2 sentences introducing the study and its main findings
- [ ] Describe How many/what drugs/combinations are being considered 
- [ ] Describe the model system
- [ ] What is the sample size? 
- [ ] What countries/regions are considered 
- [ ] What is the age range, gender, other relevant characteristics 
- [ ] Describe study setting 
- [ ] Describe  other specific inclusion-exclusion criteria 
- [ ] Describe how treatments are assigned
- [ ] Describe randomization (or not) and other relavent details about the design
- [ ] Describe the outcome that is assessed and whether it is appropriate.
- [ ] Describe whether the outcome measurements are complete
- [ ] Are outcome measurements subject to various kinds of bias?
- [ ] Describe methods used for inference
- [ ] Describe whether the methods are appropriate for the study
- [ ] Are adjustments made for possible confounders?
- [ ] Describe the estimated association
- [ ] What measures of confidence or statistical significance are provided?
- [ ] Describe whether a causal interpretation can be made
- [ ] Are there identified side effects or interactions with other drugs?
- [ ] Are there specific subgroups with different findings?
- [ ] If the study is an animal study, which animal and how relevant is that model?
- [ ] If it is a human study, what characteristics of the study population may support/limit extrapolation?
- [ ] Summary of reliability

## Appendix D {.page_break_before}
Contributors were asked to complete this template to summarize and evaluate new papers related to topics besides therapeutics and diagnostics.


<!--Hi there! Please use the template below as a guide for what information about this paper to include. It's ok to leave fields blank so that other contributors can fill them in later, or to add fields that you think are important.-->

Title: Please edit the title to add the name of the paper after the colon.

General Information
Please paste a link to the paper or a citation here:

Link:

What is the paper's [Manubot-style citation](https://github.com/greenelab/covid19-review/blob/master/USAGE.md#citations)?
<!--Leave the citation blank if you are unsure.-->

Citation:

Is this paper primarily relevant to Background or Pathogenesis? 
<!--Replace the empty brackets below with [x].
If it's primarily relevant to Diagnostics or Therapeutics, please go back and use the associated template-->

- [ ] Background
- [ ] Pathogenesis
- [ ] Methods

Please list some keywords (3-10) that help identify the relevance of this paper to COVID-19

* keyword 1 (replace me, copy and paste more than three if needed)
* keyword 2 (replace me, copy and paste more than three if needed)
* keyword 3 (replace me, copy and paste more than three if needed)

Please note the publication / review status
<!--Replace one of the empty brackets below with [x].-->

- [ ] Pre-print
- [ ] New Peer-Reviewed Paper
- [ ] Peer-Reviewed Paper Pre-2020

Which areas of expertise are particularly relevant to the paper?
<!--Replace the empty brackets below with [x].-->

- [ ] virology
- [ ] epidemiology
- [ ] biostatistics
- [ ] immunology
- [ ] pharmacology
- [ ] other:

<!-- STOP
Please fill out as much of the above as you feel able, then:
   (1) Select all the text below and cut it onto your clipboard
   (2) Submit this issue using the green button below
   (3) If you would like to submit a summary of the paper, paste the cut text from your clipboard to a new comment below and fill in the summary information
-->
Summary

Suggested questions to answer about each paper:
- What did they analyze?
- What methods did they use?
- Does this paper study COVID-19, SARS-CoV-2, or a related disease and/or virus?
- What is the main finding (or a few main takeaways)?
- What does this paper tell us about the background and/or diagnostics/therapeutics for COVID-19 / SARS-CoV-2?
- Do you have any concerns about methodology or the interpretation of these results beyond this analysis?

Any comments or notes?
